Breast Cancer

Integrative
Care

Guidelines

Examples

Integrative
Therapies

Treatment

Terrain

Wellness

Risk

Integrative
Programs

DCIS
Treatment

Care of
Your Heart

Surgery

More
Information
Printer-friendly VersionOpen a 118-page printer-formatted version of this handbook. Quick ReferenceUpdated March 2021: Open a 2-page quick reference summary of the therapies best supported by evidence for use with breast cancer: |
Not only will conventional treatment vary from one person to the next, but integrative breast cancer care will vary and should be individualized.
Key PointsBlue icons beneath the page title are quick links to sections of this page. Before investigating integrative care in breast cancer, we recommend reviewing integrative cancer care in general.
|
Authors
Laura Pole, RN, MSN, OCNS, BCCT Senior Researcher Ms. Pole is an oncology clinical nurse specialist who has been providing integrative oncology clinical care, navigation, consultation and education services for more than 30 years. View profile.
Ms. Hepp is a science researcher and communicator who has been writing and editing educational content on varied health topics for more than 20 years. View profile.
Dr. Lerner is president and co-founder of Commonweal and co-founder of the Commonweal Cancer Help Program, Healing Circles, The New School at Commonweal, and Beyond Conventional Cancer Therapies. View profile. Reviewers
Ted Schettler, MD, MPH, BCCT Advisor Dr. Schettler is science director of the Collaborative on Health and the Environment and the Science and Environmental Health Network. View profile.
Dr. Stritter is board-certified in anesthesiology and serves as a medical advocate, working primarily with women with breast cancer. View profile. Last updated August 16, 2021. |
Women with breast cancer use integrative therapies more often than any other group of people with cancer.
But despite the widespread use of integrative breast cancer therapies, informed guidance in integrating conventional and complementary breast cancer care is difficult if not impossible to find.
This summary of science-informed integrative breast cancer care is designed to provide that informed guidance.
Integrative breast cancer care has a remarkable amount to offer you. It can add to your treatment, help with side effects, benefit your quality of life, help you get well again, and reduce your risk of recurrence. Psychologically and spiritually, it can have transformative effects.
Let’s be clear: integrative cancer care means skillful choices in both conventional and complementary cancer therapies.
The very first step is deciding what your goals are. Your goals will guide you in choosing both conventional and complementary therapies. No matter what conventional therapies you choose, our 7 Healing Practices can be beneficial in many ways—physical, emotional, mental and spiritual. They are the foundation to strengthen you for rigorous conventional therapies, reduce side effects, build health and help reduce the risk of recurrence.
Diagnostic TestingAdvanced and non-standard diagnostic tests, some specific for breast cancer, are available. These tests can often identify specific therapies that will be most effective. Some require pre-planning for collection and shipping of live tissue samples. See Diagnostic Approaches and De-escalation of DCIS Treatment (below). Testing for Recurrence RiskSome tests are available to assess your risk of recurrence after successful treatment. The Oncotype DX Breast Recurrence Score test is one that can be helpful in predicting your risk of breast cancer recurrence and mortality. To date, the test is more predictive of outcomes among non-Hispanic women of European descent than among women of African-American descent in the US.1 |
Beyond the 7 Healing Practices you will find many specific integrative therapies to explore. Don’t let the number of choices deter you. We’ve arranged them in an easy order to consider, starting with those with the greatest safety, efficacy, and ease of access. Also, don’t overlook our special category of Off-label, Overlooked or Novel Cancer Approaches (we call them ONCAs). They have a lot to offer even if lifestyle changes seem too hard at this point.
I’ve known quite a few 20-year survivors of metastatic breast cancer—and I have known hundreds of women who have far outlived a metastatic prognosis.
We hope to help you live as well as you can for as long as you can with the optimal combination of conventional and complementary therapies. We hope to help you find a way to integrate the therapies that serve you best. That is how the best integrative oncologists do it—and we wish the best for you. Take it slow. Start with the simple things, like our seven healing practices, and move slowly toward the more complex decisions.
Don’t try to take all this in one bite. Take small bites, and come back as you are ready for more.
We do this for you. We hold you in our thoughts and prayers,
Michael Lerner
In early 2021, the World Health Organization announced that breast cancer is now the most common cancer diagnosis worldwide, overtaking lung cancer.2
Integrative Care in Breast Cancer
Breast cancer is actually many different diseases. Conventional treatments vary. Integrative care should also be individualized. For example, some complementary therapies that enhance immune function in some breast cancers may heighten cancer progression in others.
Getting your diagnosis right is critical to conventional treatment decisions. Unfortunately, accurate reading of pathology reports is often a weak link in cancer treatment, with unacceptably high error rates in some hospitals.
If the diagnosis is wrong, the treatment is often wrong. Many oncologists recommend a second independent reading of your pathology report—preferably from outside your medical center. Some cancer centers do this routinely, especially if they are not certain of the reading.
Further diagnostic tests (see at right), can inform your treatment. They may also help you choose the complementary therapies that may enhance your conventional treatment, help minimize side effects and improve your quality of your life.
You can also prepare yourself for what to expect. You can anticipate side effects and work to minimize them even before treatment starts. Learning what to expect helps you prepare to build your resilience for conventional treatments in the weeks and months to come.
Like conventional therapies, complementary therapies are best explored with a health professional experienced with these therapies. You may want to bring this BCCT Breast Cancer Handbook with you to discuss with your health professional.
Simple complementary and integrative approaches can improve outcomes with breast cancer. More complex approaches can be considered as you get further into your research. We cover both.
Clinical Practice Guidelines
Further Clinical Practice Guidelines
|
The Society for Integrative Oncology (SIO), the leading organization of its kind, has conducted a monumental review of randomized control trials of complementary therapies in breast cancer care.3 From this review, SIO created integrative care guidelines.
Within one year, the American Society for Clinical Oncology (ASCO) endorsed these guidelines. See the ASCO endorsement in Integrative Therapies During and After Breast Cancer Treatment: ASCO Endorsement of the SIO Clinical Practice Guideline.
The SIO reviewed randomized controlled trials published between 1990 and 2015. Researchers were looking at “the use of integrative therapies for specific clinical indications during and after breast cancer treatment, including anxiety/stress, depression/mood disorders, fatigue, quality of life/physical functioning, chemotherapy‐induced nausea and vomiting, lymphedema (swelling), chemotherapy‐induced peripheral neuropathy, pain and sleep disturbance.” Recommendations from this review:4
- Music therapy, meditation, stress management and yoga for anxiety/stress reduction
- Meditation, relaxation, yoga, massage and music therapy for depression/mood disorders
- Meditation and yoga to improve quality of life
- Acupressure and acupuncture for reducing chemotherapy-induced nausea and vomiting
- A lack of strong evidence supporting the use of ingested dietary supplements or botanical agents as supportive care and/or to manage breast cancer treatment‐related side effects
When these guidelines were presented at the 2017 SIO annual meeting, integrative oncologist and BCCT advisor Donald Abrams, MD, pointed out that the guidelines seemed conservative and that experienced integrative oncologists are safely and effectively using evidence-informed therapies that were not included in the SIO recommendations, such as some nutraceuticals and botanicals in advanced breast cancer.5
The presenter replied that these guidelines are more conservative because only randomized controlled trials were reviewed, and the guidelines are intended to serve the wider audience of oncology clinicians who are not necessarily specialized in integrative oncology care. Dr. Abrams reminded the audience that lack of evidence of effect is not the same as evidence of no effect, and that the safer the therapy that has plausible basis for benefit, the lower the burden of proof.
Guidelines from other organizations are listed at right.
Highlighted VideoBCCT advisor Brian Bouch, MD, reviews the different therapies for breast cancer care. |
Integrative Programs, Protocols and Medical Systems
For more information about programs and protocols, see our Integrative Programs and Protocols page. |
Programs and Protocols Specific to Breast Cancer
- Alschuler & Gazella complementary approaches6
- Block program7
- Chang strategies (case study)8
- Cohen & Jefferies risk reduction9
- Lemole, Mehta & McKee breast cancer protocol10
- MacDonald breast cancer program11
- McKinney breast cancer protocol12
Traditional Medicine Systems
Traditional Chinese Medicine
Traditional Chinese medicine (TCM) uses botanical and animal products, trace elements, diet and exercise in addition to acupuncture/acupressure, which may be more familiar to many Western patients.
Most controlled studies of TCM in cancer investigate acupuncture. Several Chinese herbals show activity against human breast cancer cell lines in lab and animal evidence, with clinical evidence accumulating more recently. Examples:13
- The herb Scutellaria barbatae (About Herbs) promotes programmed cell death in patients with advanced metastatic breast cancer in a phase 1 trial.14
- Chinese herbs for breast cancer improved nausea, vomiting and fatigue in a review of randomized trials.15
- Green tea, commonly used in Chinese medicine, is associated with a lower risk of breast cancer and recurrence, with some evidence of therapeutic effects.16
Ayurvedic Medicine
According to BCCT advisor Debu Tripathy, MD, no formal studies have evaluated Ayurvedic medicine as a system approach in breast cancer. However, some of the herbs used in Ayurveda—such as curcumin (turmeric) and withafarin A17 —have shown activity against breast cancer cell lines in lab studies.18
Examples of Integrative Approaches
A number of integrative oncology care programs and clinics employ complementary approaches to enhance conventional treatment and/or minimize side effects. Three programs have published studies of their integrative approaches in caring for those with advanced breast cancer. We provide a description of their research, not as endorsements of their programs, but as examples of different integrative approaches to advanced breast cancer care.
Block Center Program SupplementsSupplements used in the 2009 study of advanced metastatic breast cancer patients:19
|
The Block Center for Integrative Cancer Treatment (BCICT)
The Block Center, founded by Keith Block, MD, an integrative oncologist and BCCT advisor, offers a comprehensive cancer treatment program combining conventional treatments—often delivered in novel ways, such as according to circadian rhythms—along with nutrition and supplementation, fitness and mind-spirit instruction. The program is highly individualized and provides care to people with any kind of cancer.
Despite a higher proportion of younger and relapsed patients, survival of metastatic breast cancer patients at the Block Center was approximately double that of comparison populations and possibly even higher.
A collaborative research group looked at survival data for a consecutive case series of 90 women with advanced metastatic breast cancer who received this comprehensive treatment program at the Block Center. Findings:20
Despite a higher proportion of younger and relapsed patients, survival of metastatic breast cancer patients at the center was approximately double that of comparison populations and possibly even higher compared to trials published during this period. Explanations for the advantage relative to conventional treatment alone may include the nutritional, nutraceutical [relating to foods with medicinal properties beyond their nutritional value], exercise and psychosocial interventions, individually or in combination; self-selection of patients cannot be ruled out.
The researchers propose that the doubling of survival in those treated with the integrative program may be physiologically based and not due to self-selection. For example, patients in this program followed a low-fat diet, demonstrated in randomized controlled trials to improve relapse-free survival. Other specific program elements that may have helped with either prolonged survival or treatment tolerance:
- Increased intakes of antioxidants and phytochemicals
- Improved body composition and weight reduction due to increased exercise
- Reduction of stress hormones with mind-spirit interventions
- Higher intakes of vegetables, fiber and omega-3 fatty acids
The Block Center program also evaluates and supports a patient's quality of life and mental/spiritual responses to cancer and treatment. “Systematic training is provided in relaxation strategies, cognitive-behavioral interventions, and other approaches to enhance coping skills, pain management and sleep hygiene in order to manage the challenges associated with a cancer diagnosis and to mitigate side effects of chemotherapy, while improving treatment tolerance.”21 Being able to tolerate treatment better also means that women may be able to complete the treatment, improving their response and benefits.
The Block Program is explained in great detail in his patient-friendly book: Life over Cancer: The Block Center Program for Integrative Cancer Care.
Bastyr Integrative Oncology Care: A Naturopathic Oncology Approach
Bastyr Breast Cancer Study SupplementsNo one "Bastyr protocol" exists, as researchers continue to investigate and refine approaches. Supplements used in one Bastyr protocol for breast cancer:22
|
Naturopathic oncology care is complementary rather than alternative to conventional care, with complementary therapies used in conjunction with conventional treatments. Naturopathic oncologists are oriented to deliver integrative oncology care in tandem with their conventional oncology colleagues. For more information, see our discussion of naturopathic medicine and oncology at Integrative Medical Systems in Practice in the US and Canada.
BCCT advisor Leanna Standish, ND, is a Fellow of the American Board of Naturopathic Oncology (FABNO) and works within the research institute of the prestigious naturopathic school Bastyr University. Dr. Standish has been leading research studies looking at integrative therapies that naturopathic oncologists provide, as well as the costs and outcomes of that care.
In one study published in 2017, the Bastyr Integrative Oncology Research Clinic (BIORC), in collaboration with Fred Hutchinson Cancer Research Center, followed 324 women of all stages of breast cancer who received integrative oncology care from board-certified naturopathic oncologists in the Seattle area. The most common integrative therapies prescribed:
- Trametes versicolor (turkey tail mushroom)
- Mind-body therapies
- Acupuncture
- Injectable therapy (mistletoe, vitamin B complex, IV vitamin C, IV artesunate and IV nutrition and hydration)
The costs ranged from $1594 per year for early stage breast cancer up to $6200 per year for stage 4 breast cancer patients. About 20 percent of that cost was out-of-pocket, with the remainder paid for by insurance or written off by the university. As the researchers point out, “regardless of the stage of breast cancer, integrative [naturopathic] oncology care is low-cost relative to conventional oncology costs. Standard cancer treatments may cost as much as $10,000 to $40,000 per month.”23 The extra cost of adding complementary therapies to conventional care may be outweighed by the benefits to patients: better quality of life, symptom management and in some cases improved response to conventional treatment.
Since opening in 2009, BIORC has enrolled 704 patients in a separate prospective outcomes study treating breast, lung, colon, pancreatic, brain and skin cancers. One-third are patients with stage 4 cancer. During the study, the natural products used have been intravenous (IV) high-dose vitamin C, IV artesunate, oral curcumin, green tea and Trametes versicolor (turkey tail mushroom). Dr. Standish shared with us: “Our median overall survival was excellent compared to other published phase III clinical trials.”24 Their results for breast cancer have not yet been published.
Dr. Kleef: Hyperthermia, Immunology and Integrative Oncology Program
Dr. Ralf Kleef trained in Germany at an integrative-oriented medical school as well as at Sloan Kettering Cancer Research Institute in New York City as a postdoctoral immunology fellow. He has a clinic in Budapest, Hungary, which is on the “short list” of preferred European cancer clinics from Ralph Moss, a leading writer on integrative cancer treatments who publishes The Moss Reports.
Dr. Kleef uses what he calls “Lodoco” (low-dose combination therapy), the use of lower doses of chemotherapy and immunotherapy in combination with complementary therapies such as hyperthermia and artemisinin. He uses chemosensitivity and molecular testing to identify which drugs and natural products are more likely to be active against an individual’s cancer.
In addition to using his integrative approach with people with minimal residual disease, he is also getting early promising results in people who were previously heavily treated for cancer and come to him with stage 4 disease.
Dr. Kleef co-authored and published a case study of a woman with stage 4 triple-negative breast cancer with lung metastasis. Kleef treated this 50-year-old woman with low-dose immune checkpoint inhibitors, hyperthermia and interleukin-2. According to Kleef, “She went into complete remission of her pulmonary metastases with transient WHO I-II diarrhea and skin rash. The patient remained alive for 27 months after the start of treatment, with recurrence of metastases as a sternal mass, and up to 3 cm pleural metastases.” Kleef acknowledges that this is only one case, and urges further research using this protocol, which consists only of [European] approved drugs and treatments.25
Several individuals who have been treated at Kleef’s clinic have reported to us their favorable experiences, including patient advocate and breast cancer survivor Lindsay McDonell, although. See her story: Lindsay McDonell: Diagnostic Testing.
See the Moss Reports for a more thorough description of Dr. Kleef’s program: Moss Reports (purchase required), and Dr. Moss's blog post: Lower-dose immune drugs as effective as higher doses.
The Ecology of Breast CancerThe Ecology of Breast Cancer: The Promise of Prevention and the Hope for Healing by BCCT advisor Ted Schettler, MD, MPH, is one of the best sources of information on lifestyle and environment in relation to breast cancer risk and outcomes. Dr. Schettler proposes that individual body terrain is shaped across the lifespan by all levels, from individual to societal. “Efforts to change the design of that terrain can continue throughout life, so that breast cancer or its recurrence after initial treatment is less likely."26 |
Integrative Therapies in Breast Cancer
7 Healing Practices: The Foundation
Adding Up BenefitsStudies show that while a single lifestyle practice—such as a healthy diet or exercise—show benefit, combining practices is even more powerful.27 Breast cancer patients who adopted a healthier diet and regular exercise lowered their risk of relapse by nearly half, an effect seen in both obese and nonobese women.28 As David Servan-Schreiber explains: “In patients who already have cancer, there is a ‘dose effect’ relationship between regular application of practices that improve lifestyles and the degree of protection from the disease. The more involved these patients are in changing their ‘terrain,’ the greater the benefits.”29 |
The 7 Healing Practices listed here all promote wellness and tend to make your body terrain less hospitable to the development and progression of cancer. Some practices address cancer symptoms and side effects.
Eating Well
Dietary Fats: Healthier ChoicesFor most cancers, in general the recommendation is to eat a low-fat diet consisting of healthy fats (olive oil, nut oils, fish oils) and reduce the unhealthy fats (saturated fats found especially in red meat, trans-fats, and high amounts of omega-6 fatty acids). Limit total fat to 20 to 35 percent of dietary calories. Different types of dietary fat have different health impacts:
|
The foods you eat, plus how they're grown and prepared, have a substantial impact on your body terrain.
Key Points on Healthier Dietary Patterns
From Eating Well, Mediterranean Diet, and The Ecology of Breast Cancer (and other sources as noted):31
- Beginning in childhood, emphasize eating fruits and vegetables, especially leafy greens and those that are deep orange or yellow.
- Limit total fat to 20 to 35 percent of dietary calories. Different types of dietary fat have different health impacts—see a discussion at right.
- Eat more foods containing omega-3s, especially marine sources containing EPA and DHA.
- Eat low-fat dairy products instead of high-fat options.
- Eat less red meat and avoid processed meats.
- Include traditional, whole-soy foods, including tofu, soy milk and fermented miso and tempeh32 in your diet, starting in childhood if possible (but not during infancy). Whole forms of soy are best, while infant soy formula, supplements and highly processed soy foods—such as soybean oil, textured vegetable protein or soy protein isolate used in processed foods—are not recommended.
- Limit refined carbohydrates such as white flour, white rice, juices and sugar. Favor complex carbohydrates from whole grains, beans, vegetables and fruits.
- Add seaweed (sea vegetables) to your diet.
"Women who more closely followed a diabetes risk-reduction diet both before and after a diagnosis of breast cancer had lower risks for breast cancer–specific and all-cause mortality when compared with women with less healthy diets or those who did not substantially modify what they ate following diagnosis."33
Frequently consuming sugar-sweetened soda beverages was associated with higher overall and cancer-specific mortality among ER-positive but not ER-negative patients, and among women with higher body mass indices (BMIs). Overall mortality was higher among premenopausal but not post-menopausal women with higher consumption of sugar-sweetened beverages.34
Dr. Keith Block recommends eating medicinal mushrooms, such as shiitake, but also writes: "It is difficult to obtain clinically meaningful quantities of mushroom phytochemicals from even the healthiest diet, which is why I recommend getting them in the form of extracts."35 See Cooking Mushrooms: 5 Medicinal Mushrooms You Can Cook With for guidance on edible medicinal mushrooms.
Treating the Cancer
Several nutrient and food-preparation factors have been connected to reduced growth and spread of breast cancer. No single component has been found to clearly influence breast cancer development or outcomes.36
- Fats and plant-based foods: A large prospective study following women for 19 years found that reducing fat to 20 percent of energy and increasing vegetables, fruits, and grains in the diet significantly increased survival after breast cancer diagnosis.37
- Vegetables and fruits: Greater consumption of vegetables and fruits has been associated with lower mortality,38 although a prospective Japanese study found than an animal-product diet was associated with a decreased risk of breast cancer morbidity among premenopausal Japanese women.39
- Carotenoids: Higher baseline blood levels of carotenoids, such as beta-carotene and lycopene, are associated with improved outcomes following diagnosis and treatment.40
- Soy: Large studies of breast cancer survivors confirm that eating soy in whole food sources (not supplements or highly processed foods) is not associated with increased breast cancer proliferation, doesn’t interfere with tamoxifen and appears to increase the effectiveness of anastrozole.41 Genistein, a soy isoflavone, inhibits angiogenesis (formation of blood vessels to suppy tumors).42 A large study of combined data on US and Chinese women found that postdiagnosis soy food consumption of 10 mg/day or more showed a tendency toward a reduced risk of breast cancer-specific mortality.43 Soy food consumption has been associated with better breast cancer survival in other studies.44
- Omega-3 fatty acids from fish oil: Women who had been diagnosed and treated for early stage breast cancer who had higher intakes of EPA and DHA from food had a dose-dependent reduced risk of all-cause mortality.45
- Asparagine: The availability of an amino acid called asparagine strongly promotes metastatic potential of triple-negative breast cancer in animal studies. Restricting dietary asparagine reduces metastasis without affecting growth of the primary tumour.46 Foods rich in asparagine include dairy, whey, beef, poultry, eggs, fish, seafood, asparagus, potatoes, legumes, nuts, seeds, soy and whole grains. Foods low in asparagine include most fruits and vegetables.47
Reducing Risk
Eating a healthy diet that is low in fat and high in fruits and vegetables has been linked to a reduced risk of invasive breast cancer48 and a 25 percent reduced risk of recurrence in post-menopausal women.49 Consuming cruciferous vegetables such as broccoli, kale, Brussels sprouts, and cauliflower shows some evidence of reduced risk of breast cancer,50 as does consuming fruits and vegetables with higher total antioxidant capacity.51 Note, however, that antioxidant supplements do not show the same benefit and may even raise risk of cancer or recurrence. See more in Natural Products below.
Another large study (Women’s Healthy Eating and Living study, WHEL) included pre- and post-menopausal women and combined low fat intake with higher levels of fruits, vegetables and fiber. It found no difference in breast cancer recurrence or mortality between groups.52 However, a subsequent meta-analysis, including a secondary analysis of the WHEL study, found a potential benefit of a reduced-fat diet on risk of recurrence, even though not on survival.53
The meta-analysis includes a recommendation to look at overall dietary patterns as well as physical activity in regard to weight:54
As weight gain is a common occurrence following breast cancer diagnosis, and survivors are at increased risk for comorbid conditions such as cardiovascular disease and diabetes, achieving a healthy weight through reductions in caloric intake and increases in energy expenditure through a combination of diet, exercise, and behavioral strategies is encouraged.
Maintaining a stable weight in the early years postdiagnosis was associated with the lowest overall mortality risk.
Another study involving a large cohort of breast cancer survivors found that maintaining a stable weight in the early years postdiagnosis was associated with the lowest overall mortality risk.55
An investigation involving the Women’s Healthy Eating and Living study concluded that a diet with higher vegetable, fruit, and fiber and lower fat intakes than the five-a-day diet may reduce risk of additional breast cancer events, but only in women not experiencing hot flashes.56
The American Cancer Society recommends a dietary composition of 45–65 percent energy from carbohydrate, 10–35 percent of energy from protein, and 20–35 percent of energy from fat. They emphasize reducing the diet's energy density by limiting portions of energy-dense foods, such as high-fat and sugary items, in addition to increasing intake of low-energy-dense foods, such as vegetables and fruits.57
Nutrient and food-preparation factors connected to breast cancer:
- Micronutrients:
- Carotenoids:
- Higher baseline blood levels of carotenoids, such as beta-carotene and lycopene, are associated with lower breast cancer risk.58
- Lycopene is associated with a lower risk of estrogen-receptor-positive (ER+) and progesterone-receptor-positive (PR+) breast cancers in large, population-based studies.59
- Lycopene is associated with a lower risk of ER−/PR+ or ER−/PR− breast cancer in pooled analysis of prospective cohort studies.60
- Beta-carotene is associated with decreased risk in postmenopausal women with high alcohol intake.61
- DHA and EPA: These two omega-3 fatty acids, found in fish and fish oils, may be associated with reduced risks of breast cancer62 and of reduced risk of additional breast cancer events in patients with early stage breast cancer.63
- Iodine: high consumption of this element in Japan compared to Western societies has been associated with the low incidence of benign and cancer breast disease in Japanese women.64
- Carotenoids:
- Milk and dairy products: High intake of low-fat dairy foods, especially skim/low-fat milk, was associated with reduced risk of breast cancer in premenopausal women. No association between intake of dairy products, calcium and vitamin D and breast cancer risk was seen in postmenopausal women.65
- Trans fats: The link between trans fats and breast cancer risk is modest.66 Consumption of trans fats is consistently associated with higher mortality from all causes.67
- Omega-6 fatty acids: In most studies, although not all, higher amounts of omega-6 fatty acids compared to omega-3s are associated with higher risk of breast cancer. In many people, perhaps in part as a result of genetically determined fatty acid metabolism, a higher omega 6:3 ratio is associated with higher levels of inflammation.68
- Food preparation: Charring food (such as on the grill or in a broiler) produces known carcinogens such as heterocyclic amines, which are associated with breast cancer risk.69
- Green tea: Lower breast cancer recurrence is seen with intake greater than three cups per day; less consistent evidence regarding reduced risk of onset70
- Soy: Eating traditional (whole) soy products is associated with lower breast cancer risk, and eating them in childhood is associated with even lower breast cancer risk than soy in adulthood.71 A large study of combined data on US and Chinese women found that postdiagnosis soy food consumption of 10 mg/day or more showed a significant reduced risk of recurrence.72 Other studies show lower recurrence of breast cancer with soy consumption, even among postmenopausal women treated with tamoxifen.73 However, in HER2 positive breast cancer patients, soy consumption has been associated with a greater risk of recurrence,74 and overexpression of genes that promote cell proliferation.75
- Seaweed and edible mushrooms: Eating some varieties of seaweed76 and mushrooms (maitake and reishi)77 may be associated with lower breast cancer risk.
Whole soy food consumption of 10 mg/day or more showed a tendency toward a reduced risk of breast cancer-specific mortality and a significant reduced risk of recurrence.
Optimizing Your Terrain
- Proanthocyanidins, found in berries and grapes, are associated with lower inflammation, a contributor to breast cancer risk.78
- Refined carbohydrates and insulin sensitivity: Diets with excessive refined carbohydrates cause repetitive spikes in insulin and increase the risk of diabetes, which increases the risk of breast cancer. Elevated insulin levels also promote breast cancer. Improving insulin sensitivity in those with insulin resistance or elevated fasting blood sugar may be helpful not only in reducing breast cancer risk, but also in reducing risk of recurrence and breast cancer-related death in those diagnosed with breast cancer.79
See Eating Well and chapter 3 of Dr. Ted Schettler's The Ecology of Breast Cancer: Diet, nutrition, and breast cancer.
Moving More
From Moving More and The Ecology of Breast Cancer:
- The World Cancer Research Fund and the American Institute for Cancer Research both recommend 60 minutes of moderate-intensity or 30 minutes of vigorous-intensity exercise daily to reduce cancer risk. The American College of Sports Medicine recommends that healthy adults and cancer survivors engage in a minimum of 30 minutes of moderate-intensity exercise five days a week for health promotion.
- Even modest amounts of activity provide benefit, so starting slowly with lower intensity exercise and gradually increasing the intensity and duration is a good approach for people who have not been very active.
- Most studies show that the benefits of physical activity are heightened by increasing the activity level and duration.
- Sedentary living increases the risk of many diseases and earlier death. Prolonged sitting is unhealthy, regardless of physical activity levels at other times.
Patients may achieve higher fitness levels in a supervised program compared to a self-directed program.80 A 2019 study found that scheduling exercise to accommodate cyclical variations in fatigue due to chemotherapy may increase adherence to supervised exercise.81 Medicine & Science in Sports & Exercise. 2019 Sep 4.
See Moving More and pages 173-174 of Dr. Ted Schettler's The Ecology of Breast Cancer for tips for meeting these exercise and movement recommendations.
Treating the Cancer
Very low levels of physical activity was associated with a 22 percent increased risk of breast cancer mortality.
Moving—whether by formal exercise or by increasing daily activities such as walking, gardening or dancing—is associated with better treatment outcomes. “Most but not all studies show that women who regularly exercise after breast cancer treatment experience reduced all-cause and breast-cancer specific mortality compared to sedentary women over follow-up periods averaging four to eight years. In many studies, higher levels of physical activity or exercise before diagnosis are also associated with improved survival after diagnosis.82
Breast cancer survivors who performed the equivalent of walking three to five hours per week at an average pace had a lower risk of death from breast cancer as well as death from any cause, whether before, during or after chemotherapy. Even lower levels provided benefit, especially important during treatment.83 Another analysis from the same project found that engaging in at least 10 MET-hours per week of physical activity was associated with a 27 percent reduction in all-cause mortality and a 25 percent reduction in breast cancer mortality compared with women who were less active.84 Ten MET-hours per week is represented by any one of these activities:85
- 3½ hours of housecleaning
- 3 hours of brisk walking
- 2¼ hours of dancing
- 1 to 1½ hours bicycling 10-16 mph
Conversely, an investigation of the After Breast Cancer Pooling Project found that very low levels of physical activity (physical activity less than 1.5 MET hours per week) among cancer survivors was associated with a 22 percent increased risk of breast cancer mortality compared to those who had 1.5 or more MET hours per week.86
Managing Side Effects and Promoting Wellness
- A study found that exercise improved patients' chemotherapy completion rate without causing lymphedema or significant adverse events.87
- Regular exercise is beneficial in reducing fatigue and improving physical function after diagnosis and initial cancer treatment.88
- Women with early stage breast cancer who were more active consistently reported lower levels of depression and increased quality of life five years after the intervention compared to those who were less active.89
- Exercise combined with a healthy diet may increase benefit even more.90
- A 2019 review concluded that Nordic walking—performed with walking poles similar to ski poles—had a significant and positive impact on a number of breast cancer symptoms including lymphedema, physical fitness, disability and morbid perceptions.91
- Physical activity interventions were effective in improving executive function and self-reported concentration during breast cancer treatment.92
- A large prospective study of breast cancer patients enrolled in the Women's Health Initiative found that increasing levels of exercise before diagnosis was associated with a significant graded reduction in subsequent cardiovascular events in long-term survivors of primary breast cancer.93
- A study found that one year of football (soccer) fitness significantly improved bone mineral density, leg muscle strength, and postural balance in women treated for early-stage breast cancer.94
Reducing Risk
- “Strong evidence shows risk reductions of 20 to 80 percent for postmenopausal breast cancer with increasing physical activity.” according to Dr. Schettler.95 The evidence in premenopausal breast cancer isn’t as strong.
- Women who reported participating in at least seven hours of moderate or vigorous physical activity per week had an 18 percent lower risk of breast cancer in the Nurses Health Study, with over 16 years of follow-up. Further studies have found that lifetime physical activity was associated with lower risk of premenopausal breast cancer, while both cumulative and recent physical activity were associated with lower risk in postmenopausal women.96
- Meeting physical activity guidelines both before diagnosis and after treatment was associated with a lower risk of recurrence two years after treatment. Increased activity, even if not fully meeting guidelines, showed benefit.97
- A large 2019 analysis found that engaging in 7.5 to 15 MET-hours per week (about 2.25 to 4.5 hours of brisk walking) was associated with a lower risk of breast and other types of cancer.98
- Research shows an increased risk of various kinds of cancers among inactive individuals compared to very active people. The strongest associations in women are with postmenopausal breast cancer and cervical cancer.99 Greater activity levels are associated with a lower risk of breast cancer, even among women at higher genetic risk.100
Optimizing Your Terrain
Inactive women with newly diagnosed breast cancer were enrolled in an exercise intervention for about a month after diagnosis and until undergoing surgery. Compared to women participating in a mind-body intervention control group, those exercising demonstrated significant upregulation of 18 unique pathways, including several implicated in immunity and inflammation.101
For a discussion of the many studies examining links between activity and breast cancer, see chapter 4 of Dr. Ted Schettler's The Ecology of Breast Cancer: Exercise, physical activity, and breast cancer.
Managing Stress
As we discuss in Managing Stress, unusual or chronic unmanaged stress—and the subsequent alteration in stress biochemistry—can affect tumor growth and proliferation.
Treating the Cancer
In The Ecology of Breast Cancer, Dr. Ted Schettler suggests that chronic stress could speed the growth and development of an undiagnosed cancer.102
Dr. Schettler points out that the most significant associations of reduced stress levels with better survival are in women who don’t have metastatic disease when they are initially diagnosed and treated. But even in those with more advanced breast cancer, stress reduction has been related to longer survival in some individuals.
Therapies for Managing StressSeveral therapies have demonstrated effectiveness in reducing anxiety and stress:
|
Managing Side Effects and Promoting Wellness
Compelling evidence shows that stress reduction significantly improves quality of life after initial treatment of breast cancer and beyond.
Improved quality of life is clearly associated with stress reduction in women with all stages of breast cancer. In general, outcomes are more likely to improve when conventional therapy is combined with more comprehensive interventions that include stress reduction along with optimizing diet, exercise, sleep, and social support.103
See Managing Stress and chapter 7 in Dr. Ted Schettler's The Ecology of Breast Cancer: Stress, social support, and breast cancer.
Sleeping Well
Many women diagnosed with and being treated for breast cancer report having sleep difficulties. Anxiety and side effects of treatment can lead to sleep disruption. A vicious circle of cancer symptoms and treatment side effects can build, leading to poor sleep quality. Poor sleep then causes or worsens other symptoms, including depression, fatigue and anxiety.
Managing Side Effects and Promoting Wellness
Sleep interacts with treatments to impact your quality of life, and it can affect your ability to rebound from rigorous treatments. Repeated chemotherapy treatments impair melatonin production at night, increasingly disrupting sleep cycles as treatment continues.104 Strategies to improve disturbed sleep before starting chemotherapy may improve daily function.105
Many complementary therapies can help improve sleep and subsequently improve symptoms and quality of life. For instance, mind-body practices such as mindfulness meditation, tai chi and stress reduction practices have been found not only to improve sleep, but also to improve fatigue and depression in women with breast cancer.106
Reducing Risk
An extensive meta-analysis did not find an overall association between ever-exposure to night-shift work and the risk of breast cancer.107 However, considerable evidence shows that longer durations of shift work or rotating between night shifts and day or evening shifts is linked to higher risk of breast cancer.108
Optimizing Your Terrain
Beyond affecting normal cortisol rhythms, chronic poor sleep can disrupt many other processes and conditions with the internal terrain, fostering cancer growth and spread.
One of the problems of sleep disruption is that rhythms of the stress hormone cortisol are thrown off target. These abnormal rhythms are linked to less active natural killer cells, which is associated with shorter survival in those with breast cancer.109
Consistently poor sleep (and even too much sleep) can lead to a host of physical, mental and emotional problems. Several of these problems create an internal environment that is hospitable to cancer development, growth and spread, such as these:
- Increased inflammation
- Weakened immunity
- Insulin resistance
Tai chi can reduce inflammatory markers in breast cancer survivors with insomnia. Inflammation is a risk factor for cancer.110
Sleeping well is an often overlooked but incredibly important way of keeping yourself healthy and reducing your risk of disease.
See Sleeping Well.
Creating a Healing Environment
Exposures to toxic chemicals, light at night, radiation and electromagnetic fields are all associated with breast cancer.
Treating the Cancer
Lifetime cigarette smoking is associated with a poor prognosis among women diagnosed with breast cancer, and with breast cancer and all-cause mortality.
Lifetime cigarette smoking is associated with a poor prognosis among women diagnosed with breast cancer, and with breast cancer-specific and all-cause mortality.111
Night shift work is associated with tumor growth: “Women who have breast cancer should be advised not to work night shifts because of the strong experimental evidence showing that suppression of melatonin secretion can facilitate tumor growth.”112
Radiation to treat cancer can increase risk of a second cancer in vulnerable healthy tissue that falls in the treatment field. Some integrative oncology clinicians recommend specific complementary approaches to prevent or minimize ionizing radiation damage to normal cells from imaging or radiation therapy.
- Naturopathic physician Neil McKinney has a protocol using “radio-protectant” natural products.113
- Dr. Keith Block discusses using radiation couplers to minimize damage to normal cells while enhancing killing effects on cancer cell.114
Reducing Risk
Chemical Exposures
Many toxic chemical exposures throughout the lifespan—starting with fetal development—increase the risk of breast cancer. For instance, exposing a fetus to the hormone DES increases breast cancer risk decades later, as does pre-pubertal exposure to the pesticide DDT, including exposures in utero.115
According to a report from the Institute of Medicine, the strongest evidence indicates the following chemical exposures increase breast cancer risk:116
- Combination hormone therapy products (see more below in Reducing Risk)
- Current use of oral contraceptives (increased risk may disappear within a few years after use is discontinued117 )
- Tobacco smoking
Increasingly persuasive evidence links the following chemical exposures to breast cancer risk:
- Passive smoking
- Organic solvents besides ethanol
- Ethylene oxide
- Polycyclic aromatic hydrocarbons (PAHs)
- 1,3 butadiene
- Some agricultural chemicals
See chapter 5 of Dr. Ted Schettler's The Ecology of Breast Cancer: Environmental chemicals, contaminants, and breast cancer.
Living in areas with high levels of fine particulate matter, which is defined as particles smaller than 2.5 micrometers, or PM2.5, is associated with a breast tissue condition that increases risk of breast cancer.118
Creating a Healing Environment describes specific actions you can take to improve your environment and reduce harmful exposures. You can also find recommendations on pages 176-180 of The Ecology of Breast Cancer.
Night Work and Light at Night
Circadian Rhythms and Breast CancerWe describe the dangers of disrupting circadian rhythms (including sleep disruption) and how this can lead to multiple health problems and heighten cancer growth, proliferation and spread: |
Shift work that disrupts circadian rhythms has been classified as probably carcinogenic by the International Agency for Research on Cancer (IARC).119 Working night shifts for 20 years or more is associated with a significantly increased risk of breast cancer. The risk with shorter spans of night-shift work is still unclear.
Steps that night shift workers can take to minimize circadian disruption, helping reduce cancer risk:120
- Rapidly rotating shifts (one or two consecutive nights) cause less disruption of circadian rhythms than slowly rotating shifts (three or more consecutive shifts).
- Delay of circadian phase (scheduling sleep to start later) causes less disruption than advance of circadian phase (scheduling sleep to start earlier). Therefore, forward- rather than backward-rotating shifts are preferable. For example, scheduling work start times progressing later into the day or night—8pm, then midnight, then 6am—is less disruptive that start times that become earlier: 6am, then midnight, then 8pm.
- Permanent night work is an option to avoid circadian disruption and may be feasible if a night-oriented rhythm during days off is maintained. However, this requires avoiding bright light during the day and making certain that sleep is adequate.
- Modified light intensity during work at night can help, such as working in bright white light to increase adoption of a night rhythm or in dim red light to prevent adoption. Dim red light suppresses melatonin less than bright white light, but with a trade-off in alertness that is critical for performing many tasks.
- People working at night should be especially attentive to maintaining adequate levels of vitamin D.
- Considering the potential risks and benefits, most analysts do not recommend earlier or more intensive mammography screening in women night shift workers.
Ionizing Radiation
Ionizing radiation—including X-rays, CT scans and other medical imaging—is clearly established as a risk factor for breast cancer.
Ionizing radiation is clearly established as a risk factor for breast cancer, although very few people, nor even many physicians, are aware of the association.121
Exposure to ionizing radiation from medical sources, including X-rays, CT scans and other medical imaging, is increasing.
On the other hand, a 2020 meta-analysis found that exposure to the sun more than an hour a day can be protective against breast cancer. The researchers state that "this effect can most likely be credited to the potency of UVB radiation for producing vitamin D in the skin."122
Electromagnetic Fields
The International Agency for Research on Cancer (IARC) has classified both extra low frequency (ELF) and radio frequency (RF) electromagnetic fields as possibly carcinogenic in humans,123 although the connection to increased risk of breast cancer is not yet clear.
Disturbing case reports of breast cancer in young women carrying cell phones in their bras are noted, but no systematic study of the association has been published. Several mechanisms for how EMFs could influence breast cancer risk have been proposed. Because of this potential risk, many sources propose erring on the side of caution and reducing exposure to ELF-EMFs.
See Creating a Healing Environment and chapter 6 of Dr. Ted Schettler's The Ecology of Breast Cancer: The electromagnetic spectrum and breast cancer: Sunlight and vitamin D; shift work, artificial light, and sleep; electromagnetic fields for tips for reducing exposures.
Sharing Love and Support
Treating the Cancer
Sharing love and support has been shown to substantially help reduce the stress response and improve outcomes in women with breast cancer.
Sharing love and support has been shown to substantially help reduce the stress response and improve outcomes in women with breast cancer.124
A 2017 investigation of the After Breast Cancer Pooling Project found that larger social networks were associated with better breast cancer-specific and overall survival.125
Managing Side Effects and Promoting Wellness
Some of the earliest and most pivotal studies of social support improving quality of life have been in women with breast cancer.126
Exploring What Matters Now
Treating the Cancer
Finding meaning and setting goals are associated with better outcomes. Results of some studies:
- A study of 578 women with early-stage breast cancer were assessed using the mental adjustment to cancer (MAC) scale. The researchers found a “significantly increased risk of relapse or death at five years in women with high scores on the helplessness and hopelessness category of the MAC scale compared with those with a low score in this category.”127
- A small study of metastatic cancer of many types found extended survival among those who scored higher on these scales:128
- Ability to act and change
- Willingness to initiate change
- Participating in self-help work
- Relationships with others
- Quality of experience
- Another study of patients with many types of cancer concluded that longer-term survivors displayed a much higher degree of early involvement in their psychological self-help than did most of their nonsurviving peers.129
Managing Side Effects and Promoting Wellness
Finding meaning, setting goals, allowing and accepting difficult emotions and connecting with spirituality are associated with better outcomes:
Beyond the 7 Healing Practices: Further Integrative Therapies
Complementary therapies and lifestyle practices can be useful to enhance treatment effects, improve quality of life and possibly even extend life for those with breast cancer.
Several therapeutic approaches show potential. However, because breast cancer is actually many individual diseases with different responses to treatments, the advice of a healthcare professional knowledgeable about integrative oncology therapies is crucial.
The therapies presented here are not necessarily singly or in combination the right supplements for you to use. This list is not a recommendation from BCCT. Refer to our summaries of each of these therapies to see uses in breast cancer, where to find dosing guidelines, cautions, and their use in integrative protocols, programs and systems. A licensed health professional experienced in integrative breast cancer care can provide valuable guidance in selecting therapies.
Therapies are grouped according to their effects:
- Treating the cancer
- Managing side effects and promoting wellness
- Reducing risk
- Optimizing your terrain
We present natural products in six groups:
- Good clinical evidence of efficacy & safety, easy access
- Good clinical evidence of efficacy & safety, limited access
- Limited clinical evidence of efficacy but good safety, used in leading integrative programs
- Limited clinical evidence of efficacy, or significant cautions, but potential significant benefit
- Especially promising preclinical or emerging clinical evidence of efficacy and safety
- Evidence of no efficacy or may be dangerous
Off-label, overlooked and novel cancer approaches (ONCAs) are grouped separately:
- Group A: Good clinical evidence of efficacy
- Group B: Limited clinical evidence of efficacy
- Group C: Promising preclinical evidence only
- Group D: Evidence of no efficacy or may be dangerous
Within each section, we list only groups containing applicable therapies.
Other integrative therapies and approaches are described but not categorized. See the full summaries as linked for more information on each of these therapies.
Cells, Animals and PeopleStudies on human cells can be helpful in finding effects of drugs, radiation, natural compounds and other potential therapies on tumors. However, isolated cells or tissues in a highly controlled lab may behave very differently from tumors and other cells in real human beings. Drawing conclusions from cell studies is fraught with the potential for errors, a little bit like predicting children's final career successes from their performance in kindergarten. Yes, some differences hold all throughout the many levels and experiences on the way to the final goal, but many other intervening variables can change the outcome. Animal studies are a step up from cell studies, but differences between humans and lab animals make animal evidence unreliable in predicting how cancer patients will respond to therapies that work well with animals. While cell and animal studies are good markers for therapies to explore further, these results alone are not good evidence of a therapy's ultimate effects. In our therapy summaries, we list clinical evidence first, and then we include lab and animal evidence for further insights. When no clinical evidence is available, lab and animal evidence is offered, but we do not consider it strong evidence. This handbook focuses on therapies with clinical evidence of effects in breast cancer. However, we also include therapies with particularly promising animal evidence. These are the Group 5 therapies in each category. |
We limit our presentation here to therapies with clinical evidence—studies involving cancer patients—and not solely cell or animal evidence (see at right). Preclinical evidence is included in therapy summaries on this site for those who wish to assess that.
Treating the Cancer
Working against cancer growth or spread, improving survival, or working with other treatments or therapies to improve their anticancer action
The role of each of the 7 Healing Practices in arresting or reducing breast cancer growth and spread is described above.
Conventional Breast Cancer Therapies
Conventional treatment for breast cancer is becoming more and more specific, depending on the type, stage and characteristics of a person’s cancer. For a growing number of women, treatment is effective or even curative, especially in the case of early-stage cancer.
Screening for Cancer in Dense BreastsA large study in the Netherlands found that supplementing mammograms with magnetic resonance imaging (MRI) for women with very dense breast tissue reduced missed cancers (called interval cancers) more than mammography alone.132 |
Pregnancy and Cancer OutcomesPregnancy after breast cancer was not associated with a negative impact on patients’ outcomes—including women with hormone-receptor positive disease—in a large meta-analysis. Women with pregnancy after hormone-receptor negative disease had better overall survival and disease-free survival, even after correcting for the potential “healthy mother effect.” The safety of pregnancy after breast cancer regarding cancer outcomes was independent of BRCA status, nodal status, previous chemotherapy exposure, pregnancy interval and pregnancy outcomes.133 Breast Cancer and Pregnancy OutcomesBreast cancer survivors of childbearing age are less likely than the general public to become pregnant and may face a higher risk of certain complications, such as preterm labor. However, most survivors who do become pregnant deliver healthy babies.134 |
The National Comprehensive Cancer Network (NCCN) professional guidelines for breast cancer treatment provide enough treatment guideline scenarios to make your head spin. Fortunately, NCCN has provided patient-friendly guides in which you can look up your type and stage of breast cancer and see treatment options your doctors are likely to present to you. See "Further Clinical Practice Guidelines" in the box at right for links.
All these treatments—surgery, chemotherapy, radiation therapy, hormone therapy, immunotherapy—come with costs.
A few key points from these guidelines (links at right):
- Getting the diagnosis and the tumor characteristics right is absolutely key to figuring out the best conventional treatment approach. See Standard and Non-standard Diagnostic Approaches.
- According to breast cancer medical advocate and BCCT advisor Gwen Stritter, MD, the NCCN guidelines are really good for about 85 percent of primary [non-metastatic] breast cancers. Following the guidelines will result in response to treatment for those 85 percent of patients. Since early-stage primary cancer is likely curable by following the guidelines, the risk/benefit analysis does not favor straying from them.
- A conventional oncology doctor is not likely to stray from the NCCN guidelines.
- Although advanced breast cancer is incurable in most cases, steady improvements are seen in survival with standard therapies as well as the newer targeted agents. We at BCCT know of many women who have lived for years with recurrent or advanced breast cancer behaving like a chronic illness kept at bay at least in part by conventional treatment.
This is not to say that conventional treatments are magic bullets that get in there, destroy the cancer cells, and get out without being noticed. All these treatments—surgery, chemotherapy, radiation therapy, hormone therapy, immunotherapy—come with costs: physical, cognitive,135 emotional, social, spiritual and financial. And they don’t work for everyone all the time.
No complementary or alternative therapy is a suitable stand-alone treatment for breast cancer.
Similarly, no complementary or alternative therapy is a suitable stand-alone treatment for breast cancer. Integrating the best of both evidence-based conventional and complementary therapy may be a sensible way to bolster the effects of conventional treatment and improve your tolerance to the side effects so you can complete your treatments. This integrative approach also makes sense for reducing the risk of recurrence after treatment and possibly extending your life, as described in sections below.
Ralph Moss’ free The Ultimate Guide to Cancer:™ Do-It-Yourself (DIY) Research shows you how to use four of the main tools that doctors use to decide on the best cancer treatments. It will help you learn why some cancer treatments that look good in clinical trials may not work for “real world” patients like yourself. It will help you answer two questions that the doctor may be hesitant to answer in the detail you need to decide about treatment:
- What are my chances of actually living longer if I use this treatment?
- What are the likely side effects, and how long will they last?
Another question to ask is "What are the risks if I delay treatment?" A review and meta-analysis in late 2020 confirmed that delaying breast cancer treatment by a month or more increases the risk of dying.136
A starting place for the science and conventional therapies related to breast cancer:
- National Cancer Institute:
- Cancer.net: Breast Cancer
- Breastcancer.org
Chemosensitivity Testing
Tests are available to identify which drugs and natural products are more likely to be active against your cancer. Breast cancer medical advocate and BCCT advisor Gwen Stritter, MD, offers several considerations if you are thinking about chemosensitivity testing for breast cancer.
Strategies for Chemosensitivity Testing
Early Stage Breast Cancer
- The NCCN guidelines that your oncologist will likely follow are really good for about 85 percent of primary (non-metastatic) breast cancers. Following the guidelines will result in an excellent response to treatment for those patients. Since early stage primary cancer is likely curable by following the guidelines, the risk-benefit analysis does not favor straying from them. But in the case where chemotherapy suggested by the guidelines is not likely to result in a significant treatment response, or if the chemo doesn’t work, it makes sense to order chemosensitivity testing. I usually allow for two failed guideline treatments in primary breast cancer before trying chemosensitivity testing. Occasionally, as in the case of a particularly aggressive breast cancer, I will order chemosensitivity testing after just one line of failed chemotherapy.
- While chemosensitivity testing is very good at predicting what will work, it is best at predicting what will not work. After chemosensitivity testing, check your oncologist’s pick against your test’s ineffective list. If your oncologist’s choice is predicted to be ineffective, then share the test results and talk about using a different chemotherapy that is both in the guidelines and on the chemosensitivity effective list.
- Most estrogen-receptor positive (ER+) breast cancers are unlikely to respond to chemotherapy. They typically respond well to hormone therapies which, unfortunately, cannot be tested in most chemosensitivity platforms. However, a small number of ER+ tumors with high Ki67 values or that are clinically aggressive will respond to chemotherapy. These may also be good candidates for chemosensitivity testing.
Recurrent Local Breast Cancer
If a recurrent breast cancer is considered curable, the same cautions as for primary breast cancer apply. But in this case, consider chemosensitivity testing after just one line of failed chemotherapy.
Stage IV (Metastatic) Breast Cancer
In the case of metastatic breast cancer, sticking to the NCCN guidelines does not provide a cure. Consider doing chemosensitivity testing at the time metastatic cancer is diagnosed and use that as a guide for chemotherapy choices.
Where Your Oncologist Might Be Coming From
Very few oncologists in the US will do chemosensitivity testing right off the bat in primary breast cancer. It is possible that chemosensitivity testing results will suggest using a drug that is not in the NCCN guidelines. If the oncologist strays from the guidelines in this case, he/she could open themselves to malpractice lawsuits.
However, if you move forward with chemosensitivity testing and show the oncologist the results, he/she may follow them, especially if the guideline therapy is predicted to fail.
Conventional Treatment Interactions with Drugs and Natural Products
Commentary from BCCT advisor Jen Green, ND, FABNO, September 1, 2020: Arimidex generally has lower risk of drug interactions as compared to tamoxifen because it is metabolized by p glycoproteins and not CYP pathways in the liver. Tamoxifen, on the other hand, carries greater drug-drug and herb-drug interaction risks because it is extensively metabolized by the CYP2D6 pathway. Tamoxifen shouldn’t be combined with paroxetine/Paxil,137 fluoxetine/Prozac,138 diphenhydramine/Benadryl or cimetidine/Tagamet.139 Out of caution, it should not be combined with these natural substances:
- DIM 300mg140
- 3.6g or more of curcumin (7 capsules daily)141
- Goldenseal (About Herbs)
- St John's wort (About Herbs)
- Grapefruit
Breast Cancer Conditional Outcome CalculatorAn online tool allows patients to enter data about the type and status of her breast cancer to calculate expected cancer-related and overall life expectancy. |
Natural Products
BCCT advisor Debu Tripathy, MD, writes that “herbal and botanical agents have significant potential as bioactive agents that can affect cellular pathways involved in breast cancer, but may also cause side effects and drug interactions. . . Caution should be exercised when used with other treatments.”142
Group 1: Good clinical evidence of efficacy & safety, easy access
These therapies may be widely used in integrative cancer protocols and traditional medical systems.
Therapy | Notes |
---|---|
Flaxseed lignans | |
Melatonin |
|
Turkey tail mushroom |
|
Vitamin D (in doses up to 4000 IU per day for adults) |
|
Group 3: Limited clinical evidence of efficacy but good safety, used in leading integrative programs
Therapy | Notes |
---|---|
|
|
Ginseng (About Herbs) | |
Maitake mushroom |
|
Omega-3 fatty acid supplements See a discussion of benefits of omega-3s from foods in Eating Well above. |
|
Vitamin C |
|
Group 4: Potential significant benefit, but either limited clinical evidence of efficacy or significant cautions
May be used in leading integrative oncology programs. Therapies in this group may need more medical oversight and surveillance.
Therapy | Notes |
---|---|
Antioxidant supplements (including beta-carotene, lutein, lycopene, selenium, vitamin A, oral vitamin C, vitamin E and others) |
|
Coenzyme Q10 | |
DIM (diindolylmethane) |
|
Mistletoe | |
|
|
Vitamin E |
|
Vitamin K |
|
Group 5: Especially promising preclinical or emerging clinical evidence of efficacy and safety
Other therapies with preclinical evidence only for treating the cancer
|
Therapy | Notes |
---|---|
Fermented wheat germ extract |
|
Indole-3-carbinol (I3C) (About Herbs) |
|
Isothiocyanates (Oregon State University) |
|
L-asparaginase |
|
Medical cannabis and cannabinoids |
|
L-theanine |
|
Modified citrus pectin |
|
Shiitake mushroom |
Group 6: Evidence of no efficacy or may be dangerous
Therapy | Notes |
---|---|
714-X (National Cancer Institute) |
|
Amygdalin (Laetrile®) (About Herbs) | |
Essiac tea (Healthline) or Flor-Essence | |
Glutathione | |
High-dose oral vitamin C |
|
Hydrazine sulfate (WebMD) | |
L-glutamine |
|
Shark cartilage or Neovastat (About Herbs) |
|
Soy supplements and isoflavone isolates See discussions of beneficial whole soy foods above in Eating Well |
|
Off-label, Overlooked or Novel Cancer Approaches (ONCAs)
Off-label drug use involves a physician prescribing a drug for a disease or condition not approved by the FDA. Prescribing drugs off-label is legal if sufficient evidence indicates its usefulness for the condition or disease prescribed. However, different state medical boards have varying standards regarding off-label use of specific drugs.
These therapies have exciting potential and/or proven benefits. However, some carry higher risks of side effects, interactions with other treatments and other adverse medical events than other therapies we review. Cautions are noted with each therapy, and we strongly urge you consult your doctor before using these therapies—even over-the-counter drugs—for cancer treatment. We also note whether a prescription is needed or if a therapy is not widely available.
Group A: Good clinical evidence of efficacy
May be used in integrative protocols and programs
Therapy | Notes |
---|---|
Bisphosphonates, including clodronate (MacMillan Cancer Support) and zoledronic acid (Chemocare) |
|
Metformin |
|
Propranolol and other beta blockers |
|
Group B: Limited clinical evidence of efficacy
May be used in integrative protocols and programs
Therapy | Notes |
---|---|
Artesunate |
|
Chronomodulated therapies | |
Copper chelation with tetrathiomolybdate (TM) | |
Low-dose naltrexone |
|
Non-steroidal anti-inflammatory drugs (NSAIDs) including aspirin and COXII inhibitors |
|
Omeprazole (Drugs.com) |
|
Rapamycin |
|
Statins |
|
Group C: Promising preclinical evidence only
Therapy | Notes |
---|---|
Chloroquine (A4M Integrative Cancer Therapies presentation) |
|
Combination therapies |
|
Diets and Metabolic Therapies
- Intermittent fasting: periodic fasting around the time of chemotherapy may sensitize cancer cells to chemotherapy while protecting normal cells.323 A further investigation found that a fasting mimicking diet (FMD) for three days prior to and during neoadjuvant chemotherapy led to radiologically complete or partial response more often than a regular diet. Moreover, no difference in toxicity was seen between both groups, even though dexamethasone was omitted in the FMD group. FMD significantly curtailed chemotherapy-induced DNA damage in T-lymphocytes.324 See Dr. Alschuler's comments in Commentary below.
- Ketogenic diet:
- Clinical evidence is limited to case studies showing improvement or complete responses to ketogenic diets in combination with other therapies.325
- In preclinical studies, a low-carbohydrate ketogenic diet slowed mammary tumor growth and increased tumor latency in mice,326 and this effect was increased when mice were also treated with metformin.327
- Lab studies have found that human breast cancer cells with an enzyme capable of re-using ketone bodies used nearby ketogenic fibroblast cells to fuel their growth.328
Therapies Using Heat, Cold, Sound, Light or Cutting-edge Radiotherapy
- Hyperthermia:
- Hyperthermia acts as a chemo- and radio-sensitizer and improves outcomes such as local control and overall survival.329
- A 2001 review concluded that “randomized phase III studies performed in patients with breast cancer, malignant melanoma and cervical cancer have convincingly confirmed the increased efficacy of the combination of radiotherapy with local or regional hyperthermia in comparison with radiotherapy alone.”330
- Cryoablation:
- Cryoablation uses needles to insert liquid nitrogen or a similar gas into tumors to freeze and kill cancer cells. It is typically used for small tumors that can't be removed surgically.331 A clinical trial is investigating nonsurgical cryoablation as an alternative to surgery for early-stage, small breast tumors with low-risk features (low-grade, hormone receptor–positive, and HER2-negative). Most women in the trial received both cryoablation and supplemental therapy (endocrine therapy, adjuvant radiation, or chemotherapy). An average of about three years after treatment, only about 2% of women aged 55 and older had a cancer recurrence in a preliminary report.332
Managing Side Effects and Promoting Wellness
Compelling evidence shows that stress reduction significantly improves quality of life after initial treatment of breast cancer and beyond.
Managing or relieving side effects or symptoms, reducing treatment toxicity, supporting quality of life or promoting general well-being
![]() |
The role of each of the 7 Healing Practices in managing symptoms, improving quality of life and promoting wellness is described above.
Conventional Therapies
Vaginal moisturizers and vaginal rings supplying low-dose estrogen are used to address sexual discomfort and difficulties. Although these are conventional therapies, they may not be included in many conventional treatment programs unless or until a patient expresses a need.
A recent study (not yet published) found that "just about all (99%) of the postmenopausal women who took part in the study scored low on the Female Sexual Function Index (FSFI), indicating a high degree of sexual dysfunction, including vulvovaginal dryness and severe dyspareunia (painful intercourse)."333 In a discussion of the study, a recommendation was made to physicians to ask patients about sexual difficulties. However, BCCT encourages you to report symptoms and ask for help if your doctor doesn't ask.
Other conventional therapies for managing side effects are widely available. Ask your oncologist or primary care physician for recommendations.
Natural Products
Group 1: Good clinical evidence of efficacy & safety, easy access
These therapies may be widely used in integrative cancer protocols and traditional medical systems.
Therapy | Notes |
---|---|
Astragalus |
|
Bromelain (About Herbs) | |
Coenzyme Q10 | |
Ginger | |
Guarana (About Herbs) | |
Vitamin D |
|
Group 2: Good clinical evidence of efficacy & safety, limited access
Some may require a prescription, for example.
Therapy | Notes |
---|---|
Medical cannabis and cannabinoids |
|
Mistletoe extract |
|
Group 3: Limited clinical evidence of efficacy but good safety, used in leading integrative programs
Therapy | Notes |
---|---|
Agaricales mushrooms |
|
Aromatherapy | |
Ashwagandha | |
Black cohosh |
|
Curcumin |
|
Flaxseed lignans |
|
Ginseng (About Herbs) |
|
Inositol hexaphosphate |
|
Maitake mushroom |
|
Melatonin |
|
Reishi mushroom |
|
Selenium | |
Shiitake mushroom |
|
Vitamin and mineral combination (vitamins A, E, C, B, K and D plus calcium, magnesium and trace minerals) | |
Vitamin C (supplements or intravenous) |
|
Vitamin E |
|
Group 4: Potential significant benefit, but either limited clinical evidence of efficacy or significant cautions
May be used in leading integrative oncology programs. Therapies in this group may need more medical oversight and surveillance.
Therapy | Notes |
---|---|
Acetyl-L-carnitine (About Herbs) |
|
Aloe vera (About Herbs) |
|
Boswellia |
|
Chamomile (About Herbs) |
|
Combination therapies |
|
Hyaluronic acid cream | |
L-glutamine |
|
Magnolia bark |
|
Milk thistle |
|
Omega-3 fatty acid supplements or fish oil A discussion of benefits from dietary intake of omega-3s is in Eating Well above. |
|
Rose geranium in sesame oil nasal spray (BMJ Supportive & Palliative Care) |
|
Group 5: Especially promising preclinical or emerging clinical evidence of efficacy and safety
Other therapies with preclinical evidence only for managing side effects and promoting wellness |
Therapy | Notes |
---|---|
Allicin (About Herbs) |
|
Grape seed extract and/or pycnogenol |
|
Green tea extract | |
Indole-3-carbinol (I3C) (About Herbs) |
|
Isothiocyanates (Oregon State University) |
|
Probiotics | |
Resveratrol |
|
Group 6: Evidence of no efficacy or may be dangerous
Therapy | Notes |
---|---|
Hydrazine sulfate (WebMD) | |
Soy supplements |
|
Off-label, Overlooked or Novel Cancer Approaches (ONCAs)
These therapies have exciting potential and/or proven benefits. However, some carry higher risks of side effects, interactions with other treatments and other adverse medical events than other therapies we review. Cautions are noted with each therapy, and we strongly urge you consult your doctor before using these therapies—even over-the-counter drugs—for cancer treatment. We also note whether a prescription is needed or if a therapy is not widely available.
Group A: Good clinical evidence of efficacy
May be used in integrative protocols and programs
Therapy | Notes |
---|---|
Bisphosphonates, including clodronate (MacMillan Cancer Support) and zoledronic acid (Chemocare) |
|
Propranolol and other beta blockers |
|
Group B: Limited clinical evidence of efficacy
May be used in integrative protocols and programs
Therapy | Notes |
---|---|
Chronomodulated therapies |
|
Low-dose naltrexone |
|
Group C: Promising preclinical evidence only
Therapy | Notes |
---|---|
Metformin |
|
Statins |
|
Diets and Metabolic Therapies
A diet designed to address fatigue in breast cancer survivors showed positive results in a small pilot study.507
Periodic or short-term fasting may reduce chemotherapy side effects (vomiting, diarrhea, fatigue and weakness).508 Integrative oncologist Dwight McKee, MD, has advised some of his chemotherapy patients to follow intermittent fasting during chemotherapy.
Mind-Body Approaches
Mind-body approaches including music therapy, meditation and yoga have been shown to improve side effects and symptoms. Studies investigating the effects of cognitive-behavioral therapy and hypnosis have also found benefit. A 2017 study found that cognitive-behavioral therapy plus hypnosis reduced emotional distress in women with breast cancer undergoing radiotherapy.509 A 2018 non-randomized study of women undergoing breast surgery found shorter hospital stays; less anxiety; less weakness (asthenia) during follow-up chemotherapy; less radiodermatitis; and reduced incidence of hot flashes, joint and muscle pain and asthenia while on endocrine therapy in the group receiving hypnosis sedation compared to those receiving general anesthesia.510
More evidence is described in these summaries:
- Mind-body approaches (including cognitive-behavioral therapy, hypnosis, music therapy and meditation)
- Yoga
Energy Therapies
Energy therapies with evidence for improving side effects and symptoms include these:
Manipulative and Body-based Methods
- Acupuncture and acupressure for improved depressive symptoms and anxiety,511 dry mouth,512 fatigue,513 hot flashes514 pain severity515 and peripheral neuropathy,516 but not disease-specific quality of life517
- Massage,518 perhaps including aromatherapy
Therapies Using Heat, Cold, Sound, Light or Cutting-edge Radiotherapy
- Cryotherapy (cold treatment)
- Reduced chemotherapy-induced peripheral neuropathy and dysfunction in a small clinical trial519
- Used in the Block program520
Palliative Care
If you have advanced, incurable cancer that has stopped responding to conventional treatment, your oncologist, if pushed, will likely offer you more chemotherapy to try, even when it is unlikely to work and may worsen the quality of your life or even hasten death. This may be a time to push for your physician to be honest and to talk about realistic hope for quality of life, as so much more can be done for you with good palliative care. Furthermore, many patients receiving good palliative care as well as integrative approaches may actually live longer than expected. Such approaches described above include the Block Center for Integrative Cancer Treatment and the Bastyr Integrative Oncology Research Clinic approach.
See Palliative Care.
Reducing Risk
Reducing the risk of developing cancer or the risk of recurrence
Risk Factors
Hormone Replacement Therapy and RiskA 2019 meta-analysis found an increased risk of breast cancer with all types of menopausal hormone replacement therapy except vaginally inserted estrogen.521 According to coauthor Gillian Reeves, PhD, use of menopausal hormone therapy for 10 years results in about twice the excess breast cancer risk associated with five years of use, but there appears to be little risk from use of menopausal hormone therapy for less than one year, or from topical use of vaginal estrogens that are applied locally as creams or pessaries and are not intended to reach the bloodstream.522 A 2020 study confirmed that use of hormone replacement therapy for more than five years is associated with greater risk in women genetically predisposed to breast cancer.523 |
Generally accepted individual risk factors for breast cancer include these, with varying levels of association:524
- Genetic factors and family history of breast cancer
- Pregnancy history (late age first pregnancy or no pregnancies)
- Menstrual history (early age of puberty or later age of menopause)
- Dense breast tissue
- Chest radiation
- Recent oral contraceptive use (increased risk may disappear within a few years after use is discontinued525 )
- Combination hormone therapy (see also at right)
- Cigarette smoking
- Alcohol consumption
Lifestyle and environment influence the risks of developing breast cancer and of recurrence after treatment.
Although these risk factors are important, they do not fully explain why many people develop breast cancer. Lifestyle and environment influence the risks of developing breast cancer and of recurrence after treatment.
It Takes a Village (or a Whole Country) to Reduce the Risk of Breast CancerReducing these risk factors “cannot be accomplished by individuals alone. Public health strategies to re-shape the terrain are essential.”526 Many of these can only partially be addressed by changes in individual behavior. Multi-level public-health and policy interventions at the population level are also necessary in order to re-design system conditions in more favorable ways. Dr. Schettler synthesizes the research to 2013 and presents practical measures for individuals, healthcare professionals, public health officials, community planners, businesses, schools, governments and farmers to help reduce the burden of this disease at all levels. Discussing public-health strategies is beyond the scope of this summary, but we refer readers to Dr. Schettler’s book and to the work of organizations such as the Science and Environmental Health Network and the Collaborative on Health and the Environment. |
From Dr. Ted Schettler's The Ecology of Breast Cancer527 and other sources as noted:
Breast cancer risk factors help shape conditions that foster vulnerability to the disease and less favorable outcomes. Risk factors for which the strength of evidence varies from strong to probable to plausible:
- Certain kinds of diets (see Eating Well above)
- Inadequate physical activity528
- Exposures to certain environmental chemicals or contaminants, such as some hair products529
- Body weight: even among people considered of normal weight and not overweight (BMI < 25), increased body fat was associated with increased risk of postmenopausal breast cancer.530 Higher BMI is also linked to higher risk of second primary cancers among breast cancer survivors.531
- Non-ionizing radiation
- Inadequate vitamin D status
- Shift work
- Light at night
- Stress
- Severe life events, anxiety, depression, perception of insufficient social support, or avoiding coping strategy532
- Societal contributors to these factors, such as poverty, violence, racism or other marginalization
See Creating a Healing Environment.
The role of each of the 7 Healing Practices in reducing the risks of breast cancer development and recurrence is described above. Three further factors—alcohol use, breast feeding and adult body weight—are discussed here.
Alcohol Intake
Alcohol consumption is a recognized risk factor—among those with the strongest evidence—for developing breast cancer.533
After diagnosis, some studies show that recurrence is higher in those having more than three or four drinks per week, particularly in postmenopausal women.534
The American Institute for Cancer Research states: “For cancer prevention, AICR recommends not to drink alcohol. However, our recommendations recognize that modest amounts of alcohol may have a protective effect on heart disease and type 2 diabetes. If you do drink alcohol, limit your consumption to no more than two drinks a day for men and one drink a day for women. Alcohol appears particularly harmful when combined with smoking.”535 The American Cancer Society's 2020 guidelines also state that no alcohol is best.536
Managing Fear of Cancer RecurrenceA pilot study found that acceptance and commitment therapy (ACT) reduced fear of recurrence among breast cancer survivors better than survivorship education or a 30‐minute group coaching session with survivorship readings.537 See the ACT website, which includes a link to find an ACT therapist. |
An extensive 2018 review and systematic analysis goes even further, recommending no consumption of alcohol: “The level of consumption that minimises health loss is zero.”538
Breastfeeding
Breastfeeding brings many benefits to the mother as well as the infant, including reducing the mother’s risk of breast cancer.539
Many organizations, including the University of Texas MD Anderson Cancer Center, recommend breastfeeding your infant for at least six months, and longer is better.540
Adult Body Weight
A lower body mass index is associated with a lower risk of breast cancer, even among women at higher genetic risk.541
In the Nurses' Health Study, a large, prospective cohort study spanning decades, weight gain after age 18 is associated with higher risk after menopause among women who have never used hormone therapy. Women who had lost more than 10 kilograms (22 pounds) since menopause and maintained their weight loss had a lower risk of breast cancer than women with stable weight since menopause.542 Even smaller amounts of weight loss—more than 4.4 pounds (2 kilograms)—can be beneficial, as long as the loss is sustained and not regained.543
Therapies to Reduce Risk
Natural Products
Group 3: Limited clinical evidence of efficacy but good safety, used in leading integrative programs
Therapy | Notes |
---|---|
Boswellia | |
Curcumin |
|
Flaxseed lignans |
|
Green tea extract / EGCG supplements See a discussion of the benefits of drinking green tea in Eating Well above. |
|
Omega-3 fatty acid supplements See a discussion of benefits of omega-3s from foods in Eating Well above. |
|
Probiotics |
|
Vitamin D supplementation (in doses up to 4000 IU per day for adults) |
|
Vitamin E |
Group 4: Potential significant benefit, but either limited clinical evidence of efficacy or significant cautions
May be used in leading integrative oncology programs. Therapies in this group may need more medical oversight and surveillance.
Therapy | Notes |
---|---|
Agaricales mushrooms |
|
Black cohosh |
|
DIM (diindolylmethane) | |
Indole-3-carbinol (I3C) (About Herbs) |
|
Vitamin C |
|
Vitamin K |
|
Group 5: Especially promising preclinical or emerging clinical evidence of efficacy and safety
Other therapies with preclinical evidence only for reducing risk |
Therapy | Notes |
---|---|
Ashwagandha |
|
Grape seed extract |
|
Inositol hexaphosphate |
|
Iodine |
|
Isothiocyanates (Oregon State University) |
|
Lycopene supplements See a discusion of benefits of eating lycopene-rich food in Eating Well above. |
|
Reishi mushroom |
|
Resveratrol |
|
Selenium |
|
Group 6: Evidence of no efficacy or may be dangerous
Therapy | Notes |
---|---|
High-dose oral vitamin C |
|
Off-label, Overlooked and Novel Cancer Approaches (ONCAs)
These therapies have exciting potential and/or proven benefits. However, some carry higher risks of side effects, interactions with other treatments and other adverse medical events than other therapies we review. Cautions are noted with each therapy, and we strongly urge you consult your doctor before using these therapies—even over-the-counter drugs—for cancer treatment. We also note whether a prescription is needed or if a therapy is not widely available.
Group A: Good clinical evidence of efficacy
May be used in integrative protocols and programs
Therapy | Notes |
---|---|
Bisphosphonates, including clodronate (MacMillan Cancer Support) and zoledronic acid (Chemocare) |
|
Metformin |
|
Non-steroidal anti-inflammatory drugs (NSAIDs) including aspirin and COXII inhibitors |
|
Propranolol and other beta blockers | |
Statins |
|
Diets and Metabolic Therapies
These diet and metabolic therapies are associated with lower risk of breast cancer, as described on the linked summaries:
- Mediterranean Diet
- Intermittent fasting: Women with early-stage breast cancer who fasted less than 13 hours each night had an increased risk for breast cancer recurrence compared with those fasting 13 or more hours per night.619
Optimizing Your Terrain
Creating an environment within your body that does not support cancer development, growth or spread
Natural Products
- Agaricales mushrooms
- Increased number of natural killer (NK) cells and other biologic markers in breast cancer patients620
- Astragalus
- Curcumin
- Anti-inflammatory and antioxidant, interfering with known contributors to cancer development625
- DIM (diindolylmethane)
- Anti-inflammatory effects in lab and animal studies626
- Ginseng (About Herbs)
- Improved immunology among breast cancer patients when used in combination with red ginseng, lilyturf root, and magnolia vine fruit in a small clinical study627
- Maitake mushroom
- Omega-3 fatty acids
- Anti-inflammatory630
- Reishi mushroom
- Enhanced immunity in cancer patients631
- Resveratrol
- Inhibited obesity-associated inflammation in mice632
- Shiitake mushroom
- Improved natural killer (NK) cell activity and immunosuppressive acidic protein (IAP) levels in patients receiving chemotherapy (preliminary evidence)633
Off-label, Overlooked and Novel Cancer Approaches (ONCAs)
- Non-steroidal anti-inflammatory drugs (NSAIDs) including aspirin and COXII inhibitors
- Reduced inflammation, a known driver of tumor growth634
Breast Cancer and Surgery
Having breast cancer surgery and possible reconstruction may involve extra consideration and care. Planning ahead to minimize pain or discomfort and reduce the risk of infection can bring a happier experience and better clinical outcome.
Hormone Therapy before Surgery
From medical advocate, breast cancer survivor and BCCT advisor Gwendolyn Stritter, MD
Anti-estrogen therapy, typically started after surgery, prevents breast cancer relapse and death in ER+ cancers. However, some patients do not relapse even if they do not take anti-estrogen medication. Other patients will relapse despite taking them. This means a significant number of patients taking anti-estrogens suffer from the adverse effects of treatment without the benefit of improved outcomes. Taking anti-estrogens before surgery enables your healthcare team to determine if you would respond to such treatment. This can save five to 10 years of ineffective therapy for those who would not respond. Another benefit of neoadjuvant hormone therapy: good outcomes despite less aggressive surgery, such as lumpectomy instead of mastectomy.
It is not surprising that there is a groundswell of support in some centers for giving anti-estrogens before surgery in women with ER+ breast cancer.635 This allows the patient and the oncology team to know whether a particular medication is effective against the breast cancer and, if it does not induce a partial or complete remission, allows switching to a more active treatment regimen before surgery.
I had tamoxifen before surgery for my ER+ breast cancer, and seeing most of my cancer disappear on MRI over the ensuing 6 months was very gratifying. Knowing the tamoxifen worked so well kept me highly motivated to continue it for the next 5 years.
Breast Reconstruction: Now More Options
Dr. Deb's operating room flash mob before her double mastectomy |
Two basic types of breast reconstruction are available after mastectomy:
- Breast implants
- Flap reconstruction using tissue from your own body to reconstruct the breast
Further options are available within those two categories. To learn more about the standard post-mastectomy breast reconstruction options, see an online decision aid called BRECONDA: Breast Reconstruction Decision Aid. Note that this aid does not mention prepectoral implants.
Current discussion on implants involves subpectoral expander-based breast reconstruction. For many years, the standard has been to place the implants under the pectoralis major muscle (PMM), partially detaching that muscle. Although this implant position is thought to give a better cosmetic result, many women report problems due to partial injury of the PMM with subsequent muscular deficit, breast animation and postoperative pain.
Evidence supports another way to position breast implants: placing the implant above the PMM and covering it with a dermal matrix derived from pig tissue. The procedure is called prepectoral implant placement and complete coverage with porcine acellular dermal matrix (ADM). Evidence thus far indicates this procedure provides good cosmetic results.636 However, the use of ADM has been associated with higher rates of overall complications, seroma (a buildup of fluid where tissue has been removed), infection and reconstructive failure.637 You and your surgical team need to assess risks and benefits carefully.
An article in the New York Times provides a discussion of this procedure as well as describing Dr. Deborah Cohan's experience with replacing her sub-pectoral implant with a pre-pectoral implant: New approach to breast reconstruction may reduce pain and weakness for some.
See also Dr. Susan Love's book, Dr. Susan Love’s Breast Book. 6th edition, for an in-depth discussion of reconstruction options.
Avoiding Complications after Breast Surgery
Surgery and Metastasis—and a Therapy That May Reduce RiskSome studies in humans and animals suggest that surgery may be associated with metastasis638 —possibly from the inflammatory response of wound healing. Some researchers suggest that the flood of stress hormones associated with surgery may also contribute to the metastatic process following surgery. Studies involving cells and animals—and also preliminary human studies—suggest that use of the beta-blocker propranolol during the peri-operative period is associated with reduced levels of metastasis.639 Through its anticancer and immunological activity, propranolol seems to reduce the rate of metastasis in breast and other cancers. One study found that propranolol administered at the time of surgery may reduce the establishment of brain metastases in patients with triple-negative breast cancer.640 A 2016 review suggested that propranolol be added to standard of care for nonmetastatic cancers as a strategy to reduce the rate of metastasis.641 Some research suggests that people not already using beta blockers who are diagnosed with early breast cancer may want to ask their healthcare providers whether to take beta blockers for a few days around the time of cancer surgery.642 |
Why Is It Important (Besides the Obvious)?
When planning for surgery, several decisions and actions can reduce the risk of postoperative complications. Such complications, including these, while not occurring in the majority of patients, do affect many:
- Infection
- Seroma (fluid collection in the surgical area
- Hematoma (blood collection in the surgical area)
- Reconstructive failure (loss of implant or flap)
- Pain
Of these complications, infection is one for which patient decisions and behaviors have a big impact. Also the type of surgery makes a difference—reconstructive procedures have a much higher complication rate than lumpectomy or simple mastectomy. We will be highlighting ways to avoid infection and the reconstructive techniques that are least prone to complication.
Most people are aware that complications from surgery cause increased hospitalizations and healthcare spending. But many are not aware that they can delay important time-sensitive adjuvant treatment such as chemotherapy or radiotherapy, resulting in worse survival.643 Complications also reduce patient satisfaction with the procedure itself and with the cosmetic outcome.
Fortunately, intensive study has found ways to reduce complications. Surgeons and patients now have a lot of information that will help them. First of all, it is important to know whether you or your surgical procedure have specific factors that increase your risks for problems.
Patient Characteristics and Complication Rates
The following patient characteristics and behaviors are associated with higher risk of postoperative complications:644
- Obesity, with a body mass index of 30 or higher
- Tobacco smoking
- Age 65 or older
- Hypertension
- Compromised immunity or inflammation
- Hyperglycemia (high blood sugar or poorly controlled diabetes)
Having more than one of these risk factors multiplies the risk of complications. Addressing one or more of these factors before surgery decreases complications. The overall complication rate is 12.6 percent for women older than 65 who choose immediate reconstruction after mastectomy, compared with 6.8 percent for those under 65.
Surgery Characteristics and Complication Rates
Infection rates for breast reconstruction after mastectomy can exceed 30 percent.645 Postoperative complications are higher in these situations:646
- Immediate reconstruction following mastectomy
- Flaps (LD, TRAM or DIEP)
- Bilateral procedures
- Radiation therapy during or after reconstruction
- Chemotherapy
Of note, some institutions will strongly advise delaying reconstruction until after radiation therapy for those who currently smoke simply because performing an immediate breast reconstruction after mastectomy doubles the complication rate.
Neoadjuvent or adjuvant treatments, such as chemotherapy or radiation (given prior to or after surgery) may not only increase the risk for infection but may also cause further tissue damage. If you need these treatments, talk with your doctor about the best timing of reconstructive surgery in relation to other treatments.647
Surgical infection rates vary considerably for different types of surgery, for different hospitals, and for different surgeons (or even with the same surgeon as he or she gains experience). Longer hospital stays are also associated with higher infection rates. Information on hospital postoperative infection rates can be found at Medicare.gov—Hospital Compare. Dr. Susan Love advises: "One thing that keeps people in the hospital after mastectomy is learning how to manage a drain. If possible, ask your doctor to show you and your family the drain and how to empty it at the pre-op visit."648
Antibiotic Use and Infection Rates
A systematic review in 2013 found that antibiotic prophylaxis for 24 hours following breast reconstruction reduced infection rates from 14.4 percent to 5.8 percent. No further benefit was found for continuing antibiotics past 24 hours.649
Reducing the Risk of Complications: What You and Your Surgeon Can Do
What You Can Do
- First, find out how much time you can take before surgery to develop a plan and prepare for surgery.
- Preparing your body
- Discuss which risk factors you can improve before surgery and come up with a plan of actions to take. Actions may include controlling hypertension, stress, hyperglycemia and other conditions, or stopping smoking
- Consider incorporating stress management practices in the weeks leading up to surgery. Many patients find imagery practices specific to preparing for surgery to be helpful. See Managing Stress, Stress, Mind-Body Approaches and Guided Imagery.
- In addition to effective stress management practices, use emotional support, counselling and pre-surgery medication as appropriate to help reduce preoperative psychological stress.
- If you typically clean an animal litter box or bird cage, find someone else to clean it before and for several weeks after your surgery.
- Optimizing your surgical context:
- Check postoperative infection rates for the hospital where your surgery will be performed at Medicare.gov—Hospital Compare. While individual surgeon complication rates are available for many types of surgery, they are not published for breast surgery. Having said that, infection rates tend to be higher on average with less-experienced surgeons (a pretty good rule of thumb for having good experience is to consider surgeons who have done at least four per month of your specific type of surgery for five years).
- Inform your surgical team of any supplements, herbs or other therapies you’re using prior to surgery.
- If you have financial or social barriers to good pre- and postsurgical care, ask to be referred to an oncology social worker or oncology navigator for assistance.
- Work with your surgeon to determine the timing of reconstructive surgery. If you’ll be receiving radiation or chemotherapy consider initiating those treatments before reconstructive surgery.
- Schedule your surgery as an ambulatory procedure rather than as an inpatient hospital stay if possible.
- Discuss your options for anesthesia, post-surgical pain control (see more about ERAS protocols below) and the steps in the column at right with your surgical team at the pre-op visit.
- Immediately before surgery:
- Avoid presurgical dehydration.
- See if you can postpone surgery if you develop a cold, flu, pneumonia or other infection shortly before scheduled surgery.
- After surgery
- Before leaving the hospital, be sure you (and anyone who will be assisting you at home) fully understand and follow all wound care instructions carefully. Call your physician immediately if you show any signs of infection—an ncrease of redness, swelling, pain or discharge from your wound.
- Avoid contact with soil for two or more weeks after surgery.
- Avoid procedures that might introduce infection to the breast, such as nipple piercing or a tattoo.
- Consult an integrative physician or licensed naturopath (preferably one who is certified in oncology) to recommend approaches to maintain healthy immune function to improve your wound healing and reduce your risk of infection.
- In the weeks following your surgery, if you need a medical procedure that may introduce bacteria to the body, check with your surgeon about using antibiotics to prevent infection.
What Your Surgeon Can Do
- Assess all choices and optimize risk factors, including patient characteristics and their status of adjuvant therapy, such as radiotherapy and chemotherapy.
- Avoid textured implants due to a possible increased risk of anaplastic large-cell lymphoma.650
- Because half of infections occur more than 30 days after a procedure, implement a plan for follow-up care, including appointments and phone calls.
- Reduce suppression of the immune system induced by surgery and anesthesia651
- Use regional anesthesia and IV propofol as the primary anesthetic when possible
- Provide adequate pain control throughout the surgical experience while minimizing the use of opioids such as morphine, oxycodone or codeine.
- Avoid opioids during or after surgery by using an intravenous propacetamol and anti-inflammatories such as ketorolac while in the hospital and then using oral anti-inflammatories such as ibuprofen or naproxen after discharge.
- Avoid hypothermia by maintaining core body temperature devices such as fluid warmers and external body warmers.
- Remove catheters and drains as soon as possible.
- Use antibiotic prophylaxis.
Post-surgical Pain Management
Dr. Stritter's "pole dance" following her double mastectomy |
According to one national report,652 18 percent of opioid addicts or persistent users got their first opioid prescription after surgery. Evidence also shows that use may increase your risk of cancer recurrence.653 These are both good reasons to carefully consider whether use is necessary.
Fortunately, some hospitals are now discharging even their post-mastectomy patients without any opioids at all and, despite this, are achieving better pain control than with standard treatment that includes opioids. Maimonides Medical Center in Brooklyn, New York, is on the forefront of this movement, as discussed in their 2019 paper, Mastectomy is no longer an indication for postoperative narcotic.654 Many other hospitals are instituting their own opioid-avoiding protocols. Dr. Stritter strongly recommends that you ask your surgeon at the pre-op visit whether their hospital has a post-mastectomy opioid-sparing ERAS (Enhanced Recovery After Surgery) protocol. While we are in the throes of an opioid epidemic, it makes a lot of sense to minimize unnecessary opioid prescriptions.
In addition to pain control, some retrospective studies suggest that a single intraoperative dose of NSAIDs such as ketorolac may even reduce the risk of breast cancer recurrence.655 But a single dose may not be enough.
Dr. Stritter's ApproachDr. Gwen Stritter, MD, medical advocate and board-certified anesthesiologist, had bilateral mastectomy for breast cancer. She followed this approach, without opioids, to achieve good pain control and speedy recovery after her 2014 surgery:
|
Dr. Stritter, once interested in the idea of using such a protocol for breast cancer surgery, has come to a different conclusion. “The initial reports656 were based on retrospective, observational studies that had no control group.” Dr. Stritter’s confidence in those reports evaporated when Forget published her updated report—“a definitive prospective, randomized trial—at the 2018 San Antonio symposium that showed no effect of a single dose of intraoperative ketorolac on early recurrences.”657 Dr. Stritter thinks it doesn't make physiological sense that a single dose of ketorolac would reduce the chance of recurrence or metastasis. “The healing breast would have the epigenetic, genetic and proteonomic changes of wound healing—a well-documented pro-oncogenic environment—for several weeks until the incision has healed.” That is why after her bilateral mastectomy, Dr Stritter used anti-inflammatories (and no opioids) during her entire post-operative period, not only for pain relief but in hopes of creating an anti-oncogenic tumor microenvionment.
A 2018 review of anesthetic interventions in breast cancer concluded that “based on the available evidence, an ideal anesthetic in this patient population would involve a combination of TIVA (propofol), regional anesthesia (paravertebral block), non opioid sedatives (clonidine or dexmedetomidine), and COX-2 inhibition (ketorolac).”658
Breast Cancer Surgery and Opioid DependancyEven though addiction is not common overall among opioid users with cancer, a study of women undergoing mastectomy with reconstructive surgery as part of cancer treatment investigated use of opioids and sedative-hypnotic drugs. These women are at particularly high risk of becoming dependent on opioids following surgery, with about 13 percent of women who had not used an opioid for the year before surgery becoming a chronic user in the year following surgery. More than 6 percent of women became chronic users of sedative-hypnotic drugs. The researchers recommend women work closely with the prescribing provider to attempt to minimize risk of dependence.659 |
Non-drug measures that can reduce inflammation, pain and opioid use in cancer surgery:
- Acupuncture660
- Options with less published evidence regarding effectiveness.
Also see our Integrative Approaches and Surgery page for further research on pain management in surgery for more types of cancer and other settings.
Reducing the Risk of Chronic Pain after Mastectomy or Breast Reconstruction
From medical advocate, breast cancer survivor and BCCT advisor Gwendolyn Stritter, MD
About 15 to 20 percent of patients have moderate to severe chronic pain after breast cancer surgery.666 Regional anesthesia (also known as nerve blocks) has been shown to reduce the risk of persistent pain after breast surgery667 Thoracic paravertebral blocks and PECS blocks are the two types of regional anesthesia most widely used.
Performing such nerve blocks before surgical incision allows for “light" general anesthesia (such as primarily using IV propofol instead of inhaled gases). This in turn results in quickly “waking up” from anesthesia without nausea or prolonged grogginess. Enough evidence shows that regional anesthesia lowers the chance of subsequent relapse and metastasis.668 A formal clinical trial is looking at this very issue: Regional Anesthesia and Breast Cancer Recurrence.
Not all anesthesiologists have the training or experience to do these blocks well. An appointment with the anesthesia team well in advance of surgery will increase the odds of getting these blocks before mastectomy. I had bilateral paravertebral blocks for my double mastectomy and required only oral anti-inflammatory medication for post-op pain control. My experience was documented in this video: Gwen Stritter's Painless Double Mastectomy (see at right).
Infection Response
Despite our best efforts, we can sometimes still get an infection after breast surgery. Fortunately, it is uncommon for a mild infection to cause a significant worsening of outcomes. But knowing what to do (and what not to do) will help prevent a mild infection from becoming a serious one.
What if you do get an infection:
- Report symptoms of infection immediately to your surgeon and begin treatment promptly. If antibiotics are prescribed, take as directed.
- Eat well to maintain a healthy nutritional state. Consider consulting a board-certified oncology dietician for specific dietary recommendations.
- If antibiotics are prescribed, eat well and follow other practices to restore a healthy microorganism balance. See Eating Well, Mediterranean Diet and Your Microbiome.
- Consider consulting an integrative oncology specialist about additional measures to clear infection, help wound healing, control inflammation and minimize tissue fibrosis (scarring) from surgical wounds and/or from radiation therapy.
Recovery and Remission Maintenance
BCCT does not recommend any particular remission maintenance approach. The strategies provided here are supported by evidence of improved outcomes.
Balancing Terrain
Several imbalances in your terrain can make the body more susceptible to infection, slower to heal wounds and/or more hospitable to cancer. Chronic inflammation, insulin resistance/glycemia, obesity and imbalanced stress chemistry may be particularly important to balance in relation to surgery, wound healing and reducing recurrence risk. For more information, see Body Terrain and the Tumor Microenvironment.
In his book Life over Cancer: The Block Center Program for Integrative Cancer Care, Keith Block, MD, lists glycemia, stress chemistry/biorhythms and inflammation as terrain factors common in breast cancer. Compromised immunity such as from chemotherapy, surgery, anesthesia or opioid use may also increase the risk for infection and recovery. Approaches to address these factors involve healthy lifestyle practices, such as the 7 Healing Practices. You can learn more about Dr. Block’s integrative program to address these terrain factors in his book:
- Chapter 15, Inflammation: Overcoming cancer’s fiery side
- Chapter 16, Immune Surveillance: Mounting the immune barricades
- Chapter 18, Glycemia: Breaking cancer’s sugar addiction
In their books, Lise Alschuler, ND, FABNO, and Karolyn Gazella list five key body pathways to target to make your body inhospitable to cancer. Three of those pathways most relevant to preventing and managing surgical complications are the immune system, insulin resistance and inflammation. See the following chapters:
- The Definitive Guide to Thriving after Cancer: Chapters 1-5
- The Definitive Guide to Cancer, 3rd Edition: An Integrative Approach to Prevention, Treatment, and Healing:
- Chapter 8, Immune system (including stress management)
- Chapter 9, Inflammation
- Chapter 11, Insulin resistance
- Alschuler and Gazella also devote a portion of chapters 6 and 7 to integrative approaches to preparing for, mitigating side effects from and enhancing outcomes of cancer surgery.
The Breast Cancer Companion: A Complementary Care Manual: Third Edition by Barbara MacDonald, ND, FABNO, is an excellent guide for oncology naturopaths caring for those with breast cancer. She provides guidance on natural approaches to consider across the spectrum of breast cancer: reducing inflammation; support through surgery, including wound healing; preventing recurrence and monitoring after conventional treatment is completed. See these sections in particular:
- Chapter 1, section 2.1.4, Inflammation
- Chapter 2, section 2, Diagnostic Tests and Surveillance Tests
- Chapter 4, Preparing for Surgery
- Chapter 9:
- Section 3, Monitoring while in Remission
- Section 5, Recurrence Prevention Strategies
- Section 6, Classical Naturopathic Treatment of Breast Cancer Survivors
- Section 7, Post-treatment Laboratory Testing
Post-treatment Monitoring
When you have finished treatment, discuss and develop a survivorship plan with your cancer treatment team. Your survivorship plan includes instructions and a schedule for follow-up visits, plus testing and guidance on lifestyle and other self-care practices to help you recover and prevent recurrence. The type of testing and monitoring done to assess your response to treatment and pick up on recurrence depend on your specific cancer, treatment and risk for recurrence.
You need to find a balance in monitoring for breast cancer recurrence. Talk with your oncologist about your risk of recurrence and the type and frequency of monitoring best for you. Based on your risk, ask these questions:
- Have we done everything we know to do from a treatment standpoint to treat the breast cancer?
- What type and frequency of monitoring is best for me?
- What are the available monitoring tests and tools?
Valid and reliable tests to pick up on recurrence early are under development. Blood tests such as circulating tumor DNA (ctDNA) and circulating tumor cell testing (CTC) have generated a lot of excitement, but they’re not yet ready for routine clinical use. According to BCCT advisor and breast cancer medical advocate Gwendolyn Stritter, MD, two fairly well-validated ctDNA tests, Guardant 360 and FoundationOne Liquid, are used to monitor treatment response in metastatic breast cancer. She suspects that within the next couple of years these tests may be validated for use in the post-primary/adjuvant, NED (no evidence of disease) setting as a very early warning of impending recurrence. BCCT is monitoring this situation and will update this page when new developments are announced.
Meanwhile, some women with no evidence of disease but at high risk of recurrence have requested ctDNA testing, understanding that insurance is not likely to pay for the tests. Guardant 360 will accept samples only in the case of metastatic breast cancer. Foundation Medicine’s ctDNA test costs about $5800, and—except for metastatic disease—insurance usually won’t cover the costs. Fortunately, Foundation Medicine, and perhaps other companies, do not charge the patient if the test does not reveal any ctDNA. Further, Foundation Medicine and other companies offer financial aid and discount programs in some cases.
For more information on testing see Standard and Non-standard Diagnostic Approaches. Other surveillance tools currently employed with those at increased risk of recurrence are listed on BreastCancer.org’s site: Blood Marker Tests.
DCIS Treatment
From medical advocate, breast cancer survivor and BCCT advisor Gwendolyn Stritter, MD
60 percent of the patients with DCIS would not progress to invasive breast cancer even without any treatment whatsoever.
De-escalation of DCIS Treatment
60 percent of the patients with ductal carcinoma in situ (DCIS) would not progress to invasive breast cancer even without any treatment whatsoever. But not knowing which patient will progress, combined with the potential for metastasis in those who do progress, has understandably led oncologists to overtreat everyone in the hopes of improving the survival of the 40 percent who are at risk.
Fortunately, this is beginning to change as researchers are steadily showing ways to reduce DCIS treatment while maintaining excellent outcomes. Radiation therapy is a good example. Radiation therapy decreases relapse rates for DCIS, but it does not improve survival. For some patients, the reduction in relapse outweighs other considerations and they opt for radiation therapy. Now with the advent of genomic testing, oncologists are now actively researching tests such as Oncotype DX DCIS669 and SweDCIS670 that help limit radiation therapy only to those would have a high risk of relapse without it.
Preliminary data also show that even surgery can be avoided in low-risk DCIS. This research is compelling enough that an ongoing 50-state clinical trial of active surveillance vs. surgery in underway: Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial For Low Risk DCIS (COMET).
Sentinel lymph node biopsy (SLNB) may also be unnecessary in older women, adding no survival benefit. A large retrospective study of older women diagnosed with DCIS undergoing breast-conserving surgery found no difference in rates of recurrence, occurrence in the other breast or breast cancer mortality among those who did and did not have sentinel lymph node biopsy (SLNB). The researchers concluded that their findings don't support routinely doing SLNB for older patients with DCIS having breast conservation surgery.671
If you are an older women with DCIS considering breast conserving surgery and your surgeon is suggesting SLNB, you may want to discuss the necessity of having SNLB, weighing the potential for side effects (such as lymphedema) against the benefits. Neither the National Comprehensive Cancer Network nor the American Society for Clinical Oncology recommend SLNB for women with DCIS having breast-conserving surgery.672 See also Breast Cancer Treatment in Older Women in More Information below.
It is very exciting to see the breast oncology field moving in the direction where surgery and radiation therapy are used only on the few patients who need them.673
Low-dose Tamoxifen and DCIS
It turns out that the dose of tamoxifen you are taking may be much higher than needed. This research figured prominently at the December 2018 San Antonio Breast Cancer Symposium—for good reason. It was recently published in the Journal of Clinical Oncology.
First, some background. Conventional medical research, especially cancer research, has a notable deficiency: a strong tendency to test only the “maximally tolerated dose” of any given research drug. This approach is lots cheaper and lots easier than testing two to four other doses to find the sweet spot (maximal effectiveness, minimal side effects). Accordingly, it has been known for quite a while that the standard dose of tamoxifen—20 mg—may be much higher than that necessary to prevent non-invasive breast “pre-cancers” such as DCIS, LCIS and atypical ductal hyperplasia (ADH) from progressing to invasive breast cancer.
A group in Italy randomized 500 women with non-invasive breast disease to take either 5 mg tamoxifen per day or none at all (placebo group) over the course of three years. They found the decrease in DCIS/LCIS recurrence and that of invasive breast cancer in the low-dose tamoxifen group to be equivalent to what we typically see with the 20 mg dose. They also saw a decrease in new breast cancers/pre-cancers in the other breast. But equally important, the risk of blood clotting and endometrial cancer was indistinguishable from that of the placebo group. Here’s the icing on the cake: the incidence of hot flashes and vaginal symptoms (dryness, pain during sex) was minimally increased over the placebo group.674
What’s not to love? Equal effectiveness and decreased side effects! But here are some cautions. This is a relatively small study that followed women to an average of only five years. So this protocol is not quite ready for prime time.
Having said that, here are the situations in which you should consider asking your oncologist about low-dose tamoxifen:
- You have LCIS, ADH or ER+ DCIS, and
- You are at higher risk for endometrial cancer, or
- You are at higher risk for blood clotting, or
- Because of intolerable side effects you plan to stop the tamoxifen 20 mg dose thereby increasing your risk of relapse or invasive breast cancer.
Taking Care of Your Heart: Heart Health and Breast Cancer
With contributions from BCCT Advisor Jen Green, ND, FABNO
Caring for your heart is an important part of your wellness plan. The relationship between breast cancer and heart health may work both ways:
- According to a 2018 review, following diagnosis, 35 percent of deaths in breast cancer patients are related not to breast cancer, but to cardiovascular disease.675
- A heart attack raises the risk of death from recurrence.676
Fortunately, several actions are available to reduce the risk of heart damage and cardiovascular disease. Doctors should monitor women for early signs of heart disease and manage for risk factors—cholesterol levels, blood pressure and lifestyle.677 Cancer survivors can follow these approaches to reduce risks:
- 7 Healing Practices
- Creating Healthy Habits
- Ask your doctor about the supplements and approaches in this section.
“Heart Healthy” Lifestyle Choices
Some complementary therapies may be helpful, starting with “heart healthy” lifestyle choices including the 7 Healing Practices of eating well, moving more, managing stress and sharing love and support (see also the descriptions above).
Lifestyle practices are the first steps to get your cardiovascular system in the best shape possible, before treatment if possible but also as part of your survivorship plan for health.
A clinical trial of an exercise intervention in breast cancer patients found good evidence of benefit: "Our findings strongly support that tailored exercise training during adjuvant breast cancer treatment may counteract a decline in cardiovascular function, and in particular among those receiving chemotherapy."678
Be sure to consult your doctor before starting an exercise program, particularly if you already have heart or other problems such as neuropathy that may require adjustments to a fitness plan. In this case, a cardiac or cancer rehab program may guide you in choosing safe exercise and movement therapies.
Other foundations for protecting your heart:
- Quit smoking
- Optimize your body weight
- Avoid drugs that stress the heart:
- Cocaine
- Diet pills
- Ephedra/ma huang
- Performance-enhancing drugs
- Caffeinated energy drinks679
Cardiac Toxicity and Breast Cancer Treatment
Click the image to open the brochure. |
People with breast cancer who are undergoing chemotherapy such as anthracylines (including Adriamycin/doxorubicin), targeted agents such as Herceptin/trastuzumab, and radiation therapy to the chest are at risk for heart damage. Risk is even higher for those receiving anthracyclines plus Herceptin or anthracyclines plus chest radiation.
As part of your treatment, you may be given toxic drugs and/or radiation therapy to kill cancer cells. The normal cells in and around your heart can also be killed, resulting in cardiac toxicity. Besides cell death, other types of cardiac toxicity can result from cancer treatment:680
- Cardiomyopathy
- Myocarditis
- Pericarditis
- Acute coronary syndromes
- Congestive heart failure
With people living longer after their cancer diagnosis and treatment than in the past, this problem is becoming more prevalent, so much so that a new cancer subspecialty—cardio-oncology—has developed. Many cancer treatment centers have cardio-oncology programs.
From a conventional treatment standpoint, preventing heart problems from cancer treatment involves a baseline test of heart function, monitoring those at risk for problems, and adjusting drug dosage and/or frequency or even changing to a less cardiotoxic drug. Radiation oncology is becoming more and more adept at targeting the cancerous tissue and shielding the heart and lungs. Early treatment of heart problems is more likely to prevent serious damage.
The first step is to get a baseline test of heart function (usually an echocardiogram, or ECG), and repeat this testing during treatment if you are at risk for heart problems.681 Repeat testing four and 10 years after treatment with doxorubicin.682 Survivors of childhood cancer should have an echocardiogram every one to five years ongoing683 and during late-stage pregnancy.684
An echocardiogram should be taken periodically during treatment—every three months during treatment with Herceptin/trastuzumab, according to guidelines from the American Society of Echocardiography (ASE)/European Association of Cardiovascular Imaging and European Society for Medical Oncology.685 An “echo” takes pictures of the heart and measures the strength of the heart/ejection fraction. Ejection fraction over 55 percent is normal, a mildly weak heart is at 45 to 55 percent, a moderately weak heart is 30 to 45 percent, and below 30 percent is considered severely weakened.
Natural Therapies Protective during Adriamycin/Doxorubicin Treatment
Studies on herbs or natural supplements show how these have helped reduce heart damage from Adriamycin/doxorubicin. Please connect with an integrative oncology professional or naturopathic physician for specific guidance. Also see Quality and Sources of Herbs, Supplements and Other Natural Products.
Milk thistle: In a controlled trial, cancer survivors who took milk thistle during doxorubicin treatment had better heart function compared to placebo. Study authors concluded that silymarin "can be recommended as adjuvant drug in patients with ALL under doxorubicin therapy."686 Silymarin, a main component of milk thistle, protected animal heart and liver tissue against doxorubicin-induced toxicity.687 An earlier trial showed that milk thistle is safe to combine with chemotherapy.688 See a commentary about use of milk thistle during chemotherapy treatment on our Milk Thistle summary.
Coenzyme Q10 (CoQ10): In a controlled trial, CoQ10 use with doxorubicin preserved heart function.689 In another small controlled trial in Japan, CoQ10 use during doxorubicin and radiation treatment preserved heart function.690 Researchers hypothesize that CoQ10 prevents doxorubicin from binding to heart muscle cells.691 Animal studies also show that CoQ10 supplementation improves the functional and structural integrity of the myocardium during doxorubicin treatment.692
Before taking coQ10, consult with your doctor. Because CoQ10 is an antioxidant, it may theoretically interfere with some chemotherapy drugs (such as anthracyclines and cyclophosphamide) or radiation therapy. “Recent in-vitro [cell] studies, however, have shown that CoQ10 does not affect the antineoplastic properties of doxorubicin.”693
L-carnitine (About Herbs): Many people who have low carnitine from chemotherapy will have weakness in large muscle groups, which can make your legs feel like jello when you walk up the stairs. L-carnitine is established as improving heart function following a heart attack. In a meta-analysis, use of L-carnitine after heart attack was associated with a 27 percent lower risk of dying and 65 percent lower risk of irregular heart rate.694 In a randomized controlled trial of cancer patients, L-carnitine during doxorubicin treatment improved signs of heart muscle toxicity.695 Young cancer survivors who received doxorubicin have lower plasma carnitine levels than controls, so L-carnitine has been suggested as a way to prevent heart damage.696 Many people who have low carnitine from chemotherapy will have weakness in large muscle groups, which can make your legs feel like jello when you walk up the stairs. Animal studies also show that L-carnitine supplementation improves the functional and structural integrity of the myocardium during doxorubicin treatment.697
Ginkgo (About Herbs): In a controlled trial in China, people who took Gingold during doxorubicin treatment had fewer abnormal echocardiograms compared to doxorubicin alone.698 Because ginkgo does not affect how most medicines are metabolized, it appears to be safe to combine with chemotherapy,699 tamoxifen, anastrozole or letrozole.700 Ginkgo added to aspirin (either 325 mg701 or 500 mg702 did not affect bleeding risk.
Arginine (About Herbs): In a controlled trial, people who took arginine along with doxorubicin had less shortness of breath, palpitations, and fewer ECG changes.703
Iodine: In a randomized pilot study, women who took iodine during epirubicin chemotherapy for breast cancer had significantly lower levels of heart distress enzymes (creatine kinase-MB) than those taking a placebo.704
Natural Therapies Protective during Treatment with Herceptin/Trastuzumab, Perjeta/Pertuzumab or Kadcyla/Trastuzumab Emtansine
Studies of these herbs or natural supplements show improvements in heart strength/ejection fraction. These may be useful if heart strength is reduced from Herceptin or Kadcyla treatment. Please connect with an integrative oncology professional or naturopathic physician for specific guidance. Also see Quality and Sources of Herbs, Supplements and Other Natural Products.
Hawthorn berry/crataegus (About Herbs): In a meta-analysis, hawthorne berry improved heart strength/ejection fraction and symptoms of congestive heart failure.705
L-carnitine (About Herbs): In a meta-analysis, L-carnitine improved heart strength/ejection fraction and symptoms of congestive heart failure.706
Taurine (About Herbs): In double-blind, randomized, controlled trials, taurine improved heart function and signs of congestive heart failure.707
Combination of taurine, CoQ10 and L-carnitine: In a double blind randomized controlled trial, patients who took 3 g taurine, 3 g carnitine and 150 mg CoQ10 had better heart function.708
Astragalus: In a randomized controlled trial, astragalus improved heart strength/ejection fraction.709
Berberine (WebMD): In a randomized controlled trial, berberine improved heart strength/ejection fraction, ability to exercise, symptoms of congestive heart failure, and heartbeat regularity/ventricular premature complexes.710 Dr. Barbara MacDonald recommends against taking berberine during taxol treatment.711
Magnesium (About Herbs): In a double blind randomized controlled trial, people with severe congestive heart failure who took magnesium had better symptoms and survival.712
A heart-support protocol developed by Michael Walker, ND, FABNO, includes magnesium (About Herbs), CoQ10, L-carnitine (About Herbs), fish oil, and exercise that can improve heart function that drops during treatment with Herceptin/trastuzumab or Perjeta/pertuzumab.
Commentary
BCCT advisor Gwen Stritter, MD, February 1, 2019: As a breast cancer medical advocate, I find there are certain areas that patients are really grateful to learn about. I have included a few in sections above: hormone therapy before surgery, regional anesthesia for mastectomy and de-escalation of DCIS treatment.
Naturopathic oncologist and BCCT advisor Lise Alschuler recommends overnight fasting for 13 hours, as this has been associated with improved survival after a diagnosis of breast cancer. For instance, you could finish dinner at 7pm and eat nothing else until 8am the next morning when you "break fast.” In addition, for people having significant side effects, especially gastrointestinal, from chemo, Dr. Alschuler may also recommend fasting for 48 hours—from after dinner on the day before chemo, through the day of chemo and the day following chemotherapy. The chemo fast can be a water fast (which includes coconut water and vegetable broths), or you can eat up to 600 calories per day of vegetable soup and/or low-carb vegetables. She stresses the importance of your being motivated to fast, and also that fasting during chemotherapy should be cleared with your treating oncologist. You should modify or stop the fast if you become dizzy or weak (try adding boiled eggs or nuts), or if you feel worse than if you had eaten.
BCCT advisors Gwen Stritter, MD, and Jen Green, ND, FABNO, May 9, 2019: Impact of curcumin on tamoxifen effectiveness
Many are aware that tamoxifen is what we call a pro-drug. A pro-drug is ineffective until specific enzymes in your body activate it. Tamoxifen is metabolized to endoxifen, the effective drug that prevents ER+ breast cancer patients from relapse.
An enzyme called CYP2D6 is responsible for the magic that changes tamoxifen to endoxifen. The activity of this enzyme varies from individual to individual. Part of the variance is due to genetics—some people are born with hyperactive CYP2D6; others have an enzyme that is very sluggish. Many medications—antidepressants like fluoxetine (Prozac), paroxetine (Paxil) and citalopram (Celexa) amongst a host of others—as well as assorted foods and dietary supplements can either activate or slow down CYP2D6.
When this information first started causing a stir in the breast cancer world roughly 10 years ago, researchers hypothesized that taking tamoxifen with a CYP2D6 inhibitor would cause a increase in breast cancer relapse. As it turned out, further clinical research did not bolster this theory,713 leading to a new one: genetics, drugs and dietary intake have complex interactions with the body’s enzyme system. They activate some enzymes and inhibit others. This results in a variable net effect on the concentration of important drugs. In a 2016 study, the cause of low endoxifen levels could not be identified over 50 percent of the time.714
Because such a complex system is difficult to study, researchers turned away from looking at just CYP2D6 and are focusing on the endoxifen level itself (ignoring the middleman). In one study, researchers in the Netherlands gave tamoxifen with or without curcumin 1200 mg three times a day. The group taking tamoxifen in combination with curcumin had about an 8 percent decrease in endoxifen levels. If the curcumin was compounded with piperine (often done to substantially improve curcumin absorption), endoxifen levels were further decreased by 12 percent.715
Although an 8 to 12 percent reduction doesn’t seem like much, if your genetics and/or dietary habits result in levels of endoxifen just barely in the effective range, the addition of curcumin, and especially with piperidine, could tip the scales in favor of breast cancer growth. The authors of this paper conclude: “co-treatment with curcumin could lower endoxifen concentrations below the threshold for efficacy (potentially 20 to 40 percent of the patients).”
Do keep in mind that this was a very small study, only 16 patients. However, these results are in line with previous lab and animal research so should not be discounted. On the other hand, curcumin supplementation has documented beneficial effects: decreased depression,716 anti-inflammatory effects717 and lowered cholesterol,718 to name a few.
The bottom line: if you are taking curcumin with tamoxifen, ask your integrative practitioner if s/he could substitute another supplement. If not, then request to have your endoxifen levels checked, both before and a month after starting curcumin. Quest Diagnostics, a very reputable lab, offers a “tamoxifen and metabolites” blood test.
BCCT advisor Lise Alschuler, ND, FABNO, August 9, 2018: There are instances when I use specific mushrooms, for instance: Coriolus (or Trametes) versicolor (turkey tail) for breast cancer, Agaricus blazeii for ovarian cancer and chaga mushroom for melanoma. However, it is a very valuable and reasonable strategy to use a blend that includes mushrooms, each of which is standardized to its polysaccharides and beta-glucans. The key is to use a hot water extract of the fruiting bodies or a full-spectrum extract (includes mycelium) that clearly identifies on its label the quantity of mushroom extract.
Some blends that I often recommend:
Per capsule:
- Trametes versicolor (turkey tail) (40% polysaccharides, 40% beta-glucans) - 100mg
- Grifola frondosa (maitake) 40% polysaccharides, 30% beta-glucans - 100mg
- Ganoderma lucidum (reishi), 40% polysaccharides, 15% beta-glucans - 100mg
- Lentinula edodes (shiitake), 409% polysaccharides, 40% beta-glucans - 100mg
I would recommend between 2-3 capsules twice daily.
When recommending single mushrooms, it is important to know how much beta-glucan is in each serving so that I can titrate my dose accordingly. For instance, I often use Grifola frondosa (maitake) mushroom to increase white blood cell counts. One product I use contains:
Per 6 tablets:
- Maitake (Grifola frondosa) Fruiting body powder - 600mg
- Maitake fruiting body extract, standardized to contain 30% D-fraction - 240mg (so 72mg D-fraction beta glucan)
- Vitamin C 120mg (supports bioactivity)
Costs permitting, in most clinical studies, the daily dose of mushroom extracts that is correlated with improved survival (especially in breast, colorectal, gastric cancers) is 3000mg/day.
Mushrooms do pack a punch! From a meta-analysis on Coriolus versicolor mushroom extracts in patients diagnosed with cancer:719
- Over all cancers, there was a 9 percent absolute reduction in 5-year mortality (one additional patient alive for every 11 patients treated).
- Effects were more evident for breast, gastric or colorectal cancer versus esophageal or nasopharyngeal.
BCCT advisor Keith Block, MD, advises patients on heart-damaging medications to take 200 mg or even considerably more of CoQ10 per day.720 Many heart patients are also on statins. Block says, “Because statins deplete coenzyme Q10 from your muscle cells, particularly your heart, I advise patients on statins to take at least 30 mg of coQ10 per day.“721
BCCT advisor Ted Schettler, MD, March 4, 2019: Lavender oil (as with some other essential oils) has estrogenic properties at some concentrations.722 It might be wise to avoid skin application of lavender oil in the setting of an estrogen positive breast cancer diagnosis.
- Hoskins KF, Danciu OC, Ko NY, Calip GS. Association of race/ethnicity and the 21-gene recurrence score with breast cancer-specific mortality among US women. JAMA Oncology. 2021 Jan 21:e207320.
- Reuters Staff. Breast cancer overtakes lung as most common cancer—WHO. Reuters. February 2, 2021. Viewed February 6, 2021.
- Greenlee H, DuPont-Reyes MJ et al. Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment. CA: A Cancer Journal for Clinicians. 2017 May 6;67(3):194-232.
- Greenlee H, DuPont-Reyes MJ et al. Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment. CA: A Cancer Journal for Clinicians. 2017 May 6;67(3):194-232.
- Block K, Gyllenhall C et al. Survival impact of integrative cancer care in advanced metastatic breast cancer. The Breast Journal. 2009 Jul/Aug;15(4):357-366.
- Alschuler LN, Gazella KA. The Definitive Guide to Cancer, 3rd Edition: An Integrative Approach to Prevention, Treatment, and Healing. Berkeley, California: Celestial Arts. 2010; Alschuler LN, Gazella KA. The Definitive Guide to Thriving after Cancer. Berkeley, California: Ten Speed Press. 2013.
- Block KI. Life Over Cancer: The Block Center Program for Integrative Cancer Treatment. New York: Bantam Dell. 2009.
- Chang R. Beyond the Magic Bullet: The Anti-Cancer Cocktail. New York: Square One Publishers. 2012.
- Cohen L, Jefferies A. Anticancer Living: Transform Your Life and Health with the Mix of Six. New York: Viking. 2018.
- Lemole G, Mehta P, McKee D. After Cancer Care: The Definitive Self-Care Guide to Getting and Staying Well for Patients with Cancer. New York, New York: Rodale, Inc. 2015.
- MacDonald B. The Breast Cancer Companion: A Complementary Care Manual: Third Edition. 2016.
- McKinney N. Naturopathic Oncology, 3rd Edition. Victoria, BC, Canada: Liaison Press. 2016.
- Tripathy D. Chapter 21: Integrative Medicine and Breast Cancer. In Abrams DI, Weil AT. Integrative Oncology, 2nd Edition. New York, NY: Oxford University Press. 2014.
- Rugo H, Shtivelman E et al. Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancer. Breast Cancer Research and Treatment. 2007 Sep;105(1):17-28.
- Zhang M, Liu X, Li J, He L, Tripathy D. Chinese medicinal herbs to treat the side-effects of chemotherapy in breast cancer patients. Cochrane Database of Systematic Reviews. 2007. 2, CD004921.
- Sinha D, Biswas J, Nabavi SM, Bishayee A. Tea phytochemicals for breast cancer prevention and intervention: from bench to bedside and beyond. Seminars in Cancer Biology. 2017 Oct;46:33-54; Xiang LP, Wang A et al. Suppressive effects of tea catechins on breast cancer. Nutrients. 2016 Jul 28;8(8). pii: E458; Sun CL, Yuan JM, Koh WP, Yu MC. Green tea, black tea and breast cancer risk: a meta-analysis of epidemiological studies. Carcinogenesis. 2006 Jul;27(7):1310-5.
- Royston KJ, Paul B, Nozell S, Rajbhandari R, Tollefsbol TO. Withaferin A and sulforaphane regulate breast cancer cell cycle progression through epigenetic mechanisms. Experimental Cell Research. 2018 Jul 1;368(1):67-74.
- Tripathy D. Chapter 21: Integrative Medicine and Breast Cancer in Abrams DI, Weil AT. Integrative Oncology, 2nd Edition. New York, NY: Oxford University Press. 2014.
- Block K, Gyllenhall C et al. Survival impact of integrative cancer care in advanced metastatic breast cancer. The Breast Journal. 2009 Jul/Aug;15(4):357-366.
- Block K, Gyllenhall C et al. Survival impact of integrative cancer care in advanced metastatic breast cancer. The Breast Journal. 2009 Jul/Aug;15(4):357-366.
- Block K, Gyllenhall C et al. Survival impact of integrative cancer care in advanced metastatic breast cancer. The Breast Journal. 2009 Jul/Aug;15(4):357-366.
- McKinney N. Naturopathic Oncology, 3rd Edition. Victoria, BC, Canada: Liaison Press. 2016.
- Standish LJ, Dowd F et al. Breast cancer integrative oncology care and its costs. Integrative Cancer Therapies. 2017 Mar;16(1):85-95.
- Leanna Standish, ND. Email communication, September 29, 2018.
- Kleef R, Moss R et al. Complete clinical remission of stage IV triple-negative breast cancer lung metastasis administering low-dose immune checkpoint blockade in combination with hyperthermia and interleukin-2. Integrative Cancer Therapies. 2018 Sep 7:1534735418794867.
- Schettler T. The Ecology of Breast Cancer: The Promise of Prevention and the Hope for Healing. Science and Environmental Health Network and The Collaborative on Health and the Environment. October 2013. p. 167.
- Pierce JP, Stefanick ML et al. Greater survival after breast cancer in physically active women with high vegetable-fruit intake regardless of obesity. Journal of Clinical Oncology. 2007 Jun;25(17):2345–2351.
- Pierce JP, Stefanick ML et al. Greater survival after breast cancer in physically active women with high vegetable-fruit intake regardless of obesity. Journal of Clinical Oncology. 2007 Jun 10;25(17):2345-51.
- Servan-Schreiber D. Anticancer: A New Way of Life. New York: Penguin Group. 2008.
- Huerta-Yépez S, Tirado-Rodriguez AB, Hankinson O. Role of diets rich in omega-3 and omega-6 in the development of cancer. Boletín Médico del Hospital Infantil de México. 2016 Nov - Dec;73(6):446-456.
- Schettler T. The Ecology of Breast Cancer: The Promise of Prevention and the Hope for Healing. Science and Environmental Health Network and The Collaborative on Health and the Environment. October 2013.
- Harvard Health Letter. Confused about eating soy? Harvard Health Publishing. March 2018. Viewed May 29, 2019.
- Osterweil N. Diabetes prevention diet may lower mortality risk in breast cancer. Medscape Oncology. December 10, 2020. Viewed December 14, 2020; Wang T, Farvid M et al. Publication Number: GS2-09. Diabetes risk reduction diet and survival following breast cancer. 2020 San Antonio Breast Cancer Symposium. Viewed December 14, 2020.
- Koyratty N, McCann SE et al. Sugar-sweetened soda consumption and total and breast cancer mortality: the Western New York Exposures and Breast Cancer (WEB) Study. Cancer Epidemiology, Biomarkers & Prevention. 2021 Mar 2:cebp.1242.2020.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Care. New York: Bantam Dell. 2009.
- Tripathy D. Chapter 21: Integrative Medicine and Breast Cancer. In Abrams DI, Weil AT. Integrative Oncology, 2nd Edition. New York, NY: Oxford University Press. 2014.
- Chlebowski RT, Aragaki AK et al. Dietary modification and breast cancer mortality: long-term follow-up of the Women's Health Initiative randomized trial. Journal of Clinical Oncology. 2020;38(13):1419‐1428.
- Pierce JP, Stefanick ML et al. Greater survival after breast cancer in physically active women with high vegetable-fruit intake regardless of obesity. Journal of Clinical Oncology. 2007 Jun;25(17):2345–2351.
- Kojima R, Okada E et al. Dietary patterns and breast cancer risk in a prospective Japanese study. Breast Cancer (Tokyo, Japan). 2017 Jan;24(1):152-160.
- Pierce JP. Diet and breast cancer prognosis: making sense of the Women's Healthy Eating and Living and Women's Intervention Nutrition Study trials. Current Opinion in Obstetrics & Gynecology. 2009 Feb;21(1):86-91.
- Magee PJ, Rowland I. Soy products in the management of breast cancer. Current Opinion in Clinical Nutrition and Metabolic Care. 2012 Nov;15(6):586-91.
- Varinska L, Gal P, Mojzisova G, Mirossay L, Mojzis J. Soy and breast cancer: focus on angiogenesis. International Journal of Molecular Sciences. 2015 May 22;16(5):11728-49.
- Nechuta SJ, Caan BJ et al. Soy food intake after diagnosis of breast cancer and survival: an in-depth analysis of combined evidence from cohort studies of US and Chinese women. American Journal of Clinical Nutrition. 2012 Jul;96(1):123-32.
- Zhang FF, Haslam DE et al. Dietary isoflavone intake and all-cause mortality in breast cancer survivors: the Breast Cancer Family Registry. Cancer. 2017 Jun 1;123(11):2070-2079; Chi F, Wu R, Zeng YC, Xing R, Liu Y, Xu ZG. Post-diagnosis soy food intake and breast cancer survival: a meta-analysis of cohort studies. Asian Pacific Journal of Cancer Prevention. 2013;14(4):2407-12; Caan BJ, Natarajan L et al. Soy food consumption and breast cancer prognosis. Cancer Epidemiology, Biomarkers & Prevention. 2011 May;20(5):854-8.
- Patterson RE, Flatt SW et al. Marine fatty acid intake is associated with breast cancer prognosis. Journal of Nutrition. 2011 Feb;141(2):201-6.
- Knott SRV, Wagenblast E et al. Asparagine bioavailability governs metastasis in a model of breast cancer [published correction appears in Nature. 2018 Apr 4;556(7699):135]. Nature. 2018;554(7692):378‐381.
- Cedars-Sinai Medical Center. Diet may influence the spread of a deadly type of breast cancer, study finds. Medical Xpress. February 7, 2018. Viewed June 8, 2020.
- Prentice RL, Aragaki AK et al. Low-fat dietary pattern among postmenopausal women influences long-term cancer, cardiovascular disease, and diabetes outcomes. Journal of Nutrition. 2019 Jun 8. pii: nxz107.
- Cheblowski RT, Blackburn GL et al. Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study. Journal of the National Cancer Institute. 2006 Dec 20;98(24):1767-76.
- Baena Ruiz R, Salinas Hernández P. Cancer chemoprevention by dietary phytochemicals: epidemiological evidence. Maturitas. 2016 Dec;94:13-19; Higdon JV, Delage B, Williams DE, Dashwood RH. Cruciferous vegetables and human cancer risk: epidemiologic evidence and mechanistic basis. Pharmacological Research. 2007 Mar;55(3):224-36.
- Karimi Z, Bahadoran Z et al. Dietary total antioxidant capacity and the risk of breast cancer: a case-control study. Eastern Mediterranean Health Journal. 2015 Sep 28;21(8):564-71.
- Pierce JP, Natarajan L et al. Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women’s Healthy Eating and Living (WHEL) randomized trial. Journal of the American Medical Association. 2007;298(3):289–98.
- Dieli-Conwright CM, Lee K, Kiwata JL. Reducing the risk of breast cancer recurrence: an evaluation of the effects and mechanisms of diet and exercise. Current Breast Cancer Reports. 2016;8(3):139-150.
- Dieli-Conwright CM, Lee K, Kiwata JL. Reducing the risk of breast cancer recurrence: an evaluation of the effects and mechanisms of diet and exercise. Current Breast Cancer Reports. 2016;8(3):139-150.
- Caan BJ, Kwan ML et al. Weight change and survival after breast cancer in the after breast cancer pooling project. Cancer Epidemiology, Biomarkers & Prevention. 2012 Aug;21(8):1260-71.
- Gold EB, Pierce JP et al. Dietary pattern influences breast cancer prognosis in women without hot flashes: the Women’s Healthy Eating and Living Trial. Journal of Clinical Oncology. 2009 Jan 20;27(3):352–359.
- Dieli-Conwright CM, Lee K, Kiwata JL. Reducing the risk of breast cancer recurrence: an evaluation of the effects and mechanisms of diet and exercise. Current Breast Cancer Reports. 2016;8(3):139-150.
- Toniolo P, Van Kappel AL et al. Serum carotenoids and breast cancer. American Journal of Epidemiology. 2001 Jun 15;153(12):1142-7.
- Baena Ruiz R, Salinas Hernández P. Cancer chemoprevention by dietary phytochemicals: epidemiological evidence. Maturitas. 2016 Dec;94:13-19.
- Bae JM. Reinterpretation of the results of a pooled analysis of dietary carotenoid intake and breast cancer risk by using the interval collapsing method. Epidemiology and Health. 2016 Jun 2;38:e2016024.
- Nagel G, Linseisen J et al. Dietary beta-carotene, vitamin C and E intake and breast cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). Breast Cancer Research and Treatment. 2010 Feb;119(3):753-65.
- Fabian CJ, Kimler BF, Hursting SD. Omega-3 fatty acids for breast cancer prevention and survivorship. Breast Cancer Research. 2015 May 4;17:62.
- Patterson RE, Flatt SW et al. Marine fatty acid intake is associated with breast cancer prognosis. Journal of Nutrition. 2011 Feb;141(2):201-6.
- Aceves C, Anguiano B, Delgado G. Is iodine a gatekeeper of the integrity of the mammary gland? Journal of Mammary Gland Biology and Neoplasia. 2005;10(2):189–196.
- Shin MH, Holmes MD et al. Intake of dairy products, calcium, and vitamin D and risk of breast cancer. Journal of the National Cancer Institute. 2002 Sep 4;94(17):1301-11.
- Wang J, John EM, Horn-Ross PL, Ingles SA. Dietary fat, cooking fat, and breast cancer risk in a multiethnic population. Nutrition and Cancer. 2008;60(4):492-504; Dhaka V, Gulia N, Ahlawat KS, Khatkar BS. Trans fats-sources, health risks and alternative approach—a review. Journal of Food Science and Technology. 2011 Oct;48(5):534-41.
- de Souza RJ, Mente A et al. Intake of saturated and trans unsaturated fatty acids and risk of all cause mortality, cardiovascular disease, and type 2 diabetes: systematic review and meta-analysis of observational studies. BMJ. 2015 Aug 11;351:h3978.
- Schettler T. The Ecology of Breast Cancer: The Promise of Prevention and the Hope for Healing. Science and Environmental Health Network and The Collaborative on Health and the Environment. October 2013. p. 40.
- Yasuda MT, Sakakibara H, Shimoi K. Estrogen- and stress-induced DNA damage in breast cancer and chemoprevention with dietary flavonoid. Genes and Environment. 2017 Feb 1;39:10.
- Xiang LP, Wang A et al. Suppressive effects of tea catechins on breast cancer. Nutrients. 2016 Jul 28;8(8). pii: E458.
- Wu AH, Koh WP, Wang R, Lee HP, Yu MC. Soy intake and breast cancer risk in Singapore Chinese Health Study. British Journal of Cancer. 2008 Jul 8;99(1):196-200; Wu AH, Wan P, Hankin J, Tseng CC, Yu MC, Pike MC. Adolescent and adult soy intake and risk of breast cancer in Asian-Americans. Carcinogenesis. 2002 Sep;23(9):1491-6; Wu AH, Yu MC, Tseng CC, Pike MC. Epidemiology of soy exposures and breast cancer risk. British Journal of Cancer. 2008 Jan 15;98(1):9-14.
- Nechuta SJ, Caan BJ et al. Soy food intake after diagnosis of breast cancer and survival: an in-depth analysis of combined evidence from cohort studies of US and Chinese women. American Journal of Clinical Nutrition. 2012 Jul;96(1):123-32.
- Guha N, Kwan ML et al. Soy isoflavones and risk of cancer recurrence in a cohort of breast cancer survivors: the Life After Cancer Epidemiology study. Breast Cancer Research and Treatment. 2009 Nov;118(2):395-405; Nechuta SJ, Caan BJ et al. Soy food intake after diagnosis of breast cancer and survival: an in-depth analysis of combined evidence from cohort studies of US and Chinese women. American Journal of Clinical Nutrition. 2012 Jul;96(1):123-32; Messina M, Caan BJ, Abrams DI, Hardy M, Maskarinec G. It's time for clinicians to reconsider their proscription against the use of soyfoods by breast cancer patients. Oncology (Williston Park). 2013 May;27(5):430-7.
- Woo HD, Park KS, Ro J, Kim J. Differential influence of dietary soy intake on the risk of breast cancer recurrence related to HER2 status. Nutrition and Cancer. 2012;64(2):198-205.
- Shike M, Doane AS et al. The effects of soy supplementation on gene expression in breast cancer: a randomized placebo-controlled study. Journal of the National Cancer Institute. 2014 Sep 4;106(9).
- Moussavou G, Kwak DH et al. Anticancer effects of different seaweeds on human colon and breast cancers. Marine Drugs. 2014 Sep 24;12(9):4898-911.
- Rossi P, Difrancia R et al. B-glucans from Grifola frondosa and Ganoderma lucidum in breast cancer: an example of complementary and integrative medicine. Oncotarget. 2018 May 15;9(37):24837-24856.
- Cos P, De Bruyne T et al. Proanthocyanidins in health care: current and new trends. Current Medicinal Chemistry. 2004 May;11(10):1345-59.
- Cazzaniga M, Bonanni B. Relationship between metabolic disorders and breast cancer incidence and outcomes. Is there a preventive and therapeutic role for berberine? Anticancer Research. 2018 Aug;38(8):4393-4402.
- Westphal T, Rinnerthaler G et al. Supervised versus autonomous exercise training in breast cancer patients: a multicenter randomized clinical trial. Cancer Medicine. 2018 Dec;7(12):5962-5972.
- Kirkham AA, Bland KA et al. "Chemotherapy-periodized" exercise to accommodate for cyclical variation in fatigue.
- Schettler T. The Ecology of Breast Cancer: The Promise of Prevention and the Hope for Healing. Science and Environmental Health Network and The Collaborative on Health and the Environment. October 2013. p. 73.
- Holmes MD, Chen WY, Feskanich D, Kroenke CH, Colditz GA. Physical activity and survival after breast cancer diagnosis. JAMA. 2005 May 25;293(20):2479-86; Cannioto RA, Hutson A et al. Physical activity before, during and after chemotherapy for high-risk breast cancer: relationships with survival. Journal of the National Cancer Institute. 2020;djaa046.
- Beasley JM, Kwan ML Meeting the physical activity guidelines and survival after breast cancer: findings from the after breast cancer pooling project. Breast Cancer Research and Treatment. 2012 Jan;131(2):637-43.
- Harvard Women's Health Watch. MET-hour equivalents of various physical activities. Harvard Health Publishing. December 2009. Viewed February 27, 2019.
- Nelson SH, Marinac CR et al. Impact of very low physical activity, BMI, and comorbidities on mortality among breast cancer survivors. Breast Cancer Research and Treatment. 2016 Feb;155(3):551-7.
- Courneya KS, Segal RJ et al. Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial. Journal of Clinical Oncology. 2007 Oct 1;25(28):4396-404.
- Serra MC, Ryan AS, Ortmeyer HK, Addison O, Goldberg AP. Resistance training reduces inflammation and fatigue and improves physical function in older breast cancer survivors. Menopause. 2018 Feb;25(2):211-216; Meneses-Echávez JF, González-Jiménez E, Ramírez-Vélez R. Effects of supervised exercise on cancer-related fatigue in breast cancer survivors: a systematic review and meta-analysis. BMC Cancer. 2015 Feb 21;15:77.
- Mutrie N, Campbell A, Barry S, Hefferon K, et al. Five-year follow-up of participants in a randomized controlled trial showing benefits from exercise for breast cancer survivors during adjuvant treatment. Are there lasting effects? Journal of Cancer Survivorship. 2012; Jul 27.
- Ligibel J. Lifestyle factors in cancer survivorship. Journal of Clinical Oncology. 2012 Oct 20;30(30):3697-704.
- Sánchez-Lastra MA, Torres J, Martínez-Lemos I, Ayán C. Nordic walking for women with breast cancer: a systematic review. European Journal of Cancer Care (Engl). 2019 Aug 6:e13130.
- Chan RJ, McCarthy AL, Devenish J, Sullivan KA, Chan A. Systematic review of pharmacologic and non-pharmacologic interventions to manage cognitive alterations after chemotherapy for breast cancer. European Journal of Cancer. 2015 Mar;51(4):437-50.
- Okwuosa TM, Ray RM et al. Pre-diagnosis exercise and cardiovascular events in primary breast cancer. Journal of the American College of Cardiology: CardioOncology. 2019 Sep, 1 (1) 41-50.
- Uth J, Fristrup B et al. One year of Football Fitness improves L1–L4 BMD, postural balance, and muscle strength in women treated for breast cancer. Scandinavian Journal of Medicine & Science in Sports. 2021 Apr 1.
- Schettler T. The Ecology of Breast Cancer: The Promise of Prevention and the Hope for Healing. Science and Environmental Health Network and The Collaborative on Health and the Environment. October 2013. p. 173.
- Rice MS, Eliassen AH et al. Breast cancer research in the Nurses' Health Studies: exposures across the life course. American Journal of Public Health. 2016 Sep;106(9):1592-8.
- Cannioto RA, Hutson A et al. Physical activity before, during and after chemotherapy for high-risk breast cancer: relationships with survival. Journal of the National Cancer Institute. 2020;djaa046.
- Matthews CE, Moore SC et al. Amount and intensity of leisure-time physical activity and lower cancer risk. Journal of Clinical Oncology. 2019 Dec 26:JCO1902407.
- Albanes D, Blair A, Taylor P. Physical activity and risk of cancer in the NHANES I population. American Journal of Public Health. 1989; 79(6): 744-750.
- Al Ajmi K, Lophatananon A, Mekli K, Ollier W, Muir KR. Association of nongenetic factors with breast cancer risk in genetically predisposed groups of women in the UK Biobank Cohort. JAMA Network Open. 2020;3(4):e203760.
- Ligibel JA, Dillon D et al. Impact of a pre-operative exercise intervention on breast cancer proliferation and gene expression: results from the Pre-Operative Health and Body (PreHAB) study. Clinical Cancer Research. 2019 Sep 1;25(17):5398-5406.
- Schettler T. The Ecology of Breast Cancer: The Promise of Prevention and the Hope for Healing. Science and Environmental Health Network and The Collaborative on Health and the Environment. October 2013.
- Schettler T. The Ecology of Breast Cancer: The Promise of Prevention and the Hope for Healing. Science and Environmental Health Network and The Collaborative on Health and the Environment. October 2013. p. 186.
- Li W, Kwok CC et al. Disruption of sleep, sleep-wake activity rhythm, and nocturnal melatonin production in breast cancer patients undergoing adjuvant chemotherapy: prospective cohort study. Sleep Medicine. 2018 Dec 14;55:14-21.
- Ancoli-Israel S, Liu L et al. Fatigue, sleep, and circadian rhythms prior to chemotherapy for breast cancer. Supportive Care in Cancer. 2006 Mar;14(3):201-9.
- Irwin M. Mindful Awareness Practices to Promote Sleep Health: Inflammatory Mechanisms. Keynote Presentation: Society for Integrative Oncology Conference, 2016, Miami, Florida; Irwin MR, Olmstead R et al. Tai chi chih compared with cognitive behavioral therapy for the treatment of insomnia in survivors of breast cancer: a randomized, partially blinded, noninferiority trial. Journal of Clinical Oncology. 2017 Aug 10;35(23):2656-2665; Irwin MR, Olmstead R et al. Tai chi, cellular inflammation, and transcriptome dynamics in breast cancer survivors with insomnia: a randomized controlled trial. Journal of the National Cancer Institute. Monographs. 2014 Nov;2014(50):295-301.
- Dun A, Zhao X et al. Association between night-shift work and cancer risk: updated systematic review and meta-analysis. Frontiers in Oncology. 2020 Jun 23;10:1006.
- He C, Anand ST, Ebell MH, Vena JE, Robb SW. Circadian disrupting exposures and breast cancer risk: a meta-analysis. International Archives of Occupational and Environmental Health. 2015 Jul;88: 533-47; Schernhammer ES, Laden F et al. Rotating night shifts and risk of breast cancer in women participating in the Nurses' Health Study. Journal of the National Cancer Institute. 2001 Oct 17;93(20):1563-8.
- Sephton SE, Sapolsky RM, Kraemer HC, Spiegel D. Diurnal cortisol rhythm as a predictor of breast cancer survival. Journal of the National Cancer Institute. 2000;92(12):994-1000; Andersen BL, Farrar WB et al. Stress and immune responses after surgical treatment for regional breast cancer. Journal of the National Cancer Institute. 1998 Jan 7;90(1):30-6.
- Irwin MR, Olmstead R et al. Tai chi, cellular inflammation, and transcriptome dynamics in breast cancer survivors with insomnia: a randomized controlled trial. Journal of the National Cancer Institute. Monographs. 2014 Nov;2014(50):295-301.
- Pierce JP, Patterson RE et al. Lifetime cigarette smoking and breast cancer prognosis in the After Breast Cancer Pooling Project. Journal of the National Cancer Institute. 2014 Jan;106(1):djt359.
- Schettler T. The Ecology of Breast Cancer: The Promise of Prevention and the Hope for Healing. Science and Environmental Health Network and The Collaborative on Health and the Environment. October 2013. p. 183.
- McKinney N. Naturopathic Oncology, 3rd Edition. Victoria, BC, Canada: Liaison Press. 2016. p. 64-65.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Care. New York: Bantam Dell. 2009. p. 484 and 494.
- Rodgers KM, Udesky JO, Rudel RA, Brody JG. Environmental chemicals and breast cancer: an updated review of epidemiological literature informed by biological mechanisms. Environmental Research. 2018 Jan;160:152-182; Cohn BA, La Merrill M et al. DDT exposure in utero and breast cancer. Journal of Clinical Endocrinology and Metabolism. 2015 Aug;100(8):2865-72; Cohn BA, Cirillo PM, Terry MB. DDT and breast cancer: prospective study of induction time and susceptibility windows. Journal of the National Cancer Institute. 2019 Feb 13.
- Committee on Breast Cancer and the Environment. Breast Cancer and the Environment: A Life Course Approach. Washington, DC: The National Academies Press, 2012.
- ASCO Post Staff. Study clarifies time-dependent effects of oral contraceptives on risk of ovarian, endometrial, and breast cancers. ASCO Post. December 23, 2020. Viewed January 5, 2021; Karlsson T, Johansson T, Höglund J, Ek WE, Johansson Å. Time-dependent effects of oral contraceptive use on breast, ovarian and endometrial cancers. Cancer Research. 2020 Dec 17:canres.2476.2020.
- Hood E. Breast cancer and air pollution linked by new marker. Environmental Factor. November 2020. Viewed November 2, 2020; Niehoff NM, Keil AP et al. Outdoor air pollution and terminal duct lobular involution of the normal breast. Breast Cancer Research. 2020 Sep 24;22(1):100.
- International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. July 30, 2018. Viewed October 5, 2018.
- Schettler T. The Ecology of Breast Cancer: The Promise of Prevention and the Hope for Healing. Science and Environmental Health Network and The Collaborative on Health and the Environment. October 2013. p. 182-183; Bonde J, Hansen J et al. Work at night and breast cancer—report on evidence-based options for preventive actions. Scandinavian Journal of Work, Environment and Health. 2012 Jul;38(4):380-390.
- Morère JF, Viguier J et al. Awareness and misconceptions of breast cancer risk factors among laypersons and physicians. Current Oncology Reports. 2018 Mar 5;20(Suppl 1):15.
- Hiller TWR, O'Sullivan DE, Brenner DR, Peters CE, King WD. Solar ultraviolet radiation and breast cancer risk: a systematic review and meta-analysis. Environmental Health Perspectives. 2020;128(1):16002.
- International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. July 30, 2018. Viewed October 5, 2018.
- Ozdemir D, Tas Arslan F. An investigation of the relationship between social support and coping with stress in women with breast cancer. Psychooncology. 2018 Sep;27(9):2214-2219; Alizadeh S, Khanahmadi S, Vedadhir A, Barjasteh S. The relationship between resilience with self- compassion, social support and sense of belonging in women with breast cancer. Asian Pacific Journal of Cancer Prevention. 2018 Sep 26;19(9):2469-2474.
- Kroenke CH, Michael YL et al. Postdiagnosis social networks and breast cancer mortality in the After Breast Cancer Pooling Project. Cancer. 2017 Apr 1;123(7):1228-1237.
- Spiegel D, Bloom JR, Yalom I. Group support for patients with metastatic cancer: a randomized outcome study. Archives of General Psychiatry. 1981;38:527-533; Goodwin PJ, Leszcz M et al. The effect of group psychosocial support on survival in metastatic breast cancer. New England Journal of Medicine. 2001 Dec 13;345(24):1719-26.
- Watson M, Haviland JS, Greer S, Davidson J, Bliss JM. Influence of psychological response on survival in breast cancer: a population-based cohort study. Lancet. 1999 Oct 16;354(9187):1331-6.
- Cunningham AJ, Edmonds CV, Phillips C, Soots KI, Hedley D. A prospective, longitudinal study of the relationship of psychological work to duration of survival in patients with metastatic cancer. Psychooncology. 2000 Jul-Aug;9(4):323-39.
- Cunningham AJ, Watson K. How psychological therapy may prolong survival in cancer patients: new evidence and a simple theory. Integrative Cancer Therapies; 2004 Sep;3(3):214-29.
- Block KI. Life Over Cancer. New York: Bantam Dell. 2009. p. 215; Iwamitsu Y, Shimoda K et al. The relation between negative emotional suppression and emotional distress in breast cancer diagnosis and treatment. Health Communication. 2005;18(3):201-15.
- Bai M, Lazenby M. A systematic review of associations between spiritual well-being and quality of life at the scale and factor levels in studies among patients with cancer. Journal of Palliative Medicine. 2015 Mar;18(3):286-98.
- Bakker MF, de Lange SV et al. Supplemental MRI screening for women with extremely dense breast tissue. New England Journal of Medicine. 2019 Nov 28;381(22):2091-2102.
- Blondeaux E, Perachino M et al. GS3-09. Chances of pregnancy after breast cancer, reproductive and disease outcomes: a systematic review and meta-analysis. 2020 San Antonio Breast Cancer Symposium. December 10, 2020. Viewed December 18, 2020.
- The ASCO Post Staff. SABCS 2020: meta-analysis of pregnancy outcomes in breast cancer survivors. The ASCO Post December 23, 2020. Viewed February 5, 2021; Blondeaux E, Perachino M et al. Chances of pregnancy after breast cancer, reproductive and disease outcomes: a systematic review and meta-analysis. 2020 San Antonio Breast Cancer Symposium®. Publication Number: GS3-09. Viewed February 5, 2021.
- Wagner LI, Gray RJ et al. Patient-reported cognitive impairment among women with early breast cancer randomly assigned to endocrine therapy alone versus chemoendocrine therapy: results from TAILORx. Journal of Clinical Oncology. 2020;38(17):1875-1886.
- Hanna TP, King WD et al. Mortality due to cancer treatment delay: systematic review and meta-analysis. BMJ. 2020 Nov 4;371:m4087; Reinberg S. Delaying cancer care costs lives. HealthDay. November 5, 2020. Viewed November 8, 2020.
- Kelly CM, Juurlink DN et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ. 2010;340:c693.
- Desmarais JE, Looper KJ. Interactions between tamoxifen and antidepressants via cytochrome P450 2D6. Journal of Clinical Psychiatry. 2009;70(12):1688-1697.
- National Cancer Institute. Hormone Therapy for Breast Cancer. National Institutes of Health. February 14, 2017. Viewed September 2, 2020.
- Thomson CA, Chow HHS et al. A randomized, placebo-controlled trial of diindolylmethane for breast cancer biomarker modulation in patients taking tamoxifen. Breast Cancer Research and Treatment. 2017;165(1):97-107.
- Hussaarts KGAM, Hurkmans DP et al. Impact of curcumin (with or without piperine) on the pharmacokinetics of tamoxifen. Cancers (Basel). 2019;11(3):403.
- Tripathy D. Chapter 21: Integrative Medicine and Breast Cancer in Abrams DI, Weil AT. Integrative Oncology, 2nd Edition. New York, NY: Oxford University Press. 2014.
- Mason JK, Thompson LU. Flaxseed and its lignan and oil components: can they play a role in reducing the risk of and improving the treatment of breast cancer? Applied Physiology, Nutrition, and Metabolism. 2014 Jun;39(6):663-78.
- Flower G, Fritz H et al. Flax and breast cancer: a systematic review. Integrative Cancer Therapies. 2014 May;13(3):181-92.
- Li Y, Li S et al. Melatonin for the prevention and treatment of cancer. Oncotarget. 2017 Jun 13;8(24):39896-39921.
- Li Y, Li S et al. Melatonin for the prevention and treatment of cancer. Oncotarget. 2017 Jun 13;8(24):39896-39921.
- Li Y, Li S et al. Melatonin for the prevention and treatment of cancer. Oncotarget. 2017 Jun 13;8(24):39896-39921.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Treatment. New York: Bantam Dell. 2009.
- Toi M, Hattori T et al. Randomized adjuvant trial to evaluate the addition of tamoxifen and Krestin (PSK)™ to chemotherapy in patients with primary breast cancer. 5-year results from the Nishi-Nippon Group of the Adjuvant Chemoendocrine Therapy for Breast Cancer Organization. Cancer. 1992;70:2475–2483; Eliza WL, Fai CK, Chung LP. Efficacy of Yun Zhi (Coriolus versicolor) on survival in cancer patients: systematic review and meta-analysis. Recent Patents on Inflammation & Allergy Drug Discovery. 2012 Jan;6(1):78-87.
- Iino Y, Yokoe T et al. Immunochemotherapies versus chemotherapy as adjuvant treatment after curative resection of operable breast cancer. Anticancer Research. 1995;15:2907–2911; Yokoe T, Iino Y et al. HLA antigen as predictive index for the outcome of breast cancer patients with adjuvant immunochemotherapy with PSK. Anticancer Research. 1997;17:2815–2818.
- National Cancer Institute. Medicinal Mushrooms (PDQ®)–Health Professional Version: Turkey Tail and Polysaccharide-K. October 6, 2017. Viewed February 28, 2018.
- National Cancer Institute. Medicinal Mushrooms (PDQ®)–Health Professional Version: Turkey Tail and Polysaccharide-K. October 6, 2017. Viewed February 28, 2018.
- National Cancer Institute. Medicinal Mushrooms (PDQ®)–Health Professional Version: Turkey Tail and Polysaccharide-K. October 6, 2017. Viewed February 28, 2018.
- Chiba A, Raman R et al. Serum vitamin D levels affect pathologic complete response in patients undergoing neoadjuvant systemic therapy for operable breast cancer. Clinics in Breast Cancer. 2017 Dec 11. pii: S1526-8209(17)30324-5.
- NCI Staff. Vitamin D deficiency may promote spread of some breast cancers. National Cancer Institute. April 14, 2016. Viewed November 30, 2017.
- Kim Y, Je Y. Vitamin D intake, blood 25(OH)D levels, and breast cancer risk or mortality: a meta-analysis. British Journal of Cancer. 2014 May 27;110(11):2772-84; Li M, Chen P et al. Review: the impacts of circulating 25-hydroxyvitamin D levels on cancer patient outcomes: a systematic review and meta-analysis. Journal of Clinical Endocrinology and Metabolism. 2014 Jul;99(7):2327-36; Yao S, Sheng H et al. Clinically sufficient vitamin D levels at breast cancer diagnosis and survival outcomes in a prospective cohort of 3,995 patients after a median follow-up of 10 years. Poster presentation at the ASCO 2021 Annual Meeting. Viewed June 15, 2021.
- Griffin N, Dowling M. Vitamin D supplementation and clinical outcomes in cancer survivorship. British Journal of Nursing. 2018 Oct 18;27(19):1121-1128.
- Shahvegharasl Z, Pirouzpanah S et al. Effects of cholecalciferol supplementation on serum angiogenic biomarkers in breast cancer patients treated with tamoxifen: a controlled randomized clinical trial. Nutrition. 2020;72:110656.
- Zhu L, Li L, Li Y, Wang J, Wang Q. Chinese herbal medicine as an adjunctive therapy for breast cancer: a systematic review and meta-analysis. Evidence-based Complementary and Alternative Medicine. 2016;2016:9469276.
- Yu R, Wu X, Jia L, Lou Y. Effect of Chinese herbal compound LC09 on patients with capecitabine-associated hand-foot syndrome: a randomized, double-blind, and parallel-controlled trial. Integrative Cancer Therapies. Jan-Dec 2020;19:1534735420928466.
- Chu Z, Wang Z, Liu T, Xiong S, Liu B. Evaluation of the effects of astragalus membranaceus on the pharmacokinetics of pemetrexed disodium and gemcitabine in rats by a simple high-performance liquid chromatography/UV method. Journal of Analytical Methods in Chemistry. 2019 Apr 28;2019:3162426.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Treatment. New York: Bantam Dell. 2009.
- Cui Y, Shu XO et al. Association of ginseng use with survival and quality of life among breast cancer patients. American Journal of Epidemiology. 2006 Apr 1;163(7):645-53.
- MacDonald B. The Breast Cancer Companion: A Complementary Care Manual: Third Edition. 2016.
- Rossi P, Difrancia R et al. B-glucans from Grifola frondosa and Ganoderma lucidum in breast cancer: an example of complementary and integrative medicine. Oncotarget. 2018 May 15;9(37):24837-24856.
- Rossi P, Difrancia R et al. B-glucans from Grifola frondosa and Ganoderma lucidum in breast cancer: an example of complementary and integrative medicine. Oncotarget. 2018 May 15;9(37):24837-24856.
- Alschuler LN, Gazella KA. The Definitive Guide to Cancer, 3rd Edition: An Integrative Approach to Prevention, Treatment, and Healing. Berkeley, California: Celestial Arts. 2010; Alschuler LN, Gazella KA. The Definitive Guide to Thriving after Cancer. Berkeley, California: Ten Speed Press. 2013.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Treatment. New York: Bantam Dell. 2009.
- MacDonald B. The Breast Cancer Companion: A Complementary Care Manual: Third Edition. 2016.
- Fabian CJ, Kimler BF, Hursting SD. Omega-3 fatty acids for breast cancer prevention and survivorship. Breast Cancer Research. 2015 May 4;17:62.
- Daenen LG, Cirkel GA et al. Increased plasma levels of chemoresistance-inducing fatty acid 16:4(n-3) after consumption of fish and fish oil. JAMA Oncology. 2015 Jun;1(3):350-8.
- Bougnoux P, Hajjaji N et al. Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial. British Journal of Cancer. 2009 Dec 15;101(12):1978-85.
- VanderSluis L, Mazurak VC, Damaraju S, Field CJ. Determination of the relative efficacy of eicosapentaenoic acid and docosahexaenoic acid for anti-cancer effects in human breast cancer models. International Journal of Moleculat Sciences. 2017 Dec 4;18(12). pii: E2607.
- MacDonald B. The Breast Cancer Companion: A Complementary Care Manual: Third Edition. 2016.
- Harris HR, Orsini N, Wolk A. Vitamin C and survival among women with breast cancer: a meta-analysis. European Journal of Cancer. 2014 May;50(7):1223-31.
- Kim KN, Pie JE et al. Retinoic acid and ascorbic acid act synergistically in inhibiting human breast cancer cell proliferation. Journal of Nutritional Biochemistry. 2006 Jul;17(7):454-62.
- Lee SJ, Jeong JH et al. Effect of high-dose vitamin C combined with anti-cancer treatment on breast cancer cells. Anticancer Research. 2019 Feb;39(2):751-758.
- Ramezankhani B, Taha MF, Javeri A. Vitamin C counteracts miR-302/367-induced reprogramming of human breast cancer cells and restores their invasive and proliferative capacity. Journal of Cellular Physiology. 2019 Mar;234(3):2672-2682.
- Fritz H, Flower G et al. Intravenous vitamin C and cancer: a systematic review. Integrative Cancer Therapies. 2014 Jul;13(4):280-300.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Treatment. New York: Bantam Dell. 2009.
- Poole EM, Shu X et al. Postdiagnosis supplement use and breast cancer prognosis in the After Breast Cancer Pooling Project. Breast Cancer Research and Treatment. 2013 Jun;139(2):529-37.
- Ambrosone CB, Zirpoli GR et al. Dietary supplement use during chemotherapy and survival outcomes of patients with breast cancer enrolled in a cooperative group clinical trial (SWOG S0221). Journal of Clinical Oncology. 2019 Dec 19:JCO1901203.
- Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database of Systematic Reviews. 2012 Mar 14;(3):CD007176.
- Tripathy D. Chapter 21: Integrative Medicine and Breast Cancer. In Abrams DI, Weil AT. Integrative Oncology, 2nd Edition. New York, NY: Oxford University Press. 2014.
- Lockwood K, Moesgaard S, Yamamoto T, Folkers K. Progress on therapy of breast cancer with vitamin Q10 and the regression of metastases. Biochemical and Biophysical Research Communications. 1995 Jul 6;212(1):172-7.
- Brooks SL, Rowan G, Michael M. Potential issues with complementary medicines commonly used in the cancer population: a retrospective review of a tertiary cancer center's experience. Asia-Pacific Journal of Clinical Oncology. 2018 Jun 22.
- Alschuler LN, Gazella KA. The Definitive Guide to Cancer, 3rd Edition: An Integrative Approach to Prevention, Treatment, and Healing. Berkeley, California: Celestial Arts. 2010.
- Chang R. Beyond the Magic Bullet: The Anti-Cancer Cocktail. New York: Square One Publishers. 2012.
- Alschuler LN, Gazella KA. The Definitive Guide to Cancer, 3rd Edition: An Integrative Approach to Prevention, Treatment, and Healing. Berkeley, California: Celestial Arts. 2010; Alschuler LN, Gazella KA. The Definitive Guide to Thriving after Cancer. Berkeley, California: Ten Speed Press. 2013.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Treatment. New York: Bantam Dell. 2009.
- MacDonald B. The Breast Cancer Companion: A Complementary Care Manual: Third Edition. 2016.
- McKinney N. Naturopathic Oncology, 3rd Edition. Victoria, BC, Canada: Liaison Press. 2016.
- Lemanne D, Maizes V. Advising women undergoing treatment for breast cancer: a narrative review. Journal of Alternative and Complementary Medicine. 2018 Sep/Oct;24(9-10):902-909.
- Firestone GL, Bjeldanes LF. Indole-3-carbinol and 3-3'-diindolylmethane antiproliferative signaling pathways control cell-cycle gene transcription in human breast cancer cells by regulating promoter-Sp1 transcription factor interactions. Journal of Nutrition. 2003 Jul;133(7 Suppl):2448S-2455S.
- Lee GA, Hwang KA, Choi KC. Inhibitory effects of 3,3'-diindolylmethane on epithelial-mesenchymal transition induced by endocrine disrupting chemicals in cellular and xenograft mouse models of breast cancer. Food and Chemical Toxicology. 2017 Nov;109(Pt 1):284-295.
- Thomson CA, Chow HHS et al. A randomized, placebo-controlled trial of diindolylmethane for breast cancer biomarker modulation in patients taking tamoxifen. Breast Cancer Research and Treatment. 2017 Aug;165(1):97-107.
- Chang R. Beyond the Magic Bullet: The Anti-Cancer Cocktail. New York: Square One Publishers. 2012.
- Moreno-Vega A, Vega-Riveroll L et al. Adjuvant effect of molecular iodine in conventional chemotherapy for breast cancer. randomized pilot study. Nutrients. 2019 Jul 17;11(7). pii: E1623.
- Mendieta I, Nuñez-Anita RE et al. Molecular iodine exerts antineoplastic effects by diminishing proliferation and invasive potential and activating the immune response in mammary cancer xenografts. BMC Cancer. 2019 Mar 22;19(1):261.
- Marvibaigi M, Supriyanto E, Amini N, Abdul Majid FA, Jaganathan SK. Preclinical and clinical effects of mistletoe against breast cancer. Biomed Research International. 2014;2014:785479.
- Jin X, Ruiz Beguerie J, Sze DM, Chan GC. Ganoderma lucidum (reishi mushroom) for cancer treatment. Cochrane Database of Systematic Reviews. 2016 Apr 5;4:CD007731; Rossi P, Difrancia R et al. B-glucans from Grifola frondosa and Ganoderma lucidum in breast cancer: an example of complementary and integrative medicine. Oncotarget. 2018 May 15;9(37):24837-24856.
- Wanmuang H, Leopairut J, Kositchaiwat C, Wananukul W, Bunyaratvej S. Fatal fulminant hepatitis associated with Ganoderma lucidum (Lingzhi) mushroom powder. Journal of the Medical Association of Thailand. 2007 Jan;90(1):179-81.
- Barbieri A, Quagliariello V et al. Anticancer and anti-inflammatory properties of Ganoderma lucidum extract effects on melanoma and triple-negative breast cancer treatment. Nutrients. 2017 Feb 28;9(3). pii: E210; Suarez-Arroyo IJ, Rosario-Acevedo R et al. Anti-tumor effects of Ganoderma lucidum (reishi) in inflammatory breast cancer in in vivo and in vitro models. PLoS One. 2013;8(2):e57431; Zhang Y. Ganoderma lucidum (Reishi) suppresses proliferation and migration of breast cancer cells via inhibiting Wnt/β-catenin signaling. Biochemical and Biophysical Research Communications. 2017 Jul 8;488(4):679-684; Weng CJ, Yen GC. The in vitro and in vivo experimental evidences disclose the chemopreventive effects of Ganoderma lucidum on cancer invasion and metastasis. Clinical and Experimental Metastasis. 2010 May;27(5):361-9.
- Gill SK, Rieder MJ. Toxicity of a traditional Chinese medicine, Ganoderma lucidum, in children with cancer. Canadian Journal of Clinical Pharmacology. 2008 Summer;15(2):e275-85.
- Alschuler LN, Gazella KA. The Definitive Guide to Cancer, 3rd Edition: An Integrative Approach to Prevention, Treatment, and Healing. Berkeley, California: Celestial Arts. 2010; Alschuler LN, Gazella KA. The Definitive Guide to Thriving after Cancer: A Five-Step Integrative Plan to Reduce the Risk of Recurrence and Build Lifelong Health. Berkeley, California: Ten Speed Press. 2013.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Treatment. New York: Bantam Dell. 2009.
- MacDonald B. The Breast Cancer Companion: A Complementary Care Manual: Third Edition. 2016.
- Miller ER 3rd, Pastor-Barriuso R et al. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Annals of Internal Medicine. 2005 Jan 4;142(1):37-46.
- Curtis AJ, Bullen M, Piccenna L, McNeil JJ. Vitamin E supplementation and mortality in healthy people: a meta-analysis of randomised controlled trials. Cardiovascular Drugs and Therapy. 2014 Dec;28(6):563-73.
- Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database of Systematic Reviews. 2012 Mar 14;(3):CD007176.
- Jiang Q. Natural forms of vitamin E and metabolites-regulation of cancer cell death and underlying mechanisms. IUBMB Life. 2018 Dec 11.
- Alschuler LN, Gazella KA. The Definitive Guide to Cancer, 3rd Edition: An Integrative Approach to Prevention, Treatment, and Healing. Berkeley, California: Celestial Arts. 2010; Alschuler LN, Gazella KA. The Definitive Guide to Thriving after Cancer. Berkeley, California: Ten Speed Press. 2013.
- MacDonald B. The Breast Cancer Companion: A Complementary Care Manual: Third Edition. 2016.
- Kiely M, Hodgins SJ et al. Real-time cell analysis of the inhibitory effect of vitamin K2 on adhesion and proliferation of breast cancer cells. Nutrition Research. 2015 Aug;35(8):736-43.
- Juanola-Falgarona M, Salas-Salvadó J et al. Dietary intake of vitamin K is inversely associated with mortality risk. Journal of Nutr. 2014 May;144(5):743-50.
- Zwakenberg SR, den Braver NR et al. Vitamin K intake and all-cause and cause specific mortality. Clinical Nutrition. 2017 Oct;36(5):1294-1300.
- Yeend T, Robinson K, Lockwood C, McArthur A. The effectiveness of fermented wheat germ extract as an adjunct therapy in the treatment of cancer: a systematic review. JBI Library of Systematic Reviews. 2012;10(42 Suppl):1-12.
- Marcsek Z, Kocsis Z, Jakab M, Szende B, Tompa A. The efficacy of tamoxifen in estrogen receptor-positive breast cancer cells is enhanced by a medical nutriment. Cancer Biother Radiopharm. 2004 Dec;19(6):746-53.
- Marcsek Z, Kocsis Z, Jakab M, Szende B, Tompa A. The efficacy of tamoxifen in estrogen receptor-positive breast cancer cells is enhanced by a medical nutriment. Cancer Biotherapy & Radiopharmaceuticals. 2004 Dec;19(6):746-53.
- Alschuler LN, Gazella KA. The Definitive Guide to Cancer, 3rd Edition: An Integrative Approach to Prevention, Treatment, and Healing. Berkeley, California: Celestial Arts. 2010; Alschuler LN, Gazella KA. The Definitive Guide to Thriving after Cancer. Berkeley, California: Ten Speed Press. 2013.
- Lee YR, Chen M et al. Reactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitory pathway. Science. 2019 May 17;364(6441). pii: eaau0159.
- Khan M, Maryam A, Mehmood T, Zhang Y, Ma T. Enhancing activity of anticancer drugs in multidrug resistant tumors by modulating p-glycoprotein through dietary nutraceuticals. Asian Pacific Journal of Cancer Prevention. 2015;16(16):6831-9.
- Hajra S, Patra AR, Basu A, Saha P, Bhattacharya S. Indole-3-Carbinol (I3C) enhances the sensitivity of murine breast adenocarcinoma cells to doxorubicin (DOX) through inhibition of NF-κβ, blocking angiogenesis and regulation of mitochondrial apoptotic pathway. Chemico-Biological Interactions. 2018 Jun 25;290:19-36.
- Dandawate PR, Subramaniam D, Jensen RA, Anant S. Targeting cancer stem cells and signaling pathways by phytochemicals: novel approach for breast cancer therapy. Seminars in Cancer Biology. 2016 Oct;40-41:192-208.
- Cover CM, Hsieh SJ et al. Indole-3-carbinol and tamoxifen cooperate to arrest the cell cycle of MCF-7 human breast cancer cells. Cancer Research. 1999 Mar 15;59(6):1244-51.
- Cevatemre B, Ari F et al. Combination of fenretinide and indole-3-carbinol results in synergistic cytotoxic activity inducing apoptosis against human breast cancer cells in vitro. Anticancer Drugs. 2013 Jul;24(6):577-86.
- Auborn KJ, Fan S et al. Indole-3-carbinol is a negative regulator of estrogen. Journal of Nutrition. 2003 Jul;133(7 Suppl):2470S-2475S.
- Lin H, Gao X et al. Indole-3-carbinol as inhibitors of glucocorticoid-induced apoptosis in osteoblastic cells through blocking ROS-mediated Nrf2 pathway. Biochemical and Biophyicals Research Communications. 2015 May 1;460(2):422-7.
- Wu X, Zhou QH, Xu K. Are isothiocyanates potential anti-cancer drugs? Acta Pharmacologica Sinica. 2009 May;30(5):501-12; Jaman MS, Sayeed MA. Ellagic acid, sulforaphane, and ursolic acid in the prevention and therapy of breast cancer: current evidence and future perspectives. Breast Cancer. 2018 Sep;25(5):517-528; Palliyaguru DL, Yuan JM, Kensler TW, Fahey JW. Isothiocyanates: translating the power of plants to people. Molecular Nutrition & Food Research. 2018 Sep;62(18):e1700965; Morris ME, Dave RA. Pharmacokinetics and pharmacodynamics of phenethyl isothiocyanate: implications in breast cancer prevention. AAPS Journal. 2014 Jul;16(4):705-13.
- Kaczyńska A, Herman-Antosiewicz A. Combination of lapatinib with isothiocyanates overcomes drug resistance and inhibits migration of HER2 positive breast cancer cells. Breast Cancer. 2017 Mar;24(2):271-280.
- Knott SRV, Wagenblast E et al. Asparagine bioavailability governs metastasis in a model of breast cancer [published correction appears in Nature. 2018 Apr 4;556(7699):135]. Nature. 2018;554(7692):378‐381.
- Shiromizu S, Kusunose N, Matsunaga N, Koyanagi S, Ohdo S. Optimizing the dosing schedule of l-asparaginase improves its anti-tumor activity in breast tumor-bearing mice. Journal of Pharmacological Sciences. 2018;136(4):228‐233.
- Pellati F, Borgonetti V et al. Cannabis sativa L. and nonpsychoactive cannabinoids: their chemistry and role against oxidative stress, inflammation, and cancer. Biomed Research International. 2018 Dec 4;2018:1691428; Caffarel MM, Andradas C, Pérez-Gómez E, Guzmán M, Sánchez C. Cannabinoids: a new hope for breast cancer therapy? Cancer Treatment Reviews. 2012 Nov;38(7):911-8; Alexander A, Smith PF, Rosengren RJ. Cannabinoids in the treatment of cancer. Cancer Letters. 2009 Nov 18;285(1):6-12.
- Williams J, Sergi D et al. The beneficial health effects of green tea amino acid l-theanine in animal models: promises and prospects for human trials. Phytotherapy Research. 2019 Jan 10.
- Glinsky VV, Raz A. Modified citrus pectin anti-metastatic properties: one bullet, multiple targets. Carbohydrate Research. 2009 Sep 28;344(14):1788-91.
- Israilides C, Kletsas D et al. In vitro cytostatic and immunomodulatory properties of the medicinal mushroom Lentinula edodes. Phytomedicine. 2008 Jun;15(6-7):512-9.
- Shen J, Tanida M et al. Effect of the culture extract of Lentinus edodes mycelia on splenic sympathetic activity and cancer cell proliferation. Autonomic Neuroscience. 2009 Jan 28;145(1-2):50-4.
- PDQ Integrative, Alternative, and Complementary Therapies Editorial Board. 714-X (PDQ®): Health Professional Version. PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); August 22, 2018. Viewed February 28, 2019.
- PDQ Integrative, Alternative, and Complementary Therapies Editorial Board. Laetrile/Amygdalin (PDQ®): Health Professional Version. PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); March 15, 2017; Milazzo S, Horneber M, Ernst E. Laetrile treatment for cancer. Cochrane Database of Systematic Reviews. 2015 Apr 28;(4):CD005476.
- Milazzo S, Horneber M, Ernst E. Laetrile treatment for cancer. Cochrane Database of Systematic Reviews. 2015 Apr 28;(4):CD005476.
- Cancer Research UK. Laetrile (amygdalin or vitamin B17). October 17, 2018. Viewed February 28, 2019.
- Bennett LM, Montgomery JL, Steinberg SM, Kulp KS. Flor-Essence herbal tonic does not inhibit mammary tumor development in Sprague Dawley rats. Breast Cancer Research and Treatment. 2004 Nov;88(1):87-93.
- Kulp KS, Montgomery JL et al. Essiac and Flor-Essence herbal tonics stimulate the in vitro growth of human breast cancer cells. Breast Cancer Research and Treatment. 2006 Aug;98(3):249-59.
- Ulbricht C, Weissner W et al. Essiac: systematic review by the natural standard research collaboration. Journal of the Society for Integrative Oncology. 2009 Spring;7(2):73-80.
- Cadoni E, Valletta E et al. Competitive reactions among glutathione, cisplatin and copper-phenanthroline complexes. Journal of Inorganic Biochemistry. 2017 Aug;173:126-133; Dong SC, Sha HH et al. Glutathione S-transferase π: a potential role in antitumor therapy. Drug Design, Development and Therapy. 2018 Oct 23;12:3535-3547.
- Roy A, Sarker S et al. Methylglyoxal at metronomic doses sensitizes breast cancer cells to doxorubicin and cisplatin causing synergistic induction of programmed cell death and inhibition of stemness. Biochemical Pharmacology. 2018 Oct;156:322-339.
- Rodman SN, Spence JM et al. Enhancement of radiation response in breast cancer stem cells by inhibition of thioredoxin- and glutathione-dependent metabolism. Radiation Research. 2016 Oct;186(4):385-395; Floberg JM, Schwarz JK. Manipulation of glucose and hydroperoxide metabolism to improve radiation response. Seminars in Radiation Oncology. 2019 Jan;29(1):33-41.
- Lu H, Samanta D et al. Chemotherapy triggers HIF-1-dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype. Proceedings of the National Academy of Sciences USA. 2015 Aug 18;112(33):E4600-9.
- Spremulli E, Wampler GL, Regelson W. Clinical study of hydrazine sulfate in advanced cancer patients. Cancer Chemotheapy and Pharmacology. 1979;3(2):121-4.
- Toth B. A review of the antineoplastic action of certain hydrazines and hydrazine-containing natural products. In Vivo. 1996 Jan-Feb;10(1):65-96; PDQ Integrative, Alternative, and Complementary Therapies Editorial Board. Hydrazine Sulfate (PDQ®): Health Professional Version. PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); August 23, 2018. Viewed February 28, 2019.
- Wise DR, Thompson CB. Glutamine addiction: a new therapeutic target in cancer. Trends in Biochemical Sciences. 2010 Aug;35(8):427-33.
- Loprinzi CL, Levitt R et al. Evaluation of shark cartilage in patients with advanced cancer: a North Central Cancer Treatment Group trial. Cancer. 2005 Jul 1;104(1):176-82.
- Shike M, Doane AS et al. The effects of soy supplementation on gene expression in breast cancer: a randomized placebo-controlled study. Journal of the National Cancer Institute. 2014 Sep 4;106(9). pii: dju189.
- Ma H, Sullivan-Halley J et al. Estrogenic botanical supplements, health-related quality of life, fatigue, and hormone-related symptoms in breast cancer survivors: a HEAL study report. BMC Complementary and Alternative Medicine. 2011 Nov 8;11:109.
- van Duursen MB, Nijmeijer SM, de Morree ES, de Jong PC, van den Berg M. Genistein induces breast cancer-associated aromatase and stimulates estrogen-dependent tumor cell growth in in vitro breast cancer model. Toxicology. 2011 Nov 18;289(2-3):67-73.
- Yang X, Belosay A et al. Dietary soy isoflavones increase metastasis to lungs in an experimental model of breast cancer with bone micro-tumors. Clinical & Experimental Metastasis. 2015 Apr;32(4):323-33.
- O'Carrigan B, Wong MH et al. Bisphosphonates and other bone agents for breast cancer. Cochrane Database of Systematic Reviews. 2017 Oct 30;10:CD003474; Dhesy-Thind S, Fletcher GG et al. Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: a Cancer Care Ontario and American Society of Clinical Oncology clinical practice guideline. Journal of Clinical Oncology. 2017 Jun 20;35(18):2062-2081.
- Diel IJ, Solomayer EF et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. New England Journal of Medicine. 1998 Aug 6;339(6):357-63.
- Dhesy-Thind S, Fletcher GG et al. Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: a Cancer Care Ontario and American Society of Clinical Oncology clinical practice guideline. Journal of Clinical Oncology. 2017 Jun 20;35(18):2062-2081.
- Gaafar A, Aljurf MD et al. Defective gammadelta T-cell function and granzyme B gene polymorphism in a cohort of newly diagnosed breast cancer patients. Experimental Hematology. 2009 Jul;37(7):838-48.
- Zhang T, Feng F et al. Efficacy and acceptability of neoadjuvant endocrine therapy in patients with hormone receptor-positive breast cancer: a network meta-analysis. Journal of Cellular Physiology. 2019 Jan 16.
- Hamilton E, Clay TM, Blackwell KL. New perspectives on zoledronic acid in breast cancer: potential augmentation of anticancer immune response. Cancer Investigation. 2011 Oct;29(8):533-41.
- Drugs.com. Bonefos Approval Status. Viewed March 1, 2019.
- El-Haggar SM, El-Shitany NA, Mostafa MF, El-Bassiouny NA. Metformin may protect nondiabetic breast cancer women from metastasis. Clinical & Experimental Metastasis. 2016 Apr;33(4):339-57.
- Aksoy S, Sendur MA, Altundag K. Demographic and clinico-pathological characteristics in patients with invasive breast cancer receiving metformin. Medical Oncology. 2013;30(2):590.
- Zhang P, Li H, Tan X, Chen L, Wang S. Association of metformin use with cancer incidence and mortality: a meta-analysis. Cancer Epidemiology. 2013 Jun;37(3):207-18.
- Coyle C, Cafferty FH, Vale C, Langley RE. Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis. Annals of Oncology. 2016 Dec;27(12):2184-2195.
- Jiralerspong S, Palla SL et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. Journal of Clinical Oncology. 2009 Jul 10;27(20):3297-302.
- Davies G, Lobanova L et al. Metformin inhibits the development, and promotes the resensitization, of treatment-resistant breast cancer. PLoS One. 2017 Dec 6;12(12):e0187191.
- Song CW, Lee H et al. Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells. Scientific Reports. 2012;2:362.
- Ding L, Liang G et al. Metformin prevents cancer metastasis by inhibiting M2-like polarization of tumor associated macrophages. Oncotarget. 2015 Nov 3;6(34):36441-55.
- Rico M, Baglioni M et al. Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models. Oncotarget. 2017 Jan 10;8(2):2874-2889.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Treatment. New York: Bantam Dell. 2009.
- Chang R. Beyond the Magic Bullet: The Anti-Cancer Cocktail. New York: Square One Publishers. 2012.
- McKinney N. Naturopathic Oncology, 3rd Edition. Victoria, BC, Canada: Liaison Press. 2016.
- Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K. Beta blockers and breast cancer mortality: a population- based study. J Clin Oncol. 2011 Jul 1;29(19):2635-44.
- Childers WK, Hollenbeak CS, Cheriyath P. β-blockers reduce breast cancer recurrence and breast cancer death: a meta-analysis. Clinical Breast Cancer. 2015 Dec;15(6):426-31.
- Cardwell CR, Pottegård A et al. Propranolol and survival from breast cancer: a pooled analysis of European breast cancer cohorts. Breast Cancer Research. 2016 Dec 1;18(1):119; Kim HY, Jung YJ, Lee SH, Jung HJ, Pak K. Is beta-blocker use beneficial in breast cancer? A meta-analysis. Oncology. 2017;92(5):264-268.
- Botteri E, Munzone E et al. Therapeutic effect of β-blockers in triple-negative breast cancer postmenopausal women. Breast Cancer Research and Treatment. 2013 Aug;140(3):567-75.
- Pantziarka P, Bouche G et al. Repurposing Drugs in Oncology (ReDO)-Propranolol as an anti-cancer agent. Ecancermedicalscience. 2016 Oct 12;10:680.
- Pantziarka P, Bouche G et al. Repurposing Drugs in Oncology (ReDO)-Propranolol as an anti-cancer agent. Ecancermedicalscience. 2016 Oct 12;10:680.
- Choy C, Raytis JL et al. Inhibition of β2-adrenergic receptor reduces triple-negative breast cancer brain metastases: the potential benefit of perioperative β-blockade. Oncology Reports. 2016 Jun;35(6):3135-42.
- Choi CH, Song T et al. Meta-analysis of the effects of beta blocker on survival time in cancer patients. Journal of Cancer Research and Clinical Oncology. 2014 Jul;140(7):1179-88.
- Pasquier E, Ciccolini J et al. Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment. Oncotarget. 2011 Oct;2(10):797-809.
- Kang F, Ma W et al. Propranolol inhibits glucose metabolism and 18F-FDG uptake of breast cancer through posttranscriptional downregulation of hexokinase-2. Journal of Nuclear Medicine. 2014 Mar;55(3):439-45.
- Rivero EM, Piñero CP et al. The β 2-adrenergic agonist salbutamol inhibits migration, invasion and metastasis of the human breast cancer MDA-MB- 231 cell line. Current Cancer Drug Targets. 2017;17(8):756-766.
- von Hagens C, Walter-Sack I et al. Long-term add-on therapy (compassionate use) with oral artesunate in patients with metastatic breast cancer after participating in a phase I study (ARTIC M33/2).Phytomedicine. 2018 Sep 17;54:140-148.
- Hamacher-Brady A, Stein HA et al. Artesunate activates mitochondrial apoptosis in breast cancer cells via iron-catalyzed lysosomal reactive oxygen species production. Journal of Biological Chemistry. 2011 Feb 25;286(8):6587-601.
- Bachmeier B, Fichtner I et al. Development of resistance towards artesunate in MDA-MB-231 human breast cancer cells. PLoS One. 2011;6(5):e20550.
- Block KI. Life Over Cancer. New York: Bantam Dell. 2009. p. 476; Efferth T. Cancer combination therapies with artemisinin-type drugs. Biochemical Pharmacology. 2017 Sep 1;139:56-70.
- Baker D. Application of chronotherapy to the treatment of cancer: can changing the timing of drug administration influence efficacy and toxicity? Advances in Pharmacy. 2004 Jul;2(3):222-228.
- Borniger JC, Walker Ii WH et al. Time-of-day dictates transcriptional inflammatory responses to cytotoxic chemotherapy. Scientific Reports. 2017 Jan 24;7:41220.
- Matsunaga N, Ogino T et al. Optimized dosing schedule based on circadian dynamics of mouse breast cancer stem cells improves the antitumor effects of aldehyde dehydrogenase inhibitor. Cancer Research. 2018 Jul 1;78(13):3698-3708.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Treatment. New York: Bantam Dell. 2009.
- Chan N, Willis A et al. Influencing the tumor microenvironment: a phase II study of copper depletion using tetrathiomolybdate in patients with breast cancer at high risk for recurrence and in preclinical models of lung metastases. Clinical Cancer Research. 2017 Feb 1;23(3):666-676.
- Lu H, Samanta D et al. Chemotherapy triggers HIF-1-dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype. Proceedings of the National Academy of Sciences USA. 2015 Aug 18;112(33):E4600-9.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Treatment. New York: Bantam Dell. 2009.
- Elsegood L. Ed. The LDN Book. Vermont: Chelsea Green Publishing. 2016.
- McKinney N. Naturopathic Oncology, 3rd Edition. Victoria, BC, Canada: Liaison Press. 2016.
- Retsky M, Demicheli R et al. Reduction of breast cancer relapses with perioperative non-steroidal anti-inflammatory drugs: new findings and a review. Current Medicinal Chemistry. 2013;20(33):4163-76.
- Chen WY, Holmes MD. Role of aspirin in breast cancer survival. Current Oncology Reports. 2017 Jul;19(7):48; Hugo HJ, Saunders C, Ramsay RG, Thompson EW. New insights on COX-2 in chronic inflammation driving breast cancer growth and metastasis. Journal of Mammary Gland Biology and Neoplasia. 2015 Dec;20(3-4):109-19.
- Mc Menamin ÚC, Cardwell CR, Hughes CM, Murray LJ. Low-dose aspirin use and survival in breast cancer patients: a nationwide cohort study. Cancer Epidemiology. 2017 Apr;47:20-27.
- Elwood PC, Morgan G et al. Aspirin in the treatment of cancer: reductions in metastatic spread and in mortality: a systematic review and meta-analyses of published studies. PLoS One. 2016 Apr 20;11(4):e0152402.
- McNeil JJ, Gibbs P et al. Effect of aspirin on cancer incidence and mortality in older adults. Journal of the National Cancer Institute. 2020;djaa114.
- Schapira DV, Theodossiou C, Lyman GH. The effects of NSAIDs on breast cancer prognostic factors. Oncology Reports. 1999 Mar-Apr;6(2):433-5.
- US Food and Drug Administration. FDA Drug Safety Communication: FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes. US Department of Health and Human Services. February 26, 2018. Viewed March 5, 2019.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Treatment. New York: Bantam Dell. 2009.
- Chang R. Beyond the Magic Bullet: The Anti-Cancer Cocktail. New York: Square One Publishers. 2012.
- Sardesai SD, Thomas A et al. Inhibiting fatty acid synthase in operable triple negative breast cancer. Journal of Clinical Oncology. 38: 2020 (suppl; abstr 584).
- Buck E, Eyzaguirre A et al. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Molecular Cancer Therapeutics. 2006;5(11):2676–2684.
- Kasukabe T, Okabe-Kado J, Kato N, Sassa T, Honma Y. Effects of combined treatment with rapamycin and cotylenin A, a novel differentiation-inducing agent, on human breast carcinoma MCF-7 cells and xenografts. Breast Cancer Research. 2005;7(6):R1097–R1110.
- Wang LH, Chan JL, Li W. Rapamycin together with herceptin significantly increased anti-tumor efficacy compared to either alone in ErbB2 over expressing breast cancer cells. International Journal of Cancer. 2007;121(1):157–164.
- Manthravadi S, Shrestha A, Madhusudhana S. Impact of statin use on cancer recurrence and mortality in breast cancer: a systematic review and meta-analysis. International Journal of Cancer. 2016 Sep 15;139(6):1281-8; Mansourian M, Haghjooy-Javanmard S et al. Statins use and risk of breast cancer recurrence and death: a systematic review and meta-analysis of observational studies. Journal of Pharmacy and Pharmaceutical Sciences. 2016;19(1):72-81. p. 74; Wu QJ, Tu C et al. Statin use and breast cancer survival and risk: a systematic review and meta-analysis. Oncotarget. 2015 Dec 15;6(40):42988-3004.
- Garwood ER, Kumar AS et al. Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Research and Treatment. 2010 Jan;119(1):137-44.
- Ahmadi Y, Karimian R, Panahi Y. Effects of statins on the chemoresistance—the antagonistic drug-drug interactions versus the anti-cancer effects. Biomedicine and Pharmacotherapy. 2018 Dec;108:1856-1865.
- Micallef D, Micallef S, Schembri-Wismayer P, Calleja-Agius J. Novel applications of COX-2 inhibitors, metformin, and statins for the primary chemoprevention of breast cancer. Journal of the Turkish German Gynecological Association. 2016 Dec 1;17(4):214-223. p. 221.
- Zhang Y, Cao Y et al. Chloroquine (CQ) exerts anti-breast cancer through modulating microenvironment and inducing apoptosis. International Immunopharmacology. 2017 Jan;42:100-107.
- Liang DH, Choi DS et al. The autophagy inhibitor chloroquine targets cancer stem cells in triple negative breast cancer by inducing mitochondrial damage and impairing DNA break repair. Cancer Letters. 2016 Jul 1;376(2):249-58.
- Maycotte P, Aryal S et al. Chloroquine sensitizes breast cancer cells to chemotherapy independent of autophagy. Autophagy. 2012 Feb 1;8(2):200-12.
- Shoemaker JP. Fifty-five percent complete remission of mammary carcinoma in mice with 5-fluorouracil and chloroquine. Cancer Research. 1978 Sep;38(9):2700-2.
- Rico M, Baglioni M et al. Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models. Oncotarget. 2017 Jan 10;8(2):2874-2889.
- de Groot S, Vreeswijk MP et al. The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study. BMC Cancer. 2015;15:652.
- de Groot S, Lugtenberg RT et al. Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial. Nature Communications. 2020;11(1):3083.
- İyikesici MS, Slocum AK et al. Efficacy of metabolically supported chemotherapy combined with ketogenic diet, hyperthermia, and hyperbaric oxygen therapy for stage iv triple-negative breast cancer. Cureus. 2017 Jul 7;9(7):e1445; Branca JJ, Pacini S, Ruggiero M. Effects of pre-surgical vitamin D supplementation and ketogenic diet in a patient with recurrent breast cancer. Anticancer Research. 2015 Oct;35(10):5525-32.
- Gluschnaider U, Hertz R et al. Long-chain fatty acid analogues suppress breast tumorigenesis and progression. Cancer Research. 2014 Dec 1;74(23):6991-7002.
- Zhuang Y, Chan DK, Haugrud AB, Miskimins WK. Mechanisms by which low glucose enhances the cytotoxicity of metformin to cancer cells both in vitro and in vivo. PLoS One. 2014 Sep 25;9(9):e108444.
- Martinez-Outschoorn UE, Lisanti MP, Sotgia F. Catabolic cancer-associated fibroblasts transfer energy and biomass to anabolic cancer cells, fueling tumor growth. Seminars in Cancer Biology. 2014 Apr;25:47-60; Martinez-Outschoorn UE, Lin Z et al. Ketone body utilization drives tumor growth and metastasis. Cell Cycle. 2012 Nov 1;11(21):3964-71.
- Hegewisch-Becker S, Hossfeld DK et al. Addition of hyperthermia. heat potentiates cancer therapy. [Article in German] MMW Fortschritte der Medizin. 2001 Jun 21;143(25):28-32; Vernon CC, Hand JW et al. Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: results from five randomized controlled trials. International Journal of Radiation Oncology, Biology, Physics. 1996:35(4):731-744; Vujaskovic Z, Kim DW et al. A phase I/II study of neoadjuvant liposomal doxorubicin, paclitaxel, and hyperthermia in locally advanced breast cancer. International Journal of Hyperthermia. 2010;26(5):514-521; Jones EL, Prosnitz LR et al. Thermochemoradiotherapy improves oxygenation in locally advanced breast cancer. Clinical Cancer Research. 2004;10:4287-4293.
- Hegewisch-Becker S, Hossfeld DK et al. [Addition of hyperthermia. heat potentiates cancer therapy]. [Article in German] MMW Fortschritte der Medizin. 2001 Jun 21;143(25):28-32.
- Bennett C. Cryoablation may be a treatment option for some patients. Cancer Today. March 24, 2020. Viewed May 13, 2021.
- Fine RE, Dietz JR, Boolbol SK, Berry MP. Cryoablation without excision for early-stage breast cancer; ICE3 trial update on ipsilateral breast tumor recurrence. The American Society of Breast Surgeons Official Proceedings, Volume XXII 2021 Annual Meeting Scientific Session Abstracts. Abstract 243, p 14-15.
- Nelson R. Ask about sexual function in breast cancer patients on endocrine Tx. Medscape. November 14, 2019. Viewed November 14, 2019.
- Huang WC, Kuo KT, Bamodu OA, et al. Astragalus polysaccharide (PG2) ameliorates cancer symptom clusters, as well as improves quality of life in patients with metastatic disease, through modulation of the inflammatory cascade. Cancers (Basel). 2019;11(8).
- Yu R, Wu X, Jia L, Lou Y. Effect of Chinese herbal compound LC09 on patients with capecitabine-associated hand-foot syndrome: a randomized, double-blind, and parallel-controlled trial. Integrative Cancer Therapies. Jan-Dec 2020;19:1534735420928466.
- Hao J, Zhu X, Bensoussan A. Effects of nonpharmacological interventions in chemotherapy-induced peripheral neuropathy: an overview of systematic reviews and meta-analyses. Integrative Cancer Therapies. Jan-Dec 2020;19:1534735420945027; Noh H, Yoon SW, Park B. A systematic review of herbal medicine for chemotherapy-induced peripheral neuropathy (CIPN). Evidence Based Complementary and Alternative Medicine. 2018 Feb 14;2018:6194184; Wei X, Zhu L, Wang H, Wang C, Deng Q, Li X. Efficacy of traditional Chinese medicines in preventing oxaliplatin-induced peripheral neurotoxicity in cancer patients: a network meta-analysis. Chinese Herb Med. 2017;9(2):161-168; Deng B, Jia L, Cheng Z. Radix astragali-based Chinese herbal medicine for oxaliplatin-induced peripheral neuropathy: a systematic review and meta-analysis. Evidence-based Complementary and Alternative Medicine. 2016;2016:2421876.
- Zhu L, Li L, Li Y, Wang J, Wang Q. Chinese herbal medicine as an adjunctive therapy for breast cancer: a systematic review and meta-analysis. Evidence-based Complementary and Alternative Medicine. 2016;2016:9469276.
- Zhu ZY, Xue JX et al. Reducing postsurgical exudate in breast cancer patients by using San Huang decoction to ameliorate inflammatory status: a prospective clinical trial. Current Oncology. 2018 Dec;25(6):e507-e515.
- Ding Y, Liu Y et al. Chinese medicines for preventing and treating radiation-induced pulmonary injury: A review of 2007-2017. Frontiers in Pharmacology. 2019 Sep 5;10:927.
- Beuth J, van Leendert R, Schneider B, Uhlenbruck G. Complementary medicine on side-effects of adjuvant hormone therapy in patients with breast cancer. In Vivo. 2013 Nov-Dec;27(6):869-71.
- Lucius K, Trukova K. Integrative therapies and cardiovascular disease in the breast cancer population: a review, part 1. Integrative Medicine: A Clinician's Journal (Encinitas). 2015 Aug;14(4):22-9; Conklin KA. Coenzyme q10 for prevention of anthracycline-induced cardiotoxicity. Integrative Cancer Therapies. 2005 Jun;4(2):110-30; Greenlee H, Shaw J, Lau YI, Naini A, Maurer M. Lack of effect of coenzyme q10 on doxorubicin cytotoxicity in breast cancer cell cultures. Integrative Cancer Therapies. 2012 Sep;11(3):243-50.
- Samuels N, Schiff E, Ben-Arye E. Non-herbal nutritional supplements for symptom relief in adjuvant breast cancer: creating a doctor-patient dialogue. BMJ Support Palliat Care. 2014 Sep;4(3):e1; Lesser GJ, Case D et al. A randomized, double-blind, placebo-controlled study of oral coenzyme Q10 to relieve self-reported treatment-related fatigue in newly diagnosed patients with breast cancer. Journal of Supportive Oncology. 2013 Mar;11(1):31-42.
- Marx W, Ried K et al. Ginger—mechanism of action in chemotherapy-induced nausea and vomiting: a review. Critical Reviews in Food Science and Nutrition. 2017 Jan 2;57(1):141-146; Sheikhi MA, Ebadi A, Talaeizadeh A, Rahmani H. Alternative methods to treat nausea and v—omiting from cancer chemotherapy. Chemotherapy Research and Practice. 2015;2015:818759; Marx W, Kiss N, Isenring L. Is ginger beneficial for nausea and vomiting? An update of the literature. Current Opinion in Supportive and Palliative Care. 2015 Jun;9(2):189-95; Marx WM, Teleni L et al. Ginger (Zingiber officinale) and chemotherapy-induced nausea and vomiting: a systematic literature review. Nutrition Reviews. 2013 Apr;71(4):245-54; Lee J, Oh H. Ginger as an antiemetic modality for chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis. Oncology Nursing Forum. 2013 Mar;40(2):163-70.
- Sontakke S, Thawani V, Naik MS. Ginger as an antiemetic in nausea and vomiting induced by chemotherapy: a randomized, cross-over, double blind study. Indian Journal of Pharmacology. 2003;35(1):32–36.
- Sanaati F, Najafi S, Kashaninia Z, Sadeghi M. Effect of ginger and chamomile on nausea and vomiting caused by chemotherapy in Iranian women with breast cancer. Asian Pacific Journal of Cancer Prevention. 2016;17(8):4125-9; Arslan M, Ozdemir L. Oral intake of ginger for chemotherapy-induced nausea and vomiting among women with breast cancer. Clinical Journal of Oncology Nurings. 2015 Oct;19(5):E92-7.
- Pereira PTVT, Reis AD et al. Dietary supplements and fatigue in patients with breast cancer: a systematic review. Breast Cancer Research and Treatment. 2018 Oct;171(3):515-526; Leggett S, Koczwara B, Miller M. The impact of complementary and alternative medicines on cancer symptoms, treatment side effects, quality of life, and survival in women with breast cancer—a systematic review. Nutrition and Cancer. 2015;67(3):373-91.
- Handforth C, D'Oronzo S, Coleman R, Brown J. Cancer treatment and bone health. Calcified Tissue International. 2018 Feb;102(2):251-264.
- Cepa M, Vaz C. Management of bone loss in postmenopausal breast cancer patients treated with aromatase inhibitors. Acta Reumatologica Portuguesa. 2015 Oct-Dec;40(4):323-30.
- Samuels N, Schiff E, Ben-Arye E. Non-herbal nutritional supplements for symptom relief in adjuvant breast cancer: creating a doctor-patient dialogue. BMJ Support Palliat Care. 2014 Sep;4(3):e1.
- Prieto-Alhambra D, Javaid MK et al. Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study. Breast Cancer Research and Treatment. 2011 Feb;125(3):869-78.
- Khan QJ, Reddy PS et al. Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Research and Treatment. 2010 Jan;119(1):111-8.
- Rastelli AL, Taylor ME et al. Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial. Breast Cancer Research and Treatment. 2011 Aug;129(1):107-16.
- Albert Einstein College of Medicine. Oral steroids linked to severe vitamin D deficiency in nationwide US study. ScienceDaily. September 30, 2011. Viewed March 6, 2019.
- Abrams DI. The therapeutic effects of cannabis and cannabinoids: an update from the National Academies of Sciences, Engineering and Medicine report. European Journal of Internal Medicine. 2018 Mar;49:7-11.
- Semiglazov VF, Stepula VV, Dudov A, Schnitker J, Mengs U. Quality of life is improved in breast cancer patients by Standardised Mistletoe Extract PS76A2 during chemotherapy and follow-up: a randomised, placebo-controlled, double-blind, multicentre clinical trial. Anticancer Research. 2006 Mar-Apr;26(2B):1519-29; Büssing A, Raak C, Ostermann T. Quality of life and related dimensions in cancer patients treated with mistletoe extract (iscador): a meta-analysis. Evidence-based Complementary and Alternative Medicine. 2012;2012:219402; Kienle GS , Kiene H. Complementary cancer therapy: a systematic review of prospective clinical trials on anthroposophic mistletoe extracts. European Journal of Medical Research. 2007 Mar 26;12(3):103-19; Eisenbraun J, Scheer R, Kröz M, Schad F, Huber R. Quality of life in breast cancer patients during chemotherapy and concurrent therapy with a mistletoe extract. Phytomedicine. 2011 Jan 15;18(2-3):151-7.
- Tröger W, Jezdić S et al. Quality of life and neutropenia in patients with early stage breast cancer: a randomized pilot study comparing additional treatment with mistletoe extract to chemotherapy alone. Breast Cancer (Auckland). 2009 Jul 6;3:35-45.
- Ziegler R, Grossarth-Maticek R. Individual patient data meta-analysis of survival and psychosomatic self-regulation from published prospective controlled cohort studies for long-term therapy of breast cancer patients with a mistletoe preparation (Iscador). Evidence-based Complementary and Alternative Medicine. 2010 Jun;7(2):157-66.
- Valadares F, Garbi Novaes MR, Cañete R. Effect of Agaricus sylvaticus supplementation on nutritional status and adverse events of chemotherapy of breast cancer: a randomized, placebo-controlled, double-blind clinical trial. Indian Journal of Pharmacology. 2013 May-Jun;45(3):217-22.
- Novaes MR, Valadares F, Reis MC, Gonçalves DR, Menezes Mda C. The effects of dietary supplementation with Agaricales mushrooms and other medicinal fungi on breast cancer: evidence-based medicine. Clinics (Sao Paulo). 2011;66(12):2133-9.
- Alschuler LN, Gazella KA. The Definitive Guide to Cancer, 3rd Edition: An Integrative Approach to Prevention, Treatment, and Healing. Berkeley, California: Celestial Arts. 2010; Alschuler LN, Gazella KA. The Definitive Guide to Thriving after Cancer. Berkeley, California: Ten Speed Press. 2013.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Treatment. New York: Bantam Dell. 2009.
- Kohara H, Miyauchi T. Combined modality treatment of aromatherapy, footsoak, and reflexology relieves fatigue in patients with cancer. Journal of Palliative Medicine. 2004 Dec;7(6):791-6.
- Wilkinson SM, Love SB et al. Effectiveness of aromatherapy massage in the management of anxiety and depression in patients with cancer: a multicenter randomized controlled trial. Journal of Clinical Oncology. 2007 Feb 10;25(5):532-9; Imanishi J, Kuriyama H et al. Anxiolytic effect of aromatherapy massage in patients with breast cancer. Evidence-Based Complementary and Alternative Medicine. 2009 Mar; 6(1): 123–128.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Treatment. New York: Bantam Dell. 2009.
- Biswal BM, Sulaiman SA, Ismail HC, Zakaria H, Musa KI. Effect of Withania somnifera (Ashwagandha) on the development of chemotherapy-induced fatigue and quality of life in breast cancer patients. Integrative Cancer Therapies. 2013 Jul;12(4):312-22.
- Alschuler LN, Gazella KA. The Definitive Guide to Cancer, 3rd Edition: An Integrative Approach to Prevention, Treatment, and Healing. Berkeley, California: Celestial Arts. 2010; Alschuler LN, Gazella KA. The Definitive Guide to Thriving after Cancer. Berkeley, California: Ten Speed Press. 2013.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Treatment. New York: Bantam Dell. 2009.
- MacDonald B. The Breast Cancer Companion: A Complementary Care Manual: Third Edition. 2016.
- McKinney N. Naturopathic Oncology, 3rd Edition. Victoria, BC, Canada: Liaison Press. 2016.
- Jiang K, Jin Y et al. Black cohosh improves objective sleep in postmenopausal women with sleep disturbance. Climacteric. 2015;18(4):559-67.
- Fritz H, Seely D et al. Black cohosh and breast cancer: a systematic review. Integrative Cancer Therapies. 2014 Jan;13(1):12-29; Walji R, Boon H, Guns E, Oneschuk D, Younus J. Black cohosh (Cimicifuga racemosa [L.] Nutt.): safety and efficacy for cancer patients. Supportive Care in Cancer. 2007 Aug;15(8):913-21.
- Shams T, Setia MS et al. Efficacy of black cohosh-containing preparations on menopausal symptoms: a meta-analysis. Alternative Therapies in Health and Medicine. 2010 Jan-Feb;16(1):36-44.
- Wuttke W, Gorkow C, Seidlová-Wuttke D. Effects of black cohosh (Cimicifuga racemosa) on bone turnover, vaginal mucosa, and various blood parameters in postmenopausal women: a double-blind, placebo-controlled, and conjugated estrogens-controlled study. Menopause. 2006 Mar-Apr;13(2):185-96.
- Yeung KS, Hernandez M, Mao JJ, Haviland I, Gubili J. Herbal medicine for depression and anxiety: a systematic review with assessment of potential psycho-oncologic relevance. Phytotherapy Research. 2018 May;32(5):865-891; Geller SE, Studee L. Botanical and dietary supplements for mood and anxiety in menopausal women. Menopause. 2007 May-Jun;14(3 Pt 1):541-9.
- Yang CL, Or TC, Ho MH, Lau AS. Scientific basis of botanical medicine as alternative remedies for rheumatoid arthritis. Clinical Reviews in Allergy & Immunology. 2013 Jun;44(3):284-300.
- Black Cohosh: Fact Sheet for Consumers. National Institute of Health Office of Dietary Supplements. August 30, 2018. Viewed November 6, 2018.
- MacDonald B. The Breast Cancer Companion: A Complementary Care Manual: Third Edition. 2016.
- Tajbakhsh A, Hasanzadeh M et al. Therapeutic potential of novel formulated forms of curcumin in the treatment of breast cancer by the targeting of cellular and physiological dysregulated pathways. Journal of Cellular Physiology. 2018 Mar;233(3):2183-2192; Ryan JL, Heckler CE et al. Curcumin for radiation dermatitis: a randomized, double-blind, placebo-controlled clinical trial of thirty breast cancer patients. Radiation Research. 2013;180:34-43; Ryan Wolf J, Heckler CE et al. Oral curcumin for radiation dermatitis: a URCC NCORP study of 686 breast cancer patients. Supportive Care in Cancer. 2018 May;26(5):1543-1552.
- Belcaro G, Hosoi M et al. A controlled study of a lecithinized delivery system of curcumin (Meriva®) to alleviate the adverse effects of cancer treatment. Phytotherapy Research. 2014 Mar; 28:444-50.
- Hussaarts KGAM, Hurkmans DP et al. Impact of curcumin (with or without piperine) on the pharmacokinetics of tamoxifen. Cancers (Basel). 2019 Mar 22;11(3). pii: E403.
- Lemole G, Mehta P, McKee D. After Cancer Care: The Definitive Self-Care Guide to Getting and Staying Well for Patients with Cancer. New York, New York: Rodale, Inc. 2015.
- MacDonald B. The Breast Cancer Companion: A Complementary Care Manual: Third Edition. 2016.
- Flower G, Fritz H et al. Flax and breast cancer: a systematic review. Integrative Cancer Therapies. 2014 May;13(3):181-92.
- Flower G, Fritz H et al. Flax and breast cancer: a systematic review. Integrative Cancer Therapies. 2014 May;13(3):181-92; Dew TP, Williamson G. Controlled flax interventions for the improvement of menopausal symptoms and postmenopausal bone health: a systematic review. Menopause. 2013 Nov;20(11):1207-15.
- Velalopoulou A, Tyagi S, Pietrofesa RA, Arguiri E, Christofidou-Solomidou M. The flaxseed-derived lignan phenolic secoisolariciresinol diglucoside (SDG) protects non-malignant lung cells from radiation damage. International Journal of Molecular Sciences. 2015 Dec 22;17(1). pii: E7.
- Pietrofesa R, Turowski J et al. Radiation mitigating properties of the lignan component in flaxseed. BMC Cancer. 2013 Apr 4;13:179.
- MacDonald B. The Breast Cancer Companion: A Complementary Care Manual: Third Edition. 2016.
- Cui Y, Shu XO et al. Association of ginseng use with survival and quality of life among breast cancer patients. American Journal of Epidemiology. 2006 Apr 1;163(7):645-53.
- Arring NM, Millstine D, Marks LA, Nail LM. Ginseng as a treatment for fatigue: a systematic review. Journal of Alternative and Complementary Medicine. 2018 Jul;24(7):624-633.
- Yennurajalingam S, Tannir NM et al. A double-blind, randomized, placebo-controlled trial of Panax ginseng for cancer-related fatigue in patients with advanced cancer. Journal of the National Comprehensive Canc Network. 2017 Sep;15(9):1111-1120.
- MacDonald B. The Breast Cancer Companion: A Complementary Care Manual: Third Edition. 2016.
- Bacić I, Druzijanić N, Karlo R, Skifić I, Jagić S. Efficacy of IP6 + inositol in the treatment of breast cancer patients receiving chemotherapy: prospective, randomized, pilot clinical study. Journal of Experimental & Clinical Cancer Research. 2010 Feb 12;29:12.
- Proietti S, Pasta V et al. Inositol hexaphosphate (InsP6) as an effective topical treatment for patients receiving adjuvant chemotherapy after breast surgery. European Review for Medical and Pharmacological Sciences. 2017 Jun;21(2 Suppl):43-50.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Treatment. New York: Bantam Dell. 2009.
- Rossi P, Difrancia R et al. B-glucans from Grifola frondosa and Ganoderma lucidum in breast cancer: an example of complementary and integrative medicine. Oncotarget. 2018 May 15;9(37):24837-24856.
- Alschuler LN, Gazella KA. The Definitive Guide to Cancer, 3rd Edition: An Integrative Approach to Prevention, Treatment, and Healing. Berkeley, California: Celestial Arts. 2010; Alschuler LN, Gazella KA. The Definitive Guide to Thriving after Cancer. Berkeley, California: Ten Speed Press. 2013.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Treatment. New York: Bantam Dell. 2009.
- Li Y, Li S et al. Melatonin for the prevention and treatment of cancer. Oncotarget. 2017 Jun 13;8(24):39896-39921.
- Hansen MV, Andersen LT et al. Effect of melatonin on depressive symptoms and anxiety in patients undergoing breast cancer surgery: a randomized, double-blind, placebo-controlled trial. Breast Cancer Research and Treatment. 2014 Jun;145(3):683-95; Li Y, Li S et al. Melatonin for the prevention and treatment of cancer. Oncotarget. 2017 Jun 13;8(24):39896-39921; Hansen MV. Chronobiology, cognitive function and depressive symptoms in surgical patients. Danish Medical Journal. 2014 Sep;61(9):B4914..
- Chen WY, Giobbie-Hurder A et al. A randomized, placebo-controlled trial of melatonin on breast cancer survivors: impact on sleep, mood, and hot flashes. Breast Cancer Research and Treatment. 2014;145(2):381-388.
- Hansen MV, Halladin NL, Rosenberg J, Gögenur I, Møller AM. Melatonin for pre- and postoperative anxiety in adults. Cochrane Database of Systematic Reviews. 2015 Apr 9;(4):CD009861; Posadzki PP, Bajpai R et al. Melatonin and health: an umbrella review of health outcomes and biological mechanisms of action. BMC Medicine. 2018 Feb 5;16(1):18.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Care. New York: Bantam Dell. 2009.
- Haghi-Aminjan H, Asghari MH et al. The role of melatonin on chemotherapy-induced reproductive toxicity. Journal of Pharmacy and Pharmacology. 2018 Mar;70(3):291-306.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Treatment. New York: Bantam Dell. 2009.
- Lemole G, Mehta P, McKee D. After Cancer Care: The Definitive Self-Care Guide to Getting and Staying Well for Patients with Cancer. New York, New York: Rodale, Inc. 2015.
- MacDonald B. The Breast Cancer Companion: A Complementary Care Manual: Third Edition. 2016.
- Leggett S, Koczwara B, Miller M. The impact of complementary and alternative medicines on cancer symptoms, treatment side effects, quality of life, and survival in women with breast cancer—a systematic review. Nutrition and Cancer. 2015;67(3):373-91.
- Jin X, Ruiz Beguerie J, Sze DM, Chan GC. Ganoderma lucidum (reishi mushroom) for cancer treatment. Cochrane Database of Systematic Reviews. 2016 Apr 5;4:CD007731.
- Wang CZ, Basila D et al. Effects of ganoderma lucidum extract on chemotherapy-induced nausea and vomiting in a rat model. American Journal of Chinese Medicine. 2005;33(5):807-15.
- Alschuler LN, Gazella KA. The Definitive Guide to Cancer, 3rd Edition: An Integrative Approach to Prevention, Treatment, and Healing. Berkeley, California: Celestial Arts. 2010; Alschuler LN, Gazella KA. The Definitive Guide to Thriving after Cancer. Berkeley, California: Ten Speed Press. 2013.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Treatment. New York: Bantam Dell. 2009.
- MacDonald B. The Breast Cancer Companion: A Complementary Care Manual: Third Edition. 2016.
- Samuels N, Schiff E, Ben-Arye E. Non-herbal nutritional supplements for symptom relief in adjuvant breast cancer: creating a doctor-patient dialogue. BMJ Support Palliat Care. 2014 Sep;4(3):e1.
- MacDonald B. The Breast Cancer Companion: A Complementary Care Manual: Third Edition. 2016.
- Tanigawa K, Itoh Y, Kobayashi Y. Improvement of QOL and immunological function with Lentinula edodes mycelia in patients undergoing cancer immunotherapy: an open pilot study. Alternative Therapies in Health and Medicine. 2016 Jul;22(4):36-42.
- Yamaguchi Y, Miyahara E, Hihara J. Efficacy and safety of orally administered Lentinula edodes mycelia extract for patients undergoing cancer chemotherapy: a pilot study. American Journal of Chinese Medicine. 2011;39(3):451-9.
- Alschuler LN, Gazella KA. The Definitive Guide to Cancer, 3rd Edition: An Integrative Approach to Prevention, Treatment, and Healing. Berkeley, California: Celestial Arts. 2010; Alschuler LN, Gazella KA. The Definitive Guide to Thriving after Cancer. Berkeley, California: Ten Speed Press. 2013.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Treatment. New York: Bantam Dell. 2009.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Treatment. New York: Bantam Dell. 2009.
- Vollbracht C, Schneider B et al. Intravenous vitamin C administration improves quality of life in breast cancer patients during chemo-/radiotherapy and aftercare: results of a retrospective, multicentre, epidemiological cohort study in Germany. In Vivo. 2011 Nov-Dec;25(6):983-90; Fritz H, Flower G et al. Intravenous vitamin C and cancer: a systematic review. Integrative Cancer Therapies. 2014 Jul;13(4):280-300; Carr AC, Vissers MC, Cook JS. The effect of intravenous vitamin C on cancer- and chemotherapy-related fatigue and quality of life. Frontiers in Oncology. 2014 Oct 16;4:283..
- Karatas F, Sahin S, Sever AR, Altundag K. Management of hair loss associated with endocrine therapy in patients with breast cancer: an overview. Springerplus. 2016 May 10;5:585.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Treatment. New York: Bantam Dell. 2009.
- MacDonald B. The Breast Cancer Companion: A Complementary Care Manual: Third Edition. 2016.
- Samuels N, Schiff E, Ben-Arye E. Non-herbal nutritional supplements for symptom relief in adjuvant breast cancer: creating a doctor-patient dialogue. BMJ Supportive & Palliative Care. 2014 Sep;4(3):e1.
- Greenlee H, Hershman DL, Jacobson JS. Use of antioxidant supplements during breast cancer treatment: a comprehensive review. Breast Cancer Research and Treatment. 2009 Jun;115(3):437-52.
- Chang R. Beyond the Magic Bullet: The Anti-Cancer Cocktail. New York: Square One Publishers. 2012.
- Lemole G, Mehta P, McKee D. After Cancer Care: The Definitive Self-Care Guide to Getting and Staying Well for Patients with Cancer. New York, New York: Rodale, Inc. 2015.
- MacDonald B. The Breast Cancer Companion: A Complementary Care Manual: Third Edition. 2016.
- Waldner R, Laschan C et al. Effects of doxorubicin-containing chemotherapy and a combination with L-carnitine on oxidative metabolism in patients with non-Hodgkin lymphoma. Journal of Cancer Research and Clinical Oncology. 2006 Feb;132(2):121-8.
- Greenlee H, DuPont-Reyes MJ et al. Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment. CA: A Cancer Journal for Clinicians. 2017 May 6;67(3):194-232.
- Greenlee H, DuPont-Reyes MJ et al. Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment. CA: A Cancer Journal for Clinicians. 2017 May 6;67(3):194-232.
- Sahebjamee M, Mansourian A et al. Comparative efficacy of aloe vera and benzydamine mouthwashes on radiation-induced oral mucositis: a triple-blind, randomised, controlled clinical trial. Oral Health & Preventive Dentistry. 2015;13(4):309-15.
- Rao S, Hegde SK et al. An aloe vera-based cosmeceutical cream delays and mitigates ionizing radiation-induced dermatitis in head and neck cancer patients undergoing curative radiotherapy: a clinical study. Medicines (Basel). 2017 Jun 24;4(3). pii: E44.
- Stubbe CE, Valero M. Complementary strategies for the management of radiation therapy side effects. Journal of the Advanced Practitioner in Oncology. 2013 Jul;4(4):219-31.
- Togni S, Maramaldi G, Bonetta A, Giacomelli L, Di Pierro F. Clinical evaluation of safety and efficacy of Boswellia-based cream for prevention of adjuvant radiotherapy skin damage in mammary carcinoma: a randomized placebo controlled trial. European Review for Medical and Pharmacological Sciences. 2015 Apr;19(8):1338-44.
- Sanaati F, Najafi S, Kashaninia Z, Sadeghi M. Effect of ginger and chamomile on nausea and vomiting caused by chemotherapy in Iranian women with breast cancer. Asian Pacific Journal of Cancer Prevention. 2016;17(8):4125-9.
- Chang YD, Smith J et al. Single institute experience with methylphenidate and American ginseng in cancer-related fatigue. American Journal of Hospice and Palliative Care. 2018 Jan;35(1):144-150.
- Di Franco R, Calvanese M et al. Skin toxicity from external beam radiation therapy in breast cancer patients: protective effects of resveratrol, lycopene, vitamin C and anthocianin (Ixor®). Radiation Oncology. 2012 Jan 30;7:12.
- Iwase S, Kawaguchi T et al. Efficacy and safety of an amino acid jelly containing coenzyme Q10 and L-carnitine in controlling fatigue in breast cancer patients receiving chemotherapy: a multi-institutional, randomized, exploratory trial (JORTC-CAM01). Supportive Care in Cancer. 2016 Feb;24(2):637-646.
- Samuels N, Schiff E, Ben-Arye E. Non-herbal nutritional supplements for symptom relief in adjuvant breast cancer: creating a doctor-patient dialogue. BMJ Support Palliat Care. 2014 Sep;4(3):e1.
- Liguori V, Guillemin C, Pesce GF, Mirimanoff RO, Bernier J. Double-blind, randomized clinical study comparing hyaluronic acid cream to placebo in patients treated with radiotherapy. Radiotherapy and Oncology. 1997 Feb;42(2):155-61.
- Pinnix C, Perkins GH et al. Topical hyaluronic acid vs. standard of care for the prevention of radiation dermatitis after adjuvant radiotherapy for breast cancer: single-blind randomized phase III clinical trial. International Journal of Radiation Oncology, Biology, Physics. 2012 Jul 15;83(4):1089-94.
- Moreno-Vega A, Vega-Riveroll L et al. Adjuvant effect of molecular iodine in conventional chemotherapy for breast cancer. randomized pilot study. Nutrients. 2019 Jul 17;11(7). pii: E1623.
- Patrick L Iodine: deficiency and therapeutic considerations. Alternative Medicine Review. 2008 Jun;13(2):116-27.
- Sun J, Wang H, Hu H. Glutamine for chemotherapy induced diarrhea: a meta-analysis. Asia Pacific Journal of Clinical Nutrition. 2012;21(3):380-5.
- Greenlee H, Hershman DL, Jacobson JS. Use of antioxidant supplements during breast cancer treatment: a comprehensive review. Breast Cancer Research and Treatment. 2009 Jun;115(3):437-52; Leggett S, Koczwara B, Miller M. The impact of complementary and alternative medicines on cancer symptoms, treatment side effects, quality of life, and survival in women with breast cancer—a systematic review. Nutrition and Cancer. 2015;67(3):373-91.
- Samuels N, Schiff E, Ben-Arye E. Non-herbal nutritional supplements for symptom relief in adjuvant breast cancer: creating a doctor-patient dialogue. BMJ Supportive & Palliative Care. 2014 Sep;4(3):e1.
- Rubio I, Suva LJ et al. Oral glutamine reduces radiation morbidity in breast conservation surgery. Journal of Parenteral and Enteral Nutrition. 2013 Sep;37(5):623-30.
- Wise DR, Thompson CB. Glutamine addiction: a new therapeutic target in cancer. Trends in Biochemical Sciences. 2010 Aug;35(8):427-33.
- Agosta C, Atlante M, Benvenuti C. Randomized controlled study on clinical efficacy of isoflavones plus Lactobacillus sporogenes, associated or not with a natural anxiolytic agent in menopause. Minerva Ginecologica. 2011 Feb;63(1):11-7.
- Huang L, Zhang K et al. Honokiol protects against doxorubicin cardiotoxicity via improving mitochondrial function in mouse hearts. Scientific Reports. 2017 Sep 20;7(1):11989.
- Ladas EJ, Kelly KM. Milk thistle: is there a role for its use as an adjunct therapy in patients with cancer? Journal of Alternative and Complementary Medicine. 2003 Jun;9(3):411-6.
- Rašković A, Stilinović N et al. The protective effects of silymarin against doxorubicin-induced cardiotoxicity and hepatotoxicity in rats. Molecules. 2011 Oct 12;16(10):8601-13.
- Post-White J, Ladas EJ, Kelly KM. Advances in the use of milk thistle (Silybum marianum). Integrative Cancer Therapies. 2007 Jun;6(2):104-9.
- Malewicz B, Wang Z et al. Enhancement of mammary carcinogenesis in two rodent models by silymarin dietary supplements. Carcinogenesis. 2006 Sep;27(9):1739-47.
- Verschoyle RD, Brown K, Steward WP, Gescher AJ. Consumption of silibinin, a flavonolignan from milk thistle, and mammary cancer development in the C3(1) SV40 T,t antigen transgenic multiple mammary adenocarcinoma (TAg) mouse. Cancer Chemotherapy and Pharmacology. 2008 Jul;62(2):369-72.
- Lemole G, Mehta P, McKee D. After Cancer Care: The Definitive Self-Care Guide to Getting and Staying Well for Patients with Cancer. New York, New York: Rodale, Inc. 2015.
- Hutchins-Wiese HL, Picho K et al. High-dose eicosapentaenoic acid and docosahexaenoic acid supplementation reduces bone resorption in postmenopausal breast cancer survivors on aromatase inhibitors: a pilot study. Nutrition and Cancer. 2014;66(1):68-76.
- Ghoreishi Z, Esfahani A et al. Omega-3 fatty acids are protective against paclitaxel-induced peripheral neuropathy: a randomized double-blind placebo controlled trial. BMC Cancer. 2012 Aug 15;12:355.
- de Aguiar Pastore Silva J, Emilia de Souza Fabre M, Waitzberg DL. Omega-3 supplements for patients in chemotherapy and/or radiotherapy: a systematic review. Clinical Nutrition. 2015 Jun;34(3):359-66.
- Suzumura DN, Schleder JC et al. Fish oil supplementation enhances pulmonary strength and endurance in women undergoing chemotherapy. Nutrition and Cancer. 2016 Aug-Sep;68(6):935-42.
- Bonatto SJ, Oliveira HH et al. Fish oil supplementation improves neutrophil function during cancer chemotherapy. Lipids. 2012 Apr;47(4):383-9.
- Daenen LG, Cirkel GA et al. Increased plasma levels of chemoresistance-inducing fatty acid 16:4(n-3) after consumption of fish and fish oil. JAMA Oncology. 2015 Jun;1(3):350-8.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Treatment. New York: Bantam Dell. 2009.
- Lemole G, Mehta P, McKee D. After Cancer Care: The Definitive Self-Care Guide to Getting and Staying Well for Patients with Cancer. New York, New York: Rodale, Inc. 2015.
- MacDonald B. The Breast Cancer Companion: A Complementary Care Manual: Third Edition. 2016.
- Cathcart-Rake EJ, Smith D, Zahrieh D, Loprinzi CL. Rose geranium in sesame oil nasal spray: a treatment for nasal vestibulitis? BMJ Supportive & Palliative Care. 2018 Sep 26. pii: bmjspcare-2018-001569.
- Abdel-Daim MM, Kilany OE, Khalifa HA, Ahmed AAM. Allicin ameliorates doxorubicin-induced cardiotoxicity in rats via suppression of oxidative stress, inflammation and apoptosis. Cancer Chemotherapy and Pharmacology. 2017 Oct;80(4):745-753.
- Cheah KY, Howarth GS, Bastian SE. Grape seed extract dose-responsively decreases disease severity in a rat model of mucositis; concomitantly enhancing chemotherapeutic effectiveness in colon cancer cells. PLoS One. 2014 Jan 21;9(1):e85184.
- Olaku OO, Ojukwu MO, Zia FZ, White JD. The role of grape seed extract in the treatment of chemo/radiotherapy induced toxicity: a systematic review of preclinical studies. Nutrition and Cancer. 2015;67(5):730-40.
- Brooker S, Martin S et al. Double-blind, placebo-controlled, randomised phase II trial of IH636 grape seed proanthocyanidin extract (GSPE) in patients with radiation-induced breast induration. Radiotherapy and Oncology. 2006 Apr;79(1):45-51.
- Lemole G, Mehta P, McKee D. After Cancer Care: The Definitive Self-Care Guide to Getting and Staying Well for Patients with Cancer. New York, New York: Rodale, Inc. 2015.
- Wang H, Lai YJ, Chan YL, Li TL, Wu CJ. Epigallocatechin-3-gallate effectively attenuates skeletal muscle atrophy caused by cancer cachexia. Cancer Letters. 2011 Jun 1;305(1):40-9.
- Mirza KA, Pereira SL, Edens NK, Tisdale MJ. Attenuation of muscle wasting in murine C2C 12 myotubes by epigallocatechin-3-gallate. Journal of Cachexia, Sarcopenia and Muscle. 2014 Dec;5(4):339-45.
- Hajra S, Patra AR, Basu A, Bhattacharya S. Prevention of doxorubicin (DOX)-induced genotoxicity and cardiotoxicity: effect of plant derived small molecule indole-3-carbinol (I3C) on oxidative stress and inflammation. Biomedicine & Pharmacotherapy. 2018 May;101:228-243.
- Pore SK, Hahm ER et al. Prevention of breast cancer-induced osteolytic bone resorption by benzyl isothiocyanate. Carcinogenesis. 2018 Feb 9;39(2):134-145.
- Mego M, Chovanec J et al. Prevention of irinotecan induced diarrhea by probiotics: a randomized double blind, placebo controlled pilot study. Complementary Therapies in Medicine. 2015 Jun;23(3):356-62.
- Huang L, Chiang Chiau JS et al. SCID/NOD mice model for 5-FU induced intestinal mucositis: safety and effects of probiotics as therapy. Pediatrics and Neonatology. 2018 Jul 26. pii: S1875-9572(17)30682-4.
- Ciorba MA, Riehl TE et al. Lactobacillus probiotic protects intestinal epithelium from radiation injury in a TLR-2/cyclo-oxygenase-2-dependent manner. Gut. 2012 Jun;61(6):829-38; Riehl T, Cohn S, Tessner T, Schloemann S, Stenson WF. Lipopolysaccharide is radioprotective in the mouse intestine through a prostaglandin-mediated mechanism. Gastroenterology. 2000 Jun;118(6):1106-16.
- Bastos RW, Pedroso SH et al. Saccharomyces cerevisiae UFMG A-905 treatment reduces intestinal damage in a murine model of irinotecan-induced mucositis. Beneficial Microbes. 2016 Sep;7(4):549-57.
- Gerhard D, Sousa FJDSS et al. Probiotic therapy reduces inflammation and improves intestinal morphology in rats with induced oral mucositis. Brazilian Oral Research. 2017 Jul 3;31:e71.
- Kato S, Hamouda N et al. Probiotic Bifidobacterium bifidum G9-1 attenuates 5-fluorouracil-induced intestinal mucositis in mice via suppression of dysbiosis-related secondary inflammatory responses. Clinical and Experimental Pharmacology and Physiology. 2017 Oct;44(10):1017-1025.
- MacDonald B. The Breast Cancer Companion: A Complementary Care Manual: Third Edition. 2016.
- Gu J, Hu W, Zhang DD. Resveratrol, a polyphenol phytoalexin, protects against doxorubicin-induced cardiotoxicity. Journal of Cellcular and Molecular Medicine. 2015 Oct;19(10):2324-8; Gu J, Hu W et al. Resveratrol-induced autophagy promotes survival and attenuates doxorubicin-induced cardiotoxicity. International Immunopharmacology. 2016 Mar;32:1-7.
- Yavuzsen T, Davis MP, Walsh D, LeGrand S, Lagman R. Systematic review of the treatment of cancer-associated anorexia and weight loss. Journal of Clinical Oncol.ogy 2005 Nov 20;23(33):8500-11; Gagnon B, Bruera E. A review of the drug treatment of cachexia associated with cancer. Drugs. 1998 May;55(5):675-88.
- MacGregor CA, Canney PA, Patterson G, McDonald R, Paul J. A randomised double-blind controlled trial of oral soy supplements versus placebo for treatment of menopausal symptoms in patients with early breast cancer. European Journal of Cancer. 2005 Mar;41(5):708-14.
- Hadji P, Coleman RE et al. Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. Annals of Oncology. 2016 Mar;27(3):379-90.
- Bauer M, Bryce J, Hadji P. Aromatase inhibitor-associated bone loss and its management with bisphosphonates in patients with breast cancer. Breast Cancer (Dove Med Press). 2012 Jun 20;4:91-101.
- O'Carrigan B, Wong MH et al. Bisphosphonates and other bone agents for breast cancer. Cochrane Database of Systematic Reviews. 2017 Oct 30;10:CD003474.
- Drugs.com. Bonefos Approval Status. Viewed March 1, 2019.
- Bhattacharyya GS, Babu KG et al. Effect of coadministered beta blocker and COX-2 inhibitor to patients with pancreatic cancer prior to receiving albumin-bound (Nab) paclitaxel. Journal of Clinical Oncology. 2015 Jan;33(3_suppl):302-302.
- Lindgren ME, Fagundes CP et al. Beta-blockers may reduce intrusive thoughts in newly diagnosed cancer patients. Psychooncology. 2013 Aug;22(8):1889-94.
- Ma Y, Bai F et al. Beta-blockers for the primary prevention of anthracycline-induced cardiotoxicity: a meta-analysis of randomized controlled trials. BMC Pharmacol Toxicol. 2019 Apr 25;20(1):18.
- Wittayanukorn S, Qian J et al. Prevention of trastuzumab and anthracycline-induced cardiotoxicity using angiotensin-converting enzyme inhibitors or β-blockers in older adults with breast cancer. American Journal of Clinical Oncology. 2018 Sep;41(9):909-918; Fanous I, Dillon P. Cancer treatment-related cardiac toxicity: prevention, assessment and management. Medical Oncology. 2016 Aug;33(8):84; Yun S, Vincelette ND, Abraham I. Cardioprotective role of β-blockers and angiotensin antagonists in early-onset anthracyclines-induced cardiotoxicity in adult patients: a systematic review and meta-analysis. Postgraduate Medical Journal. 2015 Nov;91(1081):627-33.
- Lemole G, Mehta P, McKee D. After Cancer Care: The Definitive Self-Care Guide to Getting and Staying Well for Patients with Cancer. New York, New York: Rodale, Inc. 2015.
- Noh JM, Choi DH et al. Comparison of acute skin reaction following morning versus late afternoon radiotherapy in patients with breast cancer who have undergone curative surgical resection. Journal of Radiation Research. 2014 May;55(3):553-8.
- Deprés-Brummer P, Berthault-Cvitkovic F et al. Circadian rhythm-modulated (CRM) chemotherapy of metastatic breast cancer with mitoxantrone, 5-fluorouracil, and folinic acid: preliminary results of a phase I trial. Journal of Infusional Chemotherapy. 1995;5(3 Suppl 1):144-7.
- Sultan A, Choudhary V, Parganiha A. Worsening of rest-activity circadian rhythm and quality of life in female breast cancer patients along progression of chemotherapy cycles. Chronobiology International. 2017;34(5):609-623.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Treatment. New York: Bantam Dell. 2009.
- Brown N, Panksepp J. Low-dose naltrexone for disease prevention and quality of life. Medical Hypotheses. 2009 Mar; 72; 333-337.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Treatment. New York: Bantam Dell. 2009.
- Elsegood L. Ed. The LDN Book. Vermont: Chelsea Green Publishing. 2016.
- McKinney N. Naturopathic Oncology, 3rd Edition. Victoria, BC, Canada: Liaison Press. 2016.
- Patterson S. Metformin may have broad utility in cancer. MD Anderson Cancer Center. November-December 2014. Viewed January 19, 2018.
- Zhou W, Kavelaars A, Heijnen CJ. Metformin prevents cisplatin-induced cognitive impairment and brain damage in mice. PLoS ONE. 2016;11(3):e0151890.
- Henninger C, Fritz G et al. Statins in anthracycline-induced cardiotoxicity: Rac and Rho, and the heartbreakers. Cell Death & Disease. 2017 Jan 19;8(1):e2564.
- Zick SM, Colacino J et al. Fatigue reduction diet in breast cancer survivors: a pilot randomized clinical trial. Breast Cancer Research and Treatment. 2017 Jan;161(2):299-310.
- Safdie FM, Dorff T et al. Fasting and cancer treatment in humans: a case series report. Aging (Milano) 2009;1:988–1007; Bauersfeld SP, Kessler CS et al. The effects of short-term fasting on quality of life and tolerance to chemotherapy in patients with breast and ovarian cancer: a randomized cross-over pilot study. BMC Cancer. 2018 Apr 27;18(1):476.
- Montgomery GH, Sucala M, Dillon MJ, Schnur JB. Cognitive-behavioral therapy plus hypnosis for distress during breast radiotherapy: a randomized trial. American Journal of Clinical Hypnosis. 2017 Oct;60(2):109-122.
- Berlière M, Roelants F et al. The advantages of hypnosis intervention on breast cancer surgery and adjuvant therapy. Breast. 2018 Feb;37:114-118.
- Zick SM, Sen A. Impact of self-acupressure on co-occurring symptoms in cancer survivors. JNCI Cancer Spectrum. 2018 Nov 1;2(4): pky064.
- Deng GE, Frenkel M et al. Evidence-based clinical practice guidelines for integrative oncology: complementary therapies and botanicals. Journal of the Society for Integrative Oncology. 2009 Summer;7(3):85-120.
- Zhang Y, Lin L, Li H, Hu Y, Tian L Effects of acupuncture on cancer-related fatigue: a meta-analysis. Support Care Cancer. 2018 Feb;26(2):415-425.
- Mao JJ, Bowman MA et al. Electroacupuncture versus gabapentin for hot flashes among breast cancer survivors: a randomized placebo-controlled trial. Journal of Clinical Oncology. 2015 Nov 1;33(31):3615-20.
- Zick SM, Sen A. Impact of self-acupressure on co-occurring symptoms in cancer survivors. JNCI Cancer Spectrum. 2018 Nov 1;2(4): pky064.
- Kim TH, Kang JW, Lee MS. Current evidence of acupuncture for symptoms related to breast cancer survivors: a PRISMA-compliant systematic review of clinical studies in Korea. Medicine (Baltimore). 2018 Aug;97(32):e11793; Lu W, Giobbie-Hurder A et al. Acupuncture for chemotherapy-induced peripheral neuropathy in breast cancer survivors: a randomized controlled pilot trial. Oncologist. 2020;25(4):310-318.
- Brinkhaus B, Kirschbaum B et al. Prophylactic acupuncture treatment during chemotherapy with breast cancer: a randomized pragmatic trial with a retrospective nested qualitative study. Breast Cancer Research and Treatment. 2019 Dec;178(3):617-628.
- Sturgeon M, Wetta-Hall R, Hart T, Good M, Dakhil S. Effects of therapeutic massage on the quality of life among patients with breast cancer during treatment. The Journal of Alternative and Complementary Medicine. 2009 Apr;15(4):373-80.
- Hanai A, Ishiguro H et al. Effects of cryotherapy on objective and subjective symptoms of paclitaxel-induced neuropathy: prospective self-controlled trial. Journal of the National Cancer Institute. 2018 Feb 1;110(2):141-148; Schuler U, Heller S. [Chemotherapy-induced peripheral neuropathy and neuropathic pain]. [Article in German] Schmerz. 2017 Aug;31(4):413-425.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Treatment. New York: Bantam Dell. 2009.
- Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 2019 Aug 29. pii: S0140-6736(19)31709-X.
- Nelson R. Menopausal hormone therapy and breast cancer link confirmed. Medscape. August 29, 2019. Viewed September 24, 2019.
- Al Ajmi K, Lophatananon A, Mekli K, Ollier W, Muir KR. Association of nongenetic factors with breast cancer risk in genetically predisposed groups of women in the UK Biobank Cohort. JAMA Network Open. 2020;3(4):e203760.
- Schettler T. The Ecology of Breast Cancer: The Promise of Prevention and the Hope for Healing. Science and Environmental Health Network and The Collaborative on Health and the Environment. October 2013; Sun YS, Zhao Z et al. Risk factors and preventions of breast cancer. International Journal of Biological Sciences. 2017 Nov 1;13(11):1387-1397; Rice MS, Eliassen AH et al. Breast cancer research in the Nurses' Health Studies: exposures across the life course. American Journal of Public Health. 2016 Sep;106(9):1592-8.
- ASCO Post Staff. Study clarifies time-dependent effects of oral contraceptives on risk of ovarian, endometrial, and breast cancers. ASCO Post. December 23, 2020. Viewed January 5, 2021; Karlsson T, Johansson T, Höglund J, Ek WE, Johansson Å. Time-dependent effects of oral contraceptive use on breast, ovarian and endometrial cancers. Cancer Research. 2020 Dec 17:canres.2476.2020.
- Schettler T. The Ecology of Breast Cancer: The Promise of Prevention and the Hope for Healing. Science and Environmental Health Network and The Collaborative on Health and the Environment. October 2013.
- Schettler T. The Ecology of Breast Cancer: The Promise of Prevention and the Hope for Healing. Science and Environmental Health Network and The Collaborative on Health and the Environment. October 2013.
- Al Ajmi K, Lophatananon A, Mekli K, Ollier W, Muir KR. Association of nongenetic factors with breast cancer risk in genetically predisposed groups of women in the UK Biobank Cohort. JAMA Network Open. 2020;3(4):e203760.
- Eberle CE, Sandler DP, Taylor KW, White AJ. Hair dye and chemical straightener use and breast cancer risk in a large US population of black and white women. International Journal of Cancer. 2019 Dec 3.
- Arthur RS, Dannenberg AJ, Kim M, Rohan TE. The association of body fat composition with risk of breast, endometrial, ovarian and colorectal cancers among normal weight participants in the UK Biobank. British Journal of Cancer. 2021 Mar 15.
- Feigelson HS, Bodelon C, Powers JD et al. Body mass index and risk of second cancer among women with breast cancer. Journal of the National Cancer Institute. 2021 Apr 5:djab053.
- Kruk J, Aboul-Enein BH, Bernstein J, Gronostaj M. Psychological stress and cellular aging in cancer: a meta-analysis. Oxidative Medicine and Cellular Longevity. 2019 Nov 13;2019:1270397.
- National Institute on Alcohol Abuse and Alcoholism. Alcohol's Effects on the Body. National Institutes of Health. Viewed October 5, 2018; Scoccianti C, Lauby-Secretan B, Bello PY, Chajes V, Romieu I. Female breast cancer and alcohol consumption: a review of the literature. American Journal Preventive Medicine. 2014 Mar;46(3 Suppl 1):S16-25; Al Ajmi K, Lophatananon A, Mekli K, Ollier W, Muir KR. Association of nongenetic factors with breast cancer risk in genetically predisposed groups of women in the UK Biobank Cohort. JAMA Network Open. 2020;3(4):e203760.
- Simapivapan P, Boltong A, Hodge A. To what extent is alcohol consumption associated with breast cancer recurrence and second primary breast cancer?: A systematic review. Cancer Treatment Reviews. 2016 Nov;50:155-167; Kwan ML, Chen WY et al. Postdiagnosis alcohol consumption and breast cancer prognosis in the after breast cancer pooling project. Cancer Epidemiology, Biomarkers & Prevention. 2013 Jan;22(1):32-41.
- Alcohol and cancer risk. American Institute for Cancer Research. Viewed October 4, 2018.
- Rock CL, Thomson C et al. American Cancer Society guideline for diet and physical activity for cancer prevention. CA: A Cancer Journal for Clinicians. 2020;10.3322/caac.21591.
- Johns SA, Stutz PV et al. Acceptance and commitment therapy for breast cancer survivors with fear of cancer recurrence: a 3-arm pilot randomized controlled trial. Cancer. 2020;126(1):211–218.
- GBD 2016 Alcohol Collaborators. Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2018 Sep 22;392(10152):1015-1035.
- National Cancer Institute. Reproductive History and Cancer Risk. National Institutes of Health. November 9, 2016. Viewed October 5, 2018.
- Cordeiro B. Breastfeeding lowers your breast cancer risk. The University of Texas MD Anderson Cancer Center. Viewed October 5, 2018.
- Al Ajmi K, Lophatananon A, Mekli K, Ollier W, Muir KR. Association of nongenetic factors with breast cancer risk in genetically predisposed groups of women in the UK Biobank Cohort. JAMA Network Open. 2020;3(4):e203760.
- Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE. Adult weight change and risk of postmenopausal breast cancer. JAMA. 2006 Jul 12;296(2):193-201.
- Teras LR, Patel AV et al. Sustained weight loss and risk of breast cancer in women ≥50 years: a pooled analysis of prospective data. Journal of the National Cancer Institute. 2019;djz226.
- Pasta V, Gullo G et al. An association of boswellia, betaine and myo-inositol (Eumastós) in the treatment of mammographic breast density: a randomized, double-blind study. European Review for Medical and Pharmacological Sciences. 2015 Nov;19(22):4419-26.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Treatment. New York: Bantam Dell. 2009.
- McKinney N. Naturopathic Oncology, 3rd Edition. Victoria, BC, Canada: Liaison Press. 2016.
- Talib WH, Al-Hadid SA, Ali MBW, Al-Yasari IH, Ali MRA. Role of curcumin in regulating p53 in breast cancer: an overview of the mechanism of action. Breast Cancer: Targets and Therapy (Dove Med Press). 2018 Nov 29;10:207-217.
- Naeini MB, Momtazi AA et al. Antitumor effects of curcumin: a lipid perspective. Journal of Cellular Physiology. 2019 Feb 11; Banik U, Parasuraman S, Adhikary AK, Othman NH. Curcumin: the spicy modulator of breast carcinogenesis. Journal of Experimental and Clinical Cancer Research. 2017 Jul 19;36(1):98.
- Hussaarts KGAM, Hurkmans DP et al. Impact of curcumin (with or without piperine) on the pharmacokinetics of tamoxifen. Cancers (Basel). 2019 Mar 22;11(3). pii: E403.
- Alschuler LN, Gazella KA. The Definitive Guide to Cancer, 3rd Edition: An Integrative Approach to Prevention, Treatment, and Healing. Berkeley, California: Celestial Arts. 2010; Alschuler LN, Gazella KA. The Definitive Guide to Thriving after Cancer. Berkeley, California: Ten Speed Press. 2013.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Treatment. New York: Bantam Dell. 2009.
- MacDonald B. The Breast Cancer Companion: A Complementary Care Manual: Third Edition. 2016.
- Flower G, Fritz H et al. Flax and breast cancer: a systematic review. Integrative Cancer Therapies. 2014 May;13(3):181-92.
- Alschuler LN, Gazella KA. The Definitive Guide to Cancer, 3rd Edition: An Integrative Approach to Prevention, Treatment, and Healing. Berkeley, California: Celestial Arts. 2010; Alschuler LN, Gazella KA. The Definitive Guide to Thriving after Cancer. Berkeley, California: Ten Speed Press. 2013.
- McKinney N. Naturopathic Oncology, 3rd Edition. Victoria, BC, Canada: Liaison Press. 2016.
- Samavat H, Ursin G et al. A randomized controlled trial of green tea extract supplementation and mammographic density in postmenopausal women at increased risk of breast cancer. Cancer Prevention Research (Phila). 2017 Dec;10(12):710-718.
- MacDonald B. The Breast Cancer Companion: A Complementary Care Manual: Third Edition. 2016.
- Fabian CJ, Kimler BF, Hursting SD. Omega-3 fatty acids for breast cancer prevention and survivorship. Breast Cancer Research. 2015 May 4;17:62.
- Patterson RE, Flatt SW et al. Marine fatty acid intake is associated with breast cancer prognosis. Journal of Nutrition. 2011 Feb;141(2):201-6.
- Alschuler LN, Gazella KA. The Definitive Guide to Cancer, 3rd Edition: An Integrative Approach to Prevention, Treatment, and Healing. Berkeley, California: Celestial Arts. 2010; Alschuler LN, Gazella KA. The Definitive Guide to Thriving after Cancer. Berkeley, California: Ten Speed Press. 2013.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Treatment. New York: Bantam Dell. 2009.
- Chang R. Beyond the Magic Bullet: The Anti-Cancer Cocktail. New York: Square One Publishers. 2012.
- Lemole G, Mehta P, McKee D. After Cancer Care: The Definitive Self-Care Guide to Getting and Staying Well for Patients with Cancer. New York, New York: Rodale, Inc. 2015.
- McKinney N. Naturopathic Oncology, 3rd Edition. Victoria, BC, Canada: Liaison Press. 2016.
- de Moreno de LeBlanc A, Matar C, Perdigón G. The application of probiotics in cancer. British Journal of Nutrition. 2007 Oct;98 Suppl 1:S105-10; Toi M, Hirota S et al. Probiotic beverage with soy isoflavone consumption for breast cancer prevention: a case-control study. Current Nutrition and Food Science. 2013 Aug;9(3):194-200.
- Alschuler LN, Gazella KA. The Definitive Guide to Cancer, 3rd Edition: An Integrative Approach to Prevention, Treatment, and Healing. Berkeley, California: Celestial Arts. 2010; Alschuler LN, Gazella KA. The Definitive Guide to Thriving after Cancer. Berkeley, California: Ten Speed Press. 2013.
- Lappe J, Watson P et al. Effect of vitamin D and calcium supplementation on cancer incidence in older women: a randomized clinical trial. JAMA. 2017 Mar 28;317(12):1234-1243.
- Cauley JA, Chlebowski RT et al. Calcium plus vitamin D supplementation and health outcomes five years after active intervention ended: the Women's Health Initiative. Journal of Women’s Health. 2013 Nov;22(11):915-29.
- Poole EM, Shu X et al. Postdiagnosis supplement use and breast cancer prognosis in the After Breast Cancer Pooling Project. Breast Cancer Research and Treatment. 2013 Jun;139(2):529-37.
- Pande M, Thompson PA et al. Genetic variants in the vitamin D pathway and breast cancer disease-free survival. Carcinogenesis. 2013 Mar;34(3):587-94.
- Alschuler LN, Gazella KA. The Definitive Guide to Cancer, 3rd Edition: An Integrative Approach to Prevention, Treatment, and Healing. Berkeley, California: Celestial Arts. 2010; Alschuler LN, Gazella KA. The Definitive Guide to Thriving after Cancer. Berkeley, California: Ten Speed Press. 2013.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Treatment. New York: Bantam Dell. 2009.
- MacDonald B. The Breast Cancer Companion: A Complementary Care Manual: Third Edition. 2016.
- Poole EM, Shu X et al. Postdiagnosis supplement use and breast cancer prognosis in the After Breast Cancer Pooling Project. Breast Cancer Research and Treatment. 2013 Jun;139(2):529-37.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Treatment. New York: Bantam Dell. 2009.
- Li J, Zou L et al. Dietary mushroom intake may reduce the risk of breast cancer: evidence from a meta-analysis of observational studies. PLoS One. 2014 Apr 1;9(4):e93437.
- Patel S, Goyal A. Recent developments in mushrooms as anti-cancer therapeutics: a review. 3 Biotech. 2012 Mar;2(1):1-15; Li J, Zou L et al. Dietary mushroom intake may reduce the risk of breast cancer: evidence from a meta-analysis of observational studies. PLoS One. 2014 Apr 1;9(4):e93437.
- Fritz H, Seely D et al. Black cohosh and breast cancer: a systematic review. Integrative Cancer Therapies. 2014 Jan;13(1):12-29.
- Black Cohosh: Fact Sheet for Consumers. National Institute of Health Office of Dietary Supplements. August 30, 2018. Viewed November 6, 2018.
- Thomson CA, Ho E, Strom MB. Chemopreventive properties of 3,3'-diindolylmethane in breast cancer: evidence from experimental and human studies. Nutrition Reviews. 2016 Jul;74(7):432-43.
- Thomson CA, Chow HHS et al. A randomized, placebo-controlled trial of diindolylmethane for breast cancer biomarker modulation in patients taking tamoxifen. Breast Cancer Research and Treatment. 2017 Aug;165(1):97-107.
- Baena Ruiz R, Salinas Hernández P. Cancer chemoprevention by dietary phytochemicals: epidemiological evidence. Maturitas. 2016 Dec;94:13-19.
- Alschuler LN, Gazella KA. The Definitive Guide to Cancer, 3rd Edition: An Integrative Approach to Prevention, Treatment, and Healing. Berkeley, California: Celestial Arts. 2010; Alschuler LN, Gazella KA. The Definitive Guide to Thriving after Cancer. Berkeley, California: Ten Speed Press. 2013.
- Bakker MF, Peeters PH et al. Plasma carotenoids, vitamin C, tocopherols, and retinol and the risk of breast cancer in the European Prospective Investigation into Cancer and Nutrition cohort. American Journal of Clinical Nutrition. 2016 Feb;103(2):454-64; Misotti AM, Gnagnarella P. Vitamin supplement consumption and breast cancer risk: a review. Ecancermedicalscience. 2013 Oct 23;7:365; Lazzeroni M, Gandini S et al. The science behind vitamins and natural compounds for breast cancer prevention. Getting the most prevention out of it. Breast. 2011 Oct;20 Suppl 3:S36-41.
- Cadeau C, Fournier A et al. Vitamin C supplement intake and postmenopausal breast cancer risk: interaction with dietary vitamin C. American Journal of Clinical Nutrition. 2016 Jul;104(1):228-34.
- Nechuta S, Lu W et al. Vitamin supplement use during breast cancer treatment and survival: a prospective cohort study. Cancer Epidemiology, Biomarkers & Prevention. 2011 Feb;20(2):262-71; Poole EM, Shu X et al. Postdiagnosis supplement use and breast cancer prognosis in the After Breast Cancer Pooling Project. Breast Cancer Research and Treatment. 2013 Jun;139(2):529-37.
- Nimptsch K, Rohrmann S, Kaaks R, Linseisen J. Dietary vitamin K intake in relation to cancer incidence and mortality: results from the Heidelberg cohort of the European Prospective Investigation into Cancer and Nutrition (EPIC-Heidelberg). American Journal of Clinical Nutrition. 2010 May;91(5):1348-58.
- Sehrawat A, Samanta SK et al. Withaferin A-mediated apoptosis in breast cancer cells is associated with alterations in mitochondrial dynamics. Mitochondrion. 2019 Jan 24. pii: S1567-7249(18)30225-3.
- Kim H, Hall P et al. Chemoprevention by grape seed extract and genistein in carcinogen-induced mammary cancer in rats is diet dependent. Journal of Nutrition. 2004 Dec;134(12 Suppl):3445S-3452S.
- Shamsuddin AM, Vucenik I. Mammary tumor inhibition by IP6: a review. Anticancer Research. 1999 Sep-Oct;19(5A):3671-4.
- García-Solís P, Alfaro Y et al. Inhibition of N-methyl-N-nitrosourea-induced mammary carcinogenesis by molecular iodine (I2) but not by iodide (I-) treatment Evidence that I2 prevents cancer promotion. Molecular and Cellular Endocrinology. 2005 May 31;236(1-2):49-57.
- Zhang Y, Kensler TW, Cho CG, Posner GH, Talalay P. Anticarcinogenic activities of sulforaphane and structurally related synthetic norbornyl isothiocyanates. Proceedings of the National Academy of Sciences USA. 1994 Apr 12;91(8):3147-50.
- Koh MS, Hwang JS, Moon AR. Lycopene inhibits proliferation, invasion and migration of human breast cancer cells. Biomolecules & Therapeutics. 2010;18:92–8; Ko EY, Moon A. Natural products for chemoprevention of breast cancer. Journal of Cancer Prevention. 2015 Dec;20(4):223-31.
- Greenlee H, Kwan ML et al. Antioxidant supplement use after breast cancer diagnosis and mortality in the Life After Cancer Epidemiology (LACE) cohort. Cancer. 2012 Apr 15;118(8):2048-58.
- Kladar NV, Gavarić NS, Božin BN. Ganoderma: insights into anticancer effects. European Journal of Cancer Prevention. 2016 Sep;25(5):462-71.
- Rossi EL, Khatib SA et al. Resveratrol inhibits obesity-associated adipose tissue dysfunction and tumor growth in a mouse model of postmenopausal claudin-low breast cancer. Molecular Carcinogenesis. 2018 Mar;57(3):393-407.
- Medina D, Thompson H, Ganther H, Ip C. Se-methylselenocysteine: a new compound for chemoprevention of breast cancer. Nutrition and Cancer. 2001;40(1):12-7.
- Hutchinson J, Burley VJ, Greenwood DC, Thomas JD, Cade JE. High-dose vitamin C supplement use is associated with self-reported histories of breast cancer and other illnesses in the UK Women's Cohort Study. Public Health Nutrition. 2011 May;14(5):768-77.
- Ou YJ, Chiu HF, Wong YH, Yang CC, Yang YH. Bisphosphonate use and the risk of breast cancer: a meta-analysis of observational studies. Pharmacoepidemiology and Drug Safety. 2017 Oct;26(10):1286-1295.
- Dhesy-Thind S, Fletcher GG et al. Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: a Cancer Care Ontario and American Society of Clinical Oncology clinical practice guideline. Journal of Clinical Oncology. 2017 Jun 20;35(18):2062-2081.
- Dhesy-Thind S, Fletcher GG et al. Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: a Cancer Care Ontario and American Society of Clinical Oncology clinical practice guideline. Journal of Clinical Oncology. 2017 Jun 20;35(18):2062-2081.
- Dhesy-Thind S, Fletcher GG et al. Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: a Cancer Care Ontario and American Society of Clinical Oncology clinical practice guideline. Journal of Clinical Oncology. 2017 Jun 20;35(18):2062-2081.
- Calip GS, Yu O, Elmore JG, Boudreau DM. Comparative safety of diabetes medications and risk of incident invasive breast cancer: a population-based cohort study. Cancer Causes & Control. 2016 May;27(5):709-20.
- Chlebowski RT, McTiernan A et al. Diabetes, metformin, and breast cancer in postmenopausal women. Journal of Clinical Oncology. 2012 Aug 10;30(23):2844-52.
- Zhang P, Li H, Tan X, Chen L, Wang S. Association of metformin use with cancer incidence and mortality: a meta-analysis. Cancer Epidemiology. 2013 Jun;37(3):207-18.
- Coyle C, Cafferty FH, Vale C, Langley RE. Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis. Annals of Oncology. 2016 Dec;27(12):2184-2195.
- Moris D, Kontos M, Spartalis E, Fentiman IS. The role of NSAIDs in breast cancer prevention and relapse: current evidence and future perspectives. Breast Care (Basel). 2016 Oct;11(5):339-344; Cuzick J. Preventive therapy for cancer. Lancet Oncology. 2017 Aug;18(8):e472-e482.
- Zhang X, Smith-Warner SA et al. Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and postmenopausal breast cancer incidence. Journal of Clinical Oncology. 2012 Oct 1;30(28):3468-77.
- Zhong S, Chen L et al. Aspirin use and risk of breast cancer: systematic review and meta-analysis of observational studies. Cancer Epidemiology, Biomarkers & Prevention. 2015 Nov;24(11):1645-55.
- Holmes MD, Chen WY et al. Aspirin intake and survival after breast cancer. Journal of Clinical Oncology. 2010 Mar 20;28(9):1467-72.
- Desmedt C, Demicheli R et al. Potential benefit of intra-operative administration of ketorolac on breast cancer recurrence according to the patient's body mass index. Journal of the National Cancer Institute. 2018 Oct 1;110(10):1115-1122.
- Moris D, Kontos M, Spartalis E, Fentiman IS. The role of NSAIDs in breast cancer prevention and relapse: current evidence and future perspectives. Breast Care (Basel). 2016 Oct;11(5):339-344.
- Forget P, Bouche G et al. Intraoperative ketorolac in high-risk breast cancer patients with and without inflammation. A prospective, randomized, placebo-controlled clinical trial. Cancer Research 2019;79(4 Suppl):Abstract # P1-20-01.
- US Food and Drug Administration. FDA Drug Safety Communication: FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes. US Department of Health and Human Services. February 26, 2018. Viewed March 5, 2019.
- Botteri E, Munzone E et al. Therapeutic effect of β-blockers in triple-negative breast cancer postmenopausal women. Breast Cancer Research and Treatment. 2013 Aug;140(3):567-75.
- Kim HY, Jung YJ, Lee SH, Jung HJ, Pak K. Is beta-blocker use beneficial in breast cancer? A meta-analysis. Oncology. 2017;92(5):264-268; Childers WK, Hollenbeak CS, Cheriyath P. β-blockers reduce breast cancer recurrence and breast cancer death: a meta-analysis. Clinical Breast Cancer. 2015 Dec;15(6):426-31.
- Bonovas S, Filioussi K, Tsavaris N, Sitaras NM. Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. Journal of Clinical Oncology. 2005 Dec 1;23(34):8606-12.
- Kwan ML, Habel LA, Flick ED, Quesenberry CP, Caan B. Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors. Breast Cancer Research and Treatment. 2008;109(3):573–579; Ahern TP, Pedersen L et al. Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. Journal of the National Cancer Institute. 2011;103(19):1461–1468.
- Marinac CR, Nelson SH et al. Prolonged nightly fasting and breast cancer prognosis. JAMA Oncology. 2016 Aug 1;2(8):1049-55.
- Novaes MR, Valadares F, Reis MC, Gonçalves DR, Menezes Mda C. The effects of dietary supplementation with Agaricales mushrooms and other medicinal fungi on breast cancer: evidence-based medicine. Clinics (Sao Paulo). 2011;66(12):2133-9.
- Ong SKL, Shanmugam MK et al. Focus on formononetin: anticancer potential and molecular targets. Cancers (Basel). 2019;11(5):611.
- Huang WC, Kuo KT, Bamodu OA, et al. Astragalus polysaccharide (PG2) ameliorates cancer symptom clusters, as well as improves quality of life in patients with metastatic disease, through modulation of the inflammatory cascade. Cancers (Basel). 2019;11(8).
- Denzler K, Moore et al. Characterization of the physiological response following in vivo administration of Astragalus membranaceus. Evidence-based Complementary and Alternative Medicine. 2016;2016:6861078; Li S, Sun Y et al. Anti-tumor effects and mechanisms of Astragalus membranaceus (AM) and its specific immunopotentiation: status and prospect. Journal of Ethnopharmacology. 2020 Aug 10;258:112797.
- Chen MH, May BH, Zhou IW, Zhang AL, Xue CC. Integrative medicine for relief of nausea and vomiting in the treatment of colorectal cancer using oxaliplatin-based chemotherapy: a systematic review and meta-analysis. Phytotherapy Research. 2016;30(5):741–753.
- Griffiths K, Aggarwal BB et al. Food antioxidants and their anti-inflammatory properties: a potential role in cardiovascular diseases and cancer prevention. Diseases. 2016 Aug 1;4(3). pii: E28; Baraya YS, Wong KK, Yaacob NS. The immunomodulatory potential of selected bioactive plant-based compounds in breast cancer: a review. Anticancer Agents in Medicinal Chemistry. 2017;17(6):770-783.
- Ampofo E, Schmitt BM, Menger MD, Laschke MW. Targeting the microcirculation by indole-3-carbinol and its main derivate 3,3,'-diindolylmethane: effects on angiogenesis, thrombosis and inflammation. Mini Reviews in Medicinal Chemistry. 2018;18(11):962-968.
- Lopes CM, Dourado A, Oliveira R. Phytotherapy and nutritional supplements on breast cancer. Biomed Research International. 2017;2017:7207983.
- Rossi P, Difrancia R et al. B-glucans from Grifola frondosa and Ganoderma lucidum in breast cancer: an example of complementary and integrative medicine. Oncotarget. 2018 May 15;9(37):24837-24856.
- Rossi P, Difrancia R et al. B-glucans from Grifola frondosa and Ganoderma lucidum in breast cancer: an example of complementary and integrative medicine. Oncotarget. 2018 May 15;9(37):24837-24856.
- Laviano A, Rianda S, Molfino A, Rossi Fanelli F. Omega-3 fatty acids in cancer. Current Opinion in Clinical Nutrition and Metabolic Care. 2013 Mar;16(2):156-61; Schunck WH, Konkel A, Fischer R, Weylandt KH. Therapeutic potential of omega-3 fatty acid-derived epoxyeicosanoids in cardiovascular and inflammatory diseases. Pharmacology & Therapeutics. 2018 Mar;183:177-204; Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nature Reviews. Immunology. 2008 May;8(5):349-61.
- Jin X, Ruiz Beguerie J, Sze DM, Chan GC. Ganoderma lucidum (reishi mushroom) for cancer treatment. Cochrane Database of Systematic Reviews. 2016 Apr 5;4:CD007731; Rossi P, Difrancia R et al. B-glucans from Grifola frondosa and Ganoderma lucidum in breast cancer: an example of complementary and integrative medicine. Oncotarget. 2018 May 15;9(37):24837-24856.
- Rossi EL, Khatib SA et al. Resveratrol inhibits obesity-associated adipose tissue dysfunction and tumor growth in a mouse model of postmenopausal claudin-low breast cancer. Molecular Carcinogenesis. 2018 Mar;57(3):393-407.
- Yamaguchi Y, Miyahara E, Hihara J. Efficacy and safety of orally administered Lentinula edodes mycelia extract for patients undergoing cancer chemotherapy: a pilot study. American Journal of Chinese Medicine. 2011;39(3):451-9.
- Todoric J, Antonucci L, Karin M. Targeting inflammation in cancer prevention and therapy. Cancer Prev Res (Phila). 2016 Dec;9(12):895-905.
- Reinert T, Gonçalves R, Ellis MJ. Current status of neoadjuvant endocrine therapy in early stage breast cancer. Current Treatment Options in Oncology. 2018 Apr 16;19(5):23.
- Sewell J, Sharima A et al. Pre-pectoral implant-based immediate breast reconstruction with Braxon Porcine Acellular Dermal Matrix: Is it safe with radiotherapy? European Journal of Surgical Oncology. 2018 Jun;44(6); Bettinger LN, Waters LM, Reese SW, Kutner SE, Jacobs DI. Comparative study of prepectoral and subpectoral expander-based breast reconstruction and Clavien IIIb score outcomes. Plastic and Reconstructive Surgery Global Open. 2017 Jul 26;5(7):e1433; Reitsamer R, Peintinger F. Prepectoral implant placement and complete coverage with porcine acellular dermal matrix: a new technique for direct-to-implant breast reconstruction after nipple-sparing mastectomy. Journal of Plastic, Reconstructive & Aesthetic Surgery. 2015 Feb;68(2):162-7.
- Kim JY, Davila AA et al. A meta-analysis of human acellular dermis and submuscular tissue expander breast reconstruction. Plastic and Reconstructive Surgery. 2012 Jan;129(1):28-41.
- Horowitz M, Neeman E, Sharon E, Ben-Eliyahu S. Exploiting the critical perioperative period to improve long-term cancer outcomes. Nature Reviews. Clinical Oncology. 2015 Apr;12(4):213-26.
- Lee JW, Shahzad MM et al. Surgical stress promotes tumor growth in ovarian carcinoma. Clinical Cancer Research. 2009 Apr 15;15(8):2695-702.
- Choy C, Raytis JL et al. Inhibition of β2-adrenergic receptor reduces triple-negative breast cancer brain metastases: the potential benefit of perioperative β-blockade. Oncology Reports. 2016 Jun;35(6):3135-42.
- Pantziarka P, Bouche G et al. Repurposing Drugs in Oncology (ReDO)-Propranolol as an anti-cancer agent. Ecancermedicalscience. 2016 Oct 12;10:680.
- Hiller JG, Cole SW et al. Preoperative β-blockade with propranolol reduces biomarkers of metastasis in breast cancer: a phase II randomized trial. Clinical Cancer Research. 2020;26(8):1803-1811; Cote J. Could a common and inexpensive heart medicine (beta-blockers) help cancer patients live longer? Cancer Prevention and Treatment Fund. Viewed October 31, 2017; Weberpals J, Jansen L et al. Pre- and post-diagnostic β-blocker use and lung cancer survival: a population-based cohort study. Scientific Reports. 2017 Jun 6;7(1):2911.
- Kupstas AR, Hoskins TL et al. Effect of surgery type on time to adjuvant chemotherapy and impact of delay on breast cancer survival: a National Cancer Database analysis. Annals of Surgical Oncology. 2019 Jul 22.
- Wilkins EG, Hamill JB et al. Complications in postmastectomy breast reconstruction one-year outcomes of the Mastectomy Reconstruction Outcomes Consortium (MROC) study. Annals of Surgery. 2018 Jan; 267(1):164-170); McCarthy CM, Mehrara BJ et al. Predicting complications following expander/implant breast reconstruction: an outcomes analysis based on preoperative clinical risk. Plastic and Reconstructive Surgery. 2008 Jun;121(6):1886-92; Sada A, Day CN et al. Mastectomy and immediate breast reconstruction in the elderly: trends and outcomes. Surgery. 2019 Aug 5. pii: S0039-6060(19)30357-5; Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Care. New York: Bantam Dell. 2009.
- Washer LL, Gutowski K. Breast implant infections. Infectious Disease Clinics of North America. 2012 Mar;26(1):111-25.
- Wilkins EG, Hamill JB et al. Complications in postmastectomy breast reconstruction one-year outcomes of the Mastectomy Reconstruction Outcomes Consortium (MROC) study. Annals of Surgery. 2018 Jan; 267(1):164-170; Ooi A, Song DH.Reducing infection risk in implant-based breast-reconstruction surgery: challenges and solutions. Breast Cancer: Targets and Therapies. 2016 Sep 1;8:161-72; O'Connell RL, Rattay T et al.The impact of immediate breast reconstruction on the time to delivery of adjuvant therapy: the iBRA-2 study. British Journal of Cancer. 2019 Apr;120(9):883-895.
- Department of Surgery. Breast Reconstruction. University of California San Francisco. Viewed April 11, 2019.
- Love SM. Dr. Susan Love’s Breast Book. 6th edition. De Capo Press. 2015. p. 342.
- Phillips BT, Bishawi M, Dagum AB, Khan SU, Bui DT. A systematic review of antibiotic use and infection in breast reconstruction: what is the evidence? Plastic and Reconstructive Surgery. 2013 Jan;131(1):1-13.
- Ooi A, Song DH. Reducing infection risk in implant-based breast-reconstruction surgery: challenges and solutions. Breast Cancer: Targets and Therapies. 2016 Sep 1;8:161-72.
- Cho JS, Lee MH et al. The effects of perioperative anesthesia and analgesia on immune function in patients undergoing breast cancer resection: a prospective randomized study. International Journal of Medical Sciences. 2017 Aug 18;14(10):970-976.
- 2018 Exposing a Silent Gateway to Persistent Opioid Use – A Choices Matter Status Report. Pacira BioSciences, Inc. Viewed September 10, 2019.
- Aich A, Gupta P, Gupta K. Could perioperative opioid use increase the risk of cancer progression and metastases? International Anesthesiology Clinics. 2016 Fall;54(4):e1-e16.
- Rojas KE, Fortes TA et al. Mastectomy is no longer an indication for postoperative narcotic. Americal Journal of Surgery. 2019 Jul 18. pii: S0002-9610(19)30177-1.
- Retsky M, Demicheli R et al. Reduction of breast cancer relapses with perioperative non-steroidal anti-inflammatory drugs: new findings and a review. Current Medicinal Chemistry. 2013;20(33):4163-76.
- Retsky M, Demicheli R et al. Reduction of breast cancer relapses with perioperative non-steroidal anti-inflammatory drugs: new findings and a review. Current Medicinal Chemistry. 2013;20(33):4163-76.
- Forget P, Bouche G et al. Intraoperative ketorolac in high-risk breast cancer patients with and without inflammation. A prospective, randomized, placebo-controlled clinical trial. Cancer Research 2019;79(4 Suppl):Abstract # P1-20-01.
- Eden C, Esses G, Katz D, DeMaria S Jr. Effects of anesthetic interventions on breast cancer behavior, cancer-related patient outcomes, and postoperative recovery. Surgical Oncology. 2018 Jun;27(2):266-274.
- The ASCO Post Staff. SABCS 2020: Opioid and sedative-hypnotic use after mastectomy with reconstructive surgery. December 23, 2020. Viewed February 5, 2021; Cogan JC, Raghunathan RR et al. Persistent controlled substance use following mastectomy with reconstruction surgery. Publication Number: GS3-0. 2020 San Antonio Breast Cancer Symposium®. Viewed February 5, 2021.
- Runowicz CD, Leach CR et al. American Cancer Society/American Society for Clinical Oncology breast cancer survivorship care guideline. CA: A Cancer Journal for Clinicians. 2016 Jan-Feb;66(1):43-73.
- Gan TJ, Jiao KR, Zenn M, Georgiade G. A randomized controlled comparison of electro-acupoint stimulation or ondansetron versus placebo for the prevention of postoperative nausea and vomiting. Anesthesia and Analgesia. 2004 Oct;99(4):1070-5.
- Yu JM, Qu PS et al. Observation on the analgesic effect of transcutaneous electrical acupoint stimulation for breast radical carcinoma operation. Zhen Ci Yan Jiu. 2010 Feb;35(1):43-6.
- do Carmo Almeida TC, Dos Santos Figueiredo FW et al. Effects of transcutaneous electrical nerve stimulation on proinflammatory cytokines: systematic review and meta-analysis. Mediators of Inflammation. 2018 Apr 2;2018:1094352; Jahangirifard A, Razavi M, Ahmadi ZH, Forozeshfard M. Effect of TENS on postoperative pain and pulmonary function in patients undergoing coronary artery bypass surgery. Pain Management Nursing. 2018 Aug;19(4):408-414.
- Strauch B, Herman C, Dabb R, Ignarro LJ, Pilla AA. Evidence-based use of pulsed electromagnetic field therapy in clinical plastic surgery. Aesthetic Surgery Journal. 2009 Mar-Apr;29(2):135-43; Rohde CH, Taylor EM et al. Pulsed electromagnetic fields reduce postoperative interleukin-1β, pain, and inflammation: a double-blind, placebo-controlled study in TRAM flap breast reconstruction patients. Plastic and Reconstructive Surgery. 2015 May;135(5):808e-817e. Hedén P, Pilla AA. Effects of pulsed electromagnetic fields on postoperative pain: a double-blind randomized pilot study in breast augmentation patients. Aesthetic Plastic Surgery. 2008 Jul;32(4):660-6; Rohde C, Chiang A, Adipoju O, Casper D, Pilla AA. Effects of pulsed electromagnetic fields on interleukin-1 beta and postoperative pain: a double-blind, placebo-controlled, pilot study in breast reduction patients. Plastic and Reconstructive Surgery. 2010 Jun;125(6):1620-9; Taylor EM, Hardy KL, Alonso A, Pilla AA, Rohde CH. Pulsed electromagnetic fields dosing impacts postoperative pain in breast reduction patients. Journal of Surgical Research. 2015 Jan;193(1):504-10.
- Sværdborg M, Momsen OH, Damsgaard TE. Pulsed electromagnetic fields for postoperative pain treatment after breast augmentation: a double-blind, placebo-controlled study. Aesthetic Surgery Journal. 2016 Jun;36(6):NP199-201.
- Meretoja TJ, Andersen KG et al. Clinical prediction model and tool for assessing risk of persistent pain after breast cancer surgery. Journal of Clinical Oncology. 2017 May 20;35(15):1660-1667.
- .Levene JL, Weinstein EJ et al. Local anesthetics and regional anesthesia versus conventional analgesia for preventing persistent postoperative pain in adults and children: a Cochrane systematic review and meta-analysis update. Journal of Clinical Anesthesia. 2019 Aug;55:116-127; Kairaluoma PM, Bachmann MS, Rosenberg PH, Pere PJ. Preincisional paravertebral block reduces the prevalence of chronic pain after breast surgery. Anesthesia and Analgesia. 2006 Sep;103(3):703-8.
- Kim R. Anesthetic technique and cancer recurrence in oncologic surgery: unraveling the puzzle. Cancer Metastasis Review. 2017 Mar;36(1):159-177.
- Breastcancer.org: Another study confirms Oncotype DX DCIS recurrence score predicts recurrence. Breastcancer.org. July 24, 2015. Viewed November 9, 2018.
- London S. DCIS risk signature is validated in SweDCIS population. Oncology Practice. December 26, 2017. Viewed November 9, 2018.
- Hung P, Wang S-Y et al. Long-term outcomes of sentinel lymph node biopsy for ductal carcinoma in situ. JNCI Cancer Spectrum. 2019 Dec; 3(4):pkz052.
- Chalasani P, Kiluk JV et al. Breast Cancer Guidelines. Medscape. October 24, 2019. Viewed November 6, 2019.
- Martinez-Perez C, Turnbull AK et al. Current treatment trends and the need for better predictive tools in the management of ductal carcinoma in situ of the breast. Cancer Treatment Reviews. 2017 Apr;55:163-172.
- DeCensi A, Puntoni M et al. Randomized placebo controlled trial of low-dose tamoxifen to prevent local and contralateral recurrence in breast intraepithelial neoplasia. Journal of Clinical Oncology. 2019 Apr 11:JCO1801779.
- Lemanne D, Maizes V. Advising women undergoing treatment for breast cancer: a narrative review. Journal of Alternative and Complementary Medicine. 2018 Sep/Oct;24(9-10):902-909.
- Koelwyn GJ, Newman AAC et al. Myocardial infarction accelerates breast cancer via innate immune reprogramming. Nature Medicine. 2020;26(9):1452-1458.
- Koelwyn GJ, Newman AAC et al. Myocardial infarction accelerates breast cancer via innate immune reprogramming. Nature Medicine. 2020;26(9):1452-1458.
- Thune I, Husøy A et al. Cardiovascular function and the effect of exercise training during adjuvant breast cancer treatment. Results from The EBBA-II trial. Presentation at the San Antonio Breast Cancer Symposium (SABCS) 2018. December 7, 2018.
- Gray B, Ingles J, Medi C, Driscoll T, Semsarian C. Cardiovascular effects of energy drinks in familial long QT syndrome: a randomized cross-over study. International Journal of Cardiology. 2017 Mar 15;231:150-154.
- National Comprehensive Cancer Network: Patient and Caregiver Resources: Cardiac Toxicity. 2018. Viewed September 28, 2018.
- Zamorano J-L, Saltijeral A, Perez de Isla L. Cardiac monitoring for patients under chemotherapy. E-Journal of Cardiology Practice. 2008 Nov 25;7(11).
- Curigliano G, Cardinale D et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Annals of Oncology. 2012 Oct;23 Suppl 7:vii155-66.
- Denlinger CS, Sanft T et al. Survivorship, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2018 Oct;16(10):1216-1247.
- Children's Oncology Group. Heart Health: Health LinkHealthy living after treatment of childhood cancer. October 2013. Viewed April 2, 2019.
- Tan C, Denlinger C. Cardiovascular toxicity in cancer survivors: current guidelines and future directions. American College of Cardiology. June 29, 2018. Viewed April 2, 2019.
- Hagag AA, El Shehaby WA, El-Abasy AI, Mabrouk MM. Protective role of silymarin in early doxorubicin induced cardiac dysfunction in children with acute lymphoblastic leukemia. Infectious Disorders Drug Targets. 2018 Aug 3.
- Rašković A, Stilinović N et al. The protective effects of silymarin against doxorubicin-induced cardiotoxicity and hepatotoxicity in rats. Molecules. 2011 Oct 12;16(10):8601-13.
- Ladas EJ, Kroll DJ et al. A randomized, controlled, double-blind, pilot study of milk thistle for the treatment of hepatotoxicity in childhood acute lymphoblastic leukemia (ALL). Cancer. 2010 Jan 15;116(2):506-13.
- Iarussi D, Auricchio U et al. Protective effect of coenzyme Q10 on anthracyclines cardiotoxicity: control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma. Molecular Aspects of Medicine. 1994;15 Suppl:s207-12.
- Takimoto M, Sakurai T et al. [Protective effect of CoQ 10 administration on cardial toxicity in FAC therapy]. [Article in Japanese]. Gan To Kagaku Ryoho. 1982 Jan;9(1):116-21.
- Okuma K, Furuta I, Ota K. [Protective effect of coenzyme Q10 in cardiotoxicity induced by adriamycin]. [Article in Japanese]. Gan To Kagaku Ryoho. 1984 Mar;11(3):502-8.
- Mustafa HN, Hegazy GA, Awdan SAE, AbdelBaset M. Protective role of CoQ10 or L-carnitine on the integrity of the myocardium in doxorubicin induced toxicity. Tissue Cell. 2017 Jun;49(3):410-426.
- The Summaries. Coenzyme Q10. CAM-Cancer. June 21, 2016. Viewed October 8, 2018.
- DiNicolantonio JJ, Lavie CJ, Fares H, Menezes AR, O'Keefe JH. L-carnitine in the secondary prevention of cardiovascular disease: systematic review and meta-analysis. Mayo Clinic Proceedings. 2013 Jun;88(6):544-51.
- Waldner R, Laschan C et al. Effects of doxorubicin-containing chemotherapy and a combination with L-carnitine on oxidative metabolism in patients with non-Hodgkin lymphoma. Journal of Cancer Research and Clinical Oncology. 2006 Feb;132(2):121-8.
- Waldner R, Laschan C et al. Effects of doxorubicin-containing chemotherapy and a combination with L-carnitine on oxidative metabolism in patients with non-Hodgkin lymphoma. Journal of Cancer Research and Clinical Oncology. 2006 Feb;132(2):121-8.
- Mustafa HN, Hegazy GA, Awdan SAE, AbdelBaset M. Protective role of CoQ10 or L-carnitine on the integrity of the myocardium in doxorubicin induced toxicity. Tissue Cell. 2017 Jun;49(3):410-426.
- Yi SY, Nan KJ, Chen SJ. [Effect of extract of Ginkgo biloba on doxorubicin-associated cardiotoxicity in patients with breast cancer]. [Article in Chinese]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2008 Jan;28(1):68-70.
- Markowitz JS, Donovan JL, Lindsay DeVane C, Sipkes L, Chavin KD. Multiple-dose administration of Ginkgo biloba did not affect cytochrome P-450 2D6 or 3A4 activity in normal volunteers. Journal of Clinical Psychopharmacology. 2003 Dec;23(6):576-81.
- Vardy J, Dhillon HM et al. Investigation of herb-drug interactions with ginkgo biloba in women receiving hormonal treatment for early breast cancer. Springerplus. 2013 Mar 22;2(1):126.
- Gardner CD, Zehnder JL, Rigby AJ, Nicholus JR, Farquhar JW. Effect of Ginkgo biloba (EGb 761) and aspirin on platelet aggregation and platelet function analysis among older adults at risk of cardiovascular disease: a randomized clinical trial. Blood Coagulation and Fibrinolysis. 2007 Dec;18(8):787-93.
- Wolf HR. Does Ginkgo biloba special extract EGb 761 provide additional effects on coagulation and bleeding when added to acetylsalicylic acid 500 mg daily? Drugs in R&D. 2006;7(3):163-72.
- Skrypnyk I, Maslova G, Lymanets T, Gusachenko I. L-arginine is an effective medication for prevention of endothelial dysfunction, a predictor of anthracycline cardiotoxicity in patients with acute leukemia. Experimental Oncology. 2017 Dec;39(4):308-311.
- Moreno-Vega A, Vega-Riveroll L et al. Adjuvant effect of molecular iodine in conventional chemotherapy for breast cancer. randomized pilot study. Nutrients. 2019 Jul 17;11(7). pii: E1623.
- Pittler MH, Schmidt K, Ernst E. Hawthorn extract for treating chronic heart failure: meta-analysis of randomized trials. American Journal of Medicine. 2003 Jun 1;114(8):665-74.
- Song X, Qu H et al. Efficacy and safety of L-carnitine treatment for chronic heart failure: a meta-analysis of randomized controlled trials. BioMed Research International. 2017;2017:6274854.
- Azuma J, Sawamura A et al. Therapeutic effect of taurine in congestive heart failure: a double-blind crossover trial. Clinical Cardiology. 1985 May;8(5):276-82; Ahmadian M, Dabidi Roshan V, Ashourpore E. Taurine supplementation improves functional capacity, myocardial oxygen consumption, and electrical activity in heart failure. Journal of Dietary Supplements. 2017 Jul 4;14(4):422-432.
- Jeejeebhoy F, Keith M, et al. Nutritional supplementation with MyoVive repletes essential cardiac myocyte nutrients and reduces left ventricular size in patients with left ventricular dysfunction. American Heart Journal. 2002 Jun;143(6):1092-100.
- Yang QY, Lu S, Sun HR. Clinical effect of astragalus granule of different dosages on quality of life in patients with chronic heart failure. Chinese Journal of Integrative Medicine. 2011 Feb;17(2):146-9.
- Zeng XH1, Zeng XJ, Li YY. Efficacy and safety of berberine for congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. American Journal of Cardiology. 2003 Jul 15;92(2):173-6.
- MacDonald B. The Breast Cancer Companion: A Complementary Care Manual: Third Edition. 2016.
- Stepura OB, Martynow AI. Magnesium orotate in severe congestive heart failure (MACH). International Journal of Cardiology. 2009 May 1;134(1):145-7.
- Mayer SE, Weiss NS et al. CYP2D6-inhibiting medication use and inherited CYP2D6 variation in relation to adverse breast cancer outcomes after tamoxifen therapy. Cancer Causes Control. 2019 Jan;30(1):103-112.
- Fox P, Balleine RL et al. Dose escalation of tamoxifen in patients with low endoxifen level: evidence for therapeutic drug monitoring-the TADE study. Clinical Cancer Research. 2016 Jul 1;22(13):3164-71.
- Hussaarts KGAM, Hurkmans DP et al. Impact of curcumin (with or without piperine) on the pharmacokinetics of tamoxifen. Cancers (Basel). 2019 Mar 22;11(3). pii: E403.
- Sanmukhani J, Satodia V et al. Efficacy and safety of curcumin in major depressive disorder: a randomized controlled trial. Phytotherapy Research. 2014 Apr;28(4):579-85.
- Panahi Y, Saadat A, Beiraghdar F, Sahebkar A. Adjuvant therapy with bioavailability-boosted curcuminoids suppresses systemic inflammation and improves quality of life in patients with solid tumors: a randomized double-blind placebo-controlled trial. Phytotherapy Research. 2014 Oct;28(10):1461-7.
- Qin S, Huang L et al. Efficacy and safety of turmeric and curcumin in lowering blood lipid levels in patients with cardiovascular risk factors: a meta-analysis of randomized controlled trials. Nutrition Journal. 2017 Oct 11;16(1):68.
- Eliza WL, Fai CK, Chung LP. Efficacy of Yun Zhi (Coriolus versicolor) on survival in cancer patients: systematic review and meta-analysis. Recent Patents on Inflammation & Allergy Drug Discovery. 2012 Jan;6(1):78-87.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Care. New York: Bantam Dell. 2009. p. 25.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Care. New York: Bantam Dell. 2009. p. 522.
- Simões BM, Kohler B et al. Estrogenicity of essential oils is not required to relieve symptoms of urogenital atrophy in breast cancer survivors. Therapeutic Advances in Medical Oncology. 2018 Apr 2;10:1758835918766189; Henley DV, Lipson N, Korach KS, Bloch CA. Prepubertal gynecomastia linked to lavender and tea tree oils. New England Journal of Medicine. 2007 Feb 1;356(5):479-85; Diaz A, Luque L, Badar Z, Kornic S, Danon M. Prepubertal gynecomastia and chronic lavender exposure: report of three cases. Journal of Pediatric Endocrinology & Metabolism. 2016 Jan;29(1):103-7; Politano VT, McGinty D et al. Uterotrophic assay of percutaneous lavender oil in immature female rats. International Journal of Toxicology. 2013 Mar-Apr;32(2):123-9; Shinohara K, Doi H, Kumagai C, Sawano E, Tarumi W. Effects of essential oil exposure on salivary estrogen concentration in perimenopausal women. Neuroendocrinology Letters. 2017 Jan;37(8):567-572; Henley DV, Korach KS. Physiological effects and mechanisms of action of endocrine disrupting chemicals that alter estrogen signaling. Hormones (Athens). 2010 Jul-Sep;9(3):191-205.
- Hoskins KF, Danciu OC, Ko NY, Calip GS. Association of race/ethnicity and the 21-gene recurrence score with breast cancer-specific mortality among US women. JAMA Oncology. 2021 Jan 21:e207320.
- Reuters Staff. Breast cancer overtakes lung as most common cancer—WHO. Reuters. February 2, 2021. Viewed February 6, 2021.
- Greenlee H, DuPont-Reyes MJ et al. Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment. CA: A Cancer Journal for Clinicians. 2017 May 6;67(3):194-232.
- Greenlee H, DuPont-Reyes MJ et al. Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment. CA: A Cancer Journal for Clinicians. 2017 May 6;67(3):194-232.
- Block K, Gyllenhall C et al. Survival impact of integrative cancer care in advanced metastatic breast cancer. The Breast Journal. 2009 Jul/Aug;15(4):357-366.
- Alschuler LN, Gazella KA. The Definitive Guide to Cancer, 3rd Edition: An Integrative Approach to Prevention, Treatment, and Healing. Berkeley, California: Celestial Arts. 2010; Alschuler LN, Gazella KA. The Definitive Guide to Thriving after Cancer. Berkeley, California: Ten Speed Press. 2013.
- Block KI. Life Over Cancer: The Block Center Program for Integrative Cancer Treatment. New York: Bantam Dell. 2009.
- Chang R. Beyond the Magic Bullet: The Anti-Cancer Cocktail. New York: Square One Publishers. 2012.
- Cohen L, Jefferies A. Anticancer Living: Transform Your Life and Health with the Mix of Six. New York: Viking. 2018.
- Lemole G, Mehta P, McKee D. After Cancer Care: The Definitive Self-Care Guide to Getting and Staying Well for Patients with Cancer. New York, New York: Rodale, Inc. 2015.
- MacDonald B. The Breast Cancer Companion: A Complementary Care Manual: Third Edition. 2016.
- McKinney N. Naturopathic Oncology, 3rd Edition. Victoria, BC, Canada: Liaison Press. 2016.
- Tripathy D. Chapter 21: Integrative Medicine and Breast Cancer. In Abrams DI, Weil AT. Integrative Oncology, 2nd Edition. New York, NY: Oxford University Press. 2014.
- Rugo H, Shtivelman E et al. Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancer. Breast Cancer Research and Treatment. 2007 Sep;105(1):17-28.
- Zhang M, Liu X, Li J, He L, Tripathy D. Chinese medicinal herbs to treat the side-effects of chemotherapy in breast cancer patients. Cochrane Database of Systematic Reviews. 2007. 2, CD004921.
- Sinha D, Biswas J, Nabavi SM, Bishayee A. Tea phytochemicals for breast cancer prevention and intervention: from bench to bedside and beyond. Seminars in Cancer Biology. 2017 Oct;46:33-54; Xiang LP, Wang A et al. Suppressive effects of tea catechins on breast cancer. Nutrients. 2016 Jul 28;8(8). pii: E458; Sun CL, Yuan JM, Koh WP, Yu MC. Green tea, black tea and breast cancer risk: a meta-analysis of epidemiological studies. Carcinogenesis. 2006 Jul;27(7):1310-5.
- Royston KJ, Paul B, Nozell S, Rajbhandari R, Tollefsbol TO. Withaferin A and sulforaphane regulate breast cancer cell cycle progression through epigenetic mechanisms. Experimental Cell Research. 2018 Jul 1;368(1):67-74.
- Tripathy D. Chapter 21: Integrative Medicine and Breast Cancer in Abrams DI, Weil AT. Integrative Oncology, 2nd Edition. New York, NY: Oxford University Press. 2014.
- Block K, Gyllenhall C et al. Survival impact of integrative cancer care in advanced metastatic breast cancer. The Breast Journal. 2009 Jul/Aug;15(4):357-366.
- Block K, Gyllenhall C et al. Survival impact of integrative cancer care in advanced metastatic breast cancer. The Breast Journal. 2009 Jul/Aug;15(4):357-366.
- Block K, Gyllenhall C et al. Survival impact of integrative cancer care in advanced metastatic breast cancer. The Breast Journal. 2009 Jul/Aug;15(4):357-366.
- McKinney N. Naturopathic Oncology, 3rd Edition. Victoria, BC, Canada: Liaison Press. 2016.
- Standish LJ, Dowd F et al. Breast cancer integrative oncology care and its costs. Integrative Cancer Therapies. 2017 Mar;16(1):85-95.
- Leanna Standish, ND. Email communication, September 29, 2018.
- Kleef R, Moss R et al. Complete clinical remission of stage IV triple-negative breast cancer lung metastasis administering low-dose immune checkpoint blockade in combination with hyperthermia and interleukin-2. Integrative Cancer Therapies. 2018 Sep 7:1534735418794867.
- Schettler T. The Ecology of Breast Cancer: The Promise of Prevention and the Hope for Healing. Science and Environmental Health Network and The Collaborative on Health and the Environment. October 2013. p. 167.
- Pierce JP, Stefanick ML et al. Greater survival after breast cancer in physically active women with high vegetable-fruit intake regardless of obesity. Journal of Clinical Oncology. 2007 Jun;25(17):2345–2351.
- Pierce JP, Stefanick ML et al. Greater survival after breast cancer in physically active women with high vegetable-fruit intake regardless of obesity. Journal of Clinical Oncology. 2007 Jun 10;25(17):2345-51.
- Servan-Schreiber D. Anticancer: A New Way of Life. New York: Penguin Group. 2008.
- Huerta-Yépez S, Tirado-Rodriguez AB, Hankinson O. Role of diets rich in omega-3 and omega-6 in the development of cancer. Boletín Médico del Hospital Infantil de México. 2016 Nov - Dec;73(6):446-456.
- Schettler T. The Ecology of Breast Cancer: The Promise of Prevention and the Hope for Healing. Science and Environmental Health Network and The Collaborative on Health and the Environment. October 2013.
- Harvard Health Letter. Confused about eating soy? Harvard Health Publishing. March 2018. Viewed May 29, 2019.
- Osterweil N. Diabetes prevention diet may lower mortality risk in breast cancer. Medscape Oncology. December 10, 2020. Viewed December 14, 2020; Wang T, Farvid M et al. Publication Number: GS2-09. Diabetes risk reduction diet and survival following breast cancer. 2020 San Antonio Breast Cancer Symposium. Viewed December 14, 2020.
- Koyratty N, McCann SE et al. Sugar-sweetened soda consumption and total and breast cancer mortality: the Western New York Exposures and Breast Cancer (WEB) Study. Cancer Epidemiology, Biomarkers & Prevention. 2021 Mar 2:cebp.1242.2020.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Care. New York: Bantam Dell. 2009.
- Tripathy D. Chapter 21: Integrative Medicine and Breast Cancer. In Abrams DI, Weil AT. Integrative Oncology, 2nd Edition. New York, NY: Oxford University Press. 2014.
- Chlebowski RT, Aragaki AK et al. Dietary modification and breast cancer mortality: long-term follow-up of the Women's Health Initiative randomized trial. Journal of Clinical Oncology. 2020;38(13):1419‐1428.
- Pierce JP, Stefanick ML et al. Greater survival after breast cancer in physically active women with high vegetable-fruit intake regardless of obesity. Journal of Clinical Oncology. 2007 Jun;25(17):2345–2351.
- Kojima R, Okada E et al. Dietary patterns and breast cancer risk in a prospective Japanese study. Breast Cancer (Tokyo, Japan). 2017 Jan;24(1):152-160.
- Pierce JP. Diet and breast cancer prognosis: making sense of the Women's Healthy Eating and Living and Women's Intervention Nutrition Study trials. Current Opinion in Obstetrics & Gynecology. 2009 Feb;21(1):86-91.
- Magee PJ, Rowland I. Soy products in the management of breast cancer. Current Opinion in Clinical Nutrition and Metabolic Care. 2012 Nov;15(6):586-91.
- Varinska L, Gal P, Mojzisova G, Mirossay L, Mojzis J. Soy and breast cancer: focus on angiogenesis. International Journal of Molecular Sciences. 2015 May 22;16(5):11728-49.
- Nechuta SJ, Caan BJ et al. Soy food intake after diagnosis of breast cancer and survival: an in-depth analysis of combined evidence from cohort studies of US and Chinese women. American Journal of Clinical Nutrition. 2012 Jul;96(1):123-32.
- Zhang FF, Haslam DE et al. Dietary isoflavone intake and all-cause mortality in breast cancer survivors: the Breast Cancer Family Registry. Cancer. 2017 Jun 1;123(11):2070-2079; Chi F, Wu R, Zeng YC, Xing R, Liu Y, Xu ZG. Post-diagnosis soy food intake and breast cancer survival: a meta-analysis of cohort studies. Asian Pacific Journal of Cancer Prevention. 2013;14(4):2407-12; Caan BJ, Natarajan L et al. Soy food consumption and breast cancer prognosis. Cancer Epidemiology, Biomarkers & Prevention. 2011 May;20(5):854-8.
- Patterson RE, Flatt SW et al. Marine fatty acid intake is associated with breast cancer prognosis. Journal of Nutrition. 2011 Feb;141(2):201-6.
- Knott SRV, Wagenblast E et al. Asparagine bioavailability governs metastasis in a model of breast cancer [published correction appears in Nature. 2018 Apr 4;556(7699):135]. Nature. 2018;554(7692):378‐381.
- Cedars-Sinai Medical Center. Diet may influence the spread of a deadly type of breast cancer, study finds. Medical Xpress. February 7, 2018. Viewed June 8, 2020.
- Prentice RL, Aragaki AK et al. Low-fat dietary pattern among postmenopausal women influences long-term cancer, cardiovascular disease, and diabetes outcomes. Journal of Nutrition. 2019 Jun 8. pii: nxz107.
- Cheblowski RT, Blackburn GL et al. Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study. Journal of the National Cancer Institute. 2006 Dec 20;98(24):1767-76.
- Baena Ruiz R, Salinas Hernández P. Cancer chemoprevention by dietary phytochemicals: epidemiological evidence. Maturitas. 2016 Dec;94:13-19; Higdon JV, Delage B, Williams DE, Dashwood RH. Cruciferous vegetables and human cancer risk: epidemiologic evidence and mechanistic basis. Pharmacological Research. 2007 Mar;55(3):224-36.
- Karimi Z, Bahadoran Z et al. Dietary total antioxidant capacity and the risk of breast cancer: a case-control study. Eastern Mediterranean Health Journal. 2015 Sep 28;21(8):564-71.
- Pierce JP, Natarajan L et al. Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women’s Healthy Eating and Living (WHEL) randomized trial. Journal of the American Medical Association. 2007;298(3):289–98.
- Dieli-Conwright CM, Lee K, Kiwata JL. Reducing the risk of breast cancer recurrence: an evaluation of the effects and mechanisms of diet and exercise. Current Breast Cancer Reports. 2016;8(3):139-150.
- Dieli-Conwright CM, Lee K, Kiwata JL. Reducing the risk of breast cancer recurrence: an evaluation of the effects and mechanisms of diet and exercise. Current Breast Cancer Reports. 2016;8(3):139-150.
- Caan BJ, Kwan ML et al. Weight change and survival after breast cancer in the after breast cancer pooling project. Cancer Epidemiology, Biomarkers & Prevention. 2012 Aug;21(8):1260-71.
- Gold EB, Pierce JP et al. Dietary pattern influences breast cancer prognosis in women without hot flashes: the Women’s Healthy Eating and Living Trial. Journal of Clinical Oncology. 2009 Jan 20;27(3):352–359.
- Dieli-Conwright CM, Lee K, Kiwata JL. Reducing the risk of breast cancer recurrence: an evaluation of the effects and mechanisms of diet and exercise. Current Breast Cancer Reports. 2016;8(3):139-150.
- Toniolo P, Van Kappel AL et al. Serum carotenoids and breast cancer. American Journal of Epidemiology. 2001 Jun 15;153(12):1142-7.
- Baena Ruiz R, Salinas Hernández P. Cancer chemoprevention by dietary phytochemicals: epidemiological evidence. Maturitas. 2016 Dec;94:13-19.
- Bae JM. Reinterpretation of the results of a pooled analysis of dietary carotenoid intake and breast cancer risk by using the interval collapsing method. Epidemiology and Health. 2016 Jun 2;38:e2016024.
- Nagel G, Linseisen J et al. Dietary beta-carotene, vitamin C and E intake and breast cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). Breast Cancer Research and Treatment. 2010 Feb;119(3):753-65.
- Fabian CJ, Kimler BF, Hursting SD. Omega-3 fatty acids for breast cancer prevention and survivorship. Breast Cancer Research. 2015 May 4;17:62.
- Patterson RE, Flatt SW et al. Marine fatty acid intake is associated with breast cancer prognosis. Journal of Nutrition. 2011 Feb;141(2):201-6.
- Aceves C, Anguiano B, Delgado G. Is iodine a gatekeeper of the integrity of the mammary gland? Journal of Mammary Gland Biology and Neoplasia. 2005;10(2):189–196.
- Shin MH, Holmes MD et al. Intake of dairy products, calcium, and vitamin D and risk of breast cancer. Journal of the National Cancer Institute. 2002 Sep 4;94(17):1301-11.
- Wang J, John EM, Horn-Ross PL, Ingles SA. Dietary fat, cooking fat, and breast cancer risk in a multiethnic population. Nutrition and Cancer. 2008;60(4):492-504; Dhaka V, Gulia N, Ahlawat KS, Khatkar BS. Trans fats-sources, health risks and alternative approach—a review. Journal of Food Science and Technology. 2011 Oct;48(5):534-41.
- de Souza RJ, Mente A et al. Intake of saturated and trans unsaturated fatty acids and risk of all cause mortality, cardiovascular disease, and type 2 diabetes: systematic review and meta-analysis of observational studies. BMJ. 2015 Aug 11;351:h3978.
- Schettler T. The Ecology of Breast Cancer: The Promise of Prevention and the Hope for Healing. Science and Environmental Health Network and The Collaborative on Health and the Environment. October 2013. p. 40.
- Yasuda MT, Sakakibara H, Shimoi K. Estrogen- and stress-induced DNA damage in breast cancer and chemoprevention with dietary flavonoid. Genes and Environment. 2017 Feb 1;39:10.
- Xiang LP, Wang A et al. Suppressive effects of tea catechins on breast cancer. Nutrients. 2016 Jul 28;8(8). pii: E458.
- Wu AH, Koh WP, Wang R, Lee HP, Yu MC. Soy intake and breast cancer risk in Singapore Chinese Health Study. British Journal of Cancer. 2008 Jul 8;99(1):196-200; Wu AH, Wan P, Hankin J, Tseng CC, Yu MC, Pike MC. Adolescent and adult soy intake and risk of breast cancer in Asian-Americans. Carcinogenesis. 2002 Sep;23(9):1491-6; Wu AH, Yu MC, Tseng CC, Pike MC. Epidemiology of soy exposures and breast cancer risk. British Journal of Cancer. 2008 Jan 15;98(1):9-14.
- Nechuta SJ, Caan BJ et al. Soy food intake after diagnosis of breast cancer and survival: an in-depth analysis of combined evidence from cohort studies of US and Chinese women. American Journal of Clinical Nutrition. 2012 Jul;96(1):123-32.
- Guha N, Kwan ML et al. Soy isoflavones and risk of cancer recurrence in a cohort of breast cancer survivors: the Life After Cancer Epidemiology study. Breast Cancer Research and Treatment. 2009 Nov;118(2):395-405; Nechuta SJ, Caan BJ et al. Soy food intake after diagnosis of breast cancer and survival: an in-depth analysis of combined evidence from cohort studies of US and Chinese women. American Journal of Clinical Nutrition. 2012 Jul;96(1):123-32; Messina M, Caan BJ, Abrams DI, Hardy M, Maskarinec G. It's time for clinicians to reconsider their proscription against the use of soyfoods by breast cancer patients. Oncology (Williston Park). 2013 May;27(5):430-7.
- Woo HD, Park KS, Ro J, Kim J. Differential influence of dietary soy intake on the risk of breast cancer recurrence related to HER2 status. Nutrition and Cancer. 2012;64(2):198-205.
- Shike M, Doane AS et al. The effects of soy supplementation on gene expression in breast cancer: a randomized placebo-controlled study. Journal of the National Cancer Institute. 2014 Sep 4;106(9).
- Moussavou G, Kwak DH et al. Anticancer effects of different seaweeds on human colon and breast cancers. Marine Drugs. 2014 Sep 24;12(9):4898-911.
- Rossi P, Difrancia R et al. B-glucans from Grifola frondosa and Ganoderma lucidum in breast cancer: an example of complementary and integrative medicine. Oncotarget. 2018 May 15;9(37):24837-24856.
- Cos P, De Bruyne T et al. Proanthocyanidins in health care: current and new trends. Current Medicinal Chemistry. 2004 May;11(10):1345-59.
- Cazzaniga M, Bonanni B. Relationship between metabolic disorders and breast cancer incidence and outcomes. Is there a preventive and therapeutic role for berberine? Anticancer Research. 2018 Aug;38(8):4393-4402.
- Westphal T, Rinnerthaler G et al. Supervised versus autonomous exercise training in breast cancer patients: a multicenter randomized clinical trial. Cancer Medicine. 2018 Dec;7(12):5962-5972.
- Kirkham AA, Bland KA et al. "Chemotherapy-periodized" exercise to accommodate for cyclical variation in fatigue.
- Schettler T. The Ecology of Breast Cancer: The Promise of Prevention and the Hope for Healing. Science and Environmental Health Network and The Collaborative on Health and the Environment. October 2013. p. 73.
- Holmes MD, Chen WY, Feskanich D, Kroenke CH, Colditz GA. Physical activity and survival after breast cancer diagnosis. JAMA. 2005 May 25;293(20):2479-86; Cannioto RA, Hutson A et al. Physical activity before, during and after chemotherapy for high-risk breast cancer: relationships with survival. Journal of the National Cancer Institute. 2020;djaa046.
- Beasley JM, Kwan ML Meeting the physical activity guidelines and survival after breast cancer: findings from the after breast cancer pooling project. Breast Cancer Research and Treatment. 2012 Jan;131(2):637-43.
- Harvard Women's Health Watch. MET-hour equivalents of various physical activities. Harvard Health Publishing. December 2009. Viewed February 27, 2019.
- Nelson SH, Marinac CR et al. Impact of very low physical activity, BMI, and comorbidities on mortality among breast cancer survivors. Breast Cancer Research and Treatment. 2016 Feb;155(3):551-7.
- Courneya KS, Segal RJ et al. Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial. Journal of Clinical Oncology. 2007 Oct 1;25(28):4396-404.
- Serra MC, Ryan AS, Ortmeyer HK, Addison O, Goldberg AP. Resistance training reduces inflammation and fatigue and improves physical function in older breast cancer survivors. Menopause. 2018 Feb;25(2):211-216; Meneses-Echávez JF, González-Jiménez E, Ramírez-Vélez R. Effects of supervised exercise on cancer-related fatigue in breast cancer survivors: a systematic review and meta-analysis. BMC Cancer. 2015 Feb 21;15:77.
- Mutrie N, Campbell A, Barry S, Hefferon K, et al. Five-year follow-up of participants in a randomized controlled trial showing benefits from exercise for breast cancer survivors during adjuvant treatment. Are there lasting effects? Journal of Cancer Survivorship. 2012; Jul 27.
- Ligibel J. Lifestyle factors in cancer survivorship. Journal of Clinical Oncology. 2012 Oct 20;30(30):3697-704.
- Sánchez-Lastra MA, Torres J, Martínez-Lemos I, Ayán C. Nordic walking for women with breast cancer: a systematic review. European Journal of Cancer Care (Engl). 2019 Aug 6:e13130.
- Chan RJ, McCarthy AL, Devenish J, Sullivan KA, Chan A. Systematic review of pharmacologic and non-pharmacologic interventions to manage cognitive alterations after chemotherapy for breast cancer. European Journal of Cancer. 2015 Mar;51(4):437-50.
- Okwuosa TM, Ray RM et al. Pre-diagnosis exercise and cardiovascular events in primary breast cancer. Journal of the American College of Cardiology: CardioOncology. 2019 Sep, 1 (1) 41-50.
- Uth J, Fristrup B et al. One year of Football Fitness improves L1–L4 BMD, postural balance, and muscle strength in women treated for breast cancer. Scandinavian Journal of Medicine & Science in Sports. 2021 Apr 1.
- Schettler T. The Ecology of Breast Cancer: The Promise of Prevention and the Hope for Healing. Science and Environmental Health Network and The Collaborative on Health and the Environment. October 2013. p. 173.
- Rice MS, Eliassen AH et al. Breast cancer research in the Nurses' Health Studies: exposures across the life course. American Journal of Public Health. 2016 Sep;106(9):1592-8.
- Cannioto RA, Hutson A et al. Physical activity before, during and after chemotherapy for high-risk breast cancer: relationships with survival. Journal of the National Cancer Institute. 2020;djaa046.
- Matthews CE, Moore SC et al. Amount and intensity of leisure-time physical activity and lower cancer risk. Journal of Clinical Oncology. 2019 Dec 26:JCO1902407.
- Albanes D, Blair A, Taylor P. Physical activity and risk of cancer in the NHANES I population. American Journal of Public Health. 1989; 79(6): 744-750.
- Al Ajmi K, Lophatananon A, Mekli K, Ollier W, Muir KR. Association of nongenetic factors with breast cancer risk in genetically predisposed groups of women in the UK Biobank Cohort. JAMA Network Open. 2020;3(4):e203760.
- Ligibel JA, Dillon D et al. Impact of a pre-operative exercise intervention on breast cancer proliferation and gene expression: results from the Pre-Operative Health and Body (PreHAB) study. Clinical Cancer Research. 2019 Sep 1;25(17):5398-5406.
- Schettler T. The Ecology of Breast Cancer: The Promise of Prevention and the Hope for Healing. Science and Environmental Health Network and The Collaborative on Health and the Environment. October 2013.
- Schettler T. The Ecology of Breast Cancer: The Promise of Prevention and the Hope for Healing. Science and Environmental Health Network and The Collaborative on Health and the Environment. October 2013. p. 186.
- Li W, Kwok CC et al. Disruption of sleep, sleep-wake activity rhythm, and nocturnal melatonin production in breast cancer patients undergoing adjuvant chemotherapy: prospective cohort study. Sleep Medicine. 2018 Dec 14;55:14-21.
- Ancoli-Israel S, Liu L et al. Fatigue, sleep, and circadian rhythms prior to chemotherapy for breast cancer. Supportive Care in Cancer. 2006 Mar;14(3):201-9.
- Irwin M. Mindful Awareness Practices to Promote Sleep Health: Inflammatory Mechanisms. Keynote Presentation: Society for Integrative Oncology Conference, 2016, Miami, Florida; Irwin MR, Olmstead R et al. Tai chi chih compared with cognitive behavioral therapy for the treatment of insomnia in survivors of breast cancer: a randomized, partially blinded, noninferiority trial. Journal of Clinical Oncology. 2017 Aug 10;35(23):2656-2665; Irwin MR, Olmstead R et al. Tai chi, cellular inflammation, and transcriptome dynamics in breast cancer survivors with insomnia: a randomized controlled trial. Journal of the National Cancer Institute. Monographs. 2014 Nov;2014(50):295-301.
- Dun A, Zhao X et al. Association between night-shift work and cancer risk: updated systematic review and meta-analysis. Frontiers in Oncology. 2020 Jun 23;10:1006.
- He C, Anand ST, Ebell MH, Vena JE, Robb SW. Circadian disrupting exposures and breast cancer risk: a meta-analysis. International Archives of Occupational and Environmental Health. 2015 Jul;88: 533-47; Schernhammer ES, Laden F et al. Rotating night shifts and risk of breast cancer in women participating in the Nurses' Health Study. Journal of the National Cancer Institute. 2001 Oct 17;93(20):1563-8.
- Sephton SE, Sapolsky RM, Kraemer HC, Spiegel D. Diurnal cortisol rhythm as a predictor of breast cancer survival. Journal of the National Cancer Institute. 2000;92(12):994-1000; Andersen BL, Farrar WB et al. Stress and immune responses after surgical treatment for regional breast cancer. Journal of the National Cancer Institute. 1998 Jan 7;90(1):30-6.
- Irwin MR, Olmstead R et al. Tai chi, cellular inflammation, and transcriptome dynamics in breast cancer survivors with insomnia: a randomized controlled trial. Journal of the National Cancer Institute. Monographs. 2014 Nov;2014(50):295-301.
- Pierce JP, Patterson RE et al. Lifetime cigarette smoking and breast cancer prognosis in the After Breast Cancer Pooling Project. Journal of the National Cancer Institute. 2014 Jan;106(1):djt359.
- Schettler T. The Ecology of Breast Cancer: The Promise of Prevention and the Hope for Healing. Science and Environmental Health Network and The Collaborative on Health and the Environment. October 2013. p. 183.
- McKinney N. Naturopathic Oncology, 3rd Edition. Victoria, BC, Canada: Liaison Press. 2016. p. 64-65.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Care. New York: Bantam Dell. 2009. p. 484 and 494.
- Rodgers KM, Udesky JO, Rudel RA, Brody JG. Environmental chemicals and breast cancer: an updated review of epidemiological literature informed by biological mechanisms. Environmental Research. 2018 Jan;160:152-182; Cohn BA, La Merrill M et al. DDT exposure in utero and breast cancer. Journal of Clinical Endocrinology and Metabolism. 2015 Aug;100(8):2865-72; Cohn BA, Cirillo PM, Terry MB. DDT and breast cancer: prospective study of induction time and susceptibility windows. Journal of the National Cancer Institute. 2019 Feb 13.
- Committee on Breast Cancer and the Environment. Breast Cancer and the Environment: A Life Course Approach. Washington, DC: The National Academies Press, 2012.
- ASCO Post Staff. Study clarifies time-dependent effects of oral contraceptives on risk of ovarian, endometrial, and breast cancers. ASCO Post. December 23, 2020. Viewed January 5, 2021; Karlsson T, Johansson T, Höglund J, Ek WE, Johansson Å. Time-dependent effects of oral contraceptive use on breast, ovarian and endometrial cancers. Cancer Research. 2020 Dec 17:canres.2476.2020.
- Hood E. Breast cancer and air pollution linked by new marker. Environmental Factor. November 2020. Viewed November 2, 2020; Niehoff NM, Keil AP et al. Outdoor air pollution and terminal duct lobular involution of the normal breast. Breast Cancer Research. 2020 Sep 24;22(1):100.
- International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. July 30, 2018. Viewed October 5, 2018.
- Schettler T. The Ecology of Breast Cancer: The Promise of Prevention and the Hope for Healing. Science and Environmental Health Network and The Collaborative on Health and the Environment. October 2013. p. 182-183; Bonde J, Hansen J et al. Work at night and breast cancer—report on evidence-based options for preventive actions. Scandinavian Journal of Work, Environment and Health. 2012 Jul;38(4):380-390.
- Morère JF, Viguier J et al. Awareness and misconceptions of breast cancer risk factors among laypersons and physicians. Current Oncology Reports. 2018 Mar 5;20(Suppl 1):15.
- Hiller TWR, O'Sullivan DE, Brenner DR, Peters CE, King WD. Solar ultraviolet radiation and breast cancer risk: a systematic review and meta-analysis. Environmental Health Perspectives. 2020;128(1):16002.
- International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. July 30, 2018. Viewed October 5, 2018.
- Ozdemir D, Tas Arslan F. An investigation of the relationship between social support and coping with stress in women with breast cancer. Psychooncology. 2018 Sep;27(9):2214-2219; Alizadeh S, Khanahmadi S, Vedadhir A, Barjasteh S. The relationship between resilience with self- compassion, social support and sense of belonging in women with breast cancer. Asian Pacific Journal of Cancer Prevention. 2018 Sep 26;19(9):2469-2474.
- Kroenke CH, Michael YL et al. Postdiagnosis social networks and breast cancer mortality in the After Breast Cancer Pooling Project. Cancer. 2017 Apr 1;123(7):1228-1237.
- Spiegel D, Bloom JR, Yalom I. Group support for patients with metastatic cancer: a randomized outcome study. Archives of General Psychiatry. 1981;38:527-533; Goodwin PJ, Leszcz M et al. The effect of group psychosocial support on survival in metastatic breast cancer. New England Journal of Medicine. 2001 Dec 13;345(24):1719-26.
- Watson M, Haviland JS, Greer S, Davidson J, Bliss JM. Influence of psychological response on survival in breast cancer: a population-based cohort study. Lancet. 1999 Oct 16;354(9187):1331-6.
- Cunningham AJ, Edmonds CV, Phillips C, Soots KI, Hedley D. A prospective, longitudinal study of the relationship of psychological work to duration of survival in patients with metastatic cancer. Psychooncology. 2000 Jul-Aug;9(4):323-39.
- Cunningham AJ, Watson K. How psychological therapy may prolong survival in cancer patients: new evidence and a simple theory. Integrative Cancer Therapies; 2004 Sep;3(3):214-29.
- Block KI. Life Over Cancer. New York: Bantam Dell. 2009. p. 215; Iwamitsu Y, Shimoda K et al. The relation between negative emotional suppression and emotional distress in breast cancer diagnosis and treatment. Health Communication. 2005;18(3):201-15.
- Bai M, Lazenby M. A systematic review of associations between spiritual well-being and quality of life at the scale and factor levels in studies among patients with cancer. Journal of Palliative Medicine. 2015 Mar;18(3):286-98.
- Bakker MF, de Lange SV et al. Supplemental MRI screening for women with extremely dense breast tissue. New England Journal of Medicine. 2019 Nov 28;381(22):2091-2102.
- Blondeaux E, Perachino M et al. GS3-09. Chances of pregnancy after breast cancer, reproductive and disease outcomes: a systematic review and meta-analysis. 2020 San Antonio Breast Cancer Symposium. December 10, 2020. Viewed December 18, 2020.
- The ASCO Post Staff. SABCS 2020: meta-analysis of pregnancy outcomes in breast cancer survivors. The ASCO Post December 23, 2020. Viewed February 5, 2021; Blondeaux E, Perachino M et al. Chances of pregnancy after breast cancer, reproductive and disease outcomes: a systematic review and meta-analysis. 2020 San Antonio Breast Cancer Symposium®. Publication Number: GS3-09. Viewed February 5, 2021.
- Wagner LI, Gray RJ et al. Patient-reported cognitive impairment among women with early breast cancer randomly assigned to endocrine therapy alone versus chemoendocrine therapy: results from TAILORx. Journal of Clinical Oncology. 2020;38(17):1875-1886.
- Hanna TP, King WD et al. Mortality due to cancer treatment delay: systematic review and meta-analysis. BMJ. 2020 Nov 4;371:m4087; Reinberg S. Delaying cancer care costs lives. HealthDay. November 5, 2020. Viewed November 8, 2020.
- Kelly CM, Juurlink DN et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ. 2010;340:c693.
- Desmarais JE, Looper KJ. Interactions between tamoxifen and antidepressants via cytochrome P450 2D6. Journal of Clinical Psychiatry. 2009;70(12):1688-1697.
- National Cancer Institute. Hormone Therapy for Breast Cancer. National Institutes of Health. February 14, 2017. Viewed September 2, 2020.
- Thomson CA, Chow HHS et al. A randomized, placebo-controlled trial of diindolylmethane for breast cancer biomarker modulation in patients taking tamoxifen. Breast Cancer Research and Treatment. 2017;165(1):97-107.
- Hussaarts KGAM, Hurkmans DP et al. Impact of curcumin (with or without piperine) on the pharmacokinetics of tamoxifen. Cancers (Basel). 2019;11(3):403.
- Tripathy D. Chapter 21: Integrative Medicine and Breast Cancer in Abrams DI, Weil AT. Integrative Oncology, 2nd Edition. New York, NY: Oxford University Press. 2014.
- Mason JK, Thompson LU. Flaxseed and its lignan and oil components: can they play a role in reducing the risk of and improving the treatment of breast cancer? Applied Physiology, Nutrition, and Metabolism. 2014 Jun;39(6):663-78.
- Flower G, Fritz H et al. Flax and breast cancer: a systematic review. Integrative Cancer Therapies. 2014 May;13(3):181-92.
- Li Y, Li S et al. Melatonin for the prevention and treatment of cancer. Oncotarget. 2017 Jun 13;8(24):39896-39921.
- Li Y, Li S et al. Melatonin for the prevention and treatment of cancer. Oncotarget. 2017 Jun 13;8(24):39896-39921.
- Li Y, Li S et al. Melatonin for the prevention and treatment of cancer. Oncotarget. 2017 Jun 13;8(24):39896-39921.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Treatment. New York: Bantam Dell. 2009.
- Toi M, Hattori T et al. Randomized adjuvant trial to evaluate the addition of tamoxifen and Krestin (PSK)™ to chemotherapy in patients with primary breast cancer. 5-year results from the Nishi-Nippon Group of the Adjuvant Chemoendocrine Therapy for Breast Cancer Organization. Cancer. 1992;70:2475–2483; Eliza WL, Fai CK, Chung LP. Efficacy of Yun Zhi (Coriolus versicolor) on survival in cancer patients: systematic review and meta-analysis. Recent Patents on Inflammation & Allergy Drug Discovery. 2012 Jan;6(1):78-87.
- Iino Y, Yokoe T et al. Immunochemotherapies versus chemotherapy as adjuvant treatment after curative resection of operable breast cancer. Anticancer Research. 1995;15:2907–2911; Yokoe T, Iino Y et al. HLA antigen as predictive index for the outcome of breast cancer patients with adjuvant immunochemotherapy with PSK. Anticancer Research. 1997;17:2815–2818.
- National Cancer Institute. Medicinal Mushrooms (PDQ®)–Health Professional Version: Turkey Tail and Polysaccharide-K. October 6, 2017. Viewed February 28, 2018.
- National Cancer Institute. Medicinal Mushrooms (PDQ®)–Health Professional Version: Turkey Tail and Polysaccharide-K. October 6, 2017. Viewed February 28, 2018.
- National Cancer Institute. Medicinal Mushrooms (PDQ®)–Health Professional Version: Turkey Tail and Polysaccharide-K. October 6, 2017. Viewed February 28, 2018.
- Chiba A, Raman R et al. Serum vitamin D levels affect pathologic complete response in patients undergoing neoadjuvant systemic therapy for operable breast cancer. Clinics in Breast Cancer. 2017 Dec 11. pii: S1526-8209(17)30324-5.
- NCI Staff. Vitamin D deficiency may promote spread of some breast cancers. National Cancer Institute. April 14, 2016. Viewed November 30, 2017.
- Kim Y, Je Y. Vitamin D intake, blood 25(OH)D levels, and breast cancer risk or mortality: a meta-analysis. British Journal of Cancer. 2014 May 27;110(11):2772-84; Li M, Chen P et al. Review: the impacts of circulating 25-hydroxyvitamin D levels on cancer patient outcomes: a systematic review and meta-analysis. Journal of Clinical Endocrinology and Metabolism. 2014 Jul;99(7):2327-36; Yao S, Sheng H et al. Clinically sufficient vitamin D levels at breast cancer diagnosis and survival outcomes in a prospective cohort of 3,995 patients after a median follow-up of 10 years. Poster presentation at the ASCO 2021 Annual Meeting. Viewed June 15, 2021.
- Griffin N, Dowling M. Vitamin D supplementation and clinical outcomes in cancer survivorship. British Journal of Nursing. 2018 Oct 18;27(19):1121-1128.
- Shahvegharasl Z, Pirouzpanah S et al. Effects of cholecalciferol supplementation on serum angiogenic biomarkers in breast cancer patients treated with tamoxifen: a controlled randomized clinical trial. Nutrition. 2020;72:110656.
- Zhu L, Li L, Li Y, Wang J, Wang Q. Chinese herbal medicine as an adjunctive therapy for breast cancer: a systematic review and meta-analysis. Evidence-based Complementary and Alternative Medicine. 2016;2016:9469276.
- Yu R, Wu X, Jia L, Lou Y. Effect of Chinese herbal compound LC09 on patients with capecitabine-associated hand-foot syndrome: a randomized, double-blind, and parallel-controlled trial. Integrative Cancer Therapies. Jan-Dec 2020;19:1534735420928466.
- Chu Z, Wang Z, Liu T, Xiong S, Liu B. Evaluation of the effects of astragalus membranaceus on the pharmacokinetics of pemetrexed disodium and gemcitabine in rats by a simple high-performance liquid chromatography/UV method. Journal of Analytical Methods in Chemistry. 2019 Apr 28;2019:3162426.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Treatment. New York: Bantam Dell. 2009.
- Cui Y, Shu XO et al. Association of ginseng use with survival and quality of life among breast cancer patients. American Journal of Epidemiology. 2006 Apr 1;163(7):645-53.
- MacDonald B. The Breast Cancer Companion: A Complementary Care Manual: Third Edition. 2016.
- Rossi P, Difrancia R et al. B-glucans from Grifola frondosa and Ganoderma lucidum in breast cancer: an example of complementary and integrative medicine. Oncotarget. 2018 May 15;9(37):24837-24856.
- Rossi P, Difrancia R et al. B-glucans from Grifola frondosa and Ganoderma lucidum in breast cancer: an example of complementary and integrative medicine. Oncotarget. 2018 May 15;9(37):24837-24856.
- Alschuler LN, Gazella KA. The Definitive Guide to Cancer, 3rd Edition: An Integrative Approach to Prevention, Treatment, and Healing. Berkeley, California: Celestial Arts. 2010; Alschuler LN, Gazella KA. The Definitive Guide to Thriving after Cancer. Berkeley, California: Ten Speed Press. 2013.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Treatment. New York: Bantam Dell. 2009.
- MacDonald B. The Breast Cancer Companion: A Complementary Care Manual: Third Edition. 2016.
- Fabian CJ, Kimler BF, Hursting SD. Omega-3 fatty acids for breast cancer prevention and survivorship. Breast Cancer Research. 2015 May 4;17:62.
- Daenen LG, Cirkel GA et al. Increased plasma levels of chemoresistance-inducing fatty acid 16:4(n-3) after consumption of fish and fish oil. JAMA Oncology. 2015 Jun;1(3):350-8.
- Bougnoux P, Hajjaji N et al. Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial. British Journal of Cancer. 2009 Dec 15;101(12):1978-85.
- VanderSluis L, Mazurak VC, Damaraju S, Field CJ. Determination of the relative efficacy of eicosapentaenoic acid and docosahexaenoic acid for anti-cancer effects in human breast cancer models. International Journal of Moleculat Sciences. 2017 Dec 4;18(12). pii: E2607.
- MacDonald B. The Breast Cancer Companion: A Complementary Care Manual: Third Edition. 2016.
- Harris HR, Orsini N, Wolk A. Vitamin C and survival among women with breast cancer: a meta-analysis. European Journal of Cancer. 2014 May;50(7):1223-31.
- Kim KN, Pie JE et al. Retinoic acid and ascorbic acid act synergistically in inhibiting human breast cancer cell proliferation. Journal of Nutritional Biochemistry. 2006 Jul;17(7):454-62.
- Lee SJ, Jeong JH et al. Effect of high-dose vitamin C combined with anti-cancer treatment on breast cancer cells. Anticancer Research. 2019 Feb;39(2):751-758.
- Ramezankhani B, Taha MF, Javeri A. Vitamin C counteracts miR-302/367-induced reprogramming of human breast cancer cells and restores their invasive and proliferative capacity. Journal of Cellular Physiology. 2019 Mar;234(3):2672-2682.
- Fritz H, Flower G et al. Intravenous vitamin C and cancer: a systematic review. Integrative Cancer Therapies. 2014 Jul;13(4):280-300.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Treatment. New York: Bantam Dell. 2009.
- Poole EM, Shu X et al. Postdiagnosis supplement use and breast cancer prognosis in the After Breast Cancer Pooling Project. Breast Cancer Research and Treatment. 2013 Jun;139(2):529-37.
- Ambrosone CB, Zirpoli GR et al. Dietary supplement use during chemotherapy and survival outcomes of patients with breast cancer enrolled in a cooperative group clinical trial (SWOG S0221). Journal of Clinical Oncology. 2019 Dec 19:JCO1901203.
- Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database of Systematic Reviews. 2012 Mar 14;(3):CD007176.
- Tripathy D. Chapter 21: Integrative Medicine and Breast Cancer. In Abrams DI, Weil AT. Integrative Oncology, 2nd Edition. New York, NY: Oxford University Press. 2014.
- Lockwood K, Moesgaard S, Yamamoto T, Folkers K. Progress on therapy of breast cancer with vitamin Q10 and the regression of metastases. Biochemical and Biophysical Research Communications. 1995 Jul 6;212(1):172-7.
- Brooks SL, Rowan G, Michael M. Potential issues with complementary medicines commonly used in the cancer population: a retrospective review of a tertiary cancer center's experience. Asia-Pacific Journal of Clinical Oncology. 2018 Jun 22.
- Alschuler LN, Gazella KA. The Definitive Guide to Cancer, 3rd Edition: An Integrative Approach to Prevention, Treatment, and Healing. Berkeley, California: Celestial Arts. 2010.
- Chang R. Beyond the Magic Bullet: The Anti-Cancer Cocktail. New York: Square One Publishers. 2012.
- Alschuler LN, Gazella KA. The Definitive Guide to Cancer, 3rd Edition: An Integrative Approach to Prevention, Treatment, and Healing. Berkeley, California: Celestial Arts. 2010; Alschuler LN, Gazella KA. The Definitive Guide to Thriving after Cancer. Berkeley, California: Ten Speed Press. 2013.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Treatment. New York: Bantam Dell. 2009.
- MacDonald B. The Breast Cancer Companion: A Complementary Care Manual: Third Edition. 2016.
- McKinney N. Naturopathic Oncology, 3rd Edition. Victoria, BC, Canada: Liaison Press. 2016.
- Lemanne D, Maizes V. Advising women undergoing treatment for breast cancer: a narrative review. Journal of Alternative and Complementary Medicine. 2018 Sep/Oct;24(9-10):902-909.
- Firestone GL, Bjeldanes LF. Indole-3-carbinol and 3-3'-diindolylmethane antiproliferative signaling pathways control cell-cycle gene transcription in human breast cancer cells by regulating promoter-Sp1 transcription factor interactions. Journal of Nutrition. 2003 Jul;133(7 Suppl):2448S-2455S.
- Lee GA, Hwang KA, Choi KC. Inhibitory effects of 3,3'-diindolylmethane on epithelial-mesenchymal transition induced by endocrine disrupting chemicals in cellular and xenograft mouse models of breast cancer. Food and Chemical Toxicology. 2017 Nov;109(Pt 1):284-295.
- Thomson CA, Chow HHS et al. A randomized, placebo-controlled trial of diindolylmethane for breast cancer biomarker modulation in patients taking tamoxifen. Breast Cancer Research and Treatment. 2017 Aug;165(1):97-107.
- Chang R. Beyond the Magic Bullet: The Anti-Cancer Cocktail. New York: Square One Publishers. 2012.
- Moreno-Vega A, Vega-Riveroll L et al. Adjuvant effect of molecular iodine in conventional chemotherapy for breast cancer. randomized pilot study. Nutrients. 2019 Jul 17;11(7). pii: E1623.
- Mendieta I, Nuñez-Anita RE et al. Molecular iodine exerts antineoplastic effects by diminishing proliferation and invasive potential and activating the immune response in mammary cancer xenografts. BMC Cancer. 2019 Mar 22;19(1):261.
- Marvibaigi M, Supriyanto E, Amini N, Abdul Majid FA, Jaganathan SK. Preclinical and clinical effects of mistletoe against breast cancer. Biomed Research International. 2014;2014:785479.
- Jin X, Ruiz Beguerie J, Sze DM, Chan GC. Ganoderma lucidum (reishi mushroom) for cancer treatment. Cochrane Database of Systematic Reviews. 2016 Apr 5;4:CD007731; Rossi P, Difrancia R et al. B-glucans from Grifola frondosa and Ganoderma lucidum in breast cancer: an example of complementary and integrative medicine. Oncotarget. 2018 May 15;9(37):24837-24856.
- Wanmuang H, Leopairut J, Kositchaiwat C, Wananukul W, Bunyaratvej S. Fatal fulminant hepatitis associated with Ganoderma lucidum (Lingzhi) mushroom powder. Journal of the Medical Association of Thailand. 2007 Jan;90(1):179-81.
- Barbieri A, Quagliariello V et al. Anticancer and anti-inflammatory properties of Ganoderma lucidum extract effects on melanoma and triple-negative breast cancer treatment. Nutrients. 2017 Feb 28;9(3). pii: E210; Suarez-Arroyo IJ, Rosario-Acevedo R et al. Anti-tumor effects of Ganoderma lucidum (reishi) in inflammatory breast cancer in in vivo and in vitro models. PLoS One. 2013;8(2):e57431; Zhang Y. Ganoderma lucidum (Reishi) suppresses proliferation and migration of breast cancer cells via inhibiting Wnt/β-catenin signaling. Biochemical and Biophysical Research Communications. 2017 Jul 8;488(4):679-684; Weng CJ, Yen GC. The in vitro and in vivo experimental evidences disclose the chemopreventive effects of Ganoderma lucidum on cancer invasion and metastasis. Clinical and Experimental Metastasis. 2010 May;27(5):361-9.
- Gill SK, Rieder MJ. Toxicity of a traditional Chinese medicine, Ganoderma lucidum, in children with cancer. Canadian Journal of Clinical Pharmacology. 2008 Summer;15(2):e275-85.
- Alschuler LN, Gazella KA. The Definitive Guide to Cancer, 3rd Edition: An Integrative Approach to Prevention, Treatment, and Healing. Berkeley, California: Celestial Arts. 2010; Alschuler LN, Gazella KA. The Definitive Guide to Thriving after Cancer: A Five-Step Integrative Plan to Reduce the Risk of Recurrence and Build Lifelong Health. Berkeley, California: Ten Speed Press. 2013.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Treatment. New York: Bantam Dell. 2009.
- MacDonald B. The Breast Cancer Companion: A Complementary Care Manual: Third Edition. 2016.
- Miller ER 3rd, Pastor-Barriuso R et al. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Annals of Internal Medicine. 2005 Jan 4;142(1):37-46.
- Curtis AJ, Bullen M, Piccenna L, McNeil JJ. Vitamin E supplementation and mortality in healthy people: a meta-analysis of randomised controlled trials. Cardiovascular Drugs and Therapy. 2014 Dec;28(6):563-73.
- Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database of Systematic Reviews. 2012 Mar 14;(3):CD007176.
- Jiang Q. Natural forms of vitamin E and metabolites-regulation of cancer cell death and underlying mechanisms. IUBMB Life. 2018 Dec 11.
- Alschuler LN, Gazella KA. The Definitive Guide to Cancer, 3rd Edition: An Integrative Approach to Prevention, Treatment, and Healing. Berkeley, California: Celestial Arts. 2010; Alschuler LN, Gazella KA. The Definitive Guide to Thriving after Cancer. Berkeley, California: Ten Speed Press. 2013.
- MacDonald B. The Breast Cancer Companion: A Complementary Care Manual: Third Edition. 2016.
- Kiely M, Hodgins SJ et al. Real-time cell analysis of the inhibitory effect of vitamin K2 on adhesion and proliferation of breast cancer cells. Nutrition Research. 2015 Aug;35(8):736-43.
- Juanola-Falgarona M, Salas-Salvadó J et al. Dietary intake of vitamin K is inversely associated with mortality risk. Journal of Nutr. 2014 May;144(5):743-50.
- Zwakenberg SR, den Braver NR et al. Vitamin K intake and all-cause and cause specific mortality. Clinical Nutrition. 2017 Oct;36(5):1294-1300.
- Yeend T, Robinson K, Lockwood C, McArthur A. The effectiveness of fermented wheat germ extract as an adjunct therapy in the treatment of cancer: a systematic review. JBI Library of Systematic Reviews. 2012;10(42 Suppl):1-12.
- Marcsek Z, Kocsis Z, Jakab M, Szende B, Tompa A. The efficacy of tamoxifen in estrogen receptor-positive breast cancer cells is enhanced by a medical nutriment. Cancer Biother Radiopharm. 2004 Dec;19(6):746-53.
- Marcsek Z, Kocsis Z, Jakab M, Szende B, Tompa A. The efficacy of tamoxifen in estrogen receptor-positive breast cancer cells is enhanced by a medical nutriment. Cancer Biotherapy & Radiopharmaceuticals. 2004 Dec;19(6):746-53.
- Alschuler LN, Gazella KA. The Definitive Guide to Cancer, 3rd Edition: An Integrative Approach to Prevention, Treatment, and Healing. Berkeley, California: Celestial Arts. 2010; Alschuler LN, Gazella KA. The Definitive Guide to Thriving after Cancer. Berkeley, California: Ten Speed Press. 2013.
- Lee YR, Chen M et al. Reactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitory pathway. Science. 2019 May 17;364(6441). pii: eaau0159.
- Khan M, Maryam A, Mehmood T, Zhang Y, Ma T. Enhancing activity of anticancer drugs in multidrug resistant tumors by modulating p-glycoprotein through dietary nutraceuticals. Asian Pacific Journal of Cancer Prevention. 2015;16(16):6831-9.
- Hajra S, Patra AR, Basu A, Saha P, Bhattacharya S. Indole-3-Carbinol (I3C) enhances the sensitivity of murine breast adenocarcinoma cells to doxorubicin (DOX) through inhibition of NF-κβ, blocking angiogenesis and regulation of mitochondrial apoptotic pathway. Chemico-Biological Interactions. 2018 Jun 25;290:19-36.
- Dandawate PR, Subramaniam D, Jensen RA, Anant S. Targeting cancer stem cells and signaling pathways by phytochemicals: novel approach for breast cancer therapy. Seminars in Cancer Biology. 2016 Oct;40-41:192-208.
- Cover CM, Hsieh SJ et al. Indole-3-carbinol and tamoxifen cooperate to arrest the cell cycle of MCF-7 human breast cancer cells. Cancer Research. 1999 Mar 15;59(6):1244-51.
- Cevatemre B, Ari F et al. Combination of fenretinide and indole-3-carbinol results in synergistic cytotoxic activity inducing apoptosis against human breast cancer cells in vitro. Anticancer Drugs. 2013 Jul;24(6):577-86.
- Auborn KJ, Fan S et al. Indole-3-carbinol is a negative regulator of estrogen. Journal of Nutrition. 2003 Jul;133(7 Suppl):2470S-2475S.
- Lin H, Gao X et al. Indole-3-carbinol as inhibitors of glucocorticoid-induced apoptosis in osteoblastic cells through blocking ROS-mediated Nrf2 pathway. Biochemical and Biophyicals Research Communications. 2015 May 1;460(2):422-7.
- Wu X, Zhou QH, Xu K. Are isothiocyanates potential anti-cancer drugs? Acta Pharmacologica Sinica. 2009 May;30(5):501-12; Jaman MS, Sayeed MA. Ellagic acid, sulforaphane, and ursolic acid in the prevention and therapy of breast cancer: current evidence and future perspectives. Breast Cancer. 2018 Sep;25(5):517-528; Palliyaguru DL, Yuan JM, Kensler TW, Fahey JW. Isothiocyanates: translating the power of plants to people. Molecular Nutrition & Food Research. 2018 Sep;62(18):e1700965; Morris ME, Dave RA. Pharmacokinetics and pharmacodynamics of phenethyl isothiocyanate: implications in breast cancer prevention. AAPS Journal. 2014 Jul;16(4):705-13.
- Kaczyńska A, Herman-Antosiewicz A. Combination of lapatinib with isothiocyanates overcomes drug resistance and inhibits migration of HER2 positive breast cancer cells. Breast Cancer. 2017 Mar;24(2):271-280.
- Knott SRV, Wagenblast E et al. Asparagine bioavailability governs metastasis in a model of breast cancer [published correction appears in Nature. 2018 Apr 4;556(7699):135]. Nature. 2018;554(7692):378‐381.
- Shiromizu S, Kusunose N, Matsunaga N, Koyanagi S, Ohdo S. Optimizing the dosing schedule of l-asparaginase improves its anti-tumor activity in breast tumor-bearing mice. Journal of Pharmacological Sciences. 2018;136(4):228‐233.
- Pellati F, Borgonetti V et al. Cannabis sativa L. and nonpsychoactive cannabinoids: their chemistry and role against oxidative stress, inflammation, and cancer. Biomed Research International. 2018 Dec 4;2018:1691428; Caffarel MM, Andradas C, Pérez-Gómez E, Guzmán M, Sánchez C. Cannabinoids: a new hope for breast cancer therapy? Cancer Treatment Reviews. 2012 Nov;38(7):911-8; Alexander A, Smith PF, Rosengren RJ. Cannabinoids in the treatment of cancer. Cancer Letters. 2009 Nov 18;285(1):6-12.
- Williams J, Sergi D et al. The beneficial health effects of green tea amino acid l-theanine in animal models: promises and prospects for human trials. Phytotherapy Research. 2019 Jan 10.
- Glinsky VV, Raz A. Modified citrus pectin anti-metastatic properties: one bullet, multiple targets. Carbohydrate Research. 2009 Sep 28;344(14):1788-91.
- Israilides C, Kletsas D et al. In vitro cytostatic and immunomodulatory properties of the medicinal mushroom Lentinula edodes. Phytomedicine. 2008 Jun;15(6-7):512-9.
- Shen J, Tanida M et al. Effect of the culture extract of Lentinus edodes mycelia on splenic sympathetic activity and cancer cell proliferation. Autonomic Neuroscience. 2009 Jan 28;145(1-2):50-4.
- PDQ Integrative, Alternative, and Complementary Therapies Editorial Board. 714-X (PDQ®): Health Professional Version. PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); August 22, 2018. Viewed February 28, 2019.
- PDQ Integrative, Alternative, and Complementary Therapies Editorial Board. Laetrile/Amygdalin (PDQ®): Health Professional Version. PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); March 15, 2017; Milazzo S, Horneber M, Ernst E. Laetrile treatment for cancer. Cochrane Database of Systematic Reviews. 2015 Apr 28;(4):CD005476.
- Milazzo S, Horneber M, Ernst E. Laetrile treatment for cancer. Cochrane Database of Systematic Reviews. 2015 Apr 28;(4):CD005476.
- Cancer Research UK. Laetrile (amygdalin or vitamin B17). October 17, 2018. Viewed February 28, 2019.
- Bennett LM, Montgomery JL, Steinberg SM, Kulp KS. Flor-Essence herbal tonic does not inhibit mammary tumor development in Sprague Dawley rats. Breast Cancer Research and Treatment. 2004 Nov;88(1):87-93.
- Kulp KS, Montgomery JL et al. Essiac and Flor-Essence herbal tonics stimulate the in vitro growth of human breast cancer cells. Breast Cancer Research and Treatment. 2006 Aug;98(3):249-59.
- Ulbricht C, Weissner W et al. Essiac: systematic review by the natural standard research collaboration. Journal of the Society for Integrative Oncology. 2009 Spring;7(2):73-80.
- Cadoni E, Valletta E et al. Competitive reactions among glutathione, cisplatin and copper-phenanthroline complexes. Journal of Inorganic Biochemistry. 2017 Aug;173:126-133; Dong SC, Sha HH et al. Glutathione S-transferase π: a potential role in antitumor therapy. Drug Design, Development and Therapy. 2018 Oct 23;12:3535-3547.
- Roy A, Sarker S et al. Methylglyoxal at metronomic doses sensitizes breast cancer cells to doxorubicin and cisplatin causing synergistic induction of programmed cell death and inhibition of stemness. Biochemical Pharmacology. 2018 Oct;156:322-339.
- Rodman SN, Spence JM et al. Enhancement of radiation response in breast cancer stem cells by inhibition of thioredoxin- and glutathione-dependent metabolism. Radiation Research. 2016 Oct;186(4):385-395; Floberg JM, Schwarz JK. Manipulation of glucose and hydroperoxide metabolism to improve radiation response. Seminars in Radiation Oncology. 2019 Jan;29(1):33-41.
- Lu H, Samanta D et al. Chemotherapy triggers HIF-1-dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype. Proceedings of the National Academy of Sciences USA. 2015 Aug 18;112(33):E4600-9.
- Spremulli E, Wampler GL, Regelson W. Clinical study of hydrazine sulfate in advanced cancer patients. Cancer Chemotheapy and Pharmacology. 1979;3(2):121-4.
- Toth B. A review of the antineoplastic action of certain hydrazines and hydrazine-containing natural products. In Vivo. 1996 Jan-Feb;10(1):65-96; PDQ Integrative, Alternative, and Complementary Therapies Editorial Board. Hydrazine Sulfate (PDQ®): Health Professional Version. PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); August 23, 2018. Viewed February 28, 2019.
- Wise DR, Thompson CB. Glutamine addiction: a new therapeutic target in cancer. Trends in Biochemical Sciences. 2010 Aug;35(8):427-33.
- Loprinzi CL, Levitt R et al. Evaluation of shark cartilage in patients with advanced cancer: a North Central Cancer Treatment Group trial. Cancer. 2005 Jul 1;104(1):176-82.
- Shike M, Doane AS et al. The effects of soy supplementation on gene expression in breast cancer: a randomized placebo-controlled study. Journal of the National Cancer Institute. 2014 Sep 4;106(9). pii: dju189.
- Ma H, Sullivan-Halley J et al. Estrogenic botanical supplements, health-related quality of life, fatigue, and hormone-related symptoms in breast cancer survivors: a HEAL study report. BMC Complementary and Alternative Medicine. 2011 Nov 8;11:109.
- van Duursen MB, Nijmeijer SM, de Morree ES, de Jong PC, van den Berg M. Genistein induces breast cancer-associated aromatase and stimulates estrogen-dependent tumor cell growth in in vitro breast cancer model. Toxicology. 2011 Nov 18;289(2-3):67-73.
- Yang X, Belosay A et al. Dietary soy isoflavones increase metastasis to lungs in an experimental model of breast cancer with bone micro-tumors. Clinical & Experimental Metastasis. 2015 Apr;32(4):323-33.
- O'Carrigan B, Wong MH et al. Bisphosphonates and other bone agents for breast cancer. Cochrane Database of Systematic Reviews. 2017 Oct 30;10:CD003474; Dhesy-Thind S, Fletcher GG et al. Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: a Cancer Care Ontario and American Society of Clinical Oncology clinical practice guideline. Journal of Clinical Oncology. 2017 Jun 20;35(18):2062-2081.
- Diel IJ, Solomayer EF et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. New England Journal of Medicine. 1998 Aug 6;339(6):357-63.
- Dhesy-Thind S, Fletcher GG et al. Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: a Cancer Care Ontario and American Society of Clinical Oncology clinical practice guideline. Journal of Clinical Oncology. 2017 Jun 20;35(18):2062-2081.
- Gaafar A, Aljurf MD et al. Defective gammadelta T-cell function and granzyme B gene polymorphism in a cohort of newly diagnosed breast cancer patients. Experimental Hematology. 2009 Jul;37(7):838-48.
- Zhang T, Feng F et al. Efficacy and acceptability of neoadjuvant endocrine therapy in patients with hormone receptor-positive breast cancer: a network meta-analysis. Journal of Cellular Physiology. 2019 Jan 16.
- Hamilton E, Clay TM, Blackwell KL. New perspectives on zoledronic acid in breast cancer: potential augmentation of anticancer immune response. Cancer Investigation. 2011 Oct;29(8):533-41.
- Drugs.com. Bonefos Approval Status. Viewed March 1, 2019.
- El-Haggar SM, El-Shitany NA, Mostafa MF, El-Bassiouny NA. Metformin may protect nondiabetic breast cancer women from metastasis. Clinical & Experimental Metastasis. 2016 Apr;33(4):339-57.
- Aksoy S, Sendur MA, Altundag K. Demographic and clinico-pathological characteristics in patients with invasive breast cancer receiving metformin. Medical Oncology. 2013;30(2):590.
- Zhang P, Li H, Tan X, Chen L, Wang S. Association of metformin use with cancer incidence and mortality: a meta-analysis. Cancer Epidemiology. 2013 Jun;37(3):207-18.
- Coyle C, Cafferty FH, Vale C, Langley RE. Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis. Annals of Oncology. 2016 Dec;27(12):2184-2195.
- Jiralerspong S, Palla SL et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. Journal of Clinical Oncology. 2009 Jul 10;27(20):3297-302.
- Davies G, Lobanova L et al. Metformin inhibits the development, and promotes the resensitization, of treatment-resistant breast cancer. PLoS One. 2017 Dec 6;12(12):e0187191.
- Song CW, Lee H et al. Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells. Scientific Reports. 2012;2:362.
- Ding L, Liang G et al. Metformin prevents cancer metastasis by inhibiting M2-like polarization of tumor associated macrophages. Oncotarget. 2015 Nov 3;6(34):36441-55.
- Rico M, Baglioni M et al. Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models. Oncotarget. 2017 Jan 10;8(2):2874-2889.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Treatment. New York: Bantam Dell. 2009.
- Chang R. Beyond the Magic Bullet: The Anti-Cancer Cocktail. New York: Square One Publishers. 2012.
- McKinney N. Naturopathic Oncology, 3rd Edition. Victoria, BC, Canada: Liaison Press. 2016.
- Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K. Beta blockers and breast cancer mortality: a population- based study. J Clin Oncol. 2011 Jul 1;29(19):2635-44.
- Childers WK, Hollenbeak CS, Cheriyath P. β-blockers reduce breast cancer recurrence and breast cancer death: a meta-analysis. Clinical Breast Cancer. 2015 Dec;15(6):426-31.
- Cardwell CR, Pottegård A et al. Propranolol and survival from breast cancer: a pooled analysis of European breast cancer cohorts. Breast Cancer Research. 2016 Dec 1;18(1):119; Kim HY, Jung YJ, Lee SH, Jung HJ, Pak K. Is beta-blocker use beneficial in breast cancer? A meta-analysis. Oncology. 2017;92(5):264-268.
- Botteri E, Munzone E et al. Therapeutic effect of β-blockers in triple-negative breast cancer postmenopausal women. Breast Cancer Research and Treatment. 2013 Aug;140(3):567-75.
- Pantziarka P, Bouche G et al. Repurposing Drugs in Oncology (ReDO)-Propranolol as an anti-cancer agent. Ecancermedicalscience. 2016 Oct 12;10:680.
- Pantziarka P, Bouche G et al. Repurposing Drugs in Oncology (ReDO)-Propranolol as an anti-cancer agent. Ecancermedicalscience. 2016 Oct 12;10:680.
- Choy C, Raytis JL et al. Inhibition of β2-adrenergic receptor reduces triple-negative breast cancer brain metastases: the potential benefit of perioperative β-blockade. Oncology Reports. 2016 Jun;35(6):3135-42.
- Choi CH, Song T et al. Meta-analysis of the effects of beta blocker on survival time in cancer patients. Journal of Cancer Research and Clinical Oncology. 2014 Jul;140(7):1179-88.
- Pasquier E, Ciccolini J et al. Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment. Oncotarget. 2011 Oct;2(10):797-809.
- Kang F, Ma W et al. Propranolol inhibits glucose metabolism and 18F-FDG uptake of breast cancer through posttranscriptional downregulation of hexokinase-2. Journal of Nuclear Medicine. 2014 Mar;55(3):439-45.
- Rivero EM, Piñero CP et al. The β 2-adrenergic agonist salbutamol inhibits migration, invasion and metastasis of the human breast cancer MDA-MB- 231 cell line. Current Cancer Drug Targets. 2017;17(8):756-766.
- von Hagens C, Walter-Sack I et al. Long-term add-on therapy (compassionate use) with oral artesunate in patients with metastatic breast cancer after participating in a phase I study (ARTIC M33/2).Phytomedicine. 2018 Sep 17;54:140-148.
- Hamacher-Brady A, Stein HA et al. Artesunate activates mitochondrial apoptosis in breast cancer cells via iron-catalyzed lysosomal reactive oxygen species production. Journal of Biological Chemistry. 2011 Feb 25;286(8):6587-601.
- Bachmeier B, Fichtner I et al. Development of resistance towards artesunate in MDA-MB-231 human breast cancer cells. PLoS One. 2011;6(5):e20550.
- Block KI. Life Over Cancer. New York: Bantam Dell. 2009. p. 476; Efferth T. Cancer combination therapies with artemisinin-type drugs. Biochemical Pharmacology. 2017 Sep 1;139:56-70.
- Baker D. Application of chronotherapy to the treatment of cancer: can changing the timing of drug administration influence efficacy and toxicity? Advances in Pharmacy. 2004 Jul;2(3):222-228.
- Borniger JC, Walker Ii WH et al. Time-of-day dictates transcriptional inflammatory responses to cytotoxic chemotherapy. Scientific Reports. 2017 Jan 24;7:41220.
- Matsunaga N, Ogino T et al. Optimized dosing schedule based on circadian dynamics of mouse breast cancer stem cells improves the antitumor effects of aldehyde dehydrogenase inhibitor. Cancer Research. 2018 Jul 1;78(13):3698-3708.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Treatment. New York: Bantam Dell. 2009.
- Chan N, Willis A et al. Influencing the tumor microenvironment: a phase II study of copper depletion using tetrathiomolybdate in patients with breast cancer at high risk for recurrence and in preclinical models of lung metastases. Clinical Cancer Research. 2017 Feb 1;23(3):666-676.
- Lu H, Samanta D et al. Chemotherapy triggers HIF-1-dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype. Proceedings of the National Academy of Sciences USA. 2015 Aug 18;112(33):E4600-9.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Treatment. New York: Bantam Dell. 2009.
- Elsegood L. Ed. The LDN Book. Vermont: Chelsea Green Publishing. 2016.
- McKinney N. Naturopathic Oncology, 3rd Edition. Victoria, BC, Canada: Liaison Press. 2016.
- Retsky M, Demicheli R et al. Reduction of breast cancer relapses with perioperative non-steroidal anti-inflammatory drugs: new findings and a review. Current Medicinal Chemistry. 2013;20(33):4163-76.
- Chen WY, Holmes MD. Role of aspirin in breast cancer survival. Current Oncology Reports. 2017 Jul;19(7):48; Hugo HJ, Saunders C, Ramsay RG, Thompson EW. New insights on COX-2 in chronic inflammation driving breast cancer growth and metastasis. Journal of Mammary Gland Biology and Neoplasia. 2015 Dec;20(3-4):109-19.
- Mc Menamin ÚC, Cardwell CR, Hughes CM, Murray LJ. Low-dose aspirin use and survival in breast cancer patients: a nationwide cohort study. Cancer Epidemiology. 2017 Apr;47:20-27.
- Elwood PC, Morgan G et al. Aspirin in the treatment of cancer: reductions in metastatic spread and in mortality: a systematic review and meta-analyses of published studies. PLoS One. 2016 Apr 20;11(4):e0152402.
- McNeil JJ, Gibbs P et al. Effect of aspirin on cancer incidence and mortality in older adults. Journal of the National Cancer Institute. 2020;djaa114.
- Schapira DV, Theodossiou C, Lyman GH. The effects of NSAIDs on breast cancer prognostic factors. Oncology Reports. 1999 Mar-Apr;6(2):433-5.
- US Food and Drug Administration. FDA Drug Safety Communication: FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes. US Department of Health and Human Services. February 26, 2018. Viewed March 5, 2019.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Treatment. New York: Bantam Dell. 2009.
- Chang R. Beyond the Magic Bullet: The Anti-Cancer Cocktail. New York: Square One Publishers. 2012.
- Sardesai SD, Thomas A et al. Inhibiting fatty acid synthase in operable triple negative breast cancer. Journal of Clinical Oncology. 38: 2020 (suppl; abstr 584).
- Chi KH, Ko HL et al. Addition of rapamycin and hydroxychloroquine to metronomic chemotherapy as a second line treatment results in high salvage rates for refractory metastatic solid tumors: a pilot safety and effectiveness analysis in a small patient cohort. Oncotarget. 2015;6(18):16735–16745.
- Buck E, Eyzaguirre A et al. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Molecular Cancer Therapeutics. 2006;5(11):2676–2684.
- Kasukabe T, Okabe-Kado J, Kato N, Sassa T, Honma Y. Effects of combined treatment with rapamycin and cotylenin A, a novel differentiation-inducing agent, on human breast carcinoma MCF-7 cells and xenografts. Breast Cancer Research. 2005;7(6):R1097–R1110.
- Wang LH, Chan JL, Li W. Rapamycin together with herceptin significantly increased anti-tumor efficacy compared to either alone in ErbB2 over expressing breast cancer cells. International Journal of Cancer. 2007;121(1):157–164.
- Manthravadi S, Shrestha A, Madhusudhana S. Impact of statin use on cancer recurrence and mortality in breast cancer: a systematic review and meta-analysis. International Journal of Cancer. 2016 Sep 15;139(6):1281-8; Mansourian M, Haghjooy-Javanmard S et al. Statins use and risk of breast cancer recurrence and death: a systematic review and meta-analysis of observational studies. Journal of Pharmacy and Pharmaceutical Sciences. 2016;19(1):72-81. p. 74; Wu QJ, Tu C et al. Statin use and breast cancer survival and risk: a systematic review and meta-analysis. Oncotarget. 2015 Dec 15;6(40):42988-3004.
- Garwood ER, Kumar AS et al. Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Research and Treatment. 2010 Jan;119(1):137-44.
- Ahmadi Y, Karimian R, Panahi Y. Effects of statins on the chemoresistance—the antagonistic drug-drug interactions versus the anti-cancer effects. Biomedicine and Pharmacotherapy. 2018 Dec;108:1856-1865.
- Micallef D, Micallef S, Schembri-Wismayer P, Calleja-Agius J. Novel applications of COX-2 inhibitors, metformin, and statins for the primary chemoprevention of breast cancer. Journal of the Turkish German Gynecological Association. 2016 Dec 1;17(4):214-223. p. 221.
- Zhang Y, Cao Y et al. Chloroquine (CQ) exerts anti-breast cancer through modulating microenvironment and inducing apoptosis. International Immunopharmacology. 2017 Jan;42:100-107.
- Liang DH, Choi DS et al. The autophagy inhibitor chloroquine targets cancer stem cells in triple negative breast cancer by inducing mitochondrial damage and impairing DNA break repair. Cancer Letters. 2016 Jul 1;376(2):249-58.
- Maycotte P, Aryal S et al. Chloroquine sensitizes breast cancer cells to chemotherapy independent of autophagy. Autophagy. 2012 Feb 1;8(2):200-12.
- Shoemaker JP. Fifty-five percent complete remission of mammary carcinoma in mice with 5-fluorouracil and chloroquine. Cancer Research. 1978 Sep;38(9):2700-2.
- Rico M, Baglioni M et al. Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models. Oncotarget. 2017 Jan 10;8(2):2874-2889.
- de Groot S, Vreeswijk MP et al. The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study. BMC Cancer. 2015;15:652.
- de Groot S, Lugtenberg RT et al. Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial. Nature Communications. 2020;11(1):3083.
- İyikesici MS, Slocum AK et al. Efficacy of metabolically supported chemotherapy combined with ketogenic diet, hyperthermia, and hyperbaric oxygen therapy for stage iv triple-negative breast cancer. Cureus. 2017 Jul 7;9(7):e1445; Branca JJ, Pacini S, Ruggiero M. Effects of pre-surgical vitamin D supplementation and ketogenic diet in a patient with recurrent breast cancer. Anticancer Research. 2015 Oct;35(10):5525-32.
- Gluschnaider U, Hertz R et al. Long-chain fatty acid analogues suppress breast tumorigenesis and progression. Cancer Research. 2014 Dec 1;74(23):6991-7002.
- Zhuang Y, Chan DK, Haugrud AB, Miskimins WK. Mechanisms by which low glucose enhances the cytotoxicity of metformin to cancer cells both in vitro and in vivo. PLoS One. 2014 Sep 25;9(9):e108444.
- Martinez-Outschoorn UE, Lisanti MP, Sotgia F. Catabolic cancer-associated fibroblasts transfer energy and biomass to anabolic cancer cells, fueling tumor growth. Seminars in Cancer Biology. 2014 Apr;25:47-60; Martinez-Outschoorn UE, Lin Z et al. Ketone body utilization drives tumor growth and metastasis. Cell Cycle. 2012 Nov 1;11(21):3964-71.
- Hegewisch-Becker S, Hossfeld DK et al. Addition of hyperthermia. heat potentiates cancer therapy. [Article in German] MMW Fortschritte der Medizin. 2001 Jun 21;143(25):28-32; Vernon CC, Hand JW et al. Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: results from five randomized controlled trials. International Journal of Radiation Oncology, Biology, Physics. 1996:35(4):731-744; Vujaskovic Z, Kim DW et al. A phase I/II study of neoadjuvant liposomal doxorubicin, paclitaxel, and hyperthermia in locally advanced breast cancer. International Journal of Hyperthermia. 2010;26(5):514-521; Jones EL, Prosnitz LR et al. Thermochemoradiotherapy improves oxygenation in locally advanced breast cancer. Clinical Cancer Research. 2004;10:4287-4293.
- Hegewisch-Becker S, Hossfeld DK et al. [Addition of hyperthermia. heat potentiates cancer therapy]. [Article in German] MMW Fortschritte der Medizin. 2001 Jun 21;143(25):28-32.
- Bennett C. Cryoablation may be a treatment option for some patients. Cancer Today. March 24, 2020. Viewed May 13, 2021.
- Fine RE, Dietz JR, Boolbol SK, Berry MP. Cryoablation without excision for early-stage breast cancer; ICE3 trial update on ipsilateral breast tumor recurrence. The American Society of Breast Surgeons Official Proceedings, Volume XXII 2021 Annual Meeting Scientific Session Abstracts. Abstract 243, p 14-15.
- Nelson R. Ask about sexual function in breast cancer patients on endocrine Tx. Medscape. November 14, 2019. Viewed November 14, 2019.
- Huang WC, Kuo KT, Bamodu OA, et al. Astragalus polysaccharide (PG2) ameliorates cancer symptom clusters, as well as improves quality of life in patients with metastatic disease, through modulation of the inflammatory cascade. Cancers (Basel). 2019;11(8).
- Yu R, Wu X, Jia L, Lou Y. Effect of Chinese herbal compound LC09 on patients with capecitabine-associated hand-foot syndrome: a randomized, double-blind, and parallel-controlled trial. Integrative Cancer Therapies. Jan-Dec 2020;19:1534735420928466.
- Hao J, Zhu X, Bensoussan A. Effects of nonpharmacological interventions in chemotherapy-induced peripheral neuropathy: an overview of systematic reviews and meta-analyses. Integrative Cancer Therapies. Jan-Dec 2020;19:1534735420945027; Noh H, Yoon SW, Park B. A systematic review of herbal medicine for chemotherapy-induced peripheral neuropathy (CIPN). Evidence Based Complementary and Alternative Medicine. 2018 Feb 14;2018:6194184; Wei X, Zhu L, Wang H, Wang C, Deng Q, Li X. Efficacy of traditional Chinese medicines in preventing oxaliplatin-induced peripheral neurotoxicity in cancer patients: a network meta-analysis. Chinese Herb Med. 2017;9(2):161-168; Deng B, Jia L, Cheng Z. Radix astragali-based Chinese herbal medicine for oxaliplatin-induced peripheral neuropathy: a systematic review and meta-analysis. Evidence-based Complementary and Alternative Medicine. 2016;2016:2421876.
- Zhu L, Li L, Li Y, Wang J, Wang Q. Chinese herbal medicine as an adjunctive therapy for breast cancer: a systematic review and meta-analysis. Evidence-based Complementary and Alternative Medicine. 2016;2016:9469276.
- Zhu ZY, Xue JX et al. Reducing postsurgical exudate in breast cancer patients by using San Huang decoction to ameliorate inflammatory status: a prospective clinical trial. Current Oncology. 2018 Dec;25(6):e507-e515.
- Ding Y, Liu Y et al. Chinese medicines for preventing and treating radiation-induced pulmonary injury: A review of 2007-2017. Frontiers in Pharmacology. 2019 Sep 5;10:927.
- Beuth J, van Leendert R, Schneider B, Uhlenbruck G. Complementary medicine on side-effects of adjuvant hormone therapy in patients with breast cancer. In Vivo. 2013 Nov-Dec;27(6):869-71.
- Lucius K, Trukova K. Integrative therapies and cardiovascular disease in the breast cancer population: a review, part 1. Integrative Medicine: A Clinician's Journal (Encinitas). 2015 Aug;14(4):22-9; Conklin KA. Coenzyme q10 for prevention of anthracycline-induced cardiotoxicity. Integrative Cancer Therapies. 2005 Jun;4(2):110-30; Greenlee H, Shaw J, Lau YI, Naini A, Maurer M. Lack of effect of coenzyme q10 on doxorubicin cytotoxicity in breast cancer cell cultures. Integrative Cancer Therapies. 2012 Sep;11(3):243-50.
- Samuels N, Schiff E, Ben-Arye E. Non-herbal nutritional supplements for symptom relief in adjuvant breast cancer: creating a doctor-patient dialogue. BMJ Support Palliat Care. 2014 Sep;4(3):e1; Lesser GJ, Case D et al. A randomized, double-blind, placebo-controlled study of oral coenzyme Q10 to relieve self-reported treatment-related fatigue in newly diagnosed patients with breast cancer. Journal of Supportive Oncology. 2013 Mar;11(1):31-42.
- Marx W, Ried K et al. Ginger—mechanism of action in chemotherapy-induced nausea and vomiting: a review. Critical Reviews in Food Science and Nutrition. 2017 Jan 2;57(1):141-146; Sheikhi MA, Ebadi A, Talaeizadeh A, Rahmani H. Alternative methods to treat nausea and v—omiting from cancer chemotherapy. Chemotherapy Research and Practice. 2015;2015:818759; Marx W, Kiss N, Isenring L. Is ginger beneficial for nausea and vomiting? An update of the literature. Current Opinion in Supportive and Palliative Care. 2015 Jun;9(2):189-95; Marx WM, Teleni L et al. Ginger (Zingiber officinale) and chemotherapy-induced nausea and vomiting: a systematic literature review. Nutrition Reviews. 2013 Apr;71(4):245-54; Lee J, Oh H. Ginger as an antiemetic modality for chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis. Oncology Nursing Forum. 2013 Mar;40(2):163-70.
- Sontakke S, Thawani V, Naik MS. Ginger as an antiemetic in nausea and vomiting induced by chemotherapy: a randomized, cross-over, double blind study. Indian Journal of Pharmacology. 2003;35(1):32–36.
- Sanaati F, Najafi S, Kashaninia Z, Sadeghi M. Effect of ginger and chamomile on nausea and vomiting caused by chemotherapy in Iranian women with breast cancer. Asian Pacific Journal of Cancer Prevention. 2016;17(8):4125-9; Arslan M, Ozdemir L. Oral intake of ginger for chemotherapy-induced nausea and vomiting among women with breast cancer. Clinical Journal of Oncology Nurings. 2015 Oct;19(5):E92-7.
- Pereira PTVT, Reis AD et al. Dietary supplements and fatigue in patients with breast cancer: a systematic review. Breast Cancer Research and Treatment. 2018 Oct;171(3):515-526; Leggett S, Koczwara B, Miller M. The impact of complementary and alternative medicines on cancer symptoms, treatment side effects, quality of life, and survival in women with breast cancer—a systematic review. Nutrition and Cancer. 2015;67(3):373-91.
- Handforth C, D'Oronzo S, Coleman R, Brown J. Cancer treatment and bone health. Calcified Tissue International. 2018 Feb;102(2):251-264.
- Cepa M, Vaz C. Management of bone loss in postmenopausal breast cancer patients treated with aromatase inhibitors. Acta Reumatologica Portuguesa. 2015 Oct-Dec;40(4):323-30.
- Samuels N, Schiff E, Ben-Arye E. Non-herbal nutritional supplements for symptom relief in adjuvant breast cancer: creating a doctor-patient dialogue. BMJ Support Palliat Care. 2014 Sep;4(3):e1.
- Prieto-Alhambra D, Javaid MK et al. Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study. Breast Cancer Research and Treatment. 2011 Feb;125(3):869-78.
- Khan QJ, Reddy PS et al. Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Research and Treatment. 2010 Jan;119(1):111-8.
- Rastelli AL, Taylor ME et al. Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial. Breast Cancer Research and Treatment. 2011 Aug;129(1):107-16.
- Albert Einstein College of Medicine. Oral steroids linked to severe vitamin D deficiency in nationwide US study. ScienceDaily. September 30, 2011. Viewed March 6, 2019.
- Abrams DI. The therapeutic effects of cannabis and cannabinoids: an update from the National Academies of Sciences, Engineering and Medicine report. European Journal of Internal Medicine. 2018 Mar;49:7-11.
- Semiglazov VF, Stepula VV, Dudov A, Schnitker J, Mengs U. Quality of life is improved in breast cancer patients by Standardised Mistletoe Extract PS76A2 during chemotherapy and follow-up: a randomised, placebo-controlled, double-blind, multicentre clinical trial. Anticancer Research. 2006 Mar-Apr;26(2B):1519-29; Büssing A, Raak C, Ostermann T. Quality of life and related dimensions in cancer patients treated with mistletoe extract (iscador): a meta-analysis. Evidence-based Complementary and Alternative Medicine. 2012;2012:219402; Kienle GS , Kiene H. Complementary cancer therapy: a systematic review of prospective clinical trials on anthroposophic mistletoe extracts. European Journal of Medical Research. 2007 Mar 26;12(3):103-19; Eisenbraun J, Scheer R, Kröz M, Schad F, Huber R. Quality of life in breast cancer patients during chemotherapy and concurrent therapy with a mistletoe extract. Phytomedicine. 2011 Jan 15;18(2-3):151-7.
- Tröger W, Jezdić S et al. Quality of life and neutropenia in patients with early stage breast cancer: a randomized pilot study comparing additional treatment with mistletoe extract to chemotherapy alone. Breast Cancer (Auckland). 2009 Jul 6;3:35-45.
- Ziegler R, Grossarth-Maticek R. Individual patient data meta-analysis of survival and psychosomatic self-regulation from published prospective controlled cohort studies for long-term therapy of breast cancer patients with a mistletoe preparation (Iscador). Evidence-based Complementary and Alternative Medicine. 2010 Jun;7(2):157-66.
- Valadares F, Garbi Novaes MR, Cañete R. Effect of Agaricus sylvaticus supplementation on nutritional status and adverse events of chemotherapy of breast cancer: a randomized, placebo-controlled, double-blind clinical trial. Indian Journal of Pharmacology. 2013 May-Jun;45(3):217-22.
- Novaes MR, Valadares F, Reis MC, Gonçalves DR, Menezes Mda C. The effects of dietary supplementation with Agaricales mushrooms and other medicinal fungi on breast cancer: evidence-based medicine. Clinics (Sao Paulo). 2011;66(12):2133-9.
- Alschuler LN, Gazella KA. The Definitive Guide to Cancer, 3rd Edition: An Integrative Approach to Prevention, Treatment, and Healing. Berkeley, California: Celestial Arts. 2010; Alschuler LN, Gazella KA. The Definitive Guide to Thriving after Cancer. Berkeley, California: Ten Speed Press. 2013.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Treatment. New York: Bantam Dell. 2009.
- Kohara H, Miyauchi T. Combined modality treatment of aromatherapy, footsoak, and reflexology relieves fatigue in patients with cancer. Journal of Palliative Medicine. 2004 Dec;7(6):791-6.
- Wilkinson SM, Love SB et al. Effectiveness of aromatherapy massage in the management of anxiety and depression in patients with cancer: a multicenter randomized controlled trial. Journal of Clinical Oncology. 2007 Feb 10;25(5):532-9; Imanishi J, Kuriyama H et al. Anxiolytic effect of aromatherapy massage in patients with breast cancer. Evidence-Based Complementary and Alternative Medicine. 2009 Mar; 6(1): 123–128.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Treatment. New York: Bantam Dell. 2009.
- Biswal BM, Sulaiman SA, Ismail HC, Zakaria H, Musa KI. Effect of Withania somnifera (Ashwagandha) on the development of chemotherapy-induced fatigue and quality of life in breast cancer patients. Integrative Cancer Therapies. 2013 Jul;12(4):312-22.
- Alschuler LN, Gazella KA. The Definitive Guide to Cancer, 3rd Edition: An Integrative Approach to Prevention, Treatment, and Healing. Berkeley, California: Celestial Arts. 2010; Alschuler LN, Gazella KA. The Definitive Guide to Thriving after Cancer. Berkeley, California: Ten Speed Press. 2013.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Treatment. New York: Bantam Dell. 2009.
- MacDonald B. The Breast Cancer Companion: A Complementary Care Manual: Third Edition. 2016.
- McKinney N. Naturopathic Oncology, 3rd Edition. Victoria, BC, Canada: Liaison Press. 2016.
- Jiang K, Jin Y et al. Black cohosh improves objective sleep in postmenopausal women with sleep disturbance. Climacteric. 2015;18(4):559-67.
- Fritz H, Seely D et al. Black cohosh and breast cancer: a systematic review. Integrative Cancer Therapies. 2014 Jan;13(1):12-29; Walji R, Boon H, Guns E, Oneschuk D, Younus J. Black cohosh (Cimicifuga racemosa [L.] Nutt.): safety and efficacy for cancer patients. Supportive Care in Cancer. 2007 Aug;15(8):913-21.
- Shams T, Setia MS et al. Efficacy of black cohosh-containing preparations on menopausal symptoms: a meta-analysis. Alternative Therapies in Health and Medicine. 2010 Jan-Feb;16(1):36-44.
- Wuttke W, Gorkow C, Seidlová-Wuttke D. Effects of black cohosh (Cimicifuga racemosa) on bone turnover, vaginal mucosa, and various blood parameters in postmenopausal women: a double-blind, placebo-controlled, and conjugated estrogens-controlled study. Menopause. 2006 Mar-Apr;13(2):185-96.
- Yeung KS, Hernandez M, Mao JJ, Haviland I, Gubili J. Herbal medicine for depression and anxiety: a systematic review with assessment of potential psycho-oncologic relevance. Phytotherapy Research. 2018 May;32(5):865-891; Geller SE, Studee L. Botanical and dietary supplements for mood and anxiety in menopausal women. Menopause. 2007 May-Jun;14(3 Pt 1):541-9.
- Yang CL, Or TC, Ho MH, Lau AS. Scientific basis of botanical medicine as alternative remedies for rheumatoid arthritis. Clinical Reviews in Allergy & Immunology. 2013 Jun;44(3):284-300.
- Black Cohosh: Fact Sheet for Consumers. National Institute of Health Office of Dietary Supplements. August 30, 2018. Viewed November 6, 2018.
- MacDonald B. The Breast Cancer Companion: A Complementary Care Manual: Third Edition. 2016.
- Tajbakhsh A, Hasanzadeh M et al. Therapeutic potential of novel formulated forms of curcumin in the treatment of breast cancer by the targeting of cellular and physiological dysregulated pathways. Journal of Cellular Physiology. 2018 Mar;233(3):2183-2192; Ryan JL, Heckler CE et al. Curcumin for radiation dermatitis: a randomized, double-blind, placebo-controlled clinical trial of thirty breast cancer patients. Radiation Research. 2013;180:34-43; Ryan Wolf J, Heckler CE et al. Oral curcumin for radiation dermatitis: a URCC NCORP study of 686 breast cancer patients. Supportive Care in Cancer. 2018 May;26(5):1543-1552.
- Belcaro G, Hosoi M et al. A controlled study of a lecithinized delivery system of curcumin (Meriva®) to alleviate the adverse effects of cancer treatment. Phytotherapy Research. 2014 Mar; 28:444-50.
- Hussaarts KGAM, Hurkmans DP et al. Impact of curcumin (with or without piperine) on the pharmacokinetics of tamoxifen. Cancers (Basel). 2019 Mar 22;11(3). pii: E403.
- Lemole G, Mehta P, McKee D. After Cancer Care: The Definitive Self-Care Guide to Getting and Staying Well for Patients with Cancer. New York, New York: Rodale, Inc. 2015.
- MacDonald B. The Breast Cancer Companion: A Complementary Care Manual: Third Edition. 2016.
- Flower G, Fritz H et al. Flax and breast cancer: a systematic review. Integrative Cancer Therapies. 2014 May;13(3):181-92.
- Flower G, Fritz H et al. Flax and breast cancer: a systematic review. Integrative Cancer Therapies. 2014 May;13(3):181-92; Dew TP, Williamson G. Controlled flax interventions for the improvement of menopausal symptoms and postmenopausal bone health: a systematic review. Menopause. 2013 Nov;20(11):1207-15.
- Velalopoulou A, Tyagi S, Pietrofesa RA, Arguiri E, Christofidou-Solomidou M. The flaxseed-derived lignan phenolic secoisolariciresinol diglucoside (SDG) protects non-malignant lung cells from radiation damage. International Journal of Molecular Sciences. 2015 Dec 22;17(1). pii: E7.
- Pietrofesa R, Turowski J et al. Radiation mitigating properties of the lignan component in flaxseed. BMC Cancer. 2013 Apr 4;13:179.
- MacDonald B. The Breast Cancer Companion: A Complementary Care Manual: Third Edition. 2016.
- Cui Y, Shu XO et al. Association of ginseng use with survival and quality of life among breast cancer patients. American Journal of Epidemiology. 2006 Apr 1;163(7):645-53.
- Arring NM, Millstine D, Marks LA, Nail LM. Ginseng as a treatment for fatigue: a systematic review. Journal of Alternative and Complementary Medicine. 2018 Jul;24(7):624-633.
- Yennurajalingam S, Tannir NM et al. A double-blind, randomized, placebo-controlled trial of Panax ginseng for cancer-related fatigue in patients with advanced cancer. Journal of the National Comprehensive Canc Network. 2017 Sep;15(9):1111-1120.
- MacDonald B. The Breast Cancer Companion: A Complementary Care Manual: Third Edition. 2016.
- Bacić I, Druzijanić N, Karlo R, Skifić I, Jagić S. Efficacy of IP6 + inositol in the treatment of breast cancer patients receiving chemotherapy: prospective, randomized, pilot clinical study. Journal of Experimental & Clinical Cancer Research. 2010 Feb 12;29:12.
- Proietti S, Pasta V et al. Inositol hexaphosphate (InsP6) as an effective topical treatment for patients receiving adjuvant chemotherapy after breast surgery. European Review for Medical and Pharmacological Sciences. 2017 Jun;21(2 Suppl):43-50.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Treatment. New York: Bantam Dell. 2009.
- Rossi P, Difrancia R et al. B-glucans from Grifola frondosa and Ganoderma lucidum in breast cancer: an example of complementary and integrative medicine. Oncotarget. 2018 May 15;9(37):24837-24856.
- Alschuler LN, Gazella KA. The Definitive Guide to Cancer, 3rd Edition: An Integrative Approach to Prevention, Treatment, and Healing. Berkeley, California: Celestial Arts. 2010; Alschuler LN, Gazella KA. The Definitive Guide to Thriving after Cancer. Berkeley, California: Ten Speed Press. 2013.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Treatment. New York: Bantam Dell. 2009.
- Li Y, Li S et al. Melatonin for the prevention and treatment of cancer. Oncotarget. 2017 Jun 13;8(24):39896-39921.
- Hansen MV, Andersen LT et al. Effect of melatonin on depressive symptoms and anxiety in patients undergoing breast cancer surgery: a randomized, double-blind, placebo-controlled trial. Breast Cancer Research and Treatment. 2014 Jun;145(3):683-95; Li Y, Li S et al. Melatonin for the prevention and treatment of cancer. Oncotarget. 2017 Jun 13;8(24):39896-39921; Hansen MV. Chronobiology, cognitive function and depressive symptoms in surgical patients. Danish Medical Journal. 2014 Sep;61(9):B4914..
- Chen WY, Giobbie-Hurder A et al. A randomized, placebo-controlled trial of melatonin on breast cancer survivors: impact on sleep, mood, and hot flashes. Breast Cancer Research and Treatment. 2014;145(2):381-388.
- Hansen MV, Halladin NL, Rosenberg J, Gögenur I, Møller AM. Melatonin for pre- and postoperative anxiety in adults. Cochrane Database of Systematic Reviews. 2015 Apr 9;(4):CD009861; Posadzki PP, Bajpai R et al. Melatonin and health: an umbrella review of health outcomes and biological mechanisms of action. BMC Medicine. 2018 Feb 5;16(1):18.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Care. New York: Bantam Dell. 2009.
- Haghi-Aminjan H, Asghari MH et al. The role of melatonin on chemotherapy-induced reproductive toxicity. Journal of Pharmacy and Pharmacology. 2018 Mar;70(3):291-306.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Treatment. New York: Bantam Dell. 2009.
- Lemole G, Mehta P, McKee D. After Cancer Care: The Definitive Self-Care Guide to Getting and Staying Well for Patients with Cancer. New York, New York: Rodale, Inc. 2015.
- MacDonald B. The Breast Cancer Companion: A Complementary Care Manual: Third Edition. 2016.
- Leggett S, Koczwara B, Miller M. The impact of complementary and alternative medicines on cancer symptoms, treatment side effects, quality of life, and survival in women with breast cancer—a systematic review. Nutrition and Cancer. 2015;67(3):373-91.
- Jin X, Ruiz Beguerie J, Sze DM, Chan GC. Ganoderma lucidum (reishi mushroom) for cancer treatment. Cochrane Database of Systematic Reviews. 2016 Apr 5;4:CD007731.
- Wang CZ, Basila D et al. Effects of ganoderma lucidum extract on chemotherapy-induced nausea and vomiting in a rat model. American Journal of Chinese Medicine. 2005;33(5):807-15.
- Alschuler LN, Gazella KA. The Definitive Guide to Cancer, 3rd Edition: An Integrative Approach to Prevention, Treatment, and Healing. Berkeley, California: Celestial Arts. 2010; Alschuler LN, Gazella KA. The Definitive Guide to Thriving after Cancer. Berkeley, California: Ten Speed Press. 2013.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Treatment. New York: Bantam Dell. 2009.
- MacDonald B. The Breast Cancer Companion: A Complementary Care Manual: Third Edition. 2016.
- Samuels N, Schiff E, Ben-Arye E. Non-herbal nutritional supplements for symptom relief in adjuvant breast cancer: creating a doctor-patient dialogue. BMJ Support Palliat Care. 2014 Sep;4(3):e1.
- MacDonald B. The Breast Cancer Companion: A Complementary Care Manual: Third Edition. 2016.
- Tanigawa K, Itoh Y, Kobayashi Y. Improvement of QOL and immunological function with Lentinula edodes mycelia in patients undergoing cancer immunotherapy: an open pilot study. Alternative Therapies in Health and Medicine. 2016 Jul;22(4):36-42.
- Yamaguchi Y, Miyahara E, Hihara J. Efficacy and safety of orally administered Lentinula edodes mycelia extract for patients undergoing cancer chemotherapy: a pilot study. American Journal of Chinese Medicine. 2011;39(3):451-9.
- Alschuler LN, Gazella KA. The Definitive Guide to Cancer, 3rd Edition: An Integrative Approach to Prevention, Treatment, and Healing. Berkeley, California: Celestial Arts. 2010; Alschuler LN, Gazella KA. The Definitive Guide to Thriving after Cancer. Berkeley, California: Ten Speed Press. 2013.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Treatment. New York: Bantam Dell. 2009.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Treatment. New York: Bantam Dell. 2009.
- Vollbracht C, Schneider B et al. Intravenous vitamin C administration improves quality of life in breast cancer patients during chemo-/radiotherapy and aftercare: results of a retrospective, multicentre, epidemiological cohort study in Germany. In Vivo. 2011 Nov-Dec;25(6):983-90; Fritz H, Flower G et al. Intravenous vitamin C and cancer: a systematic review. Integrative Cancer Therapies. 2014 Jul;13(4):280-300; Carr AC, Vissers MC, Cook JS. The effect of intravenous vitamin C on cancer- and chemotherapy-related fatigue and quality of life. Frontiers in Oncology. 2014 Oct 16;4:283..
- Karatas F, Sahin S, Sever AR, Altundag K. Management of hair loss associated with endocrine therapy in patients with breast cancer: an overview. Springerplus. 2016 May 10;5:585.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Treatment. New York: Bantam Dell. 2009.
- MacDonald B. The Breast Cancer Companion: A Complementary Care Manual: Third Edition. 2016.
- Samuels N, Schiff E, Ben-Arye E. Non-herbal nutritional supplements for symptom relief in adjuvant breast cancer: creating a doctor-patient dialogue. BMJ Supportive & Palliative Care. 2014 Sep;4(3):e1.
- Greenlee H, Hershman DL, Jacobson JS. Use of antioxidant supplements during breast cancer treatment: a comprehensive review. Breast Cancer Research and Treatment. 2009 Jun;115(3):437-52.
- Chang R. Beyond the Magic Bullet: The Anti-Cancer Cocktail. New York: Square One Publishers. 2012.
- Lemole G, Mehta P, McKee D. After Cancer Care: The Definitive Self-Care Guide to Getting and Staying Well for Patients with Cancer. New York, New York: Rodale, Inc. 2015.
- MacDonald B. The Breast Cancer Companion: A Complementary Care Manual: Third Edition. 2016.
- Waldner R, Laschan C et al. Effects of doxorubicin-containing chemotherapy and a combination with L-carnitine on oxidative metabolism in patients with non-Hodgkin lymphoma. Journal of Cancer Research and Clinical Oncology. 2006 Feb;132(2):121-8.
- Greenlee H, DuPont-Reyes MJ et al. Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment. CA: A Cancer Journal for Clinicians. 2017 May 6;67(3):194-232.
- Greenlee H, DuPont-Reyes MJ et al. Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment. CA: A Cancer Journal for Clinicians. 2017 May 6;67(3):194-232.
- Sahebjamee M, Mansourian A et al. Comparative efficacy of aloe vera and benzydamine mouthwashes on radiation-induced oral mucositis: a triple-blind, randomised, controlled clinical trial. Oral Health & Preventive Dentistry. 2015;13(4):309-15.
- Rao S, Hegde SK et al. An aloe vera-based cosmeceutical cream delays and mitigates ionizing radiation-induced dermatitis in head and neck cancer patients undergoing curative radiotherapy: a clinical study. Medicines (Basel). 2017 Jun 24;4(3). pii: E44.
- Stubbe CE, Valero M. Complementary strategies for the management of radiation therapy side effects. Journal of the Advanced Practitioner in Oncology. 2013 Jul;4(4):219-31.
- Togni S, Maramaldi G, Bonetta A, Giacomelli L, Di Pierro F. Clinical evaluation of safety and efficacy of Boswellia-based cream for prevention of adjuvant radiotherapy skin damage in mammary carcinoma: a randomized placebo controlled trial. European Review for Medical and Pharmacological Sciences. 2015 Apr;19(8):1338-44.
- Sanaati F, Najafi S, Kashaninia Z, Sadeghi M. Effect of ginger and chamomile on nausea and vomiting caused by chemotherapy in Iranian women with breast cancer. Asian Pacific Journal of Cancer Prevention. 2016;17(8):4125-9.
- Chang YD, Smith J et al. Single institute experience with methylphenidate and American ginseng in cancer-related fatigue. American Journal of Hospice and Palliative Care. 2018 Jan;35(1):144-150.
- Di Franco R, Calvanese M et al. Skin toxicity from external beam radiation therapy in breast cancer patients: protective effects of resveratrol, lycopene, vitamin C and anthocianin (Ixor®). Radiation Oncology. 2012 Jan 30;7:12.
- Iwase S, Kawaguchi T et al. Efficacy and safety of an amino acid jelly containing coenzyme Q10 and L-carnitine in controlling fatigue in breast cancer patients receiving chemotherapy: a multi-institutional, randomized, exploratory trial (JORTC-CAM01). Supportive Care in Cancer. 2016 Feb;24(2):637-646.
- Samuels N, Schiff E, Ben-Arye E. Non-herbal nutritional supplements for symptom relief in adjuvant breast cancer: creating a doctor-patient dialogue. BMJ Support Palliat Care. 2014 Sep;4(3):e1.
- Liguori V, Guillemin C, Pesce GF, Mirimanoff RO, Bernier J. Double-blind, randomized clinical study comparing hyaluronic acid cream to placebo in patients treated with radiotherapy. Radiotherapy and Oncology. 1997 Feb;42(2):155-61.
- Pinnix C, Perkins GH et al. Topical hyaluronic acid vs. standard of care for the prevention of radiation dermatitis after adjuvant radiotherapy for breast cancer: single-blind randomized phase III clinical trial. International Journal of Radiation Oncology, Biology, Physics. 2012 Jul 15;83(4):1089-94.
- Moreno-Vega A, Vega-Riveroll L et al. Adjuvant effect of molecular iodine in conventional chemotherapy for breast cancer. randomized pilot study. Nutrients. 2019 Jul 17;11(7). pii: E1623.
- Patrick L Iodine: deficiency and therapeutic considerations. Alternative Medicine Review. 2008 Jun;13(2):116-27.
- Sun J, Wang H, Hu H. Glutamine for chemotherapy induced diarrhea: a meta-analysis. Asia Pacific Journal of Clinical Nutrition. 2012;21(3):380-5.
- Greenlee H, Hershman DL, Jacobson JS. Use of antioxidant supplements during breast cancer treatment: a comprehensive review. Breast Cancer Research and Treatment. 2009 Jun;115(3):437-52; Leggett S, Koczwara B, Miller M. The impact of complementary and alternative medicines on cancer symptoms, treatment side effects, quality of life, and survival in women with breast cancer—a systematic review. Nutrition and Cancer. 2015;67(3):373-91.
- Samuels N, Schiff E, Ben-Arye E. Non-herbal nutritional supplements for symptom relief in adjuvant breast cancer: creating a doctor-patient dialogue. BMJ Supportive & Palliative Care. 2014 Sep;4(3):e1.
- Rubio I, Suva LJ et al. Oral glutamine reduces radiation morbidity in breast conservation surgery. Journal of Parenteral and Enteral Nutrition. 2013 Sep;37(5):623-30.
- Wise DR, Thompson CB. Glutamine addiction: a new therapeutic target in cancer. Trends in Biochemical Sciences. 2010 Aug;35(8):427-33.
- Agosta C, Atlante M, Benvenuti C. Randomized controlled study on clinical efficacy of isoflavones plus Lactobacillus sporogenes, associated or not with a natural anxiolytic agent in menopause. Minerva Ginecologica. 2011 Feb;63(1):11-7.
- Huang L, Zhang K et al. Honokiol protects against doxorubicin cardiotoxicity via improving mitochondrial function in mouse hearts. Scientific Reports. 2017 Sep 20;7(1):11989.
- Ladas EJ, Kelly KM. Milk thistle: is there a role for its use as an adjunct therapy in patients with cancer? Journal of Alternative and Complementary Medicine. 2003 Jun;9(3):411-6.
- Rašković A, Stilinović N et al. The protective effects of silymarin against doxorubicin-induced cardiotoxicity and hepatotoxicity in rats. Molecules. 2011 Oct 12;16(10):8601-13.
- Post-White J, Ladas EJ, Kelly KM. Advances in the use of milk thistle (Silybum marianum). Integrative Cancer Therapies. 2007 Jun;6(2):104-9.
- Malewicz B, Wang Z et al. Enhancement of mammary carcinogenesis in two rodent models by silymarin dietary supplements. Carcinogenesis. 2006 Sep;27(9):1739-47.
- Verschoyle RD, Brown K, Steward WP, Gescher AJ. Consumption of silibinin, a flavonolignan from milk thistle, and mammary cancer development in the C3(1) SV40 T,t antigen transgenic multiple mammary adenocarcinoma (TAg) mouse. Cancer Chemotherapy and Pharmacology. 2008 Jul;62(2):369-72.
- Lemole G, Mehta P, McKee D. After Cancer Care: The Definitive Self-Care Guide to Getting and Staying Well for Patients with Cancer. New York, New York: Rodale, Inc. 2015.
- Hutchins-Wiese HL, Picho K et al. High-dose eicosapentaenoic acid and docosahexaenoic acid supplementation reduces bone resorption in postmenopausal breast cancer survivors on aromatase inhibitors: a pilot study. Nutrition and Cancer. 2014;66(1):68-76.
- Ghoreishi Z, Esfahani A et al. Omega-3 fatty acids are protective against paclitaxel-induced peripheral neuropathy: a randomized double-blind placebo controlled trial. BMC Cancer. 2012 Aug 15;12:355.
- de Aguiar Pastore Silva J, Emilia de Souza Fabre M, Waitzberg DL. Omega-3 supplements for patients in chemotherapy and/or radiotherapy: a systematic review. Clinical Nutrition. 2015 Jun;34(3):359-66.
- Suzumura DN, Schleder JC et al. Fish oil supplementation enhances pulmonary strength and endurance in women undergoing chemotherapy. Nutrition and Cancer. 2016 Aug-Sep;68(6):935-42.
- Bonatto SJ, Oliveira HH et al. Fish oil supplementation improves neutrophil function during cancer chemotherapy. Lipids. 2012 Apr;47(4):383-9.
- Daenen LG, Cirkel GA et al. Increased plasma levels of chemoresistance-inducing fatty acid 16:4(n-3) after consumption of fish and fish oil. JAMA Oncology. 2015 Jun;1(3):350-8.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Treatment. New York: Bantam Dell. 2009.
- Lemole G, Mehta P, McKee D. After Cancer Care: The Definitive Self-Care Guide to Getting and Staying Well for Patients with Cancer. New York, New York: Rodale, Inc. 2015.
- MacDonald B. The Breast Cancer Companion: A Complementary Care Manual: Third Edition. 2016.
- Cathcart-Rake EJ, Smith D, Zahrieh D, Loprinzi CL. Rose geranium in sesame oil nasal spray: a treatment for nasal vestibulitis? BMJ Supportive & Palliative Care. 2018 Sep 26. pii: bmjspcare-2018-001569.
- Abdel-Daim MM, Kilany OE, Khalifa HA, Ahmed AAM. Allicin ameliorates doxorubicin-induced cardiotoxicity in rats via suppression of oxidative stress, inflammation and apoptosis. Cancer Chemotherapy and Pharmacology. 2017 Oct;80(4):745-753.
- Cheah KY, Howarth GS, Bastian SE. Grape seed extract dose-responsively decreases disease severity in a rat model of mucositis; concomitantly enhancing chemotherapeutic effectiveness in colon cancer cells. PLoS One. 2014 Jan 21;9(1):e85184.
- Olaku OO, Ojukwu MO, Zia FZ, White JD. The role of grape seed extract in the treatment of chemo/radiotherapy induced toxicity: a systematic review of preclinical studies. Nutrition and Cancer. 2015;67(5):730-40.
- Brooker S, Martin S et al. Double-blind, placebo-controlled, randomised phase II trial of IH636 grape seed proanthocyanidin extract (GSPE) in patients with radiation-induced breast induration. Radiotherapy and Oncology. 2006 Apr;79(1):45-51.
- Lemole G, Mehta P, McKee D. After Cancer Care: The Definitive Self-Care Guide to Getting and Staying Well for Patients with Cancer. New York, New York: Rodale, Inc. 2015.
- Wang H, Lai YJ, Chan YL, Li TL, Wu CJ. Epigallocatechin-3-gallate effectively attenuates skeletal muscle atrophy caused by cancer cachexia. Cancer Letters. 2011 Jun 1;305(1):40-9.
- Mirza KA, Pereira SL, Edens NK, Tisdale MJ. Attenuation of muscle wasting in murine C2C 12 myotubes by epigallocatechin-3-gallate. Journal of Cachexia, Sarcopenia and Muscle. 2014 Dec;5(4):339-45.
- Hajra S, Patra AR, Basu A, Bhattacharya S. Prevention of doxorubicin (DOX)-induced genotoxicity and cardiotoxicity: effect of plant derived small molecule indole-3-carbinol (I3C) on oxidative stress and inflammation. Biomedicine & Pharmacotherapy. 2018 May;101:228-243.
- Pore SK, Hahm ER et al. Prevention of breast cancer-induced osteolytic bone resorption by benzyl isothiocyanate. Carcinogenesis. 2018 Feb 9;39(2):134-145.
- Mego M, Chovanec J et al. Prevention of irinotecan induced diarrhea by probiotics: a randomized double blind, placebo controlled pilot study. Complementary Therapies in Medicine. 2015 Jun;23(3):356-62.
- Huang L, Chiang Chiau JS et al. SCID/NOD mice model for 5-FU induced intestinal mucositis: safety and effects of probiotics as therapy. Pediatrics and Neonatology. 2018 Jul 26. pii: S1875-9572(17)30682-4.
- Ciorba MA, Riehl TE et al. Lactobacillus probiotic protects intestinal epithelium from radiation injury in a TLR-2/cyclo-oxygenase-2-dependent manner. Gut. 2012 Jun;61(6):829-38; Riehl T, Cohn S, Tessner T, Schloemann S, Stenson WF. Lipopolysaccharide is radioprotective in the mouse intestine through a prostaglandin-mediated mechanism. Gastroenterology. 2000 Jun;118(6):1106-16.
- Bastos RW, Pedroso SH et al. Saccharomyces cerevisiae UFMG A-905 treatment reduces intestinal damage in a murine model of irinotecan-induced mucositis. Beneficial Microbes. 2016 Sep;7(4):549-57.
- Gerhard D, Sousa FJDSS et al. Probiotic therapy reduces inflammation and improves intestinal morphology in rats with induced oral mucositis. Brazilian Oral Research. 2017 Jul 3;31:e71.
- Kato S, Hamouda N et al. Probiotic Bifidobacterium bifidum G9-1 attenuates 5-fluorouracil-induced intestinal mucositis in mice via suppression of dysbiosis-related secondary inflammatory responses. Clinical and Experimental Pharmacology and Physiology. 2017 Oct;44(10):1017-1025.
- MacDonald B. The Breast Cancer Companion: A Complementary Care Manual: Third Edition. 2016.
- Gu J, Hu W, Zhang DD. Resveratrol, a polyphenol phytoalexin, protects against doxorubicin-induced cardiotoxicity. Journal of Cellcular and Molecular Medicine. 2015 Oct;19(10):2324-8; Gu J, Hu W et al. Resveratrol-induced autophagy promotes survival and attenuates doxorubicin-induced cardiotoxicity. International Immunopharmacology. 2016 Mar;32:1-7.
- Yavuzsen T, Davis MP, Walsh D, LeGrand S, Lagman R. Systematic review of the treatment of cancer-associated anorexia and weight loss. Journal of Clinical Oncol.ogy 2005 Nov 20;23(33):8500-11; Gagnon B, Bruera E. A review of the drug treatment of cachexia associated with cancer. Drugs. 1998 May;55(5):675-88.
- MacGregor CA, Canney PA, Patterson G, McDonald R, Paul J. A randomised double-blind controlled trial of oral soy supplements versus placebo for treatment of menopausal symptoms in patients with early breast cancer. European Journal of Cancer. 2005 Mar;41(5):708-14.
- Hadji P, Coleman RE et al. Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. Annals of Oncology. 2016 Mar;27(3):379-90.
- Bauer M, Bryce J, Hadji P. Aromatase inhibitor-associated bone loss and its management with bisphosphonates in patients with breast cancer. Breast Cancer (Dove Med Press). 2012 Jun 20;4:91-101.
- O'Carrigan B, Wong MH et al. Bisphosphonates and other bone agents for breast cancer. Cochrane Database of Systematic Reviews. 2017 Oct 30;10:CD003474.
- Drugs.com. Bonefos Approval Status. Viewed March 1, 2019.
- Bhattacharyya GS, Babu KG et al. Effect of coadministered beta blocker and COX-2 inhibitor to patients with pancreatic cancer prior to receiving albumin-bound (Nab) paclitaxel. Journal of Clinical Oncology. 2015 Jan;33(3_suppl):302-302.
- Lindgren ME, Fagundes CP et al. Beta-blockers may reduce intrusive thoughts in newly diagnosed cancer patients. Psychooncology. 2013 Aug;22(8):1889-94.
- Ma Y, Bai F et al. Beta-blockers for the primary prevention of anthracycline-induced cardiotoxicity: a meta-analysis of randomized controlled trials. BMC Pharmacol Toxicol. 2019 Apr 25;20(1):18.
- Wittayanukorn S, Qian J et al. Prevention of trastuzumab and anthracycline-induced cardiotoxicity using angiotensin-converting enzyme inhibitors or β-blockers in older adults with breast cancer. American Journal of Clinical Oncology. 2018 Sep;41(9):909-918; Fanous I, Dillon P. Cancer treatment-related cardiac toxicity: prevention, assessment and management. Medical Oncology. 2016 Aug;33(8):84; Yun S, Vincelette ND, Abraham I. Cardioprotective role of β-blockers and angiotensin antagonists in early-onset anthracyclines-induced cardiotoxicity in adult patients: a systematic review and meta-analysis. Postgraduate Medical Journal. 2015 Nov;91(1081):627-33.
- Lemole G, Mehta P, McKee D. After Cancer Care: The Definitive Self-Care Guide to Getting and Staying Well for Patients with Cancer. New York, New York: Rodale, Inc. 2015.
- Noh JM, Choi DH et al. Comparison of acute skin reaction following morning versus late afternoon radiotherapy in patients with breast cancer who have undergone curative surgical resection. Journal of Radiation Research. 2014 May;55(3):553-8.
- Deprés-Brummer P, Berthault-Cvitkovic F et al. Circadian rhythm-modulated (CRM) chemotherapy of metastatic breast cancer with mitoxantrone, 5-fluorouracil, and folinic acid: preliminary results of a phase I trial. Journal of Infusional Chemotherapy. 1995;5(3 Suppl 1):144-7.
- Sultan A, Choudhary V, Parganiha A. Worsening of rest-activity circadian rhythm and quality of life in female breast cancer patients along progression of chemotherapy cycles. Chronobiology International. 2017;34(5):609-623.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Treatment. New York: Bantam Dell. 2009.
- Brown N, Panksepp J. Low-dose naltrexone for disease prevention and quality of life. Medical Hypotheses. 2009 Mar; 72; 333-337.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Treatment. New York: Bantam Dell. 2009.
- Elsegood L. Ed. The LDN Book. Vermont: Chelsea Green Publishing. 2016.
- McKinney N. Naturopathic Oncology, 3rd Edition. Victoria, BC, Canada: Liaison Press. 2016.
- Patterson S. Metformin may have broad utility in cancer. MD Anderson Cancer Center. November-December 2014. Viewed January 19, 2018.
- Zhou W, Kavelaars A, Heijnen CJ. Metformin prevents cisplatin-induced cognitive impairment and brain damage in mice. PLoS ONE. 2016;11(3):e0151890.
- Henninger C, Fritz G et al. Statins in anthracycline-induced cardiotoxicity: Rac and Rho, and the heartbreakers. Cell Death & Disease. 2017 Jan 19;8(1):e2564.
- Zick SM, Colacino J et al. Fatigue reduction diet in breast cancer survivors: a pilot randomized clinical trial. Breast Cancer Research and Treatment. 2017 Jan;161(2):299-310.
- Safdie FM, Dorff T et al. Fasting and cancer treatment in humans: a case series report. Aging (Milano) 2009;1:988–1007; Bauersfeld SP, Kessler CS et al. The effects of short-term fasting on quality of life and tolerance to chemotherapy in patients with breast and ovarian cancer: a randomized cross-over pilot study. BMC Cancer. 2018 Apr 27;18(1):476.
- Montgomery GH, Sucala M, Dillon MJ, Schnur JB. Cognitive-behavioral therapy plus hypnosis for distress during breast radiotherapy: a randomized trial. American Journal of Clinical Hypnosis. 2017 Oct;60(2):109-122.
- Berlière M, Roelants F et al. The advantages of hypnosis intervention on breast cancer surgery and adjuvant therapy. Breast. 2018 Feb;37:114-118.
- Zick SM, Sen A. Impact of self-acupressure on co-occurring symptoms in cancer survivors. JNCI Cancer Spectrum. 2018 Nov 1;2(4): pky064.
- Deng GE, Frenkel M et al. Evidence-based clinical practice guidelines for integrative oncology: complementary therapies and botanicals. Journal of the Society for Integrative Oncology. 2009 Summer;7(3):85-120.
- Zhang Y, Lin L, Li H, Hu Y, Tian L Effects of acupuncture on cancer-related fatigue: a meta-analysis. Support Care Cancer. 2018 Feb;26(2):415-425.
- Mao JJ, Bowman MA et al. Electroacupuncture versus gabapentin for hot flashes among breast cancer survivors: a randomized placebo-controlled trial. Journal of Clinical Oncology. 2015 Nov 1;33(31):3615-20.
- Zick SM, Sen A. Impact of self-acupressure on co-occurring symptoms in cancer survivors. JNCI Cancer Spectrum. 2018 Nov 1;2(4): pky064.
- Kim TH, Kang JW, Lee MS. Current evidence of acupuncture for symptoms related to breast cancer survivors: a PRISMA-compliant systematic review of clinical studies in Korea. Medicine (Baltimore). 2018 Aug;97(32):e11793; Lu W, Giobbie-Hurder A et al. Acupuncture for chemotherapy-induced peripheral neuropathy in breast cancer survivors: a randomized controlled pilot trial. Oncologist. 2020;25(4):310-318.
- Brinkhaus B, Kirschbaum B et al. Prophylactic acupuncture treatment during chemotherapy with breast cancer: a randomized pragmatic trial with a retrospective nested qualitative study. Breast Cancer Research and Treatment. 2019 Dec;178(3):617-628.
- Sturgeon M, Wetta-Hall R, Hart T, Good M, Dakhil S. Effects of therapeutic massage on the quality of life among patients with breast cancer during treatment. The Journal of Alternative and Complementary Medicine. 2009 Apr;15(4):373-80.
- Hanai A, Ishiguro H et al. Effects of cryotherapy on objective and subjective symptoms of paclitaxel-induced neuropathy: prospective self-controlled trial. Journal of the National Cancer Institute. 2018 Feb 1;110(2):141-148; Schuler U, Heller S. [Chemotherapy-induced peripheral neuropathy and neuropathic pain]. [Article in German] Schmerz. 2017 Aug;31(4):413-425.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Treatment. New York: Bantam Dell. 2009.
- Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 2019 Aug 29. pii: S0140-6736(19)31709-X.
- Nelson R. Menopausal hormone therapy and breast cancer link confirmed. Medscape. August 29, 2019. Viewed September 24, 2019.
- Al Ajmi K, Lophatananon A, Mekli K, Ollier W, Muir KR. Association of nongenetic factors with breast cancer risk in genetically predisposed groups of women in the UK Biobank Cohort. JAMA Network Open. 2020;3(4):e203760.
- Schettler T. The Ecology of Breast Cancer: The Promise of Prevention and the Hope for Healing. Science and Environmental Health Network and The Collaborative on Health and the Environment. October 2013; Sun YS, Zhao Z et al. Risk factors and preventions of breast cancer. International Journal of Biological Sciences. 2017 Nov 1;13(11):1387-1397; Rice MS, Eliassen AH et al. Breast cancer research in the Nurses' Health Studies: exposures across the life course. American Journal of Public Health. 2016 Sep;106(9):1592-8.
- ASCO Post Staff. Study clarifies time-dependent effects of oral contraceptives on risk of ovarian, endometrial, and breast cancers. ASCO Post. December 23, 2020. Viewed January 5, 2021; Karlsson T, Johansson T, Höglund J, Ek WE, Johansson Å. Time-dependent effects of oral contraceptive use on breast, ovarian and endometrial cancers. Cancer Research. 2020 Dec 17:canres.2476.2020.
- Schettler T. The Ecology of Breast Cancer: The Promise of Prevention and the Hope for Healing. Science and Environmental Health Network and The Collaborative on Health and the Environment. October 2013.
- Schettler T. The Ecology of Breast Cancer: The Promise of Prevention and the Hope for Healing. Science and Environmental Health Network and The Collaborative on Health and the Environment. October 2013.
- Al Ajmi K, Lophatananon A, Mekli K, Ollier W, Muir KR. Association of nongenetic factors with breast cancer risk in genetically predisposed groups of women in the UK Biobank Cohort. JAMA Network Open. 2020;3(4):e203760.
- Eberle CE, Sandler DP, Taylor KW, White AJ. Hair dye and chemical straightener use and breast cancer risk in a large US population of black and white women. International Journal of Cancer. 2019 Dec 3.
- Arthur RS, Dannenberg AJ, Kim M, Rohan TE. The association of body fat composition with risk of breast, endometrial, ovarian and colorectal cancers among normal weight participants in the UK Biobank. British Journal of Cancer. 2021 Mar 15.
- Feigelson HS, Bodelon C, Powers JD et al. Body mass index and risk of second cancer among women with breast cancer. Journal of the National Cancer Institute. 2021 Apr 5:djab053.
- Kruk J, Aboul-Enein BH, Bernstein J, Gronostaj M. Psychological stress and cellular aging in cancer: a meta-analysis. Oxidative Medicine and Cellular Longevity. 2019 Nov 13;2019:1270397.
- National Institute on Alcohol Abuse and Alcoholism. Alcohol's Effects on the Body. National Institutes of Health. Viewed October 5, 2018; Scoccianti C, Lauby-Secretan B, Bello PY, Chajes V, Romieu I. Female breast cancer and alcohol consumption: a review of the literature. American Journal Preventive Medicine. 2014 Mar;46(3 Suppl 1):S16-25; Al Ajmi K, Lophatananon A, Mekli K, Ollier W, Muir KR. Association of nongenetic factors with breast cancer risk in genetically predisposed groups of women in the UK Biobank Cohort. JAMA Network Open. 2020;3(4):e203760.
- Simapivapan P, Boltong A, Hodge A. To what extent is alcohol consumption associated with breast cancer recurrence and second primary breast cancer?: A systematic review. Cancer Treatment Reviews. 2016 Nov;50:155-167; Kwan ML, Chen WY et al. Postdiagnosis alcohol consumption and breast cancer prognosis in the after breast cancer pooling project. Cancer Epidemiology, Biomarkers & Prevention. 2013 Jan;22(1):32-41.
- Alcohol and cancer risk. American Institute for Cancer Research. Viewed October 4, 2018.
- Rock CL, Thomson C et al. American Cancer Society guideline for diet and physical activity for cancer prevention. CA: A Cancer Journal for Clinicians. 2020;10.3322/caac.21591.
- Johns SA, Stutz PV et al. Acceptance and commitment therapy for breast cancer survivors with fear of cancer recurrence: a 3-arm pilot randomized controlled trial. Cancer. 2020;126(1):211–218.
- GBD 2016 Alcohol Collaborators. Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2018 Sep 22;392(10152):1015-1035.
- National Cancer Institute. Reproductive History and Cancer Risk. National Institutes of Health. November 9, 2016. Viewed October 5, 2018.
- Cordeiro B. Breastfeeding lowers your breast cancer risk. The University of Texas MD Anderson Cancer Center. Viewed October 5, 2018.
- Al Ajmi K, Lophatananon A, Mekli K, Ollier W, Muir KR. Association of nongenetic factors with breast cancer risk in genetically predisposed groups of women in the UK Biobank Cohort. JAMA Network Open. 2020;3(4):e203760.
- Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE. Adult weight change and risk of postmenopausal breast cancer. JAMA. 2006 Jul 12;296(2):193-201.
- Teras LR, Patel AV et al. Sustained weight loss and risk of breast cancer in women ≥50 years: a pooled analysis of prospective data. Journal of the National Cancer Institute. 2019;djz226.
- Pasta V, Gullo G et al. An association of boswellia, betaine and myo-inositol (Eumastós) in the treatment of mammographic breast density: a randomized, double-blind study. European Review for Medical and Pharmacological Sciences. 2015 Nov;19(22):4419-26.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Treatment. New York: Bantam Dell. 2009.
- McKinney N. Naturopathic Oncology, 3rd Edition. Victoria, BC, Canada: Liaison Press. 2016.
- Talib WH, Al-Hadid SA, Ali MBW, Al-Yasari IH, Ali MRA. Role of curcumin in regulating p53 in breast cancer: an overview of the mechanism of action. Breast Cancer: Targets and Therapy (Dove Med Press). 2018 Nov 29;10:207-217.
- Naeini MB, Momtazi AA et al. Antitumor effects of curcumin: a lipid perspective. Journal of Cellular Physiology. 2019 Feb 11; Banik U, Parasuraman S, Adhikary AK, Othman NH. Curcumin: the spicy modulator of breast carcinogenesis. Journal of Experimental and Clinical Cancer Research. 2017 Jul 19;36(1):98.
- Hussaarts KGAM, Hurkmans DP et al. Impact of curcumin (with or without piperine) on the pharmacokinetics of tamoxifen. Cancers (Basel). 2019 Mar 22;11(3). pii: E403.
- Alschuler LN, Gazella KA. The Definitive Guide to Cancer, 3rd Edition: An Integrative Approach to Prevention, Treatment, and Healing. Berkeley, California: Celestial Arts. 2010; Alschuler LN, Gazella KA. The Definitive Guide to Thriving after Cancer. Berkeley, California: Ten Speed Press. 2013.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Treatment. New York: Bantam Dell. 2009.
- MacDonald B. The Breast Cancer Companion: A Complementary Care Manual: Third Edition. 2016.
- Flower G, Fritz H et al. Flax and breast cancer: a systematic review. Integrative Cancer Therapies. 2014 May;13(3):181-92.
- Alschuler LN, Gazella KA. The Definitive Guide to Cancer, 3rd Edition: An Integrative Approach to Prevention, Treatment, and Healing. Berkeley, California: Celestial Arts. 2010; Alschuler LN, Gazella KA. The Definitive Guide to Thriving after Cancer. Berkeley, California: Ten Speed Press. 2013.
- McKinney N. Naturopathic Oncology, 3rd Edition. Victoria, BC, Canada: Liaison Press. 2016.
- Samavat H, Ursin G et al. A randomized controlled trial of green tea extract supplementation and mammographic density in postmenopausal women at increased risk of breast cancer. Cancer Prevention Research (Phila). 2017 Dec;10(12):710-718.
- MacDonald B. The Breast Cancer Companion: A Complementary Care Manual: Third Edition. 2016.
- Fabian CJ, Kimler BF, Hursting SD. Omega-3 fatty acids for breast cancer prevention and survivorship. Breast Cancer Research. 2015 May 4;17:62.
- Patterson RE, Flatt SW et al. Marine fatty acid intake is associated with breast cancer prognosis. Journal of Nutrition. 2011 Feb;141(2):201-6.
- Alschuler LN, Gazella KA. The Definitive Guide to Cancer, 3rd Edition: An Integrative Approach to Prevention, Treatment, and Healing. Berkeley, California: Celestial Arts. 2010; Alschuler LN, Gazella KA. The Definitive Guide to Thriving after Cancer. Berkeley, California: Ten Speed Press. 2013.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Treatment. New York: Bantam Dell. 2009.
- Chang R. Beyond the Magic Bullet: The Anti-Cancer Cocktail. New York: Square One Publishers. 2012.
- Lemole G, Mehta P, McKee D. After Cancer Care: The Definitive Self-Care Guide to Getting and Staying Well for Patients with Cancer. New York, New York: Rodale, Inc. 2015.
- McKinney N. Naturopathic Oncology, 3rd Edition. Victoria, BC, Canada: Liaison Press. 2016.
- de Moreno de LeBlanc A, Matar C, Perdigón G. The application of probiotics in cancer. British Journal of Nutrition. 2007 Oct;98 Suppl 1:S105-10; Toi M, Hirota S et al. Probiotic beverage with soy isoflavone consumption for breast cancer prevention: a case-control study. Current Nutrition and Food Science. 2013 Aug;9(3):194-200.
- Alschuler LN, Gazella KA. The Definitive Guide to Cancer, 3rd Edition: An Integrative Approach to Prevention, Treatment, and Healing. Berkeley, California: Celestial Arts. 2010; Alschuler LN, Gazella KA. The Definitive Guide to Thriving after Cancer. Berkeley, California: Ten Speed Press. 2013.
- Lappe J, Watson P et al. Effect of vitamin D and calcium supplementation on cancer incidence in older women: a randomized clinical trial. JAMA. 2017 Mar 28;317(12):1234-1243.
- Cauley JA, Chlebowski RT et al. Calcium plus vitamin D supplementation and health outcomes five years after active intervention ended: the Women's Health Initiative. Journal of Women’s Health. 2013 Nov;22(11):915-29.
- Poole EM, Shu X et al. Postdiagnosis supplement use and breast cancer prognosis in the After Breast Cancer Pooling Project. Breast Cancer Research and Treatment. 2013 Jun;139(2):529-37.
- Pande M, Thompson PA et al. Genetic variants in the vitamin D pathway and breast cancer disease-free survival. Carcinogenesis. 2013 Mar;34(3):587-94.
- Alschuler LN, Gazella KA. The Definitive Guide to Cancer, 3rd Edition: An Integrative Approach to Prevention, Treatment, and Healing. Berkeley, California: Celestial Arts. 2010; Alschuler LN, Gazella KA. The Definitive Guide to Thriving after Cancer. Berkeley, California: Ten Speed Press. 2013.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Treatment. New York: Bantam Dell. 2009.
- MacDonald B. The Breast Cancer Companion: A Complementary Care Manual: Third Edition. 2016.
- Poole EM, Shu X et al. Postdiagnosis supplement use and breast cancer prognosis in the After Breast Cancer Pooling Project. Breast Cancer Research and Treatment. 2013 Jun;139(2):529-37.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Treatment. New York: Bantam Dell. 2009.
- Li J, Zou L et al. Dietary mushroom intake may reduce the risk of breast cancer: evidence from a meta-analysis of observational studies. PLoS One. 2014 Apr 1;9(4):e93437.
- Patel S, Goyal A. Recent developments in mushrooms as anti-cancer therapeutics: a review. 3 Biotech. 2012 Mar;2(1):1-15; Li J, Zou L et al. Dietary mushroom intake may reduce the risk of breast cancer: evidence from a meta-analysis of observational studies. PLoS One. 2014 Apr 1;9(4):e93437.
- Fritz H, Seely D et al. Black cohosh and breast cancer: a systematic review. Integrative Cancer Therapies. 2014 Jan;13(1):12-29.
- Black Cohosh: Fact Sheet for Consumers. National Institute of Health Office of Dietary Supplements. August 30, 2018. Viewed November 6, 2018.
- Thomson CA, Ho E, Strom MB. Chemopreventive properties of 3,3'-diindolylmethane in breast cancer: evidence from experimental and human studies. Nutrition Reviews. 2016 Jul;74(7):432-43.
- Thomson CA, Chow HHS et al. A randomized, placebo-controlled trial of diindolylmethane for breast cancer biomarker modulation in patients taking tamoxifen. Breast Cancer Research and Treatment. 2017 Aug;165(1):97-107.
- Baena Ruiz R, Salinas Hernández P. Cancer chemoprevention by dietary phytochemicals: epidemiological evidence. Maturitas. 2016 Dec;94:13-19.
- Alschuler LN, Gazella KA. The Definitive Guide to Cancer, 3rd Edition: An Integrative Approach to Prevention, Treatment, and Healing. Berkeley, California: Celestial Arts. 2010; Alschuler LN, Gazella KA. The Definitive Guide to Thriving after Cancer. Berkeley, California: Ten Speed Press. 2013.
- Bakker MF, Peeters PH et al. Plasma carotenoids, vitamin C, tocopherols, and retinol and the risk of breast cancer in the European Prospective Investigation into Cancer and Nutrition cohort. American Journal of Clinical Nutrition. 2016 Feb;103(2):454-64; Misotti AM, Gnagnarella P. Vitamin supplement consumption and breast cancer risk: a review. Ecancermedicalscience. 2013 Oct 23;7:365; Lazzeroni M, Gandini S et al. The science behind vitamins and natural compounds for breast cancer prevention. Getting the most prevention out of it. Breast. 2011 Oct;20 Suppl 3:S36-41.
- Cadeau C, Fournier A et al. Vitamin C supplement intake and postmenopausal breast cancer risk: interaction with dietary vitamin C. American Journal of Clinical Nutrition. 2016 Jul;104(1):228-34.
- Nechuta S, Lu W et al. Vitamin supplement use during breast cancer treatment and survival: a prospective cohort study. Cancer Epidemiology, Biomarkers & Prevention. 2011 Feb;20(2):262-71; Poole EM, Shu X et al. Postdiagnosis supplement use and breast cancer prognosis in the After Breast Cancer Pooling Project. Breast Cancer Research and Treatment. 2013 Jun;139(2):529-37.
- Nimptsch K, Rohrmann S, Kaaks R, Linseisen J. Dietary vitamin K intake in relation to cancer incidence and mortality: results from the Heidelberg cohort of the European Prospective Investigation into Cancer and Nutrition (EPIC-Heidelberg). American Journal of Clinical Nutrition. 2010 May;91(5):1348-58.
- Sehrawat A, Samanta SK et al. Withaferin A-mediated apoptosis in breast cancer cells is associated with alterations in mitochondrial dynamics. Mitochondrion. 2019 Jan 24. pii: S1567-7249(18)30225-3.
- Kim H, Hall P et al. Chemoprevention by grape seed extract and genistein in carcinogen-induced mammary cancer in rats is diet dependent. Journal of Nutrition. 2004 Dec;134(12 Suppl):3445S-3452S.
- Shamsuddin AM, Vucenik I. Mammary tumor inhibition by IP6: a review. Anticancer Research. 1999 Sep-Oct;19(5A):3671-4.
- García-Solís P, Alfaro Y et al. Inhibition of N-methyl-N-nitrosourea-induced mammary carcinogenesis by molecular iodine (I2) but not by iodide (I-) treatment Evidence that I2 prevents cancer promotion. Molecular and Cellular Endocrinology. 2005 May 31;236(1-2):49-57.
- Zhang Y, Kensler TW, Cho CG, Posner GH, Talalay P. Anticarcinogenic activities of sulforaphane and structurally related synthetic norbornyl isothiocyanates. Proceedings of the National Academy of Sciences USA. 1994 Apr 12;91(8):3147-50.
- Koh MS, Hwang JS, Moon AR. Lycopene inhibits proliferation, invasion and migration of human breast cancer cells. Biomolecules & Therapeutics. 2010;18:92–8; Ko EY, Moon A. Natural products for chemoprevention of breast cancer. Journal of Cancer Prevention. 2015 Dec;20(4):223-31.
- Greenlee H, Kwan ML et al. Antioxidant supplement use after breast cancer diagnosis and mortality in the Life After Cancer Epidemiology (LACE) cohort. Cancer. 2012 Apr 15;118(8):2048-58.
- Kladar NV, Gavarić NS, Božin BN. Ganoderma: insights into anticancer effects. European Journal of Cancer Prevention. 2016 Sep;25(5):462-71.
- Rossi EL, Khatib SA et al. Resveratrol inhibits obesity-associated adipose tissue dysfunction and tumor growth in a mouse model of postmenopausal claudin-low breast cancer. Molecular Carcinogenesis. 2018 Mar;57(3):393-407.
- Medina D, Thompson H, Ganther H, Ip C. Se-methylselenocysteine: a new compound for chemoprevention of breast cancer. Nutrition and Cancer. 2001;40(1):12-7.
- Hutchinson J, Burley VJ, Greenwood DC, Thomas JD, Cade JE. High-dose vitamin C supplement use is associated with self-reported histories of breast cancer and other illnesses in the UK Women's Cohort Study. Public Health Nutrition. 2011 May;14(5):768-77.
- Ou YJ, Chiu HF, Wong YH, Yang CC, Yang YH. Bisphosphonate use and the risk of breast cancer: a meta-analysis of observational studies. Pharmacoepidemiology and Drug Safety. 2017 Oct;26(10):1286-1295.
- Dhesy-Thind S, Fletcher GG et al. Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: a Cancer Care Ontario and American Society of Clinical Oncology clinical practice guideline. Journal of Clinical Oncology. 2017 Jun 20;35(18):2062-2081.
- Dhesy-Thind S, Fletcher GG et al. Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: a Cancer Care Ontario and American Society of Clinical Oncology clinical practice guideline. Journal of Clinical Oncology. 2017 Jun 20;35(18):2062-2081.
- Dhesy-Thind S, Fletcher GG et al. Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: a Cancer Care Ontario and American Society of Clinical Oncology clinical practice guideline. Journal of Clinical Oncology. 2017 Jun 20;35(18):2062-2081.
- Calip GS, Yu O, Elmore JG, Boudreau DM. Comparative safety of diabetes medications and risk of incident invasive breast cancer: a population-based cohort study. Cancer Causes & Control. 2016 May;27(5):709-20.
- Chlebowski RT, McTiernan A et al. Diabetes, metformin, and breast cancer in postmenopausal women. Journal of Clinical Oncology. 2012 Aug 10;30(23):2844-52.
- Zhang P, Li H, Tan X, Chen L, Wang S. Association of metformin use with cancer incidence and mortality: a meta-analysis. Cancer Epidemiology. 2013 Jun;37(3):207-18.
- Coyle C, Cafferty FH, Vale C, Langley RE. Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis. Annals of Oncology. 2016 Dec;27(12):2184-2195.
- Moris D, Kontos M, Spartalis E, Fentiman IS. The role of NSAIDs in breast cancer prevention and relapse: current evidence and future perspectives. Breast Care (Basel). 2016 Oct;11(5):339-344; Cuzick J. Preventive therapy for cancer. Lancet Oncology. 2017 Aug;18(8):e472-e482.
- Zhang X, Smith-Warner SA et al. Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and postmenopausal breast cancer incidence. Journal of Clinical Oncology. 2012 Oct 1;30(28):3468-77.
- Zhong S, Chen L et al. Aspirin use and risk of breast cancer: systematic review and meta-analysis of observational studies. Cancer Epidemiology, Biomarkers & Prevention. 2015 Nov;24(11):1645-55.
- Holmes MD, Chen WY et al. Aspirin intake and survival after breast cancer. Journal of Clinical Oncology. 2010 Mar 20;28(9):1467-72.
- Desmedt C, Demicheli R et al. Potential benefit of intra-operative administration of ketorolac on breast cancer recurrence according to the patient's body mass index. Journal of the National Cancer Institute. 2018 Oct 1;110(10):1115-1122.
- Moris D, Kontos M, Spartalis E, Fentiman IS. The role of NSAIDs in breast cancer prevention and relapse: current evidence and future perspectives. Breast Care (Basel). 2016 Oct;11(5):339-344.
- Forget P, Bouche G et al. Intraoperative ketorolac in high-risk breast cancer patients with and without inflammation. A prospective, randomized, placebo-controlled clinical trial. Cancer Research 2019;79(4 Suppl):Abstract # P1-20-01.
- US Food and Drug Administration. FDA Drug Safety Communication: FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes. US Department of Health and Human Services. February 26, 2018. Viewed March 5, 2019.
- Botteri E, Munzone E et al. Therapeutic effect of β-blockers in triple-negative breast cancer postmenopausal women. Breast Cancer Research and Treatment. 2013 Aug;140(3):567-75.
- Kim HY, Jung YJ, Lee SH, Jung HJ, Pak K. Is beta-blocker use beneficial in breast cancer? A meta-analysis. Oncology. 2017;92(5):264-268; Childers WK, Hollenbeak CS, Cheriyath P. β-blockers reduce breast cancer recurrence and breast cancer death: a meta-analysis. Clinical Breast Cancer. 2015 Dec;15(6):426-31.
- Bonovas S, Filioussi K, Tsavaris N, Sitaras NM. Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. Journal of Clinical Oncology. 2005 Dec 1;23(34):8606-12.
- Kwan ML, Habel LA, Flick ED, Quesenberry CP, Caan B. Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors. Breast Cancer Research and Treatment. 2008;109(3):573–579; Ahern TP, Pedersen L et al. Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. Journal of the National Cancer Institute. 2011;103(19):1461–1468.
- Marinac CR, Nelson SH et al. Prolonged nightly fasting and breast cancer prognosis. JAMA Oncology. 2016 Aug 1;2(8):1049-55.
- Novaes MR, Valadares F, Reis MC, Gonçalves DR, Menezes Mda C. The effects of dietary supplementation with Agaricales mushrooms and other medicinal fungi on breast cancer: evidence-based medicine. Clinics (Sao Paulo). 2011;66(12):2133-9.
- Ong SKL, Shanmugam MK et al. Focus on formononetin: anticancer potential and molecular targets. Cancers (Basel). 2019;11(5):611.
- Huang WC, Kuo KT, Bamodu OA, et al. Astragalus polysaccharide (PG2) ameliorates cancer symptom clusters, as well as improves quality of life in patients with metastatic disease, through modulation of the inflammatory cascade. Cancers (Basel). 2019;11(8).
- Denzler K, Moore et al. Characterization of the physiological response following in vivo administration of Astragalus membranaceus. Evidence-based Complementary and Alternative Medicine. 2016;2016:6861078; Li S, Sun Y et al. Anti-tumor effects and mechanisms of Astragalus membranaceus (AM) and its specific immunopotentiation: status and prospect. Journal of Ethnopharmacology. 2020 Aug 10;258:112797.
- Chen MH, May BH, Zhou IW, Zhang AL, Xue CC. Integrative medicine for relief of nausea and vomiting in the treatment of colorectal cancer using oxaliplatin-based chemotherapy: a systematic review and meta-analysis. Phytotherapy Research. 2016;30(5):741–753.
- Griffiths K, Aggarwal BB et al. Food antioxidants and their anti-inflammatory properties: a potential role in cardiovascular diseases and cancer prevention. Diseases. 2016 Aug 1;4(3). pii: E28; Baraya YS, Wong KK, Yaacob NS. The immunomodulatory potential of selected bioactive plant-based compounds in breast cancer: a review. Anticancer Agents in Medicinal Chemistry. 2017;17(6):770-783.
- Ampofo E, Schmitt BM, Menger MD, Laschke MW. Targeting the microcirculation by indole-3-carbinol and its main derivate 3,3,'-diindolylmethane: effects on angiogenesis, thrombosis and inflammation. Mini Reviews in Medicinal Chemistry. 2018;18(11):962-968.
- Lopes CM, Dourado A, Oliveira R. Phytotherapy and nutritional supplements on breast cancer. Biomed Research International. 2017;2017:7207983.
- Rossi P, Difrancia R et al. B-glucans from Grifola frondosa and Ganoderma lucidum in breast cancer: an example of complementary and integrative medicine. Oncotarget. 2018 May 15;9(37):24837-24856.
- Rossi P, Difrancia R et al. B-glucans from Grifola frondosa and Ganoderma lucidum in breast cancer: an example of complementary and integrative medicine. Oncotarget. 2018 May 15;9(37):24837-24856.
- Laviano A, Rianda S, Molfino A, Rossi Fanelli F. Omega-3 fatty acids in cancer. Current Opinion in Clinical Nutrition and Metabolic Care. 2013 Mar;16(2):156-61; Schunck WH, Konkel A, Fischer R, Weylandt KH. Therapeutic potential of omega-3 fatty acid-derived epoxyeicosanoids in cardiovascular and inflammatory diseases. Pharmacology & Therapeutics. 2018 Mar;183:177-204; Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nature Reviews. Immunology. 2008 May;8(5):349-61.
- Jin X, Ruiz Beguerie J, Sze DM, Chan GC. Ganoderma lucidum (reishi mushroom) for cancer treatment. Cochrane Database of Systematic Reviews. 2016 Apr 5;4:CD007731; Rossi P, Difrancia R et al. B-glucans from Grifola frondosa and Ganoderma lucidum in breast cancer: an example of complementary and integrative medicine. Oncotarget. 2018 May 15;9(37):24837-24856.
- Rossi EL, Khatib SA et al. Resveratrol inhibits obesity-associated adipose tissue dysfunction and tumor growth in a mouse model of postmenopausal claudin-low breast cancer. Molecular Carcinogenesis. 2018 Mar;57(3):393-407.
- Yamaguchi Y, Miyahara E, Hihara J. Efficacy and safety of orally administered Lentinula edodes mycelia extract for patients undergoing cancer chemotherapy: a pilot study. American Journal of Chinese Medicine. 2011;39(3):451-9.
- Todoric J, Antonucci L, Karin M. Targeting inflammation in cancer prevention and therapy. Cancer Prev Res (Phila). 2016 Dec;9(12):895-905.
- Reinert T, Gonçalves R, Ellis MJ. Current status of neoadjuvant endocrine therapy in early stage breast cancer. Current Treatment Options in Oncology. 2018 Apr 16;19(5):23.
- Sewell J, Sharima A et al. Pre-pectoral implant-based immediate breast reconstruction with Braxon Porcine Acellular Dermal Matrix: Is it safe with radiotherapy? European Journal of Surgical Oncology. 2018 Jun;44(6); Bettinger LN, Waters LM, Reese SW, Kutner SE, Jacobs DI. Comparative study of prepectoral and subpectoral expander-based breast reconstruction and Clavien IIIb score outcomes. Plastic and Reconstructive Surgery Global Open. 2017 Jul 26;5(7):e1433; Reitsamer R, Peintinger F. Prepectoral implant placement and complete coverage with porcine acellular dermal matrix: a new technique for direct-to-implant breast reconstruction after nipple-sparing mastectomy. Journal of Plastic, Reconstructive & Aesthetic Surgery. 2015 Feb;68(2):162-7.
- Kim JY, Davila AA et al. A meta-analysis of human acellular dermis and submuscular tissue expander breast reconstruction. Plastic and Reconstructive Surgery. 2012 Jan;129(1):28-41.
- Horowitz M, Neeman E, Sharon E, Ben-Eliyahu S. Exploiting the critical perioperative period to improve long-term cancer outcomes. Nature Reviews. Clinical Oncology. 2015 Apr;12(4):213-26.
- Lee JW, Shahzad MM et al. Surgical stress promotes tumor growth in ovarian carcinoma. Clinical Cancer Research. 2009 Apr 15;15(8):2695-702.
- Choy C, Raytis JL et al. Inhibition of β2-adrenergic receptor reduces triple-negative breast cancer brain metastases: the potential benefit of perioperative β-blockade. Oncology Reports. 2016 Jun;35(6):3135-42.
- Pantziarka P, Bouche G et al. Repurposing Drugs in Oncology (ReDO)-Propranolol as an anti-cancer agent. Ecancermedicalscience. 2016 Oct 12;10:680.
- Hiller JG, Cole SW et al. Preoperative β-blockade with propranolol reduces biomarkers of metastasis in breast cancer: a phase II randomized trial. Clinical Cancer Research. 2020;26(8):1803-1811; Cote J. Could a common and inexpensive heart medicine (beta-blockers) help cancer patients live longer? Cancer Prevention and Treatment Fund. Viewed October 31, 2017; Weberpals J, Jansen L et al. Pre- and post-diagnostic β-blocker use and lung cancer survival: a population-based cohort study. Scientific Reports. 2017 Jun 6;7(1):2911.
- Kupstas AR, Hoskins TL et al. Effect of surgery type on time to adjuvant chemotherapy and impact of delay on breast cancer survival: a National Cancer Database analysis. Annals of Surgical Oncology. 2019 Jul 22.
- Wilkins EG, Hamill JB et al. Complications in postmastectomy breast reconstruction one-year outcomes of the Mastectomy Reconstruction Outcomes Consortium (MROC) study. Annals of Surgery. 2018 Jan; 267(1):164-170); McCarthy CM, Mehrara BJ et al. Predicting complications following expander/implant breast reconstruction: an outcomes analysis based on preoperative clinical risk. Plastic and Reconstructive Surgery. 2008 Jun;121(6):1886-92; Sada A, Day CN et al. Mastectomy and immediate breast reconstruction in the elderly: trends and outcomes. Surgery. 2019 Aug 5. pii: S0039-6060(19)30357-5; Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Care. New York: Bantam Dell. 2009.
- Washer LL, Gutowski K. Breast implant infections. Infectious Disease Clinics of North America. 2012 Mar;26(1):111-25.
- Wilkins EG, Hamill JB et al. Complications in postmastectomy breast reconstruction one-year outcomes of the Mastectomy Reconstruction Outcomes Consortium (MROC) study. Annals of Surgery. 2018 Jan; 267(1):164-170; Ooi A, Song DH.Reducing infection risk in implant-based breast-reconstruction surgery: challenges and solutions. Breast Cancer: Targets and Therapies. 2016 Sep 1;8:161-72; O'Connell RL, Rattay T et al.The impact of immediate breast reconstruction on the time to delivery of adjuvant therapy: the iBRA-2 study. British Journal of Cancer. 2019 Apr;120(9):883-895.
- Department of Surgery. Breast Reconstruction. University of California San Francisco. Viewed April 11, 2019.
- Love SM. Dr. Susan Love’s Breast Book. 6th edition. De Capo Press. 2015. p. 342.
- Phillips BT, Bishawi M, Dagum AB, Khan SU, Bui DT. A systematic review of antibiotic use and infection in breast reconstruction: what is the evidence? Plastic and Reconstructive Surgery. 2013 Jan;131(1):1-13.
- Ooi A, Song DH. Reducing infection risk in implant-based breast-reconstruction surgery: challenges and solutions. Breast Cancer: Targets and Therapies. 2016 Sep 1;8:161-72.
- Cho JS, Lee MH et al. The effects of perioperative anesthesia and analgesia on immune function in patients undergoing breast cancer resection: a prospective randomized study. International Journal of Medical Sciences. 2017 Aug 18;14(10):970-976.
- 2018 Exposing a Silent Gateway to Persistent Opioid Use – A Choices Matter Status Report. Pacira BioSciences, Inc. Viewed September 10, 2019.
- Aich A, Gupta P, Gupta K. Could perioperative opioid use increase the risk of cancer progression and metastases? International Anesthesiology Clinics. 2016 Fall;54(4):e1-e16.
- Rojas KE, Fortes TA et al. Mastectomy is no longer an indication for postoperative narcotic. Americal Journal of Surgery. 2019 Jul 18. pii: S0002-9610(19)30177-1.
- Retsky M, Demicheli R et al. Reduction of breast cancer relapses with perioperative non-steroidal anti-inflammatory drugs: new findings and a review. Current Medicinal Chemistry. 2013;20(33):4163-76.
- Retsky M, Demicheli R et al. Reduction of breast cancer relapses with perioperative non-steroidal anti-inflammatory drugs: new findings and a review. Current Medicinal Chemistry. 2013;20(33):4163-76.
- Forget P, Bouche G et al. Intraoperative ketorolac in high-risk breast cancer patients with and without inflammation. A prospective, randomized, placebo-controlled clinical trial. Cancer Research 2019;79(4 Suppl):Abstract # P1-20-01.
- Eden C, Esses G, Katz D, DeMaria S Jr. Effects of anesthetic interventions on breast cancer behavior, cancer-related patient outcomes, and postoperative recovery. Surgical Oncology. 2018 Jun;27(2):266-274.
- The ASCO Post Staff. SABCS 2020: Opioid and sedative-hypnotic use after mastectomy with reconstructive surgery. December 23, 2020. Viewed February 5, 2021; Cogan JC, Raghunathan RR et al. Persistent controlled substance use following mastectomy with reconstruction surgery. Publication Number: GS3-0. 2020 San Antonio Breast Cancer Symposium®. Viewed February 5, 2021.
- Runowicz CD, Leach CR et al. American Cancer Society/American Society for Clinical Oncology breast cancer survivorship care guideline. CA: A Cancer Journal for Clinicians. 2016 Jan-Feb;66(1):43-73.
- Gan TJ, Jiao KR, Zenn M, Georgiade G. A randomized controlled comparison of electro-acupoint stimulation or ondansetron versus placebo for the prevention of postoperative nausea and vomiting. Anesthesia and Analgesia. 2004 Oct;99(4):1070-5.
- Yu JM, Qu PS et al. Observation on the analgesic effect of transcutaneous electrical acupoint stimulation for breast radical carcinoma operation. Zhen Ci Yan Jiu. 2010 Feb;35(1):43-6.
- do Carmo Almeida TC, Dos Santos Figueiredo FW et al. Effects of transcutaneous electrical nerve stimulation on proinflammatory cytokines: systematic review and meta-analysis. Mediators of Inflammation. 2018 Apr 2;2018:1094352; Jahangirifard A, Razavi M, Ahmadi ZH, Forozeshfard M. Effect of TENS on postoperative pain and pulmonary function in patients undergoing coronary artery bypass surgery. Pain Management Nursing. 2018 Aug;19(4):408-414.
- Strauch B, Herman C, Dabb R, Ignarro LJ, Pilla AA. Evidence-based use of pulsed electromagnetic field therapy in clinical plastic surgery. Aesthetic Surgery Journal. 2009 Mar-Apr;29(2):135-43; Rohde CH, Taylor EM et al. Pulsed electromagnetic fields reduce postoperative interleukin-1β, pain, and inflammation: a double-blind, placebo-controlled study in TRAM flap breast reconstruction patients. Plastic and Reconstructive Surgery. 2015 May;135(5):808e-817e. Hedén P, Pilla AA. Effects of pulsed electromagnetic fields on postoperative pain: a double-blind randomized pilot study in breast augmentation patients. Aesthetic Plastic Surgery. 2008 Jul;32(4):660-6; Rohde C, Chiang A, Adipoju O, Casper D, Pilla AA. Effects of pulsed electromagnetic fields on interleukin-1 beta and postoperative pain: a double-blind, placebo-controlled, pilot study in breast reduction patients. Plastic and Reconstructive Surgery. 2010 Jun;125(6):1620-9; Taylor EM, Hardy KL, Alonso A, Pilla AA, Rohde CH. Pulsed electromagnetic fields dosing impacts postoperative pain in breast reduction patients. Journal of Surgical Research. 2015 Jan;193(1):504-10.
- Sværdborg M, Momsen OH, Damsgaard TE. Pulsed electromagnetic fields for postoperative pain treatment after breast augmentation: a double-blind, placebo-controlled study. Aesthetic Surgery Journal. 2016 Jun;36(6):NP199-201.
- Meretoja TJ, Andersen KG et al. Clinical prediction model and tool for assessing risk of persistent pain after breast cancer surgery. Journal of Clinical Oncology. 2017 May 20;35(15):1660-1667.
- .Levene JL, Weinstein EJ et al. Local anesthetics and regional anesthesia versus conventional analgesia for preventing persistent postoperative pain in adults and children: a Cochrane systematic review and meta-analysis update. Journal of Clinical Anesthesia. 2019 Aug;55:116-127; Kairaluoma PM, Bachmann MS, Rosenberg PH, Pere PJ. Preincisional paravertebral block reduces the prevalence of chronic pain after breast surgery. Anesthesia and Analgesia. 2006 Sep;103(3):703-8.
- Kim R. Anesthetic technique and cancer recurrence in oncologic surgery: unraveling the puzzle. Cancer Metastasis Review. 2017 Mar;36(1):159-177.
- Breastcancer.org: Another study confirms Oncotype DX DCIS recurrence score predicts recurrence. Breastcancer.org. July 24, 2015. Viewed November 9, 2018.
- London S. DCIS risk signature is validated in SweDCIS population. Oncology Practice. December 26, 2017. Viewed November 9, 2018.
- Hung P, Wang S-Y et al. Long-term outcomes of sentinel lymph node biopsy for ductal carcinoma in situ. JNCI Cancer Spectrum. 2019 Dec; 3(4):pkz052.
- Chalasani P, Kiluk JV et al. Breast Cancer Guidelines. Medscape. October 24, 2019. Viewed November 6, 2019.
- Martinez-Perez C, Turnbull AK et al. Current treatment trends and the need for better predictive tools in the management of ductal carcinoma in situ of the breast. Cancer Treatment Reviews. 2017 Apr;55:163-172.
- DeCensi A, Puntoni M et al. Randomized placebo controlled trial of low-dose tamoxifen to prevent local and contralateral recurrence in breast intraepithelial neoplasia. Journal of Clinical Oncology. 2019 Apr 11:JCO1801779.
- Lemanne D, Maizes V. Advising women undergoing treatment for breast cancer: a narrative review. Journal of Alternative and Complementary Medicine. 2018 Sep/Oct;24(9-10):902-909.
- Koelwyn GJ, Newman AAC et al. Myocardial infarction accelerates breast cancer via innate immune reprogramming. Nature Medicine. 2020;26(9):1452-1458.
- Koelwyn GJ, Newman AAC et al. Myocardial infarction accelerates breast cancer via innate immune reprogramming. Nature Medicine. 2020;26(9):1452-1458.
- Thune I, Husøy A et al. Cardiovascular function and the effect of exercise training during adjuvant breast cancer treatment. Results from The EBBA-II trial. Presentation at the San Antonio Breast Cancer Symposium (SABCS) 2018. December 7, 2018.
- Gray B, Ingles J, Medi C, Driscoll T, Semsarian C. Cardiovascular effects of energy drinks in familial long QT syndrome: a randomized cross-over study. International Journal of Cardiology. 2017 Mar 15;231:150-154.
- National Comprehensive Cancer Network: Patient and Caregiver Resources: Cardiac Toxicity. 2018. Viewed September 28, 2018.
- Zamorano J-L, Saltijeral A, Perez de Isla L. Cardiac monitoring for patients under chemotherapy. E-Journal of Cardiology Practice. 2008 Nov 25;7(11).
- Curigliano G, Cardinale D et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Annals of Oncology. 2012 Oct;23 Suppl 7:vii155-66.
- Denlinger CS, Sanft T et al. Survivorship, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2018 Oct;16(10):1216-1247.
- Children's Oncology Group. Heart Health: Health LinkHealthy living after treatment of childhood cancer. October 2013. Viewed April 2, 2019.
- Tan C, Denlinger C. Cardiovascular toxicity in cancer survivors: current guidelines and future directions. American College of Cardiology. June 29, 2018. Viewed April 2, 2019.
- Hagag AA, El Shehaby WA, El-Abasy AI, Mabrouk MM. Protective role of silymarin in early doxorubicin induced cardiac dysfunction in children with acute lymphoblastic leukemia. Infectious Disorders Drug Targets. 2018 Aug 3.
- Rašković A, Stilinović N et al. The protective effects of silymarin against doxorubicin-induced cardiotoxicity and hepatotoxicity in rats. Molecules. 2011 Oct 12;16(10):8601-13.
- Ladas EJ, Kroll DJ et al. A randomized, controlled, double-blind, pilot study of milk thistle for the treatment of hepatotoxicity in childhood acute lymphoblastic leukemia (ALL). Cancer. 2010 Jan 15;116(2):506-13.
- Iarussi D, Auricchio U et al. Protective effect of coenzyme Q10 on anthracyclines cardiotoxicity: control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma. Molecular Aspects of Medicine. 1994;15 Suppl:s207-12.
- Takimoto M, Sakurai T et al. [Protective effect of CoQ 10 administration on cardial toxicity in FAC therapy]. [Article in Japanese]. Gan To Kagaku Ryoho. 1982 Jan;9(1):116-21.
- Okuma K, Furuta I, Ota K. [Protective effect of coenzyme Q10 in cardiotoxicity induced by adriamycin]. [Article in Japanese]. Gan To Kagaku Ryoho. 1984 Mar;11(3):502-8.
- Mustafa HN, Hegazy GA, Awdan SAE, AbdelBaset M. Protective role of CoQ10 or L-carnitine on the integrity of the myocardium in doxorubicin induced toxicity. Tissue Cell. 2017 Jun;49(3):410-426.
- The Summaries. Coenzyme Q10. CAM-Cancer. June 21, 2016. Viewed October 8, 2018.
- DiNicolantonio JJ, Lavie CJ, Fares H, Menezes AR, O'Keefe JH. L-carnitine in the secondary prevention of cardiovascular disease: systematic review and meta-analysis. Mayo Clinic Proceedings. 2013 Jun;88(6):544-51.
- Waldner R, Laschan C et al. Effects of doxorubicin-containing chemotherapy and a combination with L-carnitine on oxidative metabolism in patients with non-Hodgkin lymphoma. Journal of Cancer Research and Clinical Oncology. 2006 Feb;132(2):121-8.
- Waldner R, Laschan C et al. Effects of doxorubicin-containing chemotherapy and a combination with L-carnitine on oxidative metabolism in patients with non-Hodgkin lymphoma. Journal of Cancer Research and Clinical Oncology. 2006 Feb;132(2):121-8.
- Mustafa HN, Hegazy GA, Awdan SAE, AbdelBaset M. Protective role of CoQ10 or L-carnitine on the integrity of the myocardium in doxorubicin induced toxicity. Tissue Cell. 2017 Jun;49(3):410-426.
- Yi SY, Nan KJ, Chen SJ. [Effect of extract of Ginkgo biloba on doxorubicin-associated cardiotoxicity in patients with breast cancer]. [Article in Chinese]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2008 Jan;28(1):68-70.
- Markowitz JS, Donovan JL, Lindsay DeVane C, Sipkes L, Chavin KD. Multiple-dose administration of Ginkgo biloba did not affect cytochrome P-450 2D6 or 3A4 activity in normal volunteers. Journal of Clinical Psychopharmacology. 2003 Dec;23(6):576-81.
- Vardy J, Dhillon HM et al. Investigation of herb-drug interactions with ginkgo biloba in women receiving hormonal treatment for early breast cancer. Springerplus. 2013 Mar 22;2(1):126.
- Gardner CD, Zehnder JL, Rigby AJ, Nicholus JR, Farquhar JW. Effect of Ginkgo biloba (EGb 761) and aspirin on platelet aggregation and platelet function analysis among older adults at risk of cardiovascular disease: a randomized clinical trial. Blood Coagulation and Fibrinolysis. 2007 Dec;18(8):787-93.
- Wolf HR. Does Ginkgo biloba special extract EGb 761 provide additional effects on coagulation and bleeding when added to acetylsalicylic acid 500 mg daily? Drugs in R&D. 2006;7(3):163-72.
- Skrypnyk I, Maslova G, Lymanets T, Gusachenko I. L-arginine is an effective medication for prevention of endothelial dysfunction, a predictor of anthracycline cardiotoxicity in patients with acute leukemia. Experimental Oncology. 2017 Dec;39(4):308-311.
- Moreno-Vega A, Vega-Riveroll L et al. Adjuvant effect of molecular iodine in conventional chemotherapy for breast cancer. randomized pilot study. Nutrients. 2019 Jul 17;11(7). pii: E1623.
- Pittler MH, Schmidt K, Ernst E. Hawthorn extract for treating chronic heart failure: meta-analysis of randomized trials. American Journal of Medicine. 2003 Jun 1;114(8):665-74.
- Song X, Qu H et al. Efficacy and safety of L-carnitine treatment for chronic heart failure: a meta-analysis of randomized controlled trials. BioMed Research International. 2017;2017:6274854.
- Azuma J, Sawamura A et al. Therapeutic effect of taurine in congestive heart failure: a double-blind crossover trial. Clinical Cardiology. 1985 May;8(5):276-82; Ahmadian M, Dabidi Roshan V, Ashourpore E. Taurine supplementation improves functional capacity, myocardial oxygen consumption, and electrical activity in heart failure. Journal of Dietary Supplements. 2017 Jul 4;14(4):422-432.
- Jeejeebhoy F, Keith M, et al. Nutritional supplementation with MyoVive repletes essential cardiac myocyte nutrients and reduces left ventricular size in patients with left ventricular dysfunction. American Heart Journal. 2002 Jun;143(6):1092-100.
- Yang QY, Lu S, Sun HR. Clinical effect of astragalus granule of different dosages on quality of life in patients with chronic heart failure. Chinese Journal of Integrative Medicine. 2011 Feb;17(2):146-9.
- Zeng XH1, Zeng XJ, Li YY. Efficacy and safety of berberine for congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. American Journal of Cardiology. 2003 Jul 15;92(2):173-6.
- MacDonald B. The Breast Cancer Companion: A Complementary Care Manual: Third Edition. 2016.
- Stepura OB, Martynow AI. Magnesium orotate in severe congestive heart failure (MACH). International Journal of Cardiology. 2009 May 1;134(1):145-7.
- Mayer SE, Weiss NS et al. CYP2D6-inhibiting medication use and inherited CYP2D6 variation in relation to adverse breast cancer outcomes after tamoxifen therapy. Cancer Causes Control. 2019 Jan;30(1):103-112.
- Fox P, Balleine RL et al. Dose escalation of tamoxifen in patients with low endoxifen level: evidence for therapeutic drug monitoring-the TADE study. Clinical Cancer Research. 2016 Jul 1;22(13):3164-71.
- Hussaarts KGAM, Hurkmans DP et al. Impact of curcumin (with or without piperine) on the pharmacokinetics of tamoxifen. Cancers (Basel). 2019 Mar 22;11(3). pii: E403.
- Sanmukhani J, Satodia V et al. Efficacy and safety of curcumin in major depressive disorder: a randomized controlled trial. Phytotherapy Research. 2014 Apr;28(4):579-85.
- Panahi Y, Saadat A, Beiraghdar F, Sahebkar A. Adjuvant therapy with bioavailability-boosted curcuminoids suppresses systemic inflammation and improves quality of life in patients with solid tumors: a randomized double-blind placebo-controlled trial. Phytotherapy Research. 2014 Oct;28(10):1461-7.
- Qin S, Huang L et al. Efficacy and safety of turmeric and curcumin in lowering blood lipid levels in patients with cardiovascular risk factors: a meta-analysis of randomized controlled trials. Nutrition Journal. 2017 Oct 11;16(1):68.
- Eliza WL, Fai CK, Chung LP. Efficacy of Yun Zhi (Coriolus versicolor) on survival in cancer patients: systematic review and meta-analysis. Recent Patents on Inflammation & Allergy Drug Discovery. 2012 Jan;6(1):78-87.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Care. New York: Bantam Dell. 2009. p. 25.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Care. New York: Bantam Dell. 2009. p. 522.
- Simões BM, Kohler B et al. Estrogenicity of essential oils is not required to relieve symptoms of urogenital atrophy in breast cancer survivors. Therapeutic Advances in Medical Oncology. 2018 Apr 2;10:1758835918766189; Henley DV, Lipson N, Korach KS, Bloch CA. Prepubertal gynecomastia linked to lavender and tea tree oils. New England Journal of Medicine. 2007 Feb 1;356(5):479-85; Diaz A, Luque L, Badar Z, Kornic S, Danon M. Prepubertal gynecomastia and chronic lavender exposure: report of three cases. Journal of Pediatric Endocrinology & Metabolism. 2016 Jan;29(1):103-7; Politano VT, McGinty D et al. Uterotrophic assay of percutaneous lavender oil in immature female rats. International Journal of Toxicology. 2013 Mar-Apr;32(2):123-9; Shinohara K, Doi H, Kumagai C, Sawano E, Tarumi W. Effects of essential oil exposure on salivary estrogen concentration in perimenopausal women. Neuroendocrinology Letters. 2017 Jan;37(8):567-572; Henley DV, Korach KS. Physiological effects and mechanisms of action of endocrine disrupting chemicals that alter estrogen signaling. Hormones (Athens). 2010 Jul-Sep;9(3):191-205.
More Information
General Breast Cancer Resources
- National Cancer Institute:
- About Cancer
- Breast Cancer—Patient Version
- Breast Cancer—Health Professional Version
- Contact Us for Help
Information specialists at the NCI Contact Center are available to help answer your cancer-related questions in English and Spanish whether you are a patient, family member or friend, health care provider, or researcher. We also respond to questions and requests for information about NCI and its programs and provide support in quitting smoking.
- National Breast Cancer Foundation, Inc.
- Cancer.net: Breast Cancer
- Breastcancer.org
- National Comprehensive Cancer Network: Advocacy and Support Groups; select breast cancer or another topic of interest from the dropdown menu.
- Barbara MacDonald, ND, LAc:
- Trisha Greenhalgh and Liz O’Riordan: The Complete Guide to Breast Cancer. How to Feel Empowered and Take Control
- Sat Dharam Kaur:
- Jen Green, ND, FABNO: Identifying and Treating Metabolic Syndrome in Breast Cancer
- Ottawa Integrative Cancer Centre Evidence-Based Monographs:
- Breast Cancer Action:
Treatment Resources
- ClinicalTrials.gov: Cryoablation of Low Risk Small Breast Cancer- Ice3 Trial
- Lemanne D, Maizes V. Advising women undergoing treatment for breast cancer: a narrative review. Journal of Alternative and Complementary Medicine. 2018 Sep/Oct;24(9-10):902-909.
- McKee D. Off Label Pharmaceutical ‘Cocktails’ For Cancer Treatment (excerpts relevant to breast cancer). A4M Integrative Cancer Therapies Module 6. June 6-8, 2013.
- Dhesy-Thind S, Fletcher GG et al. Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: a Cancer Care Ontario and American Society of Clinical Oncology clinical practice guideline. Journal of Clinical Oncology. 2017 Jun 20;35(18):2062-2081.
- Pereira PTVT, Reis AD et al. Dietary supplements and fatigue in patients with breast cancer: a systematic review. Breast Cancer Research and Treatment. 2018 Oct;171(3):515-526.
- Lucius K, Trukova K. Integrative therapies and cardiovascular disease in the breast cancer population: a review, part 1. Integrative Medicine (Encinitas). 2015 Aug;14(4):22-9.
- ScienceDaily: How to starve triple negative breast cancer and the study it cites: Reis LMD, Adamoski D et al. Dual inhibition of glutaminase and carnitine palmitoyltransferase decreases growth and migration of glutaminase inhibition-resistant triple-negative breast cancer cells. Journal of Biological Chemistry. 2019 Jun 14;294(24):9342-9357.
- Beth Israel Medical Center and the Balm Foundation: Preparing for Surgery
- Choosing Wisely: Tests and Treatments for Women with Breast Cancer
Financial / Support Resources
Breast Cancer Treatment in Older Women
- Shachar SS, Hurria A, Muss HB. Breast cancer in women older than 80 years. Journal of Oncology Practice. 2016 Feb;12(2):123-32.
- Ferrigni E, Bergom C, Yin Z, Szabo A, Kong AL. Breast cancer in women aged 80 years or older: an analysis of treatment patterns and disease outcomes. Clinical Breast Cancer. 2019 Jun;19(3):157-164.
- Larkin M. Little benefit from adjuvant chemo for many older breast cancer patients. Journal of Clinical Pathways. October 28, 2019.
- Hung P, Wang S-Y et al. Long-term outcomes of sentinel lymph node biopsy for ductal carcinoma in situ. JNCI Cancer Spectrum. 2019 Dec; 3(4):pkz052.
- Hamel PJ. Breast cancer in women over 70: strategies for deciding on treatment. Health Central.
- Carleton N, Zou J et al. Outcomes after sentinel lymph node biopsy and radiotherapy in older women with early-stage, estrogen receptor-positive breast cancer. JAMA Network Open. 2021 Apr 1;4(4):e216322.
Resources on Reconstruction Options and Risk of Infection
- University of California San Francisco: Breast Reconstruction
- Breastcancer.org:
- Love SM. Dr. Susan Love’s Breast Book. 6th edition. De Capo Press. 2015.
Resources on Reducing Risk of Surgical Infection
- Connect with an integrative oncology professional or naturopathic physician for guidance.
- Alschuler LN, Gazella KA. The Definitive Guide to Cancer, 3rd Edition: An Integrative Approach to Prevention, Treatment, and Healing. Berkeley, California: Celestial Arts. 2010.
- Alschuler LN, Gazella KA. The Definitive Guide to Thriving after Cancer. Berkeley, California: Ten Speed Press. 2013.
- Block KI. Life over Cancer: The Block Center Program for Integrative Cancer Care. New York: Bantam Dell. 2009.
- MacDonald B. The Breast Cancer Companion: A Complementary Care Manual: Third Edition. 2016:
- Retsky MW, Demicheli R (Editors). Perioperative Inflammation as Triggering Origin of Metastasis Development. 2017.
- Hiller JG, Perry NJ, Poulogiannis G, Riedel B, Sloan EK. Perioperative events influence cancer recurrence risk after surgery. Nature Reviews. Clinical Oncology. 2018 Apr;15(4):205-218.
- Horowitz M, Neeman E, Sharon E, Ben-Eliyahu S. Exploiting the critical perioperative period to improve long-term cancer outcomes. Nature Reviews. Clinical Oncology. 2015 Apr;12(4):213-26.
- Pantziarka P, Sukhatme V, Bouche G, Meheus L, Sukhatme VP. Repurposing Drugs in Oncology (ReDO)-diclofenac as an anti-cancer agent. Ecancermedicalscience. 2016 Jan 11;10:610.
- Ooi A, Song DH. Reducing infection risk in implant-based breast-reconstruction surgery: challenges and solutions.
More from Our Resources Database
- Gurdev Parmar and Tina Kaczor: Textbook of Naturopathic Oncology
- Public Health England: Predict Breast Cancer
- James Michaelson, PhD: Breast Cancer Conditional Outcome Calculator
- Dawn Lemanne and Victoria Maizes: Advising Women Undergoing Treatment for Breast Cancer
- Translational Behavioral Medicine: Frontiers in Mindfulness and other Complementary & Integrative Approaches in Behavioral Medicine
- Andrew Weil Center for Integrative Medicine: Breast Cancer: An Integrative Approach (2019-2021)
- BCCT, KNOW Oncology and Ottawa Integrative Cancer Centre: Patient Education Brochures
- LifeExtension Nutritional Support: Integrative Interventions for Breast Cancer
- LifeExtension Nutritional Support: Diet and Lifestyle Considerations for Breast Cancer
- Belleruth Naparstek: Guided Meditations to Promote Successful Surgery
- Mala Cunningham, PhD: Before and After Surgery
- Dr. Susan Love: Dr. Susan Love's Breast Book
- Breast Cancer Action: Breast Cancer Fact Sheets and Toolkits
- Barbara MacDonald, ND, LAc: The Breast Cancer Companion: A Complementary Care Manual: Third Edition
- Danial E. Baker: Application of chronotherapy to the treatment of cancer: can changing the timing of drug administration influence efficacy and toxicity?
- Ralph Moss, PhD: The Ultimate Guide to Cancer: DIY Research
- US Department of Health and Human Services: Physical Activity Guidelines for Americans
- Dwight McKee, MD, editor: Clinical Pearls
- September 2018 Issue of the Journal of Alternative and Complementary Medicine
- Wayne Jonas, MD: Your Healing Journey: A Patient’s Guide to Integrative Breast Cancer Care
- The New School at Commonweal: Ted Schettler: The Ecology of Breast Cancer
- Commonweal: Commonweal Cancer Help Program
- American Society of Clinical Oncology: Cancer.Net
- Raymond Chang, MD: Beyond the Magic Bullet: The Anti-Cancer Cocktail
- Donald I. Abrams, MD, and Andrew T. Weil, MD: Integrative Oncology, 2nd Edition
- Neil McKinney, BSc, ND: Naturopathic Oncology, 3rd Edition
- Ted Schettler, MD, MPH: The Ecology of Breast Cancer: The Promise of Prevention and the Hope for Healing
- Macquarie University and Western Sydney Local Health District: BRECONDA: Breast Reconstruction Decision Aid
- April Stearns: Wildfire
- The Tracey Birnhak Nutritional Counseling Services: Soy and Breast Cancer
- Ralph Moss, PhD: The Moss Reports
- Ting Bao, MD: The Role of Integrative Therapy in Cancer Care
- National Comprehensive Cancer Network Patient and Caregiver Resources
Related Pages
Personal Stories
- Leda Dederich: ‘I recognize this weird silver lining of the terminal cancer experience.’
- Janet Spitzer: Breast Cancer, Surgery and Femininity
- Lindsay McDonell: What’s Next? Living with Metastatic Breast Cancer
- Janie Brown: The Power of the Integrative Approach in Breast Cancer Treatment
- Bonnie Gintis: Self Advocacy in Assessing Options
Our Blog
In the News
- Tumor DNA assay portends metastatic breast cancer recurrence months in advance
- Breast cancer study highlights need to perform fatigue assessments
- Breast cancer study highlights need to perform fatigue assessments
- Time-restricted eating to reduce cardiovascular risk among older breast cancer survivors: a single-arm feasibility study
- Infertility and risk of breast cancer in men: a national case–control study in England and Wales